Code	Narrative	Comments
3051F	Most recent hemoglobin A1c (HbA1c) level greater than or equal to 7.0% and less than 8.0% (DM)	
3052F	Most recent hemoglobin A1c (HbA1c) level greater than or equal to 8.0% and less than or equal to 9.0% (DM)	
4185F	Histamine therapy - intravenous	
4186F	Histamine therapy - intravenous	
0002M	Liver disease, ten biochemical assays (ALT, A2-macro- globulin, apolipoprotein A-1, total bilirubin, GGT, hapto- globin, AST, glucose, total cholesterol and triglycerides) utilizing serum, prognostic algorithm reported as quanti- tative scores for fibrosis, steatosis and alcoholic/non alco- holic steatohepatitis	
0003M	Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum, prognostic algorithm reported as quantitative scores for fibrosis, steatosis and nonalcoholic steatohepatitis (NASH)	
0004M	Scoliosis, DNA analysis of 53 single nucleotide polymor-phisms (SNPs), using saliva, prognostic algorithm reported as a risk score	
0006M	Oncology (hepatic), mRNA expression levels of 161 genes, utilizing fresh hepatocellular carcinoma tumor tissue, with alpha-fetoprotein level, algorithm reported as a risk classifier	
0007M	Oncology (gastrointestinal neuroendocrine tumors), real- time PCR expression analysis of 51 genes, utilizing whole peripheral blood, algorithm reported as a nomogram of tumor disease index	
M8000	Oncology (breast), mRNA analysis of 58 genes using hybrid capture, on formalin-fixed paraffin-embedded (FFPE) tissue, prognostic algorithm reported as a risk score	
0308T	Prosthetic eye or facial quarter	
0042T	Cerebral perfusion analysis using computed tomography with contrast administration, including postprocessing of parametric maps with determination of cerebral blood flow, cerebral blood volume, and mean transit time	
0051T	Implantation of a total replacement heart system heart system (artificial heart) with recipient cardiectomy (i.e., AbioCor, etc.)	
0052T	Replacement or repair of thoracic unit of a total replacement heart system (artificial heart) (i.e., AbioCor, etc.)	
0053T	Replacement or repair of implantable component or components of total replacement heart system (artificial heart), excluding thoracic unit (i.e., AbioCor, etc.)	
0054T	Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image-guidance based on fluoroscopic images (List separately in addition to code for primary procedure)	
0055T	Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image-guidance based on CT/MRI images (List separately in addition to code for primary procedure)	
0058T	Cryopreservation; reproductive tissue, ovarian	
0071T	Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume less than 200 cc of tissue	

-	<b>I</b> -	
0072T	Focused ultrasound ablation of uterine leiomyomata, including MR	
	guidance; total leiomyomata volume greater or equal to 200 cc of tissue	
0075T	Transcatheter placement of extracranial vertebral or intrathoracic	
	carotid artery stent(s), including radiologic supervision and	
	interpretation, percutaneous; initial vessel	
0076T	Transcatheter placement of extracranial vertebral or intrathoracic	
	carotid artery stent(s), including radiologic supervision and	
	interpretation, percutaneous; each additional vessel	
0085T	Breath test for heart transplant rejection	
0098T	Revision of total disc arthroplasty, anterior approach; each additional	
	interspace	
0100T	Placement of a subconjunctival retinal prosthesis receiver and pulse	
	generator, and implantation of intra- ocular retinal electrode array, with	
	vitrectomy	
0101T	Extracorporeal shock wave involving musculoskeletal system, not	
	otherwise specified, high energy	
0102T	Extracorporeal shock wave, high energy, performed by a physician,	
	requiring anesthesia other than local, involving lateral humeral	
	epicondyle	
0106T	Quantitative sensory testing (QST), testing and interpretation per	
	extremity; using touch pressure stimuli to assess large diameter	
	sensation	
0107T	Quantitative sensory testing (QST), testing and interpretation per	
	extremity; using vibration stimuli to assess large diameter fiber	
	sensation	
0108T	Quantitative sensory testing (QST), testing and interpretation per	
	extremity; using cooling stimuli to assess small nerve fiber sensation	
	and hyperalgesia	
0109T	Quantitative sensory testing (QST), testing and interpretation per	
	extremity; using heat-pain stimuli to assess small nerve fiber	
	sensation and hyperalgesia	
0110T	Quantitative sensory testing (QST), testing and interpretation per	
	extremity; using other stimuli to assess sensation	
0111T	Long-chain (C20-22) omega-3 fatty acids in red blood cell (RBC)	
	membranes	
0126T	Common carotid intima-media thickness (IMT) study for evaluation of	
	atherosclerotic burden or coronary heart disease risk factor	
	assessment	
0133T	Upper GI endoscopy, incl esoph, stomach and duod and/ or jejun,	
	w/injection implantable material, lower esophageal sphincter	
0163T	Total disc arthroplasty (artificial disc), anterior approach, including	
	discectomy to prepare interspace (other than for decompression),	
	lumbar, each additional interspace	
0164T	Removal of total disc arthroplasty, anterior approach, lumbar, each	
	additional interspace	
0165T	Revision of total disc arthroplasty, anterior approach, lumbar, each	
	additional interspace	
0174T	Computer-aided detection (CAD) (computer algorithm analysis of	
	digital image data for lesion detection) with further physician review for	
	interpretation and report, with or without digitization of film	
	radiographic images, chest radiograph(s), performed concurrent with	
	primary interpretation	
0175T	Computer-aided detection (CAD) (computer algorithm analysis of	
	digital image data for lesion detection) with further physician review for	
	interpretation and report, with or without digitization of film	
	radiographic images, chest radiograph(s), performed remote from	
	primary interpretation	
0178T	Electrocardiogram, 64 leads or greater, with graphic presentation and	
	analysis; with interpretation and report	
	·	

0179T	Electrocardiogram, 64 leads or greater, tracing and graphics only, without interpretation and report	
0180T	Electrocardiogram, 64 leads or greater, interpretation and report only	
0182T	High doop rate electronic brooksthorony per freetien	
01821 0198T	High dose rate electronic brachytherapy per fraction  Measurement of ocular blood flow by repetitive intraocular pressure	
	sampling, with interpretation and report	
0200T	Percutaneous sacral augmentation (sacroplasty), unilateral	
	injection(s), including the use of a balloon or mechanical device, when used, 1 or more needles, includes imaging guidance and bone biopsy,	
	when performed	
0201T	Percutaneous sacral augmentation (sacroplasty), bilateral injections,	
	including the use of a balloon or mechanical device, when used, 2 or	
	more needles, includes imaging guidance and bone biopsy, when	
	performed	
0202T	Posterior vertebral joint(s) arthroplasty (e.g., facet joint[s]	
	replacement) including facetectomy, laminectomy, foraminotomy and	
	vertebral column fixation, with or without injection of bone cement, including fluoroscopy, single level, lumbar spine	
	including hadroscopy, single level, lambar spine	
0207T	Evacuation of Meibomian glands, automated, using heat and	
	intermittent pressure, unilateral	
0208T	Pure tone audiometry (threshold), automated (includes use of computer-assisted device); air only	
0209T	Pure tone audiometry (threshold), automated (includes use of	
	computer-assisted device); air and bone	
0210T	Speech audiometry threshold, automated (includes use of computer- assisted device);	
0211T	Speech audiometry threshold, automated (includes use of computer-	
	assisted device); with speech recognition	
0212T	Comprehensive audiometry threshold evaluation and speech	
	recognition (0209T, 0211T combined), automated (includes use of computer-assisted device)	
	sompator assisted device)	
0213T	Injection(s), diagnostic or therapeutic agent, paravertebral facet	
	(zygapophyseal) joint (or nerves innervating that joint) with ultrasound	
	guidance, cervical or thoracic; single level	
0214T	Injection(s), diagnostic or therapeutic agent, paravertebral facet	
	(zygapophyseal) joint (or nerves innervating that joint) with ultrasound	
	guidance, cervical or thoracic; second level (List separately in addition to code for primary procedure)	
0215T	Injection(s), diagnostic or therapeutic agent, paravertebral facet	
02101	(zygapophyseal) joint (or nerves innervating that joint) with ultrasound	
	guidance, cervical or thoracic; third and any additional level(s) (List	
	separately in addition to code for primary	
02467	Injection(a) diagnostic or thoropoutic a rout a contained for	
0216T	Injection(s), diagnostic or therapeutic agent, paravertebral facet	
	(zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; single level	
0217T	Injection(s), diagnostic or therapeutic agent, paravertebral facet	
	(zygapophyseal) joint (or nerves innervating that joint) with ultrasound	
	guidance, lumbar or sacral; second level (List separately in addition to	
	code for primary procedure)	
0218T	Injection(s), diagnostic or therapeutic agent, paravertebral facet	
	(zygapophyseal) joint (or nerves innervating that joint) with ultrasound	
	guidance, lumbar or sacral; third and any additional level(s) (List	
	separately in addition to code for primary procedure)	
0219T	Placement of posterior intrafacet implant(s), unilateral or bilateral,	
02131	including imaging and placement of bone graft(s) or synthetic	
	device(s), single level; cervical	
	<u> </u>	

0220T	Placement of posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic	
0221T	device(s), single level; thoracic  Placement of posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic	
0222T	device(s), single level; lumbar  Placement of posterior intrafacet implant(s), unilateral or bilateral,	
02221	including imaging and placement of bone graft(s) or synthetic device(s), single level; each additional vertebral segment (List separately in addition to code for primary procedure)	
0228T	Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with ultrasound guidance, cervical or thoracic; single level	
0229T	Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with ultrasound guidance, cervical or thoracic; each additional level (List separately in addition to code for primary procedure)	
0230T	Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with ultrasound guidance, lumbar or sacral; single level	
0231T	Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with ultrasound guidance, lumbar or sacral; each additional level (List separately in addition to code for primary procedure)	
0232T	Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed	
0234T	Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; renal artery	
0235T	Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; visceral artery (except renal), each vessel	
0236T	Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; abdominal aorta	
0237T	Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; brachiocephalic trunk and branches, each vessel	
0238T	Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; iliac artery, each vessel	
0253T	Insertion of anterior segment aqueous drainage device, without extraocular reservoir; internal approach, into the suprachoroidal space	
0255T	Endovascular repair of iliac artery bifurcation (e.g., aneurysm, pseudoaneurysm, arteriovenous malformation, trauma) using bifurcated endoprosthesis from the common iliac artery into both the external and internal iliac artery, unilateral; radiological supervision and interpretation	
0263T	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure including unilateral or bilateral bone marrow harvest	
0264T	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure excluding bone marrow harvest	

0265T	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; unilateral or bilateral bone marrow harvest only for intramuscular autologous bone marrow cell therapy	
0266T	Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra- operative interrogation, programming, and repositioning, when performed)	
0267T	Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)	
0268T	Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, pulse generator only (includes intra- operative interrogation, programming, and repositioning, when performed)	
0269T	Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)	
0270T	Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)	
0271T	Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)	
0272T	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (e.g., battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day);	
0273T	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (e.g., battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day); with programming	
0274T	Percutaneous laminotomy/laminectomy (intralaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy) any method under indirect image guidance (e.g., fluoroscopic, CT), with or without the use of an endoscope, single or multiple levels, unilateral or bilateral; cervical or thoracic	
0275T	Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), with or without the use of an endoscope, single or multiple levels, unilateral or bilateral; lumbar	
0278T	Transcutaneous electrical modulation pain reprocessing (e.g., scrambler therapy), each treatment session (includes placement of electrodes)	

0290T	Corneal incisions in the recipient cornea created using a laser, in preparation for penetrating or lamellar keratoplasty (List separately in addition to code for primary procedure)	
0293T	Insertion of left atrial hemodynamic monitor; complete system, includes implanted communication module and pressure sensor lead in left atrium including transseptal access, radiological supervision and interpretation, and associated injection procedures, when performed	
0294T	Insertion of left atrial hemodynamic monitor; pressure sensor lead at time of insertion of pacing cardioverter-defibrillator pulse generator including radiological supervision and interpretation and associated injection procedures, when performed (List separately in addition to code for primary procedure)	
0299T	Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; initial wound	
0300T	Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; each additional wound (List separately in addition to code for primary procedure)	
0301T	Destruction/reduction of malignant breast tumor with externally applied focused microwave, including interstitial placement of disposable catheter with combined temperature monitoring probe and microwave focusing sensocatheter under ultrasound thermotherapy guidance	
0302T	Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; complete system (includes device and electrodes)	
0303T	Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; complete system (includes electrode only)	
0304T	Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; complete system (includes device only)	
0305T	Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report	
0306T	Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report	
0307T	Removal of intracardiac ischemia monitoring device	
0309T	Arthrodesis, pre-sacral interbody technique, including disc space preparation, discectomy, with posterior instrumentation, with image guidance, includes bone graft, when performed, lumbar, L4-L5 interspace (List separately in addition to code for primary procedure)	
0310T	Motor function mapping using noninvasive navigated transcranial magnetic stimulation (nTMS) for therapeutic treatment planning, upper and lower extremity	
0312T	Vagus nerve blocking therapy (morbid obesity); laparoscopic implantation of neurostimulator electrode array, anterior and posterior vagal trunks adjacent to esophagogastric junction (EGJ), with implantation of pulse generator, includes programming, (e.g., Maestro vBloc® for weight reduction)	

0313T	Vagus nerve blocking therapy (morbid obesity); laparoscopic revision or replacement of vagal trunk neurostimulator electrode array, including connection to existing pulse generator	
0314T	Vagus nerve blocking therapy (morbid obesity); laparoscopic removal of vagal trunk neurostimulator electrode array and pulse generator	
0315T	Vagus nerve blocking therapy (morbid obesity); removal of pulse generator	
0316T	Vagus nerve blocking therapy (morbid obesity); replacement of pulse generator	
0317T	Vagus nerve blocking therapy (morbid obesity); neurostimulator pulse generator electronic analysis, includes reprogramming when performed	
0329T	Monitoring of intraocular pressure for 24 hours or longer, unilateral or bilateral, with interpretation and report	
0330T	Tear film imaging, unilateral or bilateral, with interpretation and report	
0331T	Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment;	
0332T	Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment, with tomographic SPECT	
0333T	Visual evoked potential screening of visual acuity, automated	
0335T	Extra-osseous subtalar joint implant for talotarsal stabilization	
0338T	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral	
0339T	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral	
0340T	Ablation, pulmonary tumor(s), including pleura or chest wall when involved by tumor extension, percutaneous, cryoablation, unilateral, includes imaging guidance	
0342T	Therapeutic apheresis with selective HDL delipidation and plasma reinfusion	
0347T	Placement of interstitial device(s) in bone for radiostereometric analysis (RSA)	
0348T	Radiologic examination, radiostereometric analysis (RSA), spine, (includes, cervical, thoracic and lumbosacral, when performed)	
0349T	Radiologic examination, radiostereometric analysis (RSA), upper extremity(ies), (includes shoulder, elbow and wrist, when performed)	
0350T	Radiologic examination, radiostereometric analysis (RSA); lower extremity(ies), (includes hip, proximal femur, knee, and ankle, when performed) ankle, when performed)	
0351T	Optical coherence tomography of breast or axillary lymph node, excised tissue, each specimen; real time intraoperative	
0352T	Optical coherence tomography of breast or axillary lymph node, excised tissue, each specimen; interpretation and report, real time or referred	
0353T	Optical coherence tomography of breast, surgical cavity; real time intraoperative	

0354T	Optical coherence tomography of breast, surgical cavity; interpretation and report, real time or referred	
0355T	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), colon, with interpretation and report	
0356T	Insertion of drug-eluting implant (including punctal dilation and implant removal when performed) into lacrimal canaliculus, each	
0358T	Bioelectrical impedance analysis whole body composition assessment, supine position, with interpretation and report	
0362T	Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; first 30 minutes of technician(s) time, face-to-face with the patient	
0373T	Exposure adaptive behavior treatment with protocol modification requiring two or more technicians for severe maladaptive behavior(s); first 60 minutes of technicians' time, face-to-face with patient	
0376T	Insertion of anterior segment aqueous drainage device, without extraocular reservoir, internal approach, into the trabecular meshwork; each additional device insertion (List separately in addition to code for primary procedure)	
0378T	Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional	
0379T	Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; technical support and patient instructions, surveillance, analysis and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional	
0381T	External heart rate and 3-axis accelerometer data recording up to 14 days to assess changes in heart rate and to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; includes report, scanning analysis with report, review and interpretation by a physician or other qualified health care professional	
0382T	External heart rate and 3-axis accelerometer data recording up to 14 days to assess changes in heart rate and to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; review and interpretation only	
0383T	External heart rate and 3-axis accelerometer data recording from 15 to 30 days to assess changes in heart rate to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; includes report, scanning analysis with report, review and interpretation by a physician or other qualified health care professional	
0384T	External heart rate and 3-axis accelerometer data recording from 15 to 30 days to assess changes in heart rate to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; review and interpretation only	
0385T	External heart rate and 3-axis accelerometer data recording more than 30 days to assess changes in heart rate to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; includes report, scanning analysis with report, review and interpretation by a physician or other qualified health care professional	

0386T	External heart rate and 3-axis accelerometer data recording more than 30 days to assess changes in heart rate to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; review and interpretation only	
0394T	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed	
0395T	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed	
0396T	Intra-operative use of kinetic balance sensor for implant stability during knee replacement arthroplasty (List separately in addition to code for primary procedure)	
0397T	Endoscopic retrograde cholangiopancreatography (ERCP), with optical endomicroscopy (List separately in addition to code for primary procedure)	
0398T	Magnetic resonance image guided high intensity focused ultrasound (MRgFUS), stereotactic ablation lesion, intracranial for movement disorder including stereotactic navigation and frame placement when performed	
0400T	Multi-spectral digital skin lesion analysis of clinically atypical cutaneous pigmented lesions for detection of melanomas and high risk melanocytic atypia; one to five lesions	
0401T	Multi-spectral digital skin lesion analysis of clinically atypical cutaneous pigmented lesions for detection of melanomas and high risk melanocytic atypia; six or more lesions	
0402T	Collagen cross-linking of cornea (including removal of the corneal epithelium and intraoperative pachymetry when performed)	
0404T	Transcervical uterine fibroid(s) ablation with ultrasound guidance, radiofrequency	
0405T	Oversight of the care of an extracorporeal liver assist system patient requiring review of status, review of laboratories and other studies, and revision of orders and liver assist care plan (as appropriate), within a calendar month, 30 minutes or more of non- face-to-face time	
0408T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator with transvenous electrodes	
0409T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only	
0410T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; atrial electrode only	
0411T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only	
0412T	Removal of permanent cardiac contractility modulation system; pulse generator only	
0413T	Removal of permanent cardiac contractility modulation system; transvenous electrode (atrial or ventricular)	
0414T	Removal and replacement of permanent cardiac contractility modulation system pulse generator only	
0415T	Repositioning of previously implanted cardiac contractility modulation transvenous electrode, (atrial or ventricular lead)	

0417T	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation system	
0418T	Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter; implantable cardiac contractility modulation system	
0421T	Transurethral waterjet ablation of prostate, including control of post- operative bleeding, including ultrasound guidance, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included when performed)	
0422T	Tactile breast imaging by computer- aided tactile sensors, unilateral or bilateral	
0423T	Secretory type II phospholipase A2 (sPLA2-IIA)	
0424T	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; complete system (transvenous placement of right or left stimulation lead, sensing lead, implantable pulse generator)	
0425T	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; sensing lead only	
0426T	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; stimulation lead only	
0427T	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; pulse generator only	
0428T	Removal of neurostimulator system for treatment of central sleep apnea; pulse generator only	
0429T	Removal of neurostimulator system for treatment of central sleep apnea; sensing lead only	
0430T	Removal of neurostimulator system for treatment of central sleep apnea; stimulation lead only	
0431T	Removal and replacement of neurostimulator system for treatment of central sleep apnea, pulse generator only	
0432T	Repositioning of neurostimulator system for treatment of central sleep apnea; stimulation lead only	
0433T	Repositioning of neurostimulator system for treatment of central sleep apnea; sensing lead only	
0434T	Interrogation device evaluation implanted neurostimulator pulse generator system for central sleep apnea	
0435T	Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; single session	
0436T	Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; during sleep study	
0438T	Transperineal placement of biodegradable material, peri- prostatic (via needle), single or multiple, includes image guidance	
0439T	Myocardial contrast perfusion echocardiography; at rest or with stress, for assessment of myocardial ischemia or viability (List separately in addition to code for primary procedure)	
0440T	Ablation, percutaneous, cryoablation, includes imaging guidance; upper extremity distal/peripheral nerve	
0441T	Ablation, percutaneous, cryoablation, includes imaging guidance; lower extremity distal/peripheral nerve	
0442T	Ablation, percutaneous, cryoablation, includes imaging guidance; nerve plexus or other truncal nerve (eg, brachial plexus, pudendal nerve)	

0443T	Real time spectral analysis of prostate tissue by fluorescence spectroscopy	
0444T	Initial placement of a drug-eluting ocular insert under one or more eyelids, including fitting, training, and insertion, unilateral or bilateral	
0445T	Subsequent placement of a drug- eluting ocular insert under one or more eyelids, including re-training, and removal of existing insert,	
	unilateral or bilateral	
0446T	Creation of subcutaneous pocket with insertion of implantable	
	interstitial glucose sensor, including system activation and patient	
	training	
0447T	Removal of implantable interstitial glucose sensor from subcutaneous	
	pocket via incision	
0448T	Removal of implantable interstitial glucose sensor with creation of	
	subcutaneous pocket at different anatomic site	
0449T	Insertion of aqueous drainage device	
0450T	Insertion of aqueous drainage device	
0451T	Insertion or replacement of a permanently implantable aortic counterpulsation VAD	
0452T	Insertion or replacement of a permanently implantable aortic	
	counterpulsation VAD	
0453T	Insertion or replacement of a permanently implantable aortic counterpulsation VAD	
0454T	Insertion or replacement of a permanently implantable aortic counterpulsation VAD	
0455T	Insertion or replacement of a permanently implantable aortic counterpulsation VAD	
0456T	Removal of permanently implantable aortic counterpulsation VAD	
0457T	Removal of permanently implantable aortic counterpulsation VAD	
0458T	Removal of permanently implantable aortic counterpulsation VAD	
0459T	Relocation of permanently implantable aortic counterpulsation VAD	
0460T	Repositioning of previously implanted aortic counterpulsation VAD	
0461T	Repositioning of previously implanted aortic counterpulsation VAD	
0462T	Programming device evaluation with iterative adjustment	
0462T	Interrogation device evaluation	
	Visual evoked potential	
0464T	·	
0465T	Suprachronoidal injection	
0466T	Revision or replacement of chest wall respiratory sensor	
0467T	Revision or replacement of chest wall respiratory sensor electrode or electrode array, including connection to existing pulse generator (e.g.,	
	hypoglossal nerve stimulation for treatment of obstructive sleep apnea)	
0468T	Removal of chest wall respiratory sensor electrode or electrode array	
	(e.g., hypoglossal nerve stimulation for treatment of obstructive sleep apnea)	
0563T	Evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland	
	expression, bilateral	
0565T	Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular	
	implant creation	
0566T	Autologous cellular implant derived from adipose tissue for the	
	treatment of osteoarthritis of the knees; injection of cellular implant	

	In	
0567T	Permanent fallopian tube occlusion with degradable biopolymer	
	implant, transcervical approach, including transvaginal ultrasound	
0568T	Introduction of mixture of saline and air for sonosalpingography to	
03001	confirm occlusion of fallopian tubes, transcervical approach, including	
	transvaginal ultrasound and pelvic ultrasound	
	transvagnar antaboana ana porvio antaboana	
0569T	Transcatheter tricuspid valve repair, percutaneous approach; initial	
	prosthesis	
0570T	Transcatheter tricuspid valve repair, percutaneous approach; each	
	additional prosthesis during same session (List separately in addition	
	to code for primary procedure)	
0571T	Insertion or replacement of implantable cardioverter-defibrillator	
	system with substernal electrode(s), including all imaging guidance	
	and electrophysiological evaluation (includes defibrillation threshold	
	evaluation, induction of arrhythmia, evaluation of sensing for	
	arrhythmia termination, and programming or reprogramming of	
	sensing or therapeutic parameters), when performed	
05707	leaved as a facilitation of the leaves of th	
0572T	Insertion of substernal implantable defibrillator electrode	
0573T 0574T	Removal of substernal implantable defibrillator electrode	
00/41	Repositioning of previously implanted substernal implantable defibrillator-pacing electrode	
0575T	Programming device evaluation (in person) of implantable cardioverter-	
	defibrillator system with substernal electrode, with iterative adjustment	
	of the implantable device to test the function of the device and select	
	optimal permanent programmed values with analysis, review and	
	report by a physician or other qualified health care professional	
0576T	Interrogation device evaluation (in person) of implantable cardioverter-	
	defibrillator system with substernal electrode, with analysis, review	
	and report by a physician or other qualified health care professional,	
	includes connection, recording and disconnection per patient	
	encounter	
0577T	Electrophysiological evaluation of implantable cardioverter-defibrillator	
	system with substernal electrode (includes defibrillation threshold	
	evaluation, induction of arrhythmia, evaluation of sensing for	
	arrhythmia termination, and programming or reprogramming of	
	sensing or therapeutic parameters)	
0570T		
0578T	Interrogation device evaluation(s) (remote), up to 90 days, substernal	
	lead implantable cardioverter-defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care	
	professional	
0579T	Interrogation device evaluation(s) (remote), up to 90 days, substernal	
00701	lead implantable cardioverter-defibrillator system, remote data	
	acquisition(s), receipt of transmissions and technician review,	
	technical support and distribution of results	
0580T	Removal of substernal implantable defibrillator pulse generator only	
	, , , , , , , , , , , , , , , , , , , ,	
0581T	Ablation, malignant breast tumor(s), percutaneous, cryotherapy,	
	including imaging guidance when performed, unilateral	
0582T	Transurethral ablation of malignant prostate tissue by high-energy	
	water vapor thermotherapy, including intraoperative imaging and	
	needle guidance	
0583T	Tympanostomy (requiring insertion of ventilating tube), using an	
	automated tube delivery system, iontophoresis local anesthesia	

0584T	Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; percutaneous	
0585T	Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; laparoscopic	
0586T	Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; open	
0587T	Percutaneous implantation or replacement of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve	
0588T	Revision or removal of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve	
0589T	Electronic analysis with simple programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters	
0590T	Electronic analysis with complex programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters	
0591T	Health and well-being coaching face-to-face; individual, initial assessment	
0592T	Health and well-being coaching face-to-face; individual, follow-up session, at least 30 minutes	
0593T	Health and well-being coaching face-to-face; group (2 or more individuals), at least 30 minutes	
0139U	Neurology (autism spectrum disorder [ASD]), quantitative measurements of 6 central carbon metabolites (ie, α-ketoglutarate, alanine, lactate, phenylalanine, pyruvate, and succinate), LC-MS/MS, plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD)	
0140U	Infectious disease (fungi), fungal pathogen identification, DNA (15 fungal targets), blood culture, amplified probe technique, each target reported as detected or not detected	
0141U	Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance element detection, DNA (20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, 1 pan Candida target), blood culture, amplified probe technique, each target reported as detected or not detected	

0142U	Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance element detection, DNA (21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target, 1 pan Candida target), amplified probe technique, each target reported as detected or not detected	
0143U	Drug assay, definitive, 120 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	
0144U	Drug assay, definitive, 160 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	
0145U	Drug assay, definitive, 65 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	
0146U	Drug assay, definitive, 80 or more drugs or metabolites, urine, by quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	
0147U	Drug assay, definitive, 85 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	
0148U	Drug assay, definitive, 100 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	
0149U	Drug assay, definitive, 60 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	
0150U	Drug assay, definitive, 120 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service	
0151U	Infectious disease (bacterial or viral respiratory tract infection), pathogen specific nucleic acid (DNA or RNA), 33 targets, real-time semi-quantitative PCR, bronchoalveolar lavage, sputum, or endotracheal aspirate, detection of 33 organismal and antibiotic resistance genes with limited semi-quantitative results	
0152U	Infectious disease (bacteria, fungi, parasites, and DNA viruses), DNA, PCR and next-generation sequencing, plasma, detection of >1,000 potential microbial organisms for significant positive pathogens	
0153U	Oncology (breast), mRNA, gene expression profiling by next- generation sequencing of 101 genes, utilizing formalin-fixed paraffin- embedded tissue, algorithm reported as a triple negative breast cancer clinical subtype(s) with information on immune cell involvement	

FGFR3 (fibroblast growth factor receptor 3) gene analysis (ie, p.R248C [c.742C>T], p.S249C [c.746C>G], p.G370C [c.1108G>T], p.Y373C [c.1118A>G], FGFR3-TACC3v1, and FGFR3-TACC3v3)  PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) (eg, breast cancer) gene analysis (ie, p.C420R, p.E542K, p.E545A, p.E545D [g.1635G>T only], p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, p.H1047Y)  Copy number (eg, intellectual disability, dysmorphology), sequence analysis  APC (APC regulator of WNT signaling pathway) (eg, familial adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure)  MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	
p.Y373C [c.1118A>G], FGFR3-TACC3v1, and FGFR3-TACC3v3)  PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) (eg, breast cancer) gene analysis (ie, p.C420R, p.E542K, p.E545A, p.E545D [g.1635G>T only], p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, p.H1047Y)  Copy number (eg, intellectual disability, dysmorphology), sequence analysis  APC (APC regulator of WNT signaling pathway) (eg, familial adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure)  MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in	
p.Y373C [c.1118A>G], FGFR3-TACC3v1, and FGFR3-TACC3v3)  PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) (eg, breast cancer) gene analysis (ie, p.C420R, p.E542K, p.E545A, p.E545D [g.1635G>T only], p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, p.H1047Y)  Copy number (eg, intellectual disability, dysmorphology), sequence analysis  APC (APC regulator of WNT signaling pathway) (eg, familial adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure)  MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in	
subunit alpha) (eg, breast cancer) gene analysis (ie, p.C420R, p.E542K, p.E545A, p.E545D [g.1635G>T only], p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, p.H1047Y)  Copy number (eg, intellectual disability, dysmorphology), sequence analysis  APC (APC regulator of WNT signaling pathway) (eg, familial adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure)  MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in	
subunit alpha) (eg, breast cancer) gene analysis (ie, p.C420R, p.E542K, p.E545A, p.E545D [g.1635G>T only], p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, p.H1047Y)  Copy number (eg, intellectual disability, dysmorphology), sequence analysis  APC (APC regulator of WNT signaling pathway) (eg, familial adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure)  MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in	
subunit alpha) (eg, breast cancer) gene analysis (ie, p.C420R, p.E542K, p.E545A, p.E545D [g.1635G>T only], p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, p.H1047Y)  Copy number (eg, intellectual disability, dysmorphology), sequence analysis  APC (APC regulator of WNT signaling pathway) (eg, familial adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure)  MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in	
p.E542K, p.E545A, p.E545D [g.1635G>T only], p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, p.H1047Y)  Copy number (eg, intellectual disability, dysmorphology), sequence analysis  APC (APC regulator of WNT signaling pathway) (eg, familial adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure)  MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in	
p.Q546E, p.Q546R, p.H1047L, p.H1047R, p.H1047Y)  Copy number (eg, intellectual disability, dysmorphology), sequence analysis  APC (APC regulator of WNT signaling pathway) (eg, familial adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure)  MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in	
0156U Copy number (eg, intellectual disability, dysmorphology), sequence analysis  0157U APC (APC regulator of WNT signaling pathway) (eg, familial adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure)  0158U MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in	
analysis  O157U APC (APC regulator of WNT signaling pathway) (eg, familial adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure)  O158U MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in	
analysis  O157U APC (APC regulator of WNT signaling pathway) (eg, familial adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure)  O158U MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in	
O157U APC (APC regulator of WNT signaling pathway) (eg, familial adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure)  O158U MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in	
adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure)  0158U MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in	
separately in addition to code for primary procedure)  0158U MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in	
0158U MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in	
cancer, Lynch syndrome) mRNA sequence analysis (List separately in	
cancer, Lynch syndrome) mRNA sequence analysis (List separately in	
audition to some for primary processing,	
MCUD (mutC homelen 0) (an homelen content and	
0159U MSH2 (mutS homolog 2) (eg, hereditary colon cancer, Lynch	
syndrome) mRNA sequence analysis (List separately in addition to	
code for primary procedure)	
0160U MSH6 (mutS homolog 6) (eg, hereditary colon cancer, Lynch	
syndrome) mRNA sequence analysis (List separately in addition to	
code for primary procedure)	
0161U PMS2 (PMS1 homolog 2, mismatch repair system component) (eg,	
hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA	
sequence analysis (List separately in addition to code for primary	
procedure)	
0162U Hereditary colon cancer (Lynch syndrome), targeted mRNA sequence	
analysis panel (MLH1, MSH2, MSH6, PMS2) (List separately in	
addition to code for primary procedure)	
01841 Retinal prosthesis, includes all internal and external components	
10040 Acne surgery, marsupialization	
11950 Subcutan inj filling matl	
11951 Subcutan inj filling matl (e.g., collagen); 1.1 to 5.0 cc	
11952 Subcutans inj filling matl (e.g., collagen); 5.1 to 10.0 cc	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia)	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia) 15771 Grafting of autologous fat harvested by liposuction technique to trunk,	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia) 15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia) 15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate 15772 Grafting of autologous fat harvested by liposuction technique to trunk,	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia)  15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate  15772 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia) 15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate 15772 Grafting of autologous fat harvested by liposuction technique to trunk,	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia)  15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate  15772 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia)  15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate  15772 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15773 Grafting of autologous fat harvested by liposuction technique to face,	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia)  15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate  15772 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15773 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia)  15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate  15772 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15773 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia) 15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate  15772 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15773 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate  15774 Grafting of autologous fat harvested by liposuction technique to face,	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia) 15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate  15772 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15773 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate  15774 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; each	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia) 15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate  15772 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15773 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate  15774 Grafting of autologous fat harvested by liposuction technique to face,	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia) 15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate  15772 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15773 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate  15774 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; each	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia) 15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate  15772 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15773 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate  15774 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; each additional 25 cc injectate, or part thereof (List separately in addition to code for primary procedure)	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg. fat, dermis, fascia) 15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate  15772 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15773 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate  15774 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; each additional 25 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15775 Punch graft for hair transplant	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia)  15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate  15772 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15773 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate  15774 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; each additional 25 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15775 Punch graft for hair transplant  15776 Punch graft for hair transplant; more than 15 punch grafts	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg. fat, dermis, fascia) 15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate  15772 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15773 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate  15774 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; each additional 25 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15775 Punch graft for hair transplant	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia) 15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate  15772 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15773 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate  15774 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; each additional 25 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15775 Punch graft for hair transplant 15776 Punch graft for hair transplant; more than 15 punch grafts  15780 Dermabrasion; total face (e.g., for acne scarring, fine wrinkling	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia) 15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate  15772 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15773 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate  15774 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; each additional 25 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15775 Punch graft for hair transplant 15776 Punch graft for hair transplant; more than 15 punch grafts 15780 Dermabrasion; total face (e.g., for acne scarring, fine wrinkling	
Subcutan inj filling matl (e.g., collagen); over 10.0 cc     15769   Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia)     15771   Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate     15772   Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)     15773   Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate     15774   Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; each additional 25 cc injectate, or part thereof (List separately in addition to code for primary procedure)     15775   Punch graft for hair transplant   15776   Punch graft for hair transplant; more than 15 punch grafts   15780   Dermabrasion; total face (e.g., for acne scarring, fine wrinkling   15781   Dermabrasion; regional, other than face	
11954 Subcutan inj filling matl (e.g., collagen); over 10.0 cc 15769 Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia) 15771 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate  15772 Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15773 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate  15774 Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; each additional 25 cc injectate, or part thereof (List separately in addition to code for primary procedure)  15775 Punch graft for hair transplant 15776 Punch graft for hair transplant; more than 15 punch grafts 15780 Dermabrasion; total face (e.g., for acne scarring, fine wrinkling	

15787	Abrasion, each additional four lesions or less	
15788	Chemical peel, facial, epidermal	
15789	Chemical peel/facial/dermal	
15792	Chemical peel nonfacial/epidermal	
15793	Chemical peel/nonfacial/dermal	
15819	Cervicoplasty	
15820	Blepharoplasty – lower eyelid	
15821	Blepharoplasty – lower eyelid	
15822	Blepharoplasty – upper eyelid	
15823		
15824	Blepharoplasty – upper eyelid	
	Rhytidectomy; forehead	
15825	Rhytidectomy; neck with platysmal tightening	
15826	Rhytidectomy; glabellar frown lines	
15828	Rhytidectomy; cheek, chin and neck	
15829	Rhytidectomy; subcutaneous musculoaponeurotic system (SMAS) flap	
15020		
15830	Panniculectomy	
15837	Excision, excessive skin and subcut tissue; forearm, hand	
15838	Excision, excess skin and subcut tissue; submental fat pad	
15847	Abdominoplasty	
15850	Removal of sutures under anesthesia (other than local), same surgeon	
15876	Suction assisted lipectomy; head and neck	
15877	Lipectomy – suction assisted, trunk when performed in conjunction	
	with abdominoplasty/panniculectomy	
17360	Chemical exfoliation for acne (e.g., acne paste, acid)	
17380	Electrolysis epilation, each 1/2 hour	
19105	Ablation, cryosurgical, of fibroadenoma, including ultrasound	
10100	guidance, each fibroadenoma	
19300	Mastectomy for gynecomastia	
19316	Mastopexy	
19318	Reduction mammaplasty	
19316	Mammaplasty, augmentation w/ or w/o implant	
19324	Mammaplasty, augmentation w/or w/o implant	
19325	Breast reconstruction with transverse rectus abdominis myocutaneous	
19307	flap (TRAM), single pedicle, including closure of donor site	
19368	with microvascular anastomosis (supercharing)	
19369	Breast reconstruction with transverse rectus abdominis myocutaneous	
13303	flap (TRAM), double pedicle, including closure of donor site	
	hap (114 m), additio pediate, including alocate of donor site	
19380	Revision of reconstructed breast	
19396	Preparation of moulage for custom breast implant	
20552	Trigger point injections	
20553	Trigger point injections	
20700	Manual preparation and insertion of drug-delivery device(s), deep (eg, subfascial) (List separately in addition to code for primary procedure)	
20701	Removal of drug-delivery device(s), deep (eg, subfascial) (List separately in addition to code for primary procedure)	
20702	Manual preparation and insertion of drug-delivery device(s),	
	intramedullary (List separately in addition to code for primary	
	procedure)	
20703	Removal of drug-delivery device(s), intramedullary (List separately in	
20703	addition to code for primary procedure)	
20704	Manual preparation and insertion of drug-delivery device(s), intra-	
	articular (List separately in addition to code for primary procedure)	
20705	Removal of drug-delivery device(s), intra-articular (List separately in	
	addition to code for primary procedure)	

20936		
	Allograft for spine surgery only (includes harvesting the graft); local	
	(e.g., ribs, spinous process, or laminar frag- ments) obtained from	
	same incision	
20985	Computer-assisted surgical navigational procedure for	
	musculoskeletal procedures; image-less (list separately in addition to	
	code for primary procedure)	
21050	Condylectomy, temporomandibular joint (separate procedure)	
21060	Meniscectomy, partial or complete, temporomandibular joint (separate	
21000		
	procedure)	
21073	Manipulation of temporomandibular joint(s) (TMJ), therapeutic,	
	requiring an anesthesia service (ie, general or monitored anesthesia	
	, ,	
	care)	
21076	Oral Maxillofacial Prosthesis	
04077	One I Marrille for the I Done there is	
21077	Oral Maxillofacial Prosthesis	
21079	Oral Maxillofacial Prosthesis	
21080	Oral Maxillofacial Prosthesis	
21081	Oral Maxillofacial Prosthesis	
21082	Oral Maxillofacial Prosthesis	
21083	Oral Maxillofacial Prosthesis	
21084	Oral Maxillofacial Prosthesis	
21085	Oral Maxillofacial Prosthesis	
21086	Oral Maxillofacial Prosthesis	
21087	Oral Maxillofacial Prosthesis	
21088	Oral Maxillofacial Prosthesis	
21089	Unlisted maxillofacial prosthetic procedure	
21110	Application of interdental fixation device for conditions other than	
21110		
	fracture or dislocation, includes removal	
21120	Genioplasty; augmentation (autogrft, allogrft, prosthetic material)	
	Comprisory, augmentation (autograf, amograf, procurette material)	
21121	Genioplasty; sliding osteotomy, single piece	
	Conjuntative aliding autotomica, two or mare	
21122	IGENIODIASIV. SIIGING OSIEIOMIES. IWO OF MOTE	
21122	Genioplasty; sliding ostetomies, two or more	
21123	Genioplasty; sliding, augmentatn w interposit bone grafts	
	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material	
21123	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material	
21123 21125	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or	
21123 21125 21127	Genioplasty; sliding, augmentatn w interposit bone grafts  Augmentation, mandibular body or angle; prosthetic material  Augmentation, madib body/angle; w bone graft, onlay or interpositional	
21123 21125	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only	
21123 21125 21127 21137	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only	
21123 21125 21127	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material	
21123 21125 21127 21137 21138	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft)	
21123 21125 21127 21137	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material	
21123 21125 21127 21137 21138	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft)	
21123 21125 21127 21137 21138 21139	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall	
21123 21125 21127 21137 21138	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in	
21123 21125 21127 21137 21138 21139	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall	
21123 21125 21127 21137 21138 21139	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in	
21123 21125 21127 21137 21138 21139 21141	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft	
21123 21125 21127 21137 21138 21139	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any	
21123 21125 21127 21137 21138 21139 21141	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft	
21123 21125 21127 21137 21138 21139 21141 21142	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft	
21123 21125 21127 21137 21138 21139 21141	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment	
21123 21125 21127 21137 21138 21139 21141 21142 21143	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, without bone graft	
21123 21125 21127 21137 21138 21139 21141 21142	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; single piece, segment movement in	
21123 21125 21127 21137 21138 21139 21141 21142 21143	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, without bone graft	
21123 21125 21127 21137 21138 21139 21141 21142 21143	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; single piece, segment movement in	
21123 21125 21127 21137 21138 21139 21141 21142 21143 21145	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; single piece, segment movement in any direction, requiring bone grafts (includes obtaining autografts)	
21123 21125 21127 21137 21138 21139 21141 21142 21143	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; single piece, segment movement in any direction, requiring bone grafts (includes obtaining autografts) Reconstruction midface, LeFort I; 2 pieces, segment movement in any	
21123 21125 21127 21137 21138 21139 21141 21142 21143 21145	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; single piece, segment movement in any direction, requiring bone grafts (includes obtaining autografts)	
21123 21125 21127 21137 21138 21139 21141 21142 21143 21145	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; single piece, segment movement in any direction, requiring bone grafts (includes obtaining autografts) Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts) (eg,	
21123 21125 21127 21137 21138 21139 21141 21142 21143 21145	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; single piece, segment movement in any direction, requiring bone grafts (includes obtaining autografts)  Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts) (eg, ungrafted unilateral alveolar cleft)	
21123 21125 21127 21137 21138 21139 21141 21142 21143 21145	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts)  Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts)  Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts) (eg, ungrafted unilateral alveolar cleft) Reconstruction midface, LeFort I; 3 or more pieces, segment	
21123 21125 21127 21137 21138 21139 21141 21142 21143 21145	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; single piece, segment movement in any direction, requiring bone grafts (includes obtaining autografts)  Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts) (eg, ungrafted unilateral alveolar cleft)	
21123 21125 21127 21137 21138 21139 21141 21142 21143 21145	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts)  Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts) (eg, ungrafted unilateral alveolar cleft) Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts) (eg, ungrafted unilateral alveolar cleft) Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts)	
21123 21125 21127 21137 21138 21139 21141 21142 21143 21145	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; single piece, segment movement in any direction, requiring bone grafts (includes obtaining autografts)  Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts) (eg, ungrafted unilateral alveolar cleft) Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts) (eg, ungrafted bilateral alveolar cleft or multiple	
21123 21125 21127 21137 21138 21139 21141 21142 21143 21145 21146	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; single piece, segment movement in any direction, requiring bone grafts (includes obtaining autografts)  Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts) (eg, ungrafted unilateral alveolar cleft)  Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts) (eg, ungrafted bilateral alveolar cleft or multiple osteotomies)	
21123 21125 21127 21137 21138 21139 21141 21142 21143 21145 21146	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; single piece, segment movement in any direction, requiring bone grafts (includes obtaining autografts)  Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts) (eg, ungrafted unilateral alveolar cleft)  Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts) (eg, ungrafted bilateral alveolar cleft or multiple osteotomies)	
21123 21125 21127 21137 21138 21139 21141 21142 21143 21145	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts)  Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts) (eg, ungrafted unilateral alveolar cleft) Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction requiring bone grafts (includes obtaining autografts) (eg, ungrafted bilateral alveolar cleft or multiple osteotomies) Reconstruction midface, LeFort II; anterior intrusion (eg, Treacher-	
21123 21125 21127 21137 21138 21139 21141 21142 21143 21145 21146 21147	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; single piece, segment movement in any direction, requiring bone grafts (includes obtaining autografts)  Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts)  Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts) (eg, ungrafted bilateral alveolar cleft or multiple osteotomies)  Reconstruction midface, LeFort II; anterior intrusion (eg, Treacher- Collins Syndrome)	
21123 21125 21127 21137 21138 21139 21141 21142 21143 21145 21146	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; single piece, segment movement in any direction, requiring bone grafts (includes obtaining autografts)  Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts) (eg, ungrafted unilateral alveolar cleft)  Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts) (eg, ungrafted bilateral alveolar cleft or multiple osteotomies)  Reconstruction midface, LeFort II; anterior intrusion (eg, Treacher- Collins Syndrome)  Reconstruction midface, LeFort II; any direction, requiring bone grafts	
21123 21125 21127 21137 21138 21139 21141 21142 21143 21145 21146 21147	Genioplasty; sliding, augmentatn w interposit bone grafts Augmentation, mandibular body or angle; prosthetic material Augmentation, madib body/angle; w bone graft, onlay or interpositional Reduction forehead; contouring only Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft) Reduction forehead; contouring and setback of anterior frontal sinus wall Reconstruction midface, LeFort I; single piece, segment movement in any direction (eg, for Long Face Syndrome), without bone graft Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, without bone graft Reconstruction midface, LeFort I; single piece, segment movement in any direction, requiring bone grafts (includes obtaining autografts)  Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts)  Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction, requiring bone grafts (includes obtaining autografts) (eg, ungrafted bilateral alveolar cleft or multiple osteotomies)  Reconstruction midface, LeFort II; anterior intrusion (eg, Treacher- Collins Syndrome)	

21154	Reconstruction midface, LeFort III (extracranial), any type, requiring bone grafts (includes obtaining autografts); without LeFort I	
21155	Reconstruction midface, LeFort III (extracranial), any type, requiring bone grafts (includes obtaining autografts); with LeFort I	
21159	Reconstruction midface, LeFort III (extra and intracranial) with forehead advancement (eg, mono bloc), requiring bone grafts (includes obtaining autografts); without LeFort I	
21160	Reconstruction midface, LeFort III (extra and intracranial) with forehead advancement (eg, mono bloc), requiring bone grafts (includes obtaining autografts); with LeFort I	
21172	Reconstruction superior-lateral orbital rim and lower forehead, advancement or alteration, with or without grafts (includes obtaining autografts)	
21175	Reconstruction, bifrontal, superior-lateral orbital rims and lower forehead, advancement or alteration (eg, plagiocephaly, trigonocephaly, brachycephaly), with or without grafts (includes obtaining autografts)	
21179	Reconstruction, entire or majority of forehead and/or supraorbital rims; with grafts (allograft or prosthetic material)	
21180	Reconstruction, entire or majority of forehead and/or supraorbital rims; with autograft (includes obtaining grafts)	
21208	Osteoplasty, facial bones; augmentation (autograft, allograft, or prosthetic implant)	
21209	Osteoplasty, facial bones; reduction	
21240	Arthroplasty, temporomandibular joint, with or without autograft (includes obtaining graft)	
21242	Arthroplasty, temporomandibular joint, with allograft	
21243	Arthroplasty, temporomandibular joint, with prosthetic joint replacement	
21270	Malar augmentation, prosthetic material	
21295	Reduction of masseter muscle and bone (eg, for treatment of benign masseteric hypertrophy); extraoral approach	
21296	Reduction of masseter muscle and bone (eg, for treatment of benign masseteric hypertrophy); intraoral approach	
21497	Interdental wiring, for condition other than fracture	
21499	Unlisted musculoskeletal procedure, head	
21740	Reconstructive repair of pectus excavatum or carinatum	
21742	Reconstructive repair of pectus excavatum or carinatum	
21743	Reconstructive repair of pectus excavatum or carinatum	
22505	Manipulation of spine requiring anesthesia	
22513	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (eg, kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; thoracic	
22514	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (eg, kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; lumbar	
22515	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (eg, kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; each additional thoracic or lumbar vertebral body (List separately in addition to code for primary procedure)	

22523	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device, one vertebral body, unilateral or bilateral cannulation (eg, kyphoplasty); thoracic	
22524	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device, one vertebral body, unilateral or bilateral cannulation (eg, kyphoplasty); lumbar	
22525	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device, one vertebral body, unilateral or bilateral cannulation (eg, kyphoplasty); each additional thoracic or lumbar vertebral body (List separately in addition to code for primary procedure)	
22526	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single level	
22527	Percutaneous intradiscal electrothermal annuloplasty, uni- lateral or bilateral including fluoroscopic guidance; one or more additional levels (list separately in addition to code for primary procedure)	
22841	Internal spinal fixation by wiring of spinous processes	
22857	Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression), lumbar, single interspace	
22858	Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decom- pression and microdissection); second level, cervical (List separately in addition to code for primary procedure)	
22862	Revision including replacement of total disc arthroplasty (artificial disc) anterior approach, lumbar, single inter- space	
22865	Removal of total disc arthroplasty (artificial disc), anterior approach, lumbar, single interspace	
25111	Excision of ganglion, wrist	
26531	Implantations (e.g. silicone, saline, penile, etc)	
28035	Release, tarsal tunnel	
28291	Hallux rigidus correction with cheilectomy	
28890	Extracorporeal shockwave, hi energy, by MD, incl u/s guidance, involv plantar fascia	
29800	Arthroscopy, temporomandibular joint, diagnostic, with or without synovial biopsy (separate procedure)	
29804	Arthroscopy, temporomandibular joint (TMJ), surgical	
30400	Rhinoplasty, primary; lateral and alar cartilages and/or elevation of nasal tip	
30410	Rhinoplasty, primary; complete, external parts including bony pyramid, lateral and alar cartilages, and/or elevation of nasal tip	
30430	Rhinoplasty, secondary; minor revision (small amount of nasal tip work)	
30435	Rhinoplasty, secondary; intermediate revision (bony work with osteotomies)	
30450	Rhinoplasty, secondary; major revision (nasal tip work and osteotomies)	
32701	Thoracic target(s) delineation for stereotactic body radiation therapy (SRS/SBRT), (photon or particle beam), entire course of treatment	
32850	Donor Pneumonectomy(s), from cadaver donor	
32851	Lung transplant, single; without cardiopulmonary bypass	
32852	Lung transplant, single; with cardiopulmonary bypass	
32853	Lung transplant, double (bilateral sequential or en bloc); without cardiopulmonary bypass	
	·	

32854	Lung transplant, double (bilateral sequential or en bloc); with cardiopulmonary bypass	
32855	Backbench standard preparation of cadaver donor lung allograft prior to transplantation, including dissection of allograft from surrounding soft tissues to prepare pulmonary venous/atrial cuff, pulmonary artery, and bronchus; unilateral	
32856	Backbench standard preparation of cadaver donor lung allograft prior to transplantation, including dissection of allograft from surrounding soft tissues to prepare pulmonary venous/atrial cuff, pulmonary artery, and bronchus; bilateral	
33223	Relocation of skin pocket for implantable defibrillator	
33361	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approach	
33362	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery approach	
33363	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approach	
33364	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery approach	
33365	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; transaortic approach (eg, median sternotomy, mediastinotomy)	
33367	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; cardiopulmonary bypass support with percutaneous peripheral arterial and venous cannulation (eg, femoral vessels) (List separately in addition to code for primary procedure)	
33368	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; cardiopulmonary bypass support with open peripheral arterial and venous cannulation (eg, femoral, iliac, axillary vessels) (List separately in addition to code for primary procedure)	
33369	Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; cardiopulmonary bypass support with central arterial and venous cannulation (eg, aorta, right atrium, pulmonary artery) (List separately in addition to code for primary procedure)	
33930	Donor cardiectomy-pneumonectomy	
33935	Heart-lung transplant with recipient cardiectomy-pneumonectomy	
33940	Donor cardiectomy (including cold preservation)	
33944	Backbench standard preparation of cadaver donor heart allograft prior to transplantation, including dissection of allograft from surrounding soft tissues to prepare aorta, superior vena cava, inferior vena cava, pulmonary artery, and left atrium for implantation	
33945	Heart transplant, with or without recipient cardiectomy	
33947	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; initiation, veno-arterial	
33957	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; reposition peripheral (arterial and/or venous) cannula(e), percutaneous, birth through 5 years of age (includes fluoroscopic guidance, when performed)	
33959	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; reposition peripheral (arterial and/or venous) cannula(e), open, birth through 5 years of age (includes fluoroscopic guidance, when performed)	

33963	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; reposition of central cannula(e)	
	by sternotomy or thoracotomy, birth through 5 years of age (includes fluoroscopic guidance, when performed)	
33964	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life	
33304	support (ECLS) provided by physician; reposition central cannula(e)	
	by sternotomy or thoracotomy, 6 years and older (includes	
	fluoroscopic guidance, when performed)	
33975	Insertion of ventricular assist device; extracorporeal, single ventricle	
00070	Leasting VAD Education and biometrical and	
33976 33979	Insertion VAD Extracorporeal, biventricular Insertion VAD Implantable intracorporeal, single vent	
33981	Replace extracorporeal VAD, single or bivent pump	
33990	Insertion of ventricular assist device, percutaneous including	
	radiological supervision and interpretation; arterial access only	
33991	Insertion of ventricular assist device, percutaneous including	
	radiological supervision and interpretation; both arterial and venous access, with transseptal puncture	
33993	Repositioning of percutaneous ventricular assist device with imaging	
33333	guidance at separate and distinct session from insertion	
34806	Transcatheter placement of wireless physiologic sensor in aneurysmal	
0.000	sac during endovascular repair, including radiological supervision and	
	interpretation, instrument calibration, and collection of pressure data	
36416	Collection of capillary blood specimen (e.g., finger, heel, ear stick)	
36430	Transfusion, blood or blood components	
36468	Injections of sclerosing solutions, spider veins; limb or TR	
36469	Injections of sclerosing solutions, spider veins; face	
36473	Endovenous ablation therapy of incompetent vein, extremity	
36474	Endovenous ablation therapy of incompetent vein, extremity	
36821	Arteriovenous anastomosis, open; direct, any site (eg, Cimino type) (separate procedure)	
36825	Creation of arteriovenous fistula by other than direct arteriovenous anastomosis (separate procedure); autogenous graft	
36830	Creation of arteriovenous fistula by other than direct arteriovenous	
	anastomosis (separate procedure); nonautogenous graft (eg,	
	biological collagen, thermoplastic graft)	
36831	Thrombectomy, open, arteriovenous fistula without revision,	
	autogenous or nonautogenous dialysis graft (separate procedure)	
36832	Revision, open, arteriovenous fistula; without thrombectomy,	
00002	autogenous or nonautogenous dialysis graft (separate procedure)	
36833	Revision, open, arteriovenous fistula; with thrombectomy, autogenous	
	or nonautogenous dialysis graft (separate procedure)	
36909	Dialysis circuit permanent vascular embolization or occlusion	
	(including main circuit or any accessory veins), endovascular,	
	including all imaging and radiological supervision and interpretation	
	necessary to complete the intervention (List separately in addition to code for primary procedure)	
37252	Intravascular ultrasound during diagnostic evaluation	
37253	Intravascular ultrasound during diagnostic evaluation	
37790	Penile venous occulusive procedure	
37788	Penile revascularization, artery, w/without vein graft	

38204	Management of recipient hematopoietic progenitor cell donor search	
38205	and cell acquisition	
38205	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogenic	
38206	Blood-derived hematopoietic progenitor cell harvesting for	
00200	transplantation, per collection; autologous	
38207	Transplant preparation of hematopoietic progenitor cells;	
30207	cryopreservation and storage	
38208	Transplant preparation of hematopoietic progenitor cells; thawing of	
	previously frozen harvest, without washing	
38209	Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, with washing	
38210	Transplant preparation of hematopoietic progenitor cells; specific cell	
	depletion within harvest, T-cell depletion	
38211	Transplant preparation of hematopoietic progenitor cells; tumor cell depletion	
38212	Transplant preparation of hematopoietic progenitor cells; red blood	
30212	cell removal	
38213	Transplant preparation of hematopoietic progenitor cells; platelet depletion	
38214	Transplant preparation of hematopoietic progenitor cells; plasma (volume) depletion	
38215	Transplant preparation of hematopoietic progenitor cells; cell	
	concentration in plasma, mononuclear, or buffy coat layer	
38230	Bone marrow harvesting for transplantation	
38231	Bone marrow harvesting for transplantation	
38232	Bone marrow harvesting for transplantation; autologous	
38240	Bone marrow or blood derived peripheral stem cell transplantation,	
	allogenic	
38241	Bone marrow or blood derived peripheral stem cell, transplantation autologous	
38242	Bone marrow or blood-derived peripheral stem cell transplantation;	
	allogenic donor lymphocyte infusion	
38243	Hematopoietic progenitor cell (HPC); HPC boost	
41512	Tongue base suspension, permanent suture technique	
41530	Submucosal ablation of the tongue base, radiofrequency, one or more	
	sites, per session	
41821	Operculectomy, excision pericoronal tissues	
41828	Excision of hyperplastc alveolr mucosa, each sextant or quad	
41830	Alveolectomy, including curettage of osteitis or sequestrect	
41870	Periodontal mucosal grafting	
43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed	
43252	Upper GI endoscopy including esophagus, stomach and either the duodenum and/or jejunum as appropriate	
43257	Upper GI endoscopy including esophagus, stomach and either the duodenum and/or jejunum as appropriate; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia for TX of GI reflux disease	
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure,	
	placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed	
43285	Removal of esophageal sphincter augmentation device	
43631	Gastrectomy, partial, distal; with gastroduodenostomy	
43632	Gastrectomy, partial, distal; with gastrojejunostomy	
43633	Gastrectomy, partial, distal; with Roux-en-Y reconstruction	
43634	Gastrectomy, partial, distal; with formation of intestinal pouch	
43644	Laparoscopy, surgical, gastic restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	

100.15		
43645	Laparoscopy, surgical, gastic restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	
	bypass and small intestine reconstruction to limit absorption	
43647	Laparoscopy, surgical; revision or removal of gastric neurostimulator	
43047	electrodes, antrum	
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator	
	electrodes, antrum	
43659	Unlisted laparoscopy procedure, stomach	
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of	
	adjustable gastric restrictive device (eg, gastric band and	
	subcutaneous port components	
43771	Laparoscopy, surgical, gastric restrictive procedure; revision of	
	adjustable gastric restrictive device component only	
43772	Laparoscopy, surgical, gastric restrictive procedure; removal of	
	adjustable gastric restrictive device component only	
43773	Laparoscopy, surgical, gastric restrictive procedure; removal and	
	replacement of adjustable gastric restrictive device component only	
43774	Laparoscopy, surgical, gastric restrictive procedure; removal of	
	adjustable gastric restrictive device and subcutaneous port	
40775	components	
43775	Lap sleeve gastrectomy	
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	
43843	Gastric restrictive procedure, without gastric bypass, for morbid	
43043	obesity; other than vertical-banded gastroplasty	
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-	
43043	preserving duodenoileostomy and ileoileostomy (50 to 100 cm	
	common channel) to limit absorption (biliopancreatic diversion with	
	duodenal switch)	
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity;	
43040	with short limb (less than 100 cm) Roux-en-Y gastroenterostomy	
	man short mins (loss than 100 sm) redux on 1 gastroomerostomy	
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity;	
	with small intestine reconstruction to limit absorption	
43848	Revision, open, of gastric restrictive procedure for morbid obesity,	
	other than adjustable gastric restrictive device (separate procedure)	
43855	REVISE STOMACH-BOWEL FUSION	
43860	REVISE STOMACH-BOWEL FUSION	
43865	REVISE STOMACH-BOWEL FUSION	
43881	Implantation or replacement of gastric neurostimulator	
43882	Revision or removal of gastric neurostimulator electrodes, antrum,	
	open	
43886	Gastric restrictive procedure, open; revision of subcutaneous port	
	component only	
43888	Gastric restrictive procedure, open; removal and replacement of	
	subcutaneous port component only	
44132	Donor enterectomy, open; from cadaver donor	
44133	Donor enterectomy, open; partial, from living donor	
44135	Intestinal allotransplantation; from cadaver donor	
44136	Intestinal allotransplantation; from living donor	
44137 44705	Removal of transplanted intestinal allograft, complete  Preparation of fecal microbiota for instillation, including assessment of	
44705	donor specimen	
44715	Backbench standard preparation of cadaver or living donor intestine	
44/ IO	allograft prior to transplantation, including mobilization and fashioning	
	of the superior mesenteric artery and vein	
44720	Backbench standard preparation of cadaver or living donor intestine	
	TRANSPORTED A ARTHUR DE PARALLON DE CAUAVET DE INVINCEUDIT INTESTINE	
77720	allograft prior to transplantation, venous anastomosis, each	

Backbench standard preparation of cadaver or living donor intestine allograft prior to transplantation, arterial anastomosis each	
Donor hepatectomy (including cold preservation), from cadaver donor	
Liver allotransplantation; orthotopic, partial or whole, from cadaver or living donor, any age	
Liver allotransplantation; heterotopic, partial or whole, from cadaver or living donor, any age	
Donor hepatectomy, with preparation and maintenance of allograft, from living donor; left lateral segment only (segments II and III)	
Donor hepatectomy, with preparation and maintenance of allograft, from living donor; total left lobectomy (segments II, III and IV)	
Donor hepatectomy, with preparation and maintenance of allograft, from living donor; total right lobectomy (segments V, VI, VII and VIII)	
Backbench standard preparation of cadaver donor whole liver graft prior to allotransplantation, including cholecystectomy, if necessary, and dissection and removal of surrounding soft tissues to prepare the vena cava, portal vein, hepatic artery, and common bile duct for implantation; without trisegment or lobe split	
Backbench standard preparation of cadaver donor whole liver graft prior to allotransplantation, including cholecystectomy, if necessary, and dissection and removal of surrounding soft tissues to prepare the vena cava, portal vein, hepatic artery, and common bile duct for implantation; with trisegment split of whole liver graft into 2 partial liver grafts (ie, left lateral segment [segments II and III] and right trisegment [segments I and IV through VIII])	
Backbench standard preparation of cadaver donor whole liver graft prior to allotransplantation, including cholecystectomy, if necessary, and dissection and removal of surrounding soft tissues to prepare the vena cava, portal vein, hepatic artery, and common bile duct for implantation; with lobe split of whole liver graft into 2 partial liver grafts (ie, left lobe [segments II, III, and IV] and right lobe [segments I and V through VIII])	
Backbench reconstruciton of cadaver or living donor liver graft prior to allotransplantation; venous anastomosis, each	
Backbench reconstruciton of cadaver or living donor liver graft prior to allotransplantation; arterial anastomosis, each	
PANCREAS REMOVAL/TRANSPLANT	
Donor pancreatectomy (including cold preservation), with or without duodenal segment for transplantation	
Backbench standard preparation of cadaver donor pancreas allograft prior to transplantation, including dissection of allograft from surrounding soft tissues, splenectomy, duodenotomy, ligation of bile duct, ligation of mesenteric vessels, and Y-graft arterial anastomoses from iliac artery to superior mesenteric artery and to splenic artery	
Backbench reconstruction of cadaver donor pancreas allograft prior to transplantation, venous anastomosis, each	
Transplantation of pancreatic allograft	
Removal of transplanted pancreatic allograft	
Donor nephrectomy, open from cadaver living donor (excluding	
Donor nephrectomy, open from living donor (excluding preparation and maintenance of allograft)	
	allograft prior to transplantation, arterial anastomosis each  Donor hepatectomy (including cold preservation), from cadaver donor  Liver allotransplantation; orthotopic, partial or whole, from cadaver or living donor, any age  Liver allotransplantation; heterotopic, partial or whole, from cadaver or living donor, any age  Donor hepatectomy, with preparation and maintenance of allograft, from living donor; left lateral segment only (segments II and III)  Donor hepatectomy, with preparation and maintenance of allograft, from living donor; total left lobectomy (segments II, III and IV)  Donor hepatectomy, with preparation and maintenance of allograft, from living donor; total right lobectomy (segments V, VI, VII and VIII)  Backbench standard preparation of cadaver donor whole liver graft prior to allotransplantation, including cholecystectomy, if necessary, and dissection and removal of surrounding soft tissues to prepare the vena cava, portal vein, hepatic artery, and common bile duct for implantation; without trisegment or lobe split  Backbench standard preparation of cadaver donor whole liver graft prior to allotransplantation, including cholecystectomy, if necessary, and dissection and removal of surrounding soft tissues to prepare the vena cava, portal vein, hepatic artery, and common bile duct for implantation; with trisegment split of whole liver graft into 2 partial liver grafts (ie, left lateral segment [segments II and III] and right trisegment [segments I and IV through VIII])  Backbench standard preparation of cadaver donor whole liver graft prior to allotransplantation, including cholecystectomy, if necessary, and dissection and removal of surrounding soft tissues to prepare the vena cava, portal vein, hepatic artery, and common bile duct for implantation; with lobe split of whole liver graft trito 2 partial liver grafts (ie, left lobe [segments I and IV through VIII])  Backbench reconstruction of cadaver or living donor liver graft prior to allotransplantation; renous anastomosis, each  PANCREAS REM

50323	Backbench standard preparation of cadaver donor renal allograft prior to transplantation, including dissection and removal of perinephric fat, diaphragmatic and retroperitoneal attachments, excision of adrenal gland, and preparation of ureter(s), vein(s), and renal artery(s), ligating branches, as necessary	
50325	Backbench standard preparation of living donor renal allograft (open or laparoscopic) prior to transplantation, including dissection and removal of perinephric fat and preparation of ureter(s), renal vein(s), and renal artery(s), ligating branches, as necessary	
50327	Backbench reconstruction of cadaver or living donor renal allograft prior to transplantation; venous anastomosis, each	
50328	Backbench reconstruction of cadaver or living donor renal allograft prior to transplantation; arterial anastomosis, each	
50329	Backbench reconstruction of cadaver or living donor renal allograft prior to transplantation; ureteral anastomosis, each	
50340	Recipient nephrectomy (separate procedure)	
50360	Renal allotransplantation, implantation of graft; excluding donor and recipient nephrectomy	
50365	Renal allotransplantation, implantation of graft; with recipient nephrectomy	
50370	Removal of transplanted renal allograft	
50380	Renal autotransplantation, reimplantation of kidney	
50547	Laparoscopy, surgical; donor nephrectomy from living donor	
	(excluding preparation and maintenance of allograft)	
52441	Cystourethroscopy, with insertion of permanent adjustable transprotatic implant	
52442	Cystourethroscopy, with insertion of permanent adjustable transprotatic implant	
53855	Insertion of temporary prostatic ureteral stent	
54161	Circumcision (routine) for clients one year of age or older.	
54385	Implantation	
54390	Implantation	
54400	Insertion of penile prosthesis; non-inflatable (semi-rigid)	
54401	Insertion of penile prosthesis; inflatable (self-contained)	
54405	Insertion of multi-component, inflatable penile prosthesis, including	
54408	placement of pump, cylinders, and reservoir  Repair of component(s) of a multi-component, inflatable penile	
01100	prosthesis	
54410	Removal and replacement of all components of a multi-component, inflatable penile prosthesis at the same operative session	
54416	Removal and replacement of non-inflatable (semi-rigid) or inflatable (self-contained ) penile prosthesis at the same operative session	
54417	Removal and replacement of non-inflatable (semi-rigid) or inflatable (self-contained) penile prosthesis through an infected field at the same operative session, including irrigation and debridement of infected tissue	
54660	Insertion of testicular prosthesis (separate procedure)	
54900	Epididymovasostomy, anastomosis of epididymis to vas deferens; unilateral	
54901	Epididymovasostomy, anastomosis of epididymis to vas deferens; bilateral	
55200	Vasotomy, cannulization with or without incision of vas, unilateral or bilateral (separate procedure)	
55300		
	Vasotomy for vasograms, seminal vesiculograms, or epididymograms, unilateral or bilateral	
55400		
	unilateral or bilateral	

55980	Intersex surgery; female to male	
56805	Clitoroplasty for intersex state	
57291	Construction of artificial vagina; without graft	
57292	Construction of artificial vagina; with graft	
57335	Vaginoplasty for intersex state	
58301	Removal IUD	
58321	Artificial insemination; intra-cervical	
58322	Artificial insemination; intra-uterine	
58323	Sperm washing for artificial insemination	
58350	Chromotubation of oviduct, including materials	
58672	Laparoscopy, surgical; with fimbrioplasty	
58673	Laparoscopy, surgical; with salpingostomy (salpingoneostomy)	
58750	Tubotubal anastomosis	
58752	Tubouterine implantation	
58760	Fimbrioplasty	
58970	Follicle puncture for oocyte retrieval, any method	
58974	Embryo transfer, intrauterine	
58976	Gamete, zygote, or embryo intrafallopian transfer, any method	
59897	Unlisted fetal invasive procedure, including ultrasound guidance	
29097	Onlisted retai invasive procedure, including ditrasound guidance	
59898	Unlisted laparoscopy procedure, maternity care and delivery	
59899	Unlisted procedure, maternity care and delivery	
61630	Balloon angioplasty, intracranial	
61635	Transcatheter placement of intravascular stent, intracranial	
61640	Balloon dilation of intracranial vasopasm	
61641	Balloon dilation of intracranial vasopasm	
61642	Balloon dilation of intracranial vasopasm	
61796	Stereotactic radiosurgery (particle beam, gamma ray, or linear	
	accelerator); 1 simple cranial lesion	
61797	Stereotactic radiosurgery (particle beam, gamma ray, or linear	
	accelerator); each additional cranial lesion, simple (List separately in	
	addition to code for primary procedure)	
61798	Stereotactic radiosurgery (particle beam, gamma ray, or linear	
	accelerator); 1 complex cranial lesion	
61799	Stereotactic radiosurgery (particle beam, gamma ray, or linear	
	accelerator); each additional cranial lesion, complex (List separately in	
	addition to code for primary procedure)	
61800	Application of sterotactic headframe for sterotactic radiosurgery ( List	
	separately in addition to code for primary procedure)	
61863	Twist drill, burr hole, craniotomy, or craniectomy with stereotactic	
01000	implantation of neurostimulator electrode array in subcortical site (eg,	
	thalamus, globus pallidus, subthalamic nucleus, periventricular,	
	periaqueductal gray), without use of intraoperative microelectrode	
	recording; first array	
61067	3.	
61867	Twist drill, burr hole, craniotomy, or craniectomy with stereotactic	
	implantation of neurostimulator electrode array in subcortical site (eg,	
	thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), with use of intraoperative microelectrode	
	recording; first array	
04665		
61868	Twist drill, burr hole, craniotomy, or craniectomy with stereotactic	
	implantation of neurostimulator electrode array in subcortical site (eg,	
	thalamus, globus pallidus, subthalamic nucleus, periventricular,	
	periaqueductal gray), with use of intraoperative microelectrode	
	recording; each additional array (list seperately in addition to primay	
	procedure)	
62280	Injection/infusion of neurolytic substance (eg, alcohol, phenol, iced	
	saline solutions), with or without other therapeutic substance;	
	subarachnoid	
	•	

62281	Injection/infusion of neurolytic substance (eg, alcohol, phenol, iced saline solutions), with or without other therapeutic substance; epidural, cervical or thoracic	
62282	Injection/infusion of neurolytic substance (eg, alcohol, phenol, iced saline solutions), with or without other therapeutic substance; epidural, lumbar, sacral (caudal)	
62292	Chemolase injections (Chemodiactin, Chymopapain).	
62310	Injection, single (not via indwelling catheter), not including neurolytic substances, with or without contrast (for either localization or epidurography), of diagnostic or therapeutic substance(s) (including anesthetic, antispasmodic, opioid, steroid, other solution), epidural or subarachnoid; cervical or thoracic	
62311	Injection, single (not via indwelling catheter), not including neurolytic substances, with or without contrast (for either localization or epidurography), of diagnostic or therapeutic substance(s) (including anesthetic, antispasmodic, opioid, steroid, other solution), epidural or subarachnoid; lumbar, sacral (caudal)	
62318	Injection, including catheter placement, continuous infusion or intermittent bolus, not including neurolytic substances, with or without contrast (for either localization or epidurography), of diagnostic or therapeutic substance(s) (including anesthetic, antispasmodic,opioid,steroid,othersolution), epidural or subarachnoid; cervical or thoracic	
62319	Injection, including catheter placement, continuous infusion or intermittent bolus, not including neurolytic substances, with or without contrast (for either localization or epidurography), of diagnostic or therapeutic substance(s) (including anesthetic, antispasmodic,opioid,steroid,othersolution), epidural or subarachnoid;lumbar, sacral (caudal)	
62320	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thoracic; without imaging guidance	
62321	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thoracic; with imaging guidance (ie, fluoroscopy or CT)	
62322	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance	
62323	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (ie, fluoroscopy or CT)	
62324	Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, cervical or thoracic; without imaging guidance	
-	- <del>-</del>	-

Injection(s), Including indevelor, optical, steroid, other solution), not including neurolytic substances (price), eg., anesthetic, antispasmodic, optical, steroid, other solution), not including neurolytic substances, interlainar epidural or substanched, cervical or throacis: with imaging guidance (le., fluorescopy or CT)  E3236 Injection(s), including indevelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg., anesthetic, antispasmodic, optical, steroid, other solution), not including neurolytic substances, interlainar epidural or substanched, furniture or sacral (caudall); without imaging guidance  E3237 Injection(s), including indevelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg., anesthetic, antispasmodic, optical, steroid, other solution), not including neurolytic substances, interlainar epidural or substanched (eg., anesthetic, antispasmodic, optical, steroid, other solution), not including neurolytic substances, interlainar epidural or substanched (eg., anesthetic, antispasmodic, optical, steroid, other solution), not including neurolytic substances, interlainar epidural or substanched (eg., anesthetic, antispasmodic, optical, steroid, other solution), not including neurolytic substances, interlainar epidural or substanched (eg., anesthetic, antispasmodic, optical, steroid, other solution), not including neurolytic substances, interlainar epidural or substanched (eg., anesthetic, antispasmodic, optical, and antispasmodic, optical, antispasmodi			
infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg., anesthetic, antispasmodic, opiodi, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance  Injuction(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg., anesthetic, antispasmodic, opiodi, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (le, fluoroscopy or CT)  62350 Implantation, revision or repositioning of tunneled intrathecal or epidural catheter, for long-term medication administration via an external pump or implantable reservoirinfusion pump; without laminectomy  62351 Implantation, revision or repositioning of tunneled intrathecal or epidural catheter, for long-term medication administration via an external pump or implantable reservoirinfusion pump; with laminectomy  62365 Removal of previously implanted intrathecal or epidural catheter  62360 Implantation or replacement of device for intrathecal or epidural drug infusion; subcutaneous reservoir infusion; subcutaneous reservoir infusion; nonprogrammable pump.  62362 Implantation or replacement of device for intrathecal or epidural drug infusion; onprogrammable pump, including preparation of pump, with or without programming  62365 Removal of givenum pump previously implanted for intrathecal or epidural infusion  62366 Removal of subcutaneous reservoir or pump, previously implanted for intrathecal or epidural infusion (includes evaluation of reservoir status, alarm status, drug prescription status), with treprogramming  62367 Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status), with reprogramming of reservoir status, alarm status, drug prescription status), with reprogrammi	62325	infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid,	
infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg., anesthetic, antispasmodic, opioid, sterold, other solution), not including neurolytic substances, interlaminar epidural or substanchnoid, lumbar or sacral (caudal); with imaging guidance (ie, fluoroscopy or CT)  62350 Implantation, revision or repositioning of tunneled intrathecal or epidural catheter, for long-term medication administration via an external pump or implantable reservoir/infusion pump; without laminectomy  62351 Implantation, revision or repositioning of tunneled intrathecal or epidural catheter, for long-term medication administration via an external pump or implantable reservoir/infusion pump; without laminectomy  62355 Removal of previously implanted intrathecal or epidural catheter  62360 Implantation or replacement of device for intrathecal or epidural drug infusion; subcutaneous reservoir  62361 Implantation or replacement of device for intrathecal or epidural drug infusion; subcutaneous reservoir  62362 Implantation or replacement of device for intrathecal or epidural drug infusion, reprogrammable pump  62362 Implantation or replacement of device for intrathecal or epidural drug infusion, reprogrammable pump  62363 Removal of subcutaneous reservoir or pump, previously implanted for intrathecal or epidural infusion  62364 Electronic analysis of programmable, implanted pump for intrathecal  62367 Ceresional and prescription status), with our reprogramming  62368 Electronic analysis of programmable, implanted pump for intrathecal  62369 or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status), with reprogramming and refill  62370 Electronic analysis of programmable, implanted pump for intrathecal  62360 Or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status), with reprogramming and refill  62370 (requiring skill of a physician or other qualified health care professional	62326	infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid,	
epidural catheter, for long-term medication administration via an external pump or implantable reservoir/infusion pump; without laminectomy  Implantation, revision or repositioning of tunneled intrathecal or epidural catheter, for long-term medication administration via an external pump or implantable reservoir/infusion pump; with laminectomy  Removal of previously implanted intrathecal or epidural catheter    Commonstration   Implantation or replacement of device for intrathecal or epidural drug infusion; subcutaneous reservoir infusion; outprogrammable pump    Commonstration   Implantation or replacement of device for intrathecal or epidural drug infusion; outprogrammable pump    Commonstration   Implantation or replacement of device for intrathecal or epidural drug infusion; programmable pump    Commonstration   Implantation or replacement of device for intrathecal or epidural drug infusion; programmable pump, including preparation of pump, with or without programmable pump, including preparation of pump, with or without programmable pump, including preparation of pump, with or without programmable pump, including preparation of pump, with or without programmable pump, including preparation of pump, with or without programmable pump, including preparation of pump, with or intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with our reprogramming    Commonstration   Commonst	62327	infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (ie, fluoroscopy or	
epidural catheter, for long-term medication administration via an external pump or implantable reservoir/infusion pump;with laminectomy  62355 Removal of previously implanted intrathecal or epidural catheter  62360 Implantation or replacement of device for intrathecal or epidural drug infusion; subcutaneous reservoir  62361 Implantation or replacement of device for intrathecal or epidural drug infusion; nonprogrammable pump  62362 Implantation or replacement of device for intrathecal or epidural drug infusion; nonprogrammable pump  62363 Implantation or replacement of device for intrathecal or epidural drug infusion; programmable pump, including preparation of pump, with or without programming  62365 Removal of subcutaneous reservoir or pump, previously implanted for intrathecal or epidural infusion  62367 Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); without reprogramming  62368 Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming  62369 Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill  62370 Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill (requiring skill of a physician or other qualified health care professional  63620 Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 spinal lesion  63621 Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional spinal lesion (List separately in addition to code for primary procedure)	62350	epidural catheter, for long-term medication administration via an external pump or implantable reservoir/infusion pump; without	
lmplantation or replacement of device for intrathecal or epidural drug infusion; subcutaneous reservoir  lmplantation or replacement of device for intrathecal or epidural drug infusion; nonprogrammable pump  lmplantation or replacement of device for intrathecal or epidural drug infusion; nonprogrammable pump  lmplantation or replacement of device for intrathecal or epidural drug infusion; programmable pump, including preparation of pump, with or without programming  Removal of subcutaneous reservoir or pump, previously implanted for intrathecal or epidural infusion  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); without reprogramming  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill (requiring skill of a physician or other qualified health care professional  Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); asch additional spinal lesion (List separately in addition to code for primary procedure)	62351	epidural catheter, for long-term medication administration via an external pump or implantable reservoir/infusion pump; with	
infusion; subcutaneous reservoir  62361 Implantation or replacement of device for intrathecal or epidural drug infusion; nonprogrammable pump  62362 Implantation or replacement of device for intrathecal or epidural drug infusion; programmable pump, including preparation of pump, with or without programming  62365 Removal of subcutaneous reservoir or pump, previously implanted for intrathecal or epidural infusion  62367 Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); without reprogramming  62368 Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming  62369 Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill  62370 Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill (requiring skill of a physician or other qualified health care professional  63620 Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 spinal lesion  63621 Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional spinal lesion (List separately in addition to code for primary procedure)	62355	Removal of previously implanted intrathecal or epidural catheter	
infusion; nonprogrammable pump  102362 Implantation or replacement of device for intrathecal or epidural drug infusion; programmable pump, including preparation of pump, with or without programming  102365 Removal of subcutaneous reservoir or pump, previously implanted for intrathecal or epidural infusion  102367 Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); without reprogramming  102368 Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming  102369 Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill  102370 Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill (requiring skill of a physician or other qualified health care professional  103620 Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional spinal lesion (List separately in addition to code for primary procedure)	62360		
implantation or replacement of device for intrathecal or epidural drug infusion; programmable pump, including preparation of pump, with or without programming  Removal of subcutaneous reservoir or pump, previously implanted for intrathecal or epidural infusion  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); without reprogramming  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill (requiring skill of a physician or other qualified health care professional  Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 spinal lesion  Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional spinal lesion (List separately in addition to code for primary procedure)	62361		
intrathecal or epidural infusion  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); without reprogramming  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill (requiring skill of a physician or other qualified health care professional  Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 spinal lesion  Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional spinal lesion (List separately in addition to code for primary procedure)	62362	Implantation or replacement of device for intrathecal or epidural drug infusion; programmable pump, including preparation of pump, with or	
Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); without reprogramming  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill (requiring skill of a physician or other qualified health care professional  Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 spinal lesion  Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional spinal lesion (List separately in addition to code for primary procedure)	62365		
or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill (requiring skill of a physician or other qualified health care professional  Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 spinal lesion  Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional spinal lesion (List separately in addition to code for primary procedure)	62367	Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm	
or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill  Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill (requiring skill of a physician or other qualified health care professional  Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 spinal lesion  Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional spinal lesion (List separately in addition to code for primary procedure)	62368	or epidural drug infusion (includes evaluation of reservoir status, alarm	
or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill (requiring skill of a physician or other qualified health care professional  Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 spinal lesion  Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional spinal lesion (List separately in addition to code for primary procedure)	62369	or epidural drug infusion (includes evaluation of reservoir status, alarm	
accelerator); 1 spinal lesion  Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional spinal lesion (List separately in addition to code for primary procedure)	62370	or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill	
accelerator); each additional spinal lesion (List separately in addition to code for primary procedure)	63620		
Percutaneous implantation of neurostimulator electrode array, epidural	63621	accelerator); each additional spinal lesion (List separately in addition	
	63650	Percutaneous implantation of neurostimulator electrode array, epidural	

63655	Laminectomy for implantation of neurostimulator electrodes,	
	plate/paddle, epidural	
63661	Removal of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed	
63662	Removal of spinal neurostimulator electrode plate/paddle(s) placed via	
	laminotomy or laminectomy, including fluoroscopy, when performed	
63663	Revision including replacement, when performed, of spinal	
	neurostimulator electrode percutaneous array(s), including	
	fluoroscopy, when performed	
63664	Revision including replacement, when performed, of spinal	
	neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed	
	laminectomy, including huoroscopy, when performed	
63685	Insertion or replacement of spinal neurostimulator pulse generator or	
	receiver, direct or inductive coupling	
63688	Revision or removal of implanted spinal neurostimulator pulse	
	generator or receiver	
64451	Injection(s), anesthetic agent(s) and/or steroid; nerves innervating the	
	sacroiliac joint, with image guidance (ie, fluoroscopy or computed	
64454	tomography)	
64454	Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed	
64479	Injection, anesthetic agent and/or steroid, transforaminal epidural;	
	cervical or thoracic, single level	
64480	Injection, anesthetic agent and/or steroid, transforaminal	
	epidural;cervical or thoracic, each additional level (List separately in	
	addition to code for primary procedure)	
64483	Injection, anesthetic agent and/or steroid, transforaminal epidural;lumbar or sacral, single level	
64484	Injection, anesthetic agent and/or steroid, transforaminal	
	epidural;lumbar or sacral, each additional level (List separately in	
	addition to code for primary procedure)	
64490	Injection(s), diagnostic or therapeutic agent, paravertebral facet	
	(zygapophyseal) joint (Ir nerves innervating that joint) with image	
	guidance (fluoroscopy or CT), cervical or thoracic; single level	
64491	Injection(s), diagnostic or therapeutic agent, paravertebral facet	
	(zygapophyseal) joint (or nerves innervating that joint) with image	
	guidance (fluoroscopy or CT), cervical or thoracic; second level (List	
	separately in addition to code for primary procedure)	
64492	Injection/a) diagnostic or therepoutic agent persuartehral foot	
04492	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image	
	guidance (fluoroscopy or CT), cervical or thoracic; third and any	
	additional level(s) (List separately in addition to code for primary	
	procedure)	
64493	Injection(s), diagnostic or therapeutic agent, paravertebral facet	
	(zygapophyseal) joint (or nerves innervating that joint) with image	
	guidance (fluoroscopy or CT), lumbar or sacral; single level	
64494	Injection(s), diagnostic or therapeutic agent, paravertebral facet	
34434	(zygapophyseal) joint (or nerves innervating that joint) with image	
	guidance (fluoroscopy or CT), lumbar or sacral; second level (List	
	separately in addition to code for primary procedure)	
64495	Injection(s), diagnostic or therapeutic agent, paravertebral facet	
	(zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; third and any	
	additional level(s) (List separately in addition to code for primary	
	procedure)	
L		

0.4540	Internet and the Comment of the Comm	Г
64510	Injection, anesthetic agent;stellate ganglion (cervical sympathetic)	
64520	Injection, anesthetic agent;lumbar or thoracic (paravertebral sympathetic)	
64553	Percutaneous implantation of neurostimulator electrodes, cranial nerve	
64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)	
64561	Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) including image guidance, if performed	
64565	Percutaneous implantation of neurostimulator electrodes; neuromuscular	
64566	Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming	
64568	Incision for implantation cranial nerve	
64569	Revision or replacement of cranial nerve (eg, vagus nerve) neurostimulator electrode array, including connection to existing pulse generator	
64575	Incision for implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)	
64581	Incision for implantation of neurostimulator electrode array; sacral nerve (transforaminal placement)	
64590	Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling	
64611	Chemodenervation of parotid and submandibular salivary glands, bilateral	
64612	Chemodenervation of muscle(s); muscle(s) innervated by facial nerve (e.g., for blepharospasm, hemifacial spasm)	
64615	Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)	
64620	Destruction by neurolytic agent, intercostal nerve	
64624	Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed	
64625	Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance (ie, fluoroscopy or computed tomography)	
64633	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, single facet joint	
64634	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, each additional facet joint (List separately in addition to code for primary procedure)	
64635	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, single facet joint	
64636	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, each additional facet joint (List separately in addition to code for primary procedure)	
64704	Neuroplasty, nerve of hand or foot	
64708	Neuroplasty,major peripheral nerve, arm or leg	
64712	Neuroplasty, sciatic nerve	
64722	Decompression; unspecified nerve	
65093	Evisceration of eye with implant	
65103	Enucleation w/implant muscle not attached to implant	
65105	Enucleation of eye w/implant, muscle attached to eye	
65125	Modification, ocular implant (separate procedure)	
65130	Evisceration, eye implantation in scleral shell	

65135	After enucleation, muscles not attahced to implant	
65140	After enucleation, muscles attached to implant	
65150	Reinsertion/ocular implant w/wo conjunctival graft	
65155	With use of foreign material for reinforcement and/or attachment of	
00100	muscles to implant	
65175	Removal ocular implant	
65710	Keratoplasty	
65760	Keratomileusis	
65765	Keratophakia	
65767	Epikeratoplasty	
65771	Radial keratotomy	
65772	Corneal relaxing incision for correction of surgically induced astigmatism	
65782	Ocular surface reconstruction, limbal conjunctival autograft	
65785	Implantation of instromal corneal ring segments	
67121	Remove eye implant material	
67221	Destruction of localized lesion of choroid	
67225	Destruction of localized lesion of choroid	
67900	Repair of brow ptosis (supraciliary, mid-forehead or coronal approach)	
67901	Repair of blepharoptosis; frontalis muscle technique with suture or other material	
67902	Repair of blepharoptosis; frontalis muscle technique with fascial sling (includes obtaining fascia)	
67903	Repair of blepharoptosis; (tarso) levator resection or advancement, internal approach	
67904	Repair of blepharoptosis; (tarso) Levator resection or advancement, external approach	
67906	Repair of blepharoptosis; superior rectus technique with fascial sling (includes obtaining fascia)	
67908	Repair of blepharoptosis; conjunctivo-tarso-Muller's muscle-levator resection (e.g., Fasanella-Servat type)	
67909	Reduction of overcorrection of ptosis	
67911	Correction of lid retraction	
69090	Ear piercing	
69209	Remove impacted cerumen, unilateral	
69300	Otoplasty, protruding ear, with or without size reduction	
69714	Implantation, osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; without mastoidectomy	
69715	Implantation, osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; with mastoidectomy	
69717	Replacement (including removal of existing device), osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; without mastoidectomy	
69718	Replacement (including removal of existing device), osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; with mastoidectomy	
69930	Cochlear device implantation, with or without mastoidectomy	
74261	Ct colonography, w/o dye	
74262	Ct colonography, w/dye	
74263	Computed tomographic (CT) colonography, screening, including	
	image postprocessing	
74712	Magnetic resonance (eg, proton) imaging, fetal, including placental and maternal pelvic imaging when performed; single or first gestation	

74713	Magnetic resonance (eg, proton) imaging, fetal, including placental	
	and maternal pelvic imaging when performed; each additional	
	gestation (List separately in addition to code for primary procedure)	
	gostation (Elst separatory in addition to oode for primary procedure)	
74742	Transcervical catheterization of fallopian tube, radiological supervision	
	and interpretation	
75571	Computed tomography, heart, without contrast material, with	
	quantitative evaluation of coronary calcium	
75050	•	
75958	Placement of proximal extension prosthesis for endovascular repair of	
	descending thoracic aorta	
76977	Ultrasound bone density measurement	
77061	Digital breast tomosynthesis; unilateral	
77062	Digital breast tomosynthesis; bilateral	
	· ·	
77063	Screening digital breast tomosynthesis, bilateral (List sep- arately in	
	addition to code for primary procedure)	
77071	Manual application of stress performed by physician for joint	
	radiography, including contralateral joint if indicated	
77301	IMRT Planning	
77305	Teletherapy isodose plan simple	
77306	Teletherapy isodose plan; simple (1 or 2 unmodified ports directed to	
	a single area of interest), includes basic dosimetry calculation(s)	
77307	Teletherapy isodose plan; complex (multiple treatment areas,	
17307		
	tangential ports, the use of wedges, blocking, rotational beam, or	
	special beam considerations), includes basic dosimetry calculation(s)	
77310	Teletherapy isodose plan; intermediate	
77315		
	Teletherapy Isodose plan; complex	
77316	Brachytherapy isodose plan; simple (calculation[s] made from 1 to 4	
	sources, or remote afterloading brachytherapy, 1 channel), includes	
	basic dosimetry calculation(s)	
77317	Brachytherapy isodose plan; intermediate (calculation[s] made from 5	
1	to 10 sources, or remote afterloading brachytherapy, 2-12 channels),	
	includes basic dosimetry calculation(s)	
77318	Brachytherapy isodose plan; complex (calculation[s] made from over	
	10 sources, or remote afterloading brachytherapy, over 12 channels),	
	includes basic dosimetry calculation(s)	
77321	Special Teletherapy port plan, particles, hemibody, total body	
77326		
11326	Brachytherapy isodose plan; simple (calculation made from single	
	plane, one to four sources/ribbon application, remote afterloading	
	brachytherapy, 1 to 8 sources)	
77327	Brachytherapy isodose plan; intermediate (multiplane dosage	
	calculations, application involving 5 to 10 sources/ribbons, remote	
	afterloading brachytherapy, 9 to 12 sources)	
77328	Brachytherapy isodose plan; complex (multiplane isodose plan,	
	volume implant calculations, over 10 sources/ribbons used, special	
1	spatial reconstruction, remote afterloading brachytherapy, over 12	
	sources)	
77004	,	
77331	Special radiation dosimetry	
77332	Treatment Devices; simple	
77333	Treatment Devices; intermediate	
77334	Treatment Devices; complex	
77336	Continuing medical physics consultation	
77338		
11338	Multi-leaf collimator (MLC) device(s) for IMRT, design and	
	construction per IMRT plan	
77370	Special medical physics consultation	
77385	Intensity modulated radiation treatment delivery (IMRT), includes	
	guidance and tracking, when performed; simple	
77200		
77386	Intensity modulated radiation treatment delivery (IMRT), includes	
	guidance and tracking, when performed; complex	
· · · · · · · · · · · · · · · · · · ·		

77387	Guidance for localization of target volume for delivery of radiation	
	treatment delivery, includes intrafraction tracking, when performed	
77399	Unlisted procedure, medical radiation physics	
77401	Radiation treatment delivery; superficial and/or ortho voltage	
77402	Radiation treatment delivery; single treatment area, single port or parallel opposed ports, simple blocks or no blocks up to 5 MeV	
77403	Radiation treatment delivery; single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 11-19 MeV	
77404	Radiation treatment delivery; single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 6-10 MeV	
77406	Radiation treatment delivery; single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 20 MeV and greater	
77407	Radiation treatment delivery; two separate treatment areas, three or more ports on a single treatment area use of multiple blocks; up to 5 MeV	
77408	Radiation treatment delivery; two separate treatment areas, three or more ports on a single treatment area use of multiple blocks; 6-10 MeV	
77409	Radiation treatment delivery; two separate treatment areas, three or more ports on a single treatment area use of multiple blocks; 11 - 19 MeV	
77411	Radiation treatment delivery; two separate treatment areas, three or more ports on a single treatment area use of multiple blocks; 20 MeV or greater	
77412	Radiation treatment delivery; three or more separate treatment areas; custom blocking, tangential ports wedges, rotational beam, compensators, electron beam; up to 5 MeV	
77413	Radiation treatment delivery; three or more separate treatment areas; custom blocking, tangential ports wedges, rotational beam, compensators, electron beam; 6-10 MV Complex	
77414	Radiation treatment delivery; three or more separate treatment areas; custom blocking, tangential ports wedges, rotational beam, compensators, electron beam; 11-19 MV Complex	
77416	Radiation treatment delivery; three or more separate treatment areas; custom blocking, tangential ports wedges, rotational beam, compensators, electron beam; 20 MV or greater	
77417	Therapeutic Radiology Port Films	
77418	IMRT Treatment Delivery; single or multiple fields/arcs, via narrow spatially and temporarily modulated beams, binary, dynamic MLC, per treatment session	
77421	Stereoscopic x-ray guidance for localization of target volume	
77422	High energy neutron radiation treatment delivery; single treatment area using a single port or parallel-opposed ports with no blocks or simple blocking	
77423	High energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-coplanar geometry with blocking and/or wedge, and/or compensator(s)	
77424	Intraoperative radiation treatment delivery, x-ray, single treatment session	
77425	Intraoperative radiation treatment delivery, electrons, single treatment session	
77427	Radiation treatment management, five treatments	
77431	Radiation treatment management, with complete course of therapy consisting of 1 -2 fractions	
77469	Intraoperative radiation treatment management	
		-

77470	Special treatment procedure (eg, total body irradiation, hemibody	
	radiation, per oral or endocavitary irradiation) Updated description	
	(January 2012)	
77.400	· · · · · · · · · · · · · · · · · · ·	
77499	Unlisted procedure, therapeutic radiology treatment management	
77371	Stereotactic radiosurgery treatment delivery, complete course of	
	treatment of cerebral lesion(s) 1 session, multi-source Cobalt 60	
	based	
77372	Stereotactic radiosurgery treatment delivery, complete course of	
	treatment of cerebral lesion(s) 1 session, linac based	
77373	Stereotactic body radiation therapy, treatment delivery, per fraction to	
1,1010	1	
	1 or more lesions, including image guidance, entire course not to	
	exceed 5 fractions	
77432	Stereotactic radiation treatment management cerebral lesion(s)	
	complete course of treatment consisting of 1 session	
	osmplete source of treatment consisting of 1 seconds	
77435	Stereotactic body radiation therapy, treatment management, per	
	treatment course, to one or more lesions, including image guidance,	
	entire course not to exceed 5 fractions	
77520	Proton treatment delivery: simple, without compensation	
	Proton treatment delivery; simple, without compensation	
77522	Proton treatment delivery; simple, with compensation	
77523	Proton treatment delivery; intermediate	
77525	Proton treatment delivery; complex	
77600	Hyperthermia	
77605	Hyperthermia	
77610	Hyperthermia	
77615	Hyperthermia	
77620	Hyperthermia	
	71	
77750	Infusion or instillation of radioelement solution (includes 3-month	
	follow-up care)	
77761	Intracavitary radiation source application; simple	
77762	Intracavitary radiation source application; intermediate	
77763		
-	Intracavitary radiation source application; complex	
77767	Remote afterloading high dose rate radionuclide skin surface	
	brachytherapy, includes basic dosimetry, when performed; lesion	
	diameter up to 2.0 cm or 1 channel	
77768	Remote afterloading high dose rate radionuclide skin surface	
77700		
	brachytherapy, includes basic dosimetry, when performed; lesion	
	diameter over 2.0 cm and 2 or more channels, or multiple lesions	
77770	Remote afterloading high dose rate radionuclide interstitial or	
1,,,,,		
	intracavitary brachytherapy, includes basic dosimetry, when	
	performed; 1 channel	
77771	Remote afterloading high dose rate radionuclide interstitial or	
	intracavitary brachytherapy, includes basic dosimetry, when	
1	performed; 2-12 channels	
77772	Remote afterloading high dose rate radionuclide interstitial or	
I	intracavitary brachytherapy, includes basic dosimetry, when	
I	performed; over 12 channels	
77776	,	
	Interstitial radiation source application; simple	
77777	Interstitial radiation source application; intermediate	
77778	Interstitial radiation source application; complex	
77785	Remote afterloading high dose rate radionuclide brachytherapy; 1	
1	channel	
77700		<del> </del>
77786	Remote afterloading high dose rate radionuclide brachytherapy; 2-12	
	channels	
77787	Remote afterloading high dose rate radionuclide brachytherapy; over	
1	12 channels	
77700		+
77789	Apply surface radiation	
77790	Radio Isotope Supervision, Handling, Loading	
77799	Unlisted procedure, clinical brachytherapy	
		·

Mycocardial imaging, positron emission tomography (PET), metabolic evaluation study (including ventricular wall motions) and/ore ejection fractions[s], when performed), single study, with concurrently acquired computed tomography transmission scan  78430 Mycocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); single study, at rest or stress (excise or pharmacologic), with concurrently acquired computed tomography transmission scan  78431 Mycocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); multiple studies at rest and stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan  78432 Mycocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg. mycocardial viabilities)  78433 Mycocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg. mycocardial viability) with concurrently acquired computed tomography transmission scan  78434 Absolute quantitation of mycocardial blood flow (AQMBF), positron emission tomography (PET), rest and pharmacologic stress (List separately in addition to code for primary procedure)  78459 Mycocardial imaging, positron emission tomography (PET), metabolic evaluation  78469 Mycocardial imaging, positron emission tomography (PET), perfusion, multiple studies at rest and/or stress  78570 Brain imaging, positron emission tomography (PET), metabolic evaluation  78581 Positron emission tomography (PET) imaging; limited area (eg. chest, head-neck)  78581 Positron emission tomography (PET) imaging; limited area (eg. chest, head-neck)  78681 Positron emi			
study (including ventricular wall motion[s] and/or ejection fraction[s], when performed; single study, at rest or stress (sercise or pharmacologic), with concurrently acquired computed tomography transmission scan  78431 Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed; multiple studies at rest and stress (sercise or pharmacologic), with concurrently acquired computed tomography transmission scan  78432 Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg., myocardial wiability)  78433 Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg., myocardial viability); with concurrently acquired computed tomography transmission scan  78434 Absolute quantitation of myocardial blood flow (AOMBF), positron emission tomography (PET), rest and pharmacologic stress (List separately in addition to code for primary procedure)  78459 Myocardial imaging, positron emission tomography (PET), metabolic evaluation  78491 Myocardial imaging, positron emission tomography (PET), perfusion; single study at rest or stress  78402 Myocardial imaging, positron emission tomography (PET), perfusion; multiple studies at rest and/or stress  78608 Brain imaging, positron emission tomography (PET); metabolic evaluation  78609 Brain imaging, positron emission tomography (PET); metabolic evaluation  78609 Brain imaging, positron emission tomography (PET); metabolic evaluation  78811 Positron emission tomography (PET) imaging; ilmited area (eg., chest, head/neck)  78812 Positron emission tomography (PET) imaging; ilmited area (eg., chest, head/neck)  78813 Positron emission tomography (PET) imaging; skull base to mid-thigh  78814 Pos	78429	evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), single study; with concurrently acquired	
study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); multiple studies at rest and stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan  78432 Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg, myocardial viability)  78433 Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg, myocardial viability); with concurrently acquired computed tomography transmission scan  78434 Absolute quantitation of myocardial blood flow (ACMBF), positron emission tomography (PET), rest and pharmacologic stress (List separately in addition to code for primary procedure)  78459 Myocardial imaging, positron emission tomography (PET), metabolic evaluation  78491 Myocardial imaging, positron emission tomography (PET), perfusion; single study at rest or stress  78492 Myocardial imaging, positron emission tomography (PET), perfusion; multiple studies at rest and/or stress  78608 Brain imaging, positron emission tomography (PET), metabolic evaluation  78609 Brain imaging, positron emission tomography (PET); metabolic evaluation  78801 Injection procedure for radiopharmaceutical localization by non-imaging probe study, intravenous (e.g., parathyroid adenoma)  78811 Positron emission tomography (PET) imaging; limited area (eg, chest, head/neck)  78812 Positron emission tomography (PET) imaging; skull base to mid-thigh  78813 Positron emission tomography (PET) imaging; skull base to mid-thigh  78814 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh	78430	study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); single study, at rest or stress (exercise or pharmacologic), with concurrently acquired computed tomography	
perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg., myocardial viability)  Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg., myocardial viability); with concurrently acquired computed tomography transmission scan  Absolute quantitation of myocardial blood flow (AQMBF), positron emission tomography (PET), rest and pharmacologic stress (List separately in addition to code for primary procedure)  Myocardial imaging, positron emission tomography (PET), metabolic evaluation  Myocardial imaging, positron emission tomography (PET), perfusion; single study at rest or stress  Myocardial imaging, positron emission tomography (PET), perfusion; multiple studies at rest and/or stress  Brain imaging, positron emission tomography (PET), metabolic evaluation  Reform the procedure for radiopharmaceutical localization by non-imaging probe study, intravenous (e.g., parathyroid adenoma)  Injection procedure for radiopharmaceutical localization by non-imaging probe study, intravenous (e.g., parathyroid adenoma)  Positron emission tomography (PET) imaging; limited area (eg, chest, head/neck)  Positron emission tomography (PET) imaging; skull base to mid-thigh  Positron emission tomography (PET) imaging; whole body  Positron emission tomography (PET) imaging; whole body  Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh  Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh  Positron emission tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acquired computed tomography (PET) with concurrently acqui	78431	study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); multiple studies at rest and stress (exercise or pharmacologic), with concurrently acquired computed tomography	
perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg., myocardial viability); with concurrently acquired computed tomography transmission scan  78434 Absolute quantitation of myocardial blood flow (AQMBF), positron emission tomography (PET), rest and pharmacologic stress (List separately in addition to code for primary procedure)  78459 Myocardial imaging, positron emission tomography (PET), metabolic evaluation  78491 Myocardial imaging, positron emission tomography (PET), perfusion; single study at rest or stress  78492 Myocardial imaging, positron emission tomography (PET), perfusion; multiple studies at rest and/or stress  78608 Brain imaging, positron emission tomography (PET); metabolic evaluation  78609 Brain imaging, positron emission tomography (PET); perfusion evaluation  78808 Injection procedure for radiopharmaceutical localization by non-imaging probe study, intravenous (e.g., parathyroid adenoma)  78811 Positron emission tomography (PET) imaging; limited area (eg., chest, head/neck)  78812 Positron emission tomography (PET) imaging; whole body  Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; limited area (eg., chest, head/neck)  Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh  Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh	78432	perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer	
emission tomography (PET), rest and pharmacologic stress (List separately in addition to code for primary procedure)  78459 Myocardial imaging, positron emission tomography (PET), metabolic evaluation  78491 Myocardial imaging, positron emission tomography (PET), perfusion; single study at rest or stress  78492 Myocardial imaging, positron emission tomography (PET), perfusion; multiple studies at rest and/or stress  78608 Brain imaging, positron emission tomography (PET); metabolic evaluation  78609 Brain imaging, positron emission tomography (PET); perfusion evaluation  78808 Injection procedure for radiopharmaceutical localization by non-imaging probe study, intravenous (e.g., parathyroid adenoma)  78811 Positron emission tomography (PET) imaging; limited area (eg, chest, head/neck)  78812 Positron emission tomography (PET) imaging; skull base to mid-thigh  78813 Positron emission tomography (PET) imaging; whole body  78814 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; ilmited area (eg, chest, head/neck)  78815 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh  78816 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh	78433	perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg, myocardial viability); with concurrently acquired computed	
evaluation	78434	emission tomography (PET), rest and pharmacologic stress (List	
single study at rest or stress  78492 Myocardial imaging, positron emission tomography (PET), perfusion; multiple studies at rest and/or stress  8 Brain imaging, positron emission tomography (PET); metabolic evaluation  78609 Brain imaging, positron emission tomography (PET); perfusion evaluation  78808 Injection procedure for radiopharmaceutical localization by non-imaging probe study, intravenous (e.g., parathyroid adenoma)  78811 Positron emission tomography (PET) imaging; limited area (eg, chest, head/neck)  78812 Positron emission tomography (PET) imaging; skull base to mid-thigh  78813 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; limited area (eg, chest, head/neck)  78815 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh  78816 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh	78459		
multiple studies at rest and/or stress  78608 Brain imaging, positron emission tomography (PET); metabolic evaluation  78609 Brain imaging, positron emission tomography (PET); perfusion evaluation  78808 Injection procedure for radiopharmaceutical localization by non-imaging probe study, intravenous (e.g., parathyroid adenoma)  78811 Positron emission tomography (PET) imaging; limited area (eg, chest, head/neck)  78812 Positron emission tomography (PET) imaging; skull base to mid-thigh  78813 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; limited area (eg, chest, head/neck)  78815 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh  78816 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh	78491		
evaluation  Brain imaging, positron emission tomography (PET); perfusion evaluation  R808 Injection procedure for radiopharmaceutical localization by non-imaging probe study, intravenous (e.g., parathyroid adenoma)  Positron emission tomography (PET) imaging; limited area (eg, chest, head/neck)  Positron emission tomography (PET) imaging; skull base to mid-thigh  Positron emission tomography (PET) imaging; whole body  Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; limited area (eg, chest, head/neck)  Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh  Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh	78492		
evaluation  78808 Injection procedure for radiopharmaceutical localization by non-imaging probe study, intravenous (e.g., parathyroid adenoma)  78811 Positron emission tomography (PET) imaging; limited area (eg, chest, head/neck)  78812 Positron emission tomography (PET) imaging; skull base to mid-thigh  78813 Positron emission tomography (PET) imaging; whole body  78814 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; limited area (eg, chest, head/neck)  78815 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh  78816 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical	78608		
imaging probe study, intravenous (e.g., parathyroid adenoma)  78811 Positron emission tomography (PET) imaging; limited area (eg, chest, head/neck)  78812 Positron emission tomography (PET) imaging; skull base to mid-thigh  78813 Positron emission tomography (PET) imaging; whole body  78814 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; limited area (eg, chest, head/neck)  78815 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh  78816 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical	78609		
head/neck)  78812 Positron emission tomography (PET) imaging; skull base to mid-thigh  78813 Positron emission tomography (PET) imaging; whole body  78814 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; limited area (eg, chest, head/neck)  78815 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh  78816 Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical	78808		
Positron emission tomography (PET) imaging; skull base to mid-thigh  Positron emission tomography (PET) imaging; whole body  Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; limited area (eg, chest, head/neck)  Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh  Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical computed tomography (CT) for attenuation correction and anatomical	78811		
Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; limited area (eg, chest, head/neck)  Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh  Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical	78812	·	
Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; limited area (eg, chest, head/neck)  Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh  Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical	78813	Positron emission tomography (PET) imaging; whole body	
computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh  Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical	78814	Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical	
computed tomography (CT) for attenuation correction and anatomical	78815	computed tomography (CT) for attenuation correction and anatomical	
		computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body	
81161 DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy) deletion analysis, and duplication analysis, if performed	81161		

81162	BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and	
002	ovarian cancer) gene analysis; full sequence analysis and full	
	duplication/deletion analysis	
81163	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA	
	repair associated) (eg, hereditary breast and ovarian cancer) gene	
	analysis; full sequence analysis	
81164	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA	
	repair associated) (eg, hereditary breast and ovarian cancer) gene	
	analysis; full duplication/deletion analysis (ie, detection of large gene	
	rearrangements)	
81165	BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and	
	ovarian cancer) gene analysis; full sequence analysis	
81166	BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and	
	ovarian cancer) gene analysis; full duplication/deletion analysis (ie,	
	detection of large gene rearrangements)	
81167	BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and	
01107	ovarian cancer) gene analysis; full duplication/deletion analysis (ie,	
	detection of large gene rearrangements)	
	dotooner of large gone realizangements)	
81170	ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg,	
	acquired imatinib tyrosine kinase inhibitor resistance), gene analysis,	
	variants in the kinase domain	
81171	AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental	
	retardation 2 [FRAXE]) gene analysis; evaluation to detect abnormal	
	(eg, expanded) alleles	
81172	AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental	
	retardation 2 [FRAXE]) gene analysis; characterization of alleles (eg,	
	expanded size and methylation status)	
81173	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy,	
	Kennedy disease, X chromosome inactivation) gene analysis; full	
	gene sequence	
81174	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy,	
	Kennedy disease, X chromosome inactivation) gene analysis; known	
04477	familial variant  ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene	
81177	analysis, evaluation to detect abnormal (eg, expanded) alleles	
	analysis, evaluation to detect abhornial (eg, expanded) alleles	
81178	ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis,	
01110	evaluation to detect abnormal (eg, expanded) alleles	
81179	ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis,	
	evaluation to detect abnormal (eg, expanded) alleles	
81180	ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph	
	disease) gene analysis, evaluation to detect abnormal (eg, expanded)	
	alleles	
81181	ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis,	
	evaluation to detect abnormal (eg, expanded) alleles	
81182	ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg,	
	spinocerebellar ataxia) gene analysis, evaluation to detect abnormal	
	(eg, expanded) alleles	
81183	ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis,	
04404	evaluation to detect abnormal (eg, expanded) alleles	
81184	CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg,	
	spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles	
81185	CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg,	
01100	spinocerebellar ataxia) gene analysis; full gene sequence	
81186	CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg,	
3.100	spinocerebellar ataxia) gene analysis; known familial variant	
	, , , , , , , , , , , , , , , , , , ,	

2112=	Tours (course to the state of t	T
81187	CNBP (CCHC-type zinc finger nucleic acid binding protein) (eg,	
	myotonic dystrophy type 2) gene analysis, evaluation to detect	
	abnormal (eg, expanded) alleles	
81188	CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis;	
	evaluation to detect abnormal (eg, expanded) alleles	
81189	CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis;	
	full gene sequence	
81190	CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis;	
	known familial variant(s)	
81201	APC (adenomatous polyposis coli) (eg, familial adenomatosis	
	polyposis [FAP], attenuated FAP) gene analysis; full gene sequence	
81202	APC (adenomatous polyposis coli) (eg, familial adenomatosis	
	polyposis [FAP], attenuated FAP) gene analysis; known familial	
	variants	
81203	APC (adenomatous polyposis coli) (eg, familial adenomatosis	
	polyposis [FAP], attenuated FAP) gene analysis; duplication/deletion	
	variants	
81204	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy,	
01201	Kennedy disease, X chromosome inactivation) gene analysis;	
	characterization of alleles (eg, expanded size or methylation status)	
	onaration and or another (egg, expanded elected in month database)	
81215	BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer)	<del> </del>
01215		
04040	gene analysis; known familial variant	
81216	BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer)	
	gene analysis; full sequence analysis	
81217	BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer)	
	gene analysis; known familial variant	
81219	CALR (calreticulin) (eg, myeloproliferative disorders), gene analysis,	
	common variants in exon 9	
81223	CFTR (cystic fibrosis transmembrane conductance regulator) (eg,	
	cystic fibrosis) gene analysis; full gene sequence	
81226	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg,	
	drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5,	
	*6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN)	
81228	Cytogenomic constitutional (genome-wide) microarray analysis;	
	interrogation of genomic regions for copy number variants (eg,	
	Bacterial Artificial Chromosome [BAC] or oligo-based comparative	
	genomic hybridization [CGH] microarray analysis)	
81229	Cytogenomic constitutional (genome-wide) microarray analysis;	
	interrogation of genomic regions for copy number and single	
	nucleotide polymorphism (SNP) variants for chromosomal	
	abnormalities	
81233	BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia)	
01200	gene analysis, common variants (eg, C481S, C481R, C481F)	
	gone analysis, common variants (eg. 04013, 04017, 04017)	
04004	DMDK (DM4 protein kingge) (og protein discharge) time 4)	
81234	DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene	
	analysis; evaluation to detect abnormal (expanded) alleles	
0.10		
81235	EGFR (epidermal growth factor receptor) (eg, non-small cell lung	
	cancer) gene analysis, common variants (eg, exon 19 LREA deletion,	
	L858R, T790M, G719A, G719S, L861Q)	
81236	EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit)	
	(eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene	
	analysis, full gene sequence	
81237	EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit)	
	(eg, diffuse large B-cell lymphoma) gene analysis, common variant(s)	
	(eg, codon 646)	
81239	DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene	
	analysis; characterization of alleles (eg, expanded size)	
	, , , , , , , , , , , , , , , , , , , ,	

81240	F2 (prothrombin, coagulation factor II) (eg, hereditary	
010/1	hypercoagulability) gene analysis, 20210G>A variant	
81241	F5 (coagulation Factor V) (eg, hereditary hypercoagulability) gene analysis, Leiden variant	
81243	FMR1 (Fragile X mental retardation 1) (eg, fragile X mental	
	retardation) gene analysis; evaluation to detect abnormal (eg,	
	expanded) alleles	
81244	FMR1 (Fragile X mental retardation 1) (eg, fragile X mental	
	retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)	
81246	FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia),	
	gene analysis; tyrosine kinase domain (TKD) variants (eg, D835, I836)	
81252	GJB2 (gap junction protein, beta 2, 26kDa; connexin 26) (eg,	
	nonsyndromic hearing loss) gene analysis; full gene sequence	
81253	GJB2 (gap junction protein, beta 2, 26kDa; connexin 26) (eg,	
0.1200	nonsyndromic hearing loss) gene analysis; known familial variants	
81254	GJB6 (gap junction protein, beta 6, 30kDa, connexin 30) (eg,	
	nonsyndromic hearing loss) gene analysis, common variants (eg, 309kb [del(GJB6-D13S1830)] and 232kb [del(GJB6-D13S1854)])	
	309KD [dei(G3D0-D1331630)] and 232KD [dei(G3D0-D1331634)])	
81271	HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to	
	detect abnormal (eg, expanded) alleles	
81274	HTT (huntingtin) (eg, Huntington disease) gene analysis; characterization of alleles (eg, expanded size)	
81277	Cytogenomic neoplasia (genome-wide) microarray analysis,	
	interrogation of genomic regions for copy number and loss-of-	
81280	heterozygosity variants for chromosomal abnormalities	
01200	Long QT syndrome gene analyses (eg, KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1,	
	and ANK2); full sequence analysis	
81281	Long QT syndrome gene analyses (eg, KCNQ1, KCNH2, SCN5A,	
	KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1,	
81282	and ANK2); known familial sequence variant  Long QT syndrome gene analyses (eg, KCNQ1, KCNH2, SCN5A,	
01202	KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1,	
	and ANK2); duplication/deletion variants	
81284	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to	
2122=	detect abnormal (expanded) alleles	
81285	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; characterization of alleles (eg, expanded size)	
81286	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene	
0.406=	sequence	
81287 81288	Mgmt methylation analysis  MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg,	
01200	hereditary non-polyposis colorectal cancer, Lynch syndrome) gene	
	analysis; promoter methylation analysis	
81289	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; known familial	
04635	variant(s)	
81292	MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene	
	analysis; full sequence analysis	
81293	MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg,	
	hereditary non-polyposis colorectal cancer, Lynch syndrome) gene	
	analysis; known familial variants	
81294	MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg,	
	hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants	
<u> </u>	a	

81295	MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene	
	analysis; full sequence analysis	
81296	MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg,	
	hereditary non-polyposis colorectal cancer, Lynch syndrome) gene	
04007	analysis; known familial variants	
81297	MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene	
	analysis; duplication/deletion variants	
81298	MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis	
	colorectal cancer, Lynch syndrome) gene analysis; full sequence	
	analysis	
81299	MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis	
	colorectal cancer, Lynch syndrome) gene analysis; known familial	
01200	variants	
81300	MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis;	
	duplication/deletion variants	
81301	Microsatellite instability analysis (eg, hereditary nonpolyposis	
	colorectal cancer, Lynch syndrome) of markers for mismatch repair	
	deficiency (eg, BAT25, BAT26), includes comparison of neoplastic	
	and normal tissue, if performed	
81302	MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; full sequence analysis	
81304	MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene	
	analysis; duplication/deletion variants	
81305	MYD88 (myeloid differentiation primary response 88) (eg,	
	Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia)	
	gene analysis, p.Leu265Pro (L265P) variant	
81306	NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *3, *4, *5, *6)	
81307	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic	
	cancer) gene analysis; full gene sequence	
81308	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; known familial variant	
81309	PIK3CA (phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic	
	subunit alpha) (eg, colorectal and breast cancer) gene analysis,	
	targeted sequence analysis (eg, exons 7, 9, 20)	
04040	DADDWA ( 1 fall) F	
81312	PABPN1 (poly[A] binding protein nuclear 1) (eg, oculopharyngeal muscular dystrophy) gene analysis, evaluation to detect abnormal (eg,	
	expanded) alleles	
81313	PCA3/KLK3 (prostate cancer antigen 3 [non-protein coding]/kallikrein-	
	related peptidase 3 [prostate specific antigen]) ratio (eg, prostate	
	cancer)	
81317	PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (eg,	
	hereditary non-polyposis colorectal cancer, Lynch syndrome) gene	
81318	analysis; full sequence analysis  PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (eg,	
01316	hereditary non-polyposis colorectal cancer, Lynch syndrome) gene	
	analysis; known familial variants	
81319	PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (eg,	
	hereditary non-polyposis colorectal cancer, Lynch syndrome) gene	
	analysis; duplication/deletion variants	
81320	PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic	
	leukemia) gene analysis, common variants (eg, R665W, S707F, L845F)	
81321	PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome,	
0.021	PTEN hamartoma tumor syndrome) gene analysis; full sequence	
	analysis	
	•	

81322	PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant	
81323	PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; duplication/deletion variant	
81324	PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; duplication/deletion analysis	
81325	PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; full sequence analysis	
81326	PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant	
81327	SEPT9 (Septin9) (eg, colorectal cancer) methylation analysis	
81329	SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; dosage/deletion analysis (eg, carrier testing), includes SMN2 (survival of motor neuron 2, centromeric) analysis, if performed	
81331	SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) (eg, Prader-Willi syndrome and/or Angelman syndrome), methylation analysis	
81332	SERPINA1 (serpin peptidase inhibitor, clade A, alpha-1 antiproteinase, antitrypsin, member 1) (eg, alpha-1-antitrypsin deficiency), gene analysis, common variants (eg, *S and *Z)	
81333	TGFBI (transforming growth factor beta-induced) (eg, corneal dystrophy) gene analysis, common variants (eg, R124H, R124C, R124L, R555W, R555Q)	
81336	SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; full gene sequence	
81337	SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s)	
81343	PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles	
81344	TBP (TATA box binding protein) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles	
81345	TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)	
81400	Molecular pathology procedure, Level 1 (eg, identification of single germline variant [eg, SNP] by techniques such as restriction enzyme digestion or melt curve analysis)ACADM (acyl-CoA dehydrogenase, C-4 to C-12 straight chain, MCAD) (eg, medium chain ac	
81401	Molecular pathology procedure, Level 2 (eg, 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or detection of a dynamic mutation disorder/triplet repeat) ABL (c-abl oncogene 1, receptor tyrosine	
81402	Molecular pathology procedure, Level 3 (eg, >10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants 1 exon	

81403	Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons) ABL1 (c-abl on	
81404	Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis) BTD	
81405	Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons) CYP21A2 (cytochrome P450, family 21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase iso	
81406	Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) CAPN3 (Calpain 3) (eg, limb-girdle muscular dystroph	
81407	Molecular pathology procedure, Level 8 (eg, analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform) SCN1A (sodium channel, voltage-gated, type	
81408	Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence RYR1 (ryano	
81410	Aortic dysfunction or dilation (eg, Marfan syndrome, Loeys Dietz syndrome, Ehler Danlos syndrome type IV, arterial tortuosity syndrome); genomic sequence analysis panel, must include sequencing of at least 9 genes, including FBN1, TGFBR1, TGFBR2, COL3A1, MYH11, ACTA2, SLC2A10, SMAD3, and MYLK	
81411	Aortic dysfunction or dilation (eg, Marfan syndrome, Loeys Dietz syndrome, Ehler Danlos syndrome type IV, arterial tortuosity syndrome); duplication/deletion analysis panel, must include analyses for TGFBR1, TGFBR2, MYH11, and COL3A1	
81412	Ashkenazi Jewish associated disorders (eg, Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia group C, Gaucher disease, Tay-Sachs disease), genomic sequence analysis panel, must include sequencing of at least 9 genes, including ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, and SMPD1	
81413	Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); genomic sequence analysis panel, must include sequencing of at least 10 genes, including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A	
81414	Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); duplication/deletion gene analysis panel, must include analysis of at least 2 genes, including KCNH2 and KCNQ1	
81415	Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis	

81416	Exome (e.g., unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator exome (e.g., parents, siblings) (List separately in addition to code for primary procedure)	
81417	Exome (e.g., unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained exome sequence (eg, updated knowledge or unrelated condition/syndrome)	
81420	Fetal chromosomal aneuploidy (eg, trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21	
81422	Fetal chromosomal microdeletion(s) genomic sequence analysis (eg, DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in maternal blood	
81425	Genome (e.g., unexplained constitutional or heritable disorder or syndrome); sequence analysis	
81426	Genome (e.g., unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator genome (e.g., parents, siblings) (List separately in addi- tion to code for primary procedure)	
81427	Genome (e.g., unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained genome sequence (eg, updated knowledge or unrelated condition/syndrome)	
81430	Hearing loss (e.g., nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); genomic sequence analysis panel, must include sequencing of at least 60 genes, including CDH23, CLRN1, GJB2, GPR98, MTRNR1, MYO7A, MYO15A, PCDH15, OTOF, SLC26A4, TMC1, TMPRSS3, USH1C, USH1G, USH2A, and WFS1	
81431	Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); duplication/deletion analysis panel, must include copy number analyses for STRC and DFNB1 deletions in GJB2 and GJB6 genes	
81432	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel, must include sequencing of at least 14 genes, including ATM, BRCA1, BRCA2, BRIP1, CDH1, MLH1, MSH2, MSH6, NBN, PALB2, PTEN, RAD51C, STK11, and TP53	
81433	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11	
81434	Hereditary retinal disorders (eg, retinitis pigmentosa, Leber congenital amaurosis, cone-rod dystrophy), genomic sequence analysis panel, must include sequencing of at least 15 genes, including ABCA4, CNGA1, CRB1, EYS, PDE6A, PDE6B, PRPF31, PRPH2, RDH12, RHO, RP1, RP2, RPE65, RPGR, and USH2A	
81435	Hereditary colon cancer syndromes (eg, Lynch syndrome, familial adenomatosis polyposis); genomic sequence analysis panel, must include analysis of at least 7 genes, including APC, CHEK2, MLH1, MSH2, MSH6, MUTYH, and PMS2	
81436	Hereditary colon cancer syndromes (eg, Lynch syndrome, familial adenomatosis polyposis); duplication/deletion gene analysis panel, must include analysis of at least 8 genes, including APC, MLH1, MSH2, MSH6, PMS2, EPCAM, CHEK2, and MUTYH	

81437	Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); genomic sequence analysis panel, must include sequencing of at least 6 genes, including MAX, SDHB, SDHC, SDHD, TMEM127, and VHL	
81438	Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); duplication/deletion analysis panel, must include analyses for SDHB, SDHC, SDHD, and VHL	
81439	Inherited cardiomyopathy (eg, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy) genomic sequence analysis panel, must include sequencing of at least 5 genes, including DSG2, MYBPC3, MYH7, PKP2, and TTN	
81440	Nuclear encoded mitochondrial genes (eg, neurologic or myopathic phenotypes), genomic sequence panel, must include analysis of at least 100 genes, including BCS1L, C10orf2, COQ2, COX10, DGUOK, MPV17, OPA1, PDSS2, POLG, POLG2, RRM2B, SCO1, SCO2, SLC25A4, SUCLA2, SUCLG1, TAZ, TK2, and TYMP	
81442	Noonan spectrum disorders (eg, Noonan syndrome, cardio-facio-cutaneous syndrome, Costello syndrome, LEOPARD syndrome, Noonan-like syndrome), genomic sequence analysis panel, must include sequencing of at least 12 genes, including BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1, SHOC2, and SOS1	
81443	Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish-associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)	
81445	Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS, MET, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed	
81450	Targeted genomic sequence analysis panel, hematolymphoid neoplasm or disorder, DNA and RNA analysis when performed, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KRAS, KIT, MLL, NRAS, NPM1, NOTCH1), interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed	
81455	Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm, DNA and RNA analysis when performed, 51 or greater genes (eg, ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NPM1, NRAS, MET, NOTCH1, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed	

Whole mitochondrial genome (e.g., Leigh syndrome, mitochondrial encephalomyopathy, latica acidosis, and stroke-like episodes [MELAS], myoclonic epilepsy with regged-red fibers [MERFF], neuropathy, ataxia, and retin-it is lyginemoss [NARP]. Leber hereditary optic neuropathy (LHON)], genomic sequence, must include sequence analysis of entire mitochondrial genome with heteroplasmy detection.			
Keams-Sayre syndrome, chronic progressive external ophthalmoplegia), including heteroplasmy detection, if performed ophthalmoplegia) including heteroplasmy detection, if performed syndromic XLID): genomic sequence analysis panel, must include sequencing of at least 60 genes, including ARX, ATRX, CDKLS, FGD1, FMR1, HUWF1, ILRAPL, KDMSC, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2  X-linked intellectual disability (XLID) (eg. syndromic and nonsyndromic XLID): duplication/deletion gene analysis, must include analysis of at least 60 genes, including ARX, ATRX, CDKLS, FGD1, FMR1, HUWF1, ILRAPL, KDMSC, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2  31479  Unlisted molecular pathology procedure  Autoriumnue (heumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a diseasea activity score  31490  Autoriumnue fortunatiod arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a diseasea activity score  31500  Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score  31500  Oncology (ovariam), biochemical assays of two proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin, and pre-albumin), utilizing serum, algorithm reported as a risk score  31500  Oncology (tissue of origin), microarray gene express sion profiling of > 2000 genes, utilizing formalin-fixed paraffim-embedded tissue, algorithm reported as a risk score  31500  Endocrinology (type 2 diabetes), biochemical assays of two proteins (PAPP-A, hCC (any form)), utilizing maternal serum, algorithm reported as a risk score  31500  Fetal congenital abnormalities, biochemical assays of three proteins (PAPP-A, hCC (any form)), utilizing maternal serum, algorithm reported as a risk score  31501  Fetal congenital abnormalities, biochemical assays of three analytes (APP, uE3, hCG (any form)), utilizing maternal serum, algorit	81460	encephalomyopathy, lactic acidosis, and stroke-like episodes [MELAS], myoclonic epilepsy with ragged-red fibers [MERFF], neuropathy, ataxia, and retini- tis pigmentosa [NARP], Leber hereditary optic neuropathy [LHON]), genomic sequence, must include sequence analy- sis of entire mitochondrial genome with	
syndromic XLID); genomic sequence analysis panel, must include sequencing of at least 60 genes, including ARX, ATRX, CDKL5, FGD1; FMR1; HUWE1, IL (RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2  81471 X-linked intellectual disability (XLID) (eg. syndromic and nonsyndromic XLID); duplication/deletion gene analysis, must include analysis of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, ILTAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2  81479 Unlisted molecular pathology procedure  81490 Autoimmune (fehematoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score  81493 Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score  81500 Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score  81500 Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin, and pre-albumin), utilizing serum, algorithm reported as a risk score  81501 Oncology (tissue of origin), microarray gene express-sion profiling of > 200 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a sissue similarity scores  81507 Fetal aneuploidy 21 18 13 se  Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, LCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81501 Fetal congenital abnormalities, biochemical assays of three proteins (PAPP-A, LCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81501 Fetal congenital abnormalities, biochemical assays of four analytes (APP, u.S., hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81501 Fetal congenital abnormalities, biochemical assays of four analytes (APP, u.S., hCG [any form]), utilizing	81465	Kearns-Sayre syndrome, chronic progressive external	
syndromic XLID); duplication/deletion gene analysis, must include analysis of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2  81479 Unitisted molecular pathology procedure  81490 Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score  81493 Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score  81500 Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score  81503 Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin, and pre-albumin), utilizing serum, algorithm reported as a risk score  81504 Oncology (tissue of origin), microarray gene expres-sion profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores  81506 Endocrinclogy (type 2 diabetes), biochemical assays of seven analytes  81507 Fetal aneuploidy 21 18 13 se  Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81509 Fetal congenital abnormalities, biochemical assays of three proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81510 Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81511 Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form]), plulizing maternal serum, algorithm reported as a risk score  81511 Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form]), biochemical assays of four analytes (AFP, uE3, hCG [a	81470	syndromic XLID); genomic sequence analysis panel, must include sequencing of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12,	
Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score  81493 Coronary artery disease, mRNA, gene expression profiling by realtime RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score  81500 Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score  81503 Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin, and pre-albumin), utilizing serum, algorithm reported as a risk score  81504 Oncology (tissue of origin), microarray gene expres- sion profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores  81506 Endocrinology (type 2 diabetes), biochemical assays of seven analytes  81507 Fetal aneuploidy 21 18 13 se  81508 Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81509 Fetal congenital abnormalities, biochemical assays of three analytes (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81510 Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81511 Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing)  81512 Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, hCG, hyperglycosylated hCG, DIA) utilizing maternal	81471	syndromic XLID); duplication/deletion gene analysis, must include analysis of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1,	
Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score  81493 Coronary artery disease, mRNA, gene expression profiling by realtime RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score  81500 Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score  81503 Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin, and pre-albumin), utilizing serum, algorithm reported as a risk score  81504 Oncology (tissue of origin), microarray gene expres- sion profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores  81506 Endocrinology (type 2 diabetes), biochemical assays of seven analytes  81507 Fetal aneuploidy 21 18 13 se  81508 Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81509 Fetal congenital abnormalities, biochemical assays of three analytes (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81510 Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81511 Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing)  81512 Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, hCG, hyperglycosylated hCG, DIA) utilizing maternal	81479	Unlisted molecular pathology procedure	
time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score  81500 Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score  81503 Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin, and pre-albumin), utilizing serum, algorithm reported as a risk score  81504 Oncology (tissue of origin), microarray gene expres- sion profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores  81506 Endocrinology (type 2 diabetes), biochemical assays of seven analytes  81507 Fetal aneuploidy 21 18 13 se  Fetal congenital abnormalities, biochemical assays of two proteins (PAP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81509 Fetal congenital abnormalities, biochemical assays of three proteins (PAPP-A, hCG [any form], DIA), utilizing maternal serum, algorithm reported as a risk score  81510 Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG [any form]), DIA), utilizing maternal serum, algorithm reported as a risk score  81511 Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form]), DIA) utilizing maternal serum, algorithm reported as a risk score  81512 Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form], DIA) utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing)  81512 Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, total hCG, hyperglycosylated hCG, DIA) utilizing maternal		Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a	
HE4), utilizing serum, with menopausal status, algorithm reported as a risk score  Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin, and pre-albumin), utilizing serum, algorithm reported as a risk score  Oncology (tissue of origin), microarray gene expres- sion profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores  Endocrinology (type 2 diabetes), biochemical assays of seven analytes  Endocrinology (type 2 diabetes), biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  Fetal congenital abnormalities, biochemical assays of three proteins (PAPP-A, hCG [any form], DIA), utilizing maternal serum, algorithm reported as a risk score  Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form], DIA) utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing)  Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, hCG [any form], DIA) utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing)		time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score	
apolipoprotein A1, beta-2 microglobulin, transferrin, and pre-albumin), utilizing serum, algorithm reported as a risk score  81504 Oncology (tissue of origin), microarray gene expres- sion profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores  81506 Endocrinology (type 2 diabetes), biochemical assays of seven analytes  81507 Fetal aneuploidy 21 18 13 se  81508 Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81509 Fetal congenital abnormalities, biochemical assays of three proteins (PAPP-A, hCG [any form], DIA), utilizing maternal serum, algorithm reported as a risk score  81510 Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81511 Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form], DIA) utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing)  81512 Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, total hCG, hyperglycosylated hCG, DIA) utilizing maternal		HE4), utilizing serum, with menopausal status, algorithm reported as a risk score	
2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores  Endocrinology (type 2 diabetes), biochemical assays of seven analytes  81507 Fetal aneuploidy 21 18 13 se  81508 Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81509 Fetal congenital abnormalities, biochemical assays of three proteins (PAPP-A, hCG [any form], DIA), utilizing maternal serum, algorithm reported as a risk score  81510 Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81511 Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form], DIA) utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing)  81512 Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, total hCG, hyperglycosylated hCG, DIA) utilizing maternal	81503	apolipoprotein A1, beta-2 microglobulin, transferrin, and pre-albumin),	
analytes  81507 Fetal aneuploidy 21 18 13 se  81508 Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81509 Fetal congenital abnormalities, biochemical assays of three proteins (PAPP-A, hCG [any form], DIA), utilizing maternal serum, algorithm reported as a risk score  81510 Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81511 Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form], DIA) utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing)  81512 Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, total hCG, hyperglycosylated hCG, DIA) utilizing maternal	81504	2000 genes, utilizing formalin-fixed paraffin-embedded tissue,	
Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  Fetal congenital abnormalities, biochemical assays of three proteins (PAPP-A, hCG [any form], DIA), utilizing maternal serum, algorithm reported as a risk score  Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form], DIA) utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing)  Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, total hCG, hyperglycosylated hCG, DIA) utilizing maternal	81506		
Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  Fetal congenital abnormalities, biochemical assays of three proteins (PAPP-A, hCG [any form], DIA), utilizing maternal serum, algorithm reported as a risk score  Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form], DIA) utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing)  Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, total hCG, hyperglycosylated hCG, DIA) utilizing maternal	81507		
(PAPP-A, hCG [any form], DIA), utilizing maternal serum, algorithm reported as a risk score  81510 Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81511 Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form], DIA) utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing)  81512 Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, total hCG, hyperglycosylated hCG, DIA) utilizing maternal	81508	Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score	
(AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score  81511 Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form], DIA) utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing)  81512 Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, total hCG, hyperglycosylated hCG, DIA) utilizing maternal		(PAPP-A, hCG [any form], DIA), utilizing maternal serum, algorithm reported as a risk score	
(AFP, uE3, hCG [any form], DIA) utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing)  81512 Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, total hCG, hyperglycosylated hCG, DIA) utilizing maternal	81510	(AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score	
(AFP, uE3, total hCG, hyperglycosylated hCG, DIA) utilizing maternal		(AFP, uE3, hCG [any form], DIA) utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing)	
	81512	(AFP, uE3, total hCG, hyperglycosylated hCG, DIA) utilizing maternal	

81518	Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy	
81519	Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin embedded tissue, algorithm reported as recurrence score	
81522	Oncology (breast), mRNA, gene expression profiling by RT-PCR of 12 genes (8 content and 4 housekeeping), utilizing formalin-fixed paraffinembedded tissue, algorithm reported as recurrence risk score	
81525	Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence score	
81528	Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 DNA markers (KRAS mutations, promoter methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result	
81535	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; first single drug or drug combination	
81536	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; each additional single drug or drug combination (List separately in addition to code for primary procedure)	
81538	Oncology (lung), mass spectrometric 8-protein signature, including amyloid A, utilizing serum, prognostic and predictive algorithm reported as good versus poor overall survival	
81539	Oncology (high-grade prostate cancer), biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA, and human kallikrein-2 [hK2]), utilizing plasma or serum, prognostic algorithm reported as a probability score	
81540	Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype	
81542	Oncology (prostate), mRNA, microarray gene expression profiling of 22 content genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as metastasis risk score	
81545	Oncology (thyroid), gene expression analysis of 142 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (eg, benign or suspicious)	
81552	Oncology (uveal melanoma), mRNA, gene expression profiling by real- time RT-PCR of 15 genes (12 content and 3 housekeeping), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis	
81595	Cardiology (heart transplant), mRNA, gene expression profiling by real- time quantitative PCR of 20 genes (11 content and 9 housekeeping), utilizing subfraction of peripheral blood, algorithm reported as a rejection risk score	

81596	Infactious disease abronia handtitia C virus (HCV) infaction six	
81596	Infectious disease, chronic hepatitis C virus (HCV) infection, six	
	biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm	
	reported as scores for fibrosis and necroinflammatory activity in liver	
	reported as scores for historis and necronilian matery activity in liver	
81599	Unlisted multianalyte assay with algorithmic analysis	
82777	Galectin-3	
83006	Growth stimulation expressed gene	
83018	Hair Analysis	
83037	Glycosylated (A1C) by device cleared by FDA for home use	
83631	Lactoferrin, fecal, quantitative	
83987	pH; exhaled breath condensate	
84145	Procalcitonin	
84112	Placental alpha microglobulin-1 (PAMG-1), cervicovaginal secretion,	
	qualitative	
84431	Thromboxane metabolite	
84630	Hair Analysis	
85210	Blood clotting factors	
85220	Blood clotting factors	
85230	Blood clotting factors	
85240	Blood clotting factors	
85244	Blood clotting factors	
85245	Blood clotting factors	
85246	Blood clotting factors	
85247	Blood clotting factors	
85250	Blood clotting factors	
85260	Blood clotting factors	
85270	Blood clotting factors	
85280	Blood clotting factors	
85290	Blood clotting factors	
85291	Blood clotting factors	
85292	Blood clotting factors	
85293	Blood clotting factors	
85307	Blood clotting factors	
85335	Blood clotting factors	
85347	Blood clotting factors	
85384	Blood clotting factors	
85385	Blood clotting factors	
85610	Blood clotting factors	
85611	Blood clotting factors	
85705	Blood clotting factors	
85732	Blood clotting factors	
86146	Beta 2 Glycoprotein I antibody, each	
86147	Cardiolipin (phospholipid) antibody, each Ig class	
86148	Anti-phosphatidylserine (phospholipid) antibody	
86343	Leukocyte histamine release test	
86645	TORCH Screen	
86694	TORCH Screen	
86677	Antibody; Helicobacter pylori	
86711	Antibody; JC (John Cunningham) virus	
86762	TORCH Screen	
86777	TORCH Screen	
86778	TORCH Screen	
86849	Unlisted immunology procedure	
86890	Autologous blood donations	
86891	Autologous blood donations	
86910	Blood typing for paternity testing, per individual; ABO, RH and MN	
86911	Blood typing for paternity test/per individ/abo/rh & mn/ each add'l antigen	
87563	Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma genitalium, amplified probe technique	

87622	Infectious agent detection by nucleic acid (DNA or RNA);	
	papillomavirus, human, quantification	
88000	Necropsy (autopsy), gross examination only; without CNS	
88005	Necropsy (autopsy), gross examination only; with brain	
88007	Necropsy (autopsy), gross examination only; with brain and spinal cord	
88012	Necropsy (autopsy), gross examination only; infant with brain	
88014	Necropsy (autopsy), gross examination only; stillborn or newborn with	
00014	brain	
88016	Necropsy (autopsy), gross examination only; macerated stillborn	
88020	Necropsy (autopsy), gross and microscopic; without CNS	
88025	Necropsy (autopsy), gross and microscopic; with brain	
88027	Necropsy (autopsy), gross and microscopic; with brain and spinal cord	
00027	records (autopsy), gross and microscopic, with brain and spinal cord	
88028	Necropsy (autopsy), gross and microscopic; infant with brain	
88029	Necropsy (autopsy), gross and microscopic; stillborn or newborn with brain	
00000		
88036	Necropsy (autopsy), limited, gross and/or microscopic; regional	
88037	Necropsy (autopsy), limited, gross and/or microscopic; single organ	
88040	Necropsy (autopsy); forensic examination	
88045	Necropsy (autopsy); forensic examination  Necropsy (autopsy); coroner's call	
88099	Unlisted necropsy (autopsy) procedure	
88261	Hair Analysis	
88280	Hair Analysis	
88299	Unlisted cytogenetic study	
88184	Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical	
	component only; first marker	
88185	Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical	
00100		
	component only; each additional marker (List separately in addition to	
	code for first marker)	
88189	Flow cytometry, interpretation; 16 or more markers Not specified	
88233	Hair Analysis	
88375	Optical endomicroscopic image interpretation and report	
89250	Culture of oocyte(s)/embryo(s), less than 4 days;	
89251	Culture of oocyte(s)/embryo(s), less than 4 days; with co-culture of oocyte(s)/embryos	
89253	Assisted embryo hatching, microtechniques (any method)	
89254	Oocyte identification from follicular fluid	
	,	
89255	Preparation of embryo for transfer (any method)	
89257	Sperm identification from aspiration (other than seminal fluid)	
89258	Cryopreservation; embryo(s)	
89259	Cryopreservation; sperm	
89260	Sperm isolation; simple prep (eg, sperm wash and swim-up) for insemination or diagnosis with semen analysis	
89261	Sperm isolation; complex prep (eg, Percoll gradient, albumin	
	gradient) for insemination or diagnosis with semen analysis	
89264	Sperm identification from testis tissue, fresh or cryopreserved	
89268	Insemination of oocytes	
89272	Extended culture of oocyte(s)/embryo(s), 4-7 days	
89280	Assisted oocyte fertilization, microtechnique; less than or equal to 10	
	oocytes	
89281	Assisted oocyte fertilization, microtechnique; greater than 10 oocytes	
89290	Biopsy, oocyte polar body or embryo blastomere, microtechnique (for	
	pre-implantation genetic diagnosis); less than or equal to 5 embryos	
89291	Biopsy, oocyte polar body or embryo blastomere, microtechnique (for	
30201	pre-implantation genetic diagnosis); greater than 5 embryos	

89329	Sperm evaluation: hamster penetration test	
89342	Storage, (per year); embryo(s)	
89343	Storage, (per year); sperm/semen	
89352	Thawing of cryopreserved; embryo(s)	
89353	Thawing of cryopreserved; sperm/semen, each aliquot	
88749	Unlisted in vivo (eg. transcutaneous) laboratory service	
89240	Unlisted miscellaneous pathology test	
89310	Semen analysis; motility and count (not including Huhner test)	
89320	Semen analysis; complete (volume, count, motility, and differential)	
89321	Semen analysis, presence and/or motility of sperm	
89322	Semen analysis; volume, count, motility, and differential using strict morphologic criteria (eg, Kruger)	
89325	Sperm antibodies	
89330	Sperm evaluation; cervical mucus penetration test, with or without	
00000	spinnbarkeit test	
89331	Sperm evaluation, for retrograde ejaculation, urine (sperm	
09331	concentration, motility, and morphology, as indicated)	
00225	, , ,	
89335	Cryopreservation, reproductive tissue, testicular	
89337	Cryopreservation, mature oocyte(s)	
89344	Storage, (per year); reproductive tissue, testicular/ovarian	
89346	Storage, (per year); oocyte	
89354	Thawing of cryopreserved; reproductive tissue, testicular/ovarian	
89356	Thawing of cryopreserved; oocytes, each aliquot	
89398	Unlisted reprod med lab proc	
90399	Unlisted immune globulin	
90471	Immunization administration (includes percutaneous, intradermal,	
	subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)	
90472	Immunization administration (includes percutaneous, intradermal,	
00112	subcutaneous, or intramuscular injections); each additional vaccine	
	(single or combination vaccine/toxoid) (List separately in addition to	
	code for primary procedure)	
90581	Immunizations required for travel	
90625	Cholera vaccine, live,adult dosage, 1 dose schedule, for oral use	
90632	Immunizations required for travel	
90633	Immunizations required for travel	
90634	Immunizations required for travel	
90636	Immunizations required for travel	
90653	Influenza vaccine, inactivated, subunit, adjuvanted, for intramuscular	
	use	
00604	Influenza virus vaccine, pandemic formulation, live, for intranasal use	
90064	Tilliuchza vilus vaccine, pariuchile formulation, live, for intranasar use	
90064	militariza virus vaccine, pariuernic formulation, live, for intrariasar use	
	Influenza virus vaccine, pandemic formulation,	
90666		
90666	Influenza virus vaccine, pandemic formulation,	
90666 90667	Influenza virus vaccine, pandemic formulation, Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted, for intramuscular use	
90666 90667	Influenza virus vaccine, pandemic formulation, Influenza virus vaccine (IIV), pandemic formulation, split virus,	
90666 90667 90668	Influenza virus vaccine, pandemic formulation, Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted, for intramuscular use Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use	
90666 90667 90668	Influenza virus vaccine, pandemic formulation, Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted, for intramuscular use Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant	
90666 90667 90668	Influenza virus vaccine, pandemic formulation, Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted, for intramuscular use Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, pre- servative and antibiotic	
90666 90667 90668 90682	Influenza virus vaccine, pandemic formulation, Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted, for intramuscular use Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, pre- servative and antibiotic free, for intramuscular use	
90666 90667 90668 90682	Influenza virus vaccine, pandemic formulation, Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted, for intramuscular use Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, pre- servative and antibiotic free, for intramuscular use Immunizations required for travel	
90666 90667 90668 90682 90690 90691	Influenza virus vaccine, pandemic formulation, Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted, for intramuscular use Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, pre- servative and antibiotic free, for intramuscular use Immunizations required for travel Immunizations required for travel	
90666 90667 90668 90682 90690 90691	Influenza virus vaccine, pandemic formulation, Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted, for intramuscular use Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, pre- servative and antibiotic free, for intramuscular use Immunizations required for travel Immunizations required for travel Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated	
90666 90667 90668 90682 90690 90691 90697	Influenza virus vaccine, pandemic formulation, Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted, for intramuscular use Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, pre- servative and antibiotic free, for intramuscular use Immunizations required for travel Immunizations required for travel Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine	
90666 90667 90668 90682 90690 90691 90697	Influenza virus vaccine, pandemic formulation, Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted, for intramuscular use Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, pre- servative and antibiotic free, for intramuscular use Immunizations required for travel Immunizations required for travel Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine Immunizations required for travel	
90666 90667 90668 90682 90690 90691 90697 90717 90738	Influenza virus vaccine, pandemic formulation, Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted, for intramuscular use Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, pre- servative and antibiotic free, for intramuscular use Immunizations required for travel Immunizations required for travel Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine Immunizations required for travel Immunizations required for travel	
90664 90666 90667 90668 90682 90690 90691 90697 90717 90738 90739	Influenza virus vaccine, pandemic formulation, Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted, for intramuscular use Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, pre- servative and antibiotic free, for intramuscular use Immunizations required for travel Immunizations required for travel Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine Immunizations required for travel	

90750	Zoster (shingles) vaccine (HZV), recombinant, sub-unit, adjuvanted,	
	for intramuscular injection	
90811	Interpreter services	
90813	Interpreter services	
90815	Interpreter services	
90824	Interpreter services	
90827	Interpreter services	
90829	Interpreter services	
90865	Narcosynthesis for psychiatric dx/therapeutic purposes	
90867	Therapeutic repetitive transcranial magnetic stimulation	
90868	Therapeutic repetitive transcranial magnetic stimulation	
90869	Therapeutic repetitive transcranial magnetic stimulation	
90875	Biofeedback	
90876	Biofeedback	
90880	Hypnotherapy	
90882	Psych envir interven mental health off/opd	
90885	Psychiatric evaluation of hosp records, other psychiatric reports, other	
	accum data for med diag purposes	
90889	Preparation of report of patient's psychiatric status, history, treatment,	
	or progress (other than for legal or consultative purposes) for other	
	physicians, agencies, or insurance carriers	
90899	Unlisted psychiatric service or procedure	
90911	Biofeedback training, perineal muscles, anorectal or urethral sphincter	
	3,1	
90912	Biofeedback training, perineal muscles, anorectal or urethral	
	sphincter, including EMG and/or manometry, when performed; initial	
	15 minutes of one-on-one physician or other qualified health care	
	professional contact with the patient	
90913	Biofeedback training, perineal muscles, anorectal or urethral	
00010	sphincter, including EMG and/or manometry, when performed; each	
	additional 15 minutes of one-on-one physician or other qualified health	
	care professional contact with the patient (List separately in addition to	
	code for primary procedure)	
00005		
90935	Dialysis	
90937	Dialysis	
90940 90945	Dialysis	
	Dialysis	
90947	Dialysis	
90997	Dialysis	
90999	Dialysis	
91037	Esophageal function test, gastroesophageal reflux test	
91038	Esophageal function test, gastroesophageal reflux test	
91052	Gastric analysis test with injection of stimulant of gastric secretion	
91052	, , , , , , , , , , , , , , , , , , ,	
	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy),	
	, , , , , , , , , , , , , , , , , , ,	
91111	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus with physician interpretation and report	
91111	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus with physician interpretation and report  Gastrointestinal transit and pressure measurement, stomach through	
91111	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus with physician interpretation and report  Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule with interpretation and report	
91111 91112	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus with physician interpretation and report  Gastrointestinal transit and pressure measurement, stomach through	
91111 91112	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus with physician interpretation and report  Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule with interpretation and report	
91111	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus with physician interpretation and report  Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule with interpretation and report  Colon motility (manometric) study, minimum 6 hours continuous	
91111	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus with physician interpretation and report  Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule with interpretation and report  Colon motility (manometric) study, minimum 6 hours continuous recording (including provocation tests, eg, meal, intracolonic balloon	
91111 91112 91117	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus with physician interpretation and report  Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule with interpretation and report  Colon motility (manometric) study, minimum 6 hours continuous recording (including provocation tests, eg, meal, intracolonic balloon distension, pharmacologic agents, if performed), with interpretation and report	
91111 91112 91117	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus with physician interpretation and report  Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule with interpretation and report  Colon motility (manometric) study, minimum 6 hours continuous recording (including provocation tests, eg, meal, intracolonic balloon distension, pharmacologic agents, if performed), with interpretation and report  Liver elastography, mechanically induced shear wave (eg, vibration),	
91111 91112 91117 91200	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus with physician interpretation and report  Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule with interpretation and report  Colon motility (manometric) study, minimum 6 hours continuous recording (including provocation tests, eg, meal, intracolonic balloon distension, pharmacologic agents, if performed), with interpretation and report  Liver elastography, mechanically induced shear wave (eg, vibration), without imaging, with interpretation and report	
91111 91112 91117 91200 92015	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus with physician interpretation and report  Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule with interpretation and report  Colon motility (manometric) study, minimum 6 hours continuous recording (including provocation tests, eg, meal, intracolonic balloon distension, pharmacologic agents, if performed), with interpretation and report  Liver elastography, mechanically induced shear wave (eg, vibration), without imaging, with interpretation and report  Determination of refractive state	
91052 91111 91112 91117 91200 92015 92071 92072	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus with physician interpretation and report  Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule with interpretation and report  Colon motility (manometric) study, minimum 6 hours continuous recording (including provocation tests, eg, meal, intracolonic balloon distension, pharmacologic agents, if performed), with interpretation and report  Liver elastography, mechanically induced shear wave (eg, vibration), without imaging, with interpretation and report	

92512 Nasal function studies 92531 Spontaneous nystagmus, including gaze 92532 Positional nystagmus test 92533 Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests) 92534 Optokinetic nystagmus test 92545 Hyperactivity testing 92548 Computerized dynamic posturography 92549 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT) 92588 Hair Analysis			
Comeal hysteresis determination, by air impulse stimulation  Ophthalmoscopy, extended: with retinal drawing and seleral depression of peripheral retinal disease, etg., for retinal tare, retinal detachment, retinal tumor) with interpretation and report, unilateral or bibitateral  20202 Ophthalmoscopy, extended: with drawing of optic nerve or macula (e.g., for glaucome, macular) aphthology, tumor) with interpretation and report, unilateral or bibitateral  20210 Prescription of optical and physical characteristics of and fitting of contact lens.  20211 Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for ophalia, 1 eye  20212 Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for ophalia, oth eyes  20216 Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for ophalia, both eyes  20216 Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision and direction of fitting, corneal lens for aphalia, both eyes  20226 Modification of contact lens (separate procedure), with medical supervision and direction of fitting, corneal lens for aphalia, both eyes  20236 Replacement of contact lens  20236 Pitting of speciacles, except for aphalia, bifocal  20236 Pitting of speciacles, except for aphalia, bifocal  20237 Pitting of speciacles, except for aphalia, multifocal  20236 Pitting of speciacles prothesis for aphalia, multifocal  20237 Pitting of speciacles prothesis for aphalia, multifocal  20237 Pitting of speciacles prothesis for aphalia, multifocal  20238 Pitting of speciacles prothesis for aphalia, multifocal  20238 Pitting of speciacles prothe	92132		
Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease; e.g., for retinal tear, retinal destachment, retinal destachment, retinal tumor) with interpretation and report, unilateral or bilateral particular destachment, retinal tumor) with interpretation and report, unilateral or bilateral particular destachment, retinal tumor) with interpretation and report, unilateral or bilateral retinal destachment, retinal destachment of protection of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, 1 eye contact lens, with medical supervision of adaptation; corneal lens for aphakia, 1 eye destachment of the particular destacts of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, both eyes papakia, both eyes destacts of the papakia papak		segment, with interpretation and report, unilateral or bilateral	
Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease; e.g., for retinal tear, retinal destachment, retinal destachment, retinal tumor) with interpretation and report, unilateral or bilateral particular destachment, retinal tumor) with interpretation and report, unilateral or bilateral particular destachment, retinal tumor) with interpretation and report, unilateral or bilateral retinal destachment, retinal destachment of protection of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, 1 eye contact lens, with medical supervision of adaptation; corneal lens for aphakia, 1 eye destachment of the particular destacts of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, both eyes papakia, both eyes destacts of the papakia papak	204.45		
depression of peripheral retinal disease (eg., for retinal tear, retinal detachment, retinal turnor) with interpretation and report, unilateral or bilateral  92202 Ophilaminescopy, extended: with drawing of optic nerve or macula (eg., for glaucoma, macular pathology, tumor) with interpretation and report, unilateral or bilateral  92310 Prescription of optical and physical characteristics of and fitting of contact lens  92311 Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, 1 eye  92312 Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, both eyes  92312 Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, both eyes  92316 Prescription of path phys char & fitting of contact lens, with medical supervision and direction of fitting, corneal lens for aphakia, both eyes  92326 Modification of contact lens (separate procedure), with medical supervision of adaptation  92326 Replacement of contact lens  92326 Replacement of contact lens  92327 Fitting of spectacles, except for aphakia, bronfocal  92327 Fitting of spectacles, except for aphakia, bronfocal  92328 Fitting of spectacles prosthesis for aphakia, monfocal  92329 Fitting of spectacles prosthesis for aphakia, monfocal  92329 Fitting of spectacles prosthesis for aphakia, multifocal  92329 Fitting of spectacles mounted fow vision aid, single element  92329 Fitting of spectacles mounted fow vision aid, single element  92329 Fitting of spectacles prosthesis for aphakia, multifocal  92321 Fitting of spectacles mounted fow vision aid, single element  92329 Fitting of spectacles mounted fow vision aid, single element  92321 Repair and refitting spectacles, except for aphakia  92321 Repair and refitting spectacles, except for aphakia  923222 Prostopic spectacles of aphakia, te			
detachment, retinal tumor) with interpretation and report, unilateral or bilateral statement of the process of	92201		
bilateral  92202 Ophthalmoscopy, extended; with drawing of optic nerve or macule (eg, for glaucoma, macular pathology, tumor) with interpretation and report, unificated or bilateral  92311 Prescription of optical and physical characteristics of and fitting of contact lens  92311 Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, 1 eye  92312 Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, both eyes  92312 Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, both eyes  92316 Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, both eyes  92317 Prescription of potential prescription prescription of potential prescription of potential prescription of potential prescription prescription of potential prescription prescription of pot		, , ,	
Ophthalmoscopy, extended, with drawing of optic nerve or macula (eg. for glaucoma, macular pathology, tumor) with interpretation and report, unilateral or blateral prescription of optical and physical characteristics of and fitting of contact lens.  Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, 1 eye  Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, 1 eye  Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, both eyes  Work of the prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision and direction of fitting, comeal lens for aphakia, both eyes  Work of the prescription of optical and physical characteristics of and fitting of supervision of adaptation of contact lens (separate procedure), with medical supervision of adaptation of contact lens (separate procedure), with medical supervision of adaptation of contact lens (separate procedure), with medical supervision of adaptation of contact lens (separate procedure), with medical supervision of adaptation and supervision of adaptation (separate procedure), with medical supervision of adaptation of contact lens (separate procedure), with medical supervision of adaptation of contact lens (separate procedure), with medical supervision of adaptation of contact lens (separate procedure), separate procedure), separate procedure, separate			
(eg, for glaucoma, macular pathology, tumor) with interpretation and report, unilateral or blaiteral and report, unilateral or blaiteral and physical characteristics of and fitting of contact lens. With medical supervision of adaptation; corneal lens for aphakia, 1 eye Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, 1 eye Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, both eyes Prescription of pt & phys char & fitting of contact lens, with medical supervision and direction of fitting, corneal lens for aphakia, both eyes Modification of contact lens (separate procedure), with medical supervision and direction of fitting, corneal lens for aphakia, both eyes Prescription of pt & phys char & fitting of contact lens, with medical supervision of adaptation.  Prescription of contact lens (separate procedure), with medical supervision of adaptation.  Prescription of contact lens (separate procedure), with medical supervision of adaptation.  Prescription of contact lens (separate procedure), with medical supervision of adaptation.  Prescription of contact lens (separate procedure), with medical supervision of adaptation.  Prescription of prescription of physical characteristics.  Printing of spectacles, except for aphakia, monifocal Printing of spectacles, except for aphakia, multifocal Printing of spectacle prosthesis for aphakia, multifocal Printing of spectacles, app	02202		
report, unilateral or bilateral 32310 Prescription of optical and physical characteristics of and fitting of contact lens. Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, 1 eye  22312 Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, both eyes  22316 Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, both eyes  22316 Prescription of optical physical characteristics of and fitting of supervision and direction of fitting, corneal lens for aphakia, both eyes  22326 Modification of contact lens (separate procedure), with medical supervision of adaptation  22328 Replacement of contact lens 22329 Fitting of spectacles, except for aphakia, nonfocal 22340 Fitting of spectacles, except for aphakia, incorned physical 22342 Fitting of spectacles, except for aphakia, monofocal 22342 Fitting of spectacle prosthesis for aphakia; multifocal 22345 Fitting of spectacle mounted low vision aid; single element 22346 Fitting of spectacle mounted low vision aid; single element 22347 Repair and refitting spectacles, except for aphakia, multifocal 22348 Fitting of spectacle mounted low vision aid; single element 22359 Prosthesis service of aphakia, temporary 22370 Repair and refitting spectacles, except for aphakia 22351 Prestress except for aphakia, temporary 22371 Repair and refitting spectacles, except for aphakia 22352 Prostional nystagmus test 22353 Caloric vestibular test, each irrigation (binaural, bithermal stimulation 22364 Optokinetic nystagmus test 22364 Optokinetic nystagmus test 22365 Prostoral nystagmus test 22366 Prespectacles of the use of non-speech-generating augmentative 22367 And Prespective special prostression device, face-to-face with the patient; 22368 Prespectation of oricolatory sexist; external (EECP) 22369 Ca	92202		
Prescription of optical and physical characteristics of and fitting of contact lens (prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, 1 eye (prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, both eyes (prescription of opt & phys char & fitting of contact lens, with medical supervision and direction of fitting, corneal lens for aphakia, both eyes (prescription of opt & phys char & fitting of contact lens, with medical supervision and direction of fitting, corneal lens for aphakia, both eyes (prescription of adaptation) (prescription) (prescri			
contact lens  Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, 1 eye  22312 Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, both eyes  22316 Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision and direction of fitting, corneal lens for aphakia, both eyes  22326 Modification of contact lens (separate procedure), with medical supervision adaptation  22326 Replacement of contact lens  22327 Fitting of spectacles, except for aphakia, monfocal  22341 Fitting of spectacles, except for aphakia, indical  22342 Fitting of spectacles, except for aphakia, monfocal  22343 Fitting of spectacles, except for aphakia, monfocal  22344 Fitting of spectacles, except for aphakia, monfocal  22355 Fitting of spectacle prosthesis for aphakia, monfocal  22356 Fitting of spectacle mounted low vision aid: single element  22357 Repair and refitting spectacles, except for aphakia, monfocal  22368 Prosthesis service for aphakia, temporary  22370 Repair and refitting spectacles, except for aphakia  22371 Repair and refitting spectacles, except for aphakia  22372 Nana for apiar and refitting spectacles, except for aphakia  22373 Prosthesis service for aphakia, temporary  22374 Repair and refitting spectacles, except for aphakia  22375 Prosthesis service for aphakia, temporary  22376 Repair and refitting spectacles, except for aphakia  22377 Repair and refitting spectacles, except for aphakia  22389 Prosthesis service for aphakia, temporary  2239 Prosthesis service for aphakia, temporary  2240 Prosthesis service for aphakia, temporary  2251 Nasal function studies  2252 Nasal function studies  2253 Prosthesis service for aphakia, temporary  2254 Prosthesis service for aphakia, temporary  2255 Prosthesis service for aphakia, temporary  2256 Prosthesis service for aphakia, temporary  225	02240	1 1	
Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, 1 eye Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, both eyes  92316 Prescription of pt & phys char & fitting of contact lens, with medical supervision and direction of fitting, corneal lens for aphakia, both eyes  92326 Modification of contact lens (separate procedure), with medical supervision and direction of fitting, corneal lens for aphakia, both eyes  92326 Replacement of contact lens  92336 Pitting of spectacles, except for aphakia, nonfocal  92341 Fitting of spectacles, except for aphakia, infocal  92342 Fitting of spectacles, except for aphakia, multifocal  92343 Fitting of spectacle prosthesis for aphakia, multifocal  92352 Fitting of spectacle prosthesis for aphakia, multifocal  92353 Fitting of spectacle mounted low vision aid; single element  92354 Fitting of spectacle mounted low vision aid; single element  92355 Fitting of spectacle mounted low vision aid; single element  92370 Repair and refitting spectacles, spectacle prosthesis for aphakia  92371 Repair and refitting spectacles, spectacle prosthesis for aphakia  92372 Posthesis service for aphakia, temporary  92373 Repair and refitting spectacles, spectacle prosthesis for aphakia  92374 Repair and refitting spectacles, spectacle prosthesis for aphakia  92375 Pitting of spectacle with a prostruction and adaptation constitutes four tests)  92384 Posthesis explored prostruction and test (CDP-SOT), 6 conditions (e.e, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway, platform sway, eyes closed platform sway, platform and visual sway, platform sway, eyes closed platform sway, platform and visual sway, platform and report; with motor control test (MCT) and adaptation test (ADT)  92658 Haria Analysis  92631 Carlosassist-method of circulatory assi	92310	, , ,	
contact lens, with medical supervision of adaptation; corneal lens for aphakia, 1 eyes  Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, both eyes  Prescription of opt & phys char & fitting of contact lens, with medical supervision and direction of fitting, corneal lens for aphakia, both eyes  Modification of contact lens (separate procedure), with medical supervision of adaptation  ### Ad	02211		
aphakia, 1 eye Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, both eyes  92316 Prescription of opt & phys char & fitting of contact lens, with medical supervision and direction of fitting, corneal lens for aphakia, both eyes  92325 Modification of contact lens (separate procedure), with medical supervision of adaptation  92326 Replacement of contact lens  92327 Paplacement of contact lens  92328 Replacement of contact lens  92329 Fitting of spectacles, except for aphakia; nonfocal  92329 Fitting of spectacles, except for aphakia, bifocal  92320 Fitting of spectacles, except for aphakia, monfocal  92335 Fitting of spectacles prosthesis for aphakia, monofocal  92335 Fitting of spectacle prosthesis for aphakia, monofocal  92355 Fitting of spectacle mounted low vision aid; single element  92355 Fitting of spectacle mounted low vision aid; telescopic  92358 Prosthesis service for aphakia, temporary  92370 Repair and refitting spectacles, except for aphakia  92371 Repair and refitting spectacles, except for aphakia  92371 Repair and refitting spectacles, spectacle prosthesis for aphakia  92552 Positional nystagmus test  92533 Spontaneous nystagmus test  92534 Option studies  92535 Pontaneous nystagmus test  92536 Computerized dynamic posturography  92549 Computerized dynamic posturography  92549 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and susual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)  92580 Postional nystagmus est of the use of non-speech-generating augmentative and alternative communication device  92600 Therapeutic service(s) for the use of non-speech-generating augmentative and alternative communication device  92603 Learning disability evaluation  10 Cardioassist-method of circulatory assist; external (EECP)	92311		
Prescription of optical and physical characteristics of and fitting of contact lens, with medical supervision of adaptation; corneal lens for aphakia, both eyes  Prescription of opt & phys char & fitting of contact lens, with medical supervision and direction of fitting, corneal lens for aphakia, both eyes  Modification of contact lens (separate procedure), with medical supervision and direction of fitting, corneal lens for aphakia, both eyes  Modification of contact lens (separate procedure), with medical supervision of adaptation  Replacement of contact lens  Replacement of contact lens  Replacement of contact lens  Replacement of contact lens  Pritting of spectacles, except for aphakia, nonfocal  Fitting of spectacles, except for aphakia, multifocal  Pritting of spectacles, except for aphakia, multifocal  Fitting of spectacle prosthesis for aphakia, multifocal  Fitting of spectacle mounted low vision aid; slegle element  Fitting of spectacle mounted low vision aid; slegle element  Fitting of spectacle mounted low vision aid; slegle element  Fitting of spectacle mounted low vision aid; slegle element  Pritting of spectacle mounted low vision aid; slegle element  Pritting of spectacle mounted low vision aid; slegle element  Pritting of spectacle mounted low vision aid; slegle element  Pritting of spectacle mounted low vision aid; slegle element  Pritting of spectacle mounted low vision aid; slegle element  Pritting of spectacles mounted low vision aid; slegle element  Pritting of spectacle mounted low vision aid; slegle element  Pritting of spectacles mounted low vision aid; slegle element  Pritting of spectacles mounted low vision aid; slegle element  Pritting of spectacles mounted low vision aid; slegle element  Pritting of spectacles mounted low vision aid; slegle element  Pritting of spectacles mounted low vision aid; slegle element  Pritting of spectacles mounted low vision aid; slegle element  Pritting of spectacles mounted low sleg element  Pritting of spectacles mounted low sleg element  Pritting of sp		· · · · · · · · · · · · · · · · · · ·	
contact lens, with medical supervision of adaptation; corneal lens for aphakia, both eyes  Prescription of opt & phys char & fitting of contact lens, with medical supervision and direction of fitting, corneal lens for aphakia, both eyes  92315  Modification of contact lens (separate procedure), with medical supervision of adaptation  92326  Replacement of contact lens  92340  Fitting of spectacles, except for aphakia; nonfocal  92341  Fitting of spectacles, except for aphakia, inonfocal  92342  Fitting of spectacles, except for aphakia, multifocal  92352  Fitting of spectacle prosthesis for aphakia, multifocal  92353  Fitting of spectacle prosthesis for aphakia, multifocal  92354  Fitting of spectacle mounted low vision aid; single element  92355  Fitting of spectacle mounted low vision aid; single element  92356  92370  Repair and refitting spectacles, except for aphakia, emporary  92370  Repair and refitting spectacles, except for aphakia  92371  Repair and refitting spectacles, except for aphakia  92512  Nasal function studies  92531  Spontaneous mystagmus, including gaze  92532  Positional mystagmus test  92533  Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests)  92544  Optobienic mystagmus test  92545  Computerized dynamic posturography  92549  Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)  92588  Hair Analysis  92606  Therapeutic service(s) for the use of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes  (List separately in addition to code for primary procedure.)  92633  Learning disability evaluation  Learning disability evaluation	02212		
aphakia, both eyes Prescription of opt & phys char & fitting of contact lens, with medical supervision and direction of fitting, corneal lens for aphakia, both eyes  Modification of contact lens (separate procedure), with medical supervision of adaptation  82326 Replacement of contact lens  82340 Fitting of spectacles, except for aphakia; nonfocal  82341 Fitting of spectacles, except for aphakia, bifocal  92342 Fitting of spectacles, except for aphakia, bifocal  92343 Fitting of spectacles prosthesis for aphakia, multifocal  92344 Fitting of spectacle prosthesis for aphakia, multifocal  92355 Fitting of spectacle prosthesis for aphakia, multifocal  92355 Fitting of spectacle mounted low vision aid; single element  92355 Fitting of spectacle mounted low vision aid; single element  92356 Prosthesis service for aphakia, temporary  92370 Repair and refitting spectacles, except for aphakia  92371 Repair and refitting spectacles, except for aphakia  92372 Paperi and refitting spectacles, except for aphakia  92512 Nasal function studies  92523 Positional systagmus, including gaze  92530 Positional systagmus lend positional standard positional systagmus test  92531 Optokinetic nystagmus test  92540 Optokinetic nystagmus test  92541 Optokinetic nystagmus test  92542 Optokinetic nystagmus test  92543 Optokinetic nystagmus test  92549 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (i.e. eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)  92588 Hair Analysis  Evaluation for prescription of non-speech-generating augmentative and alternative communication device including programming and modification  10 10 10 10 10 10 10 10 10 10 10 10 10 1	92312		
Prescription of opt & phys char & fitting of contact lens, with medical supervision and direction of fitting, comeal lens for aphakia, both eyes  92325 Modification of contact lens (separate procedure), with medical supervision of adaptation  92326 Replacement of contact lens  92340 Fitting of spectacles, except for aphakia; nonfocal  92341 Fitting of spectacles, except for aphakia, infocal  92342 Fitting of spectacles, except for aphakia, multifocal  92353 Fitting of spectacles, except for aphakia, multifocal  92353 Fitting of spectacle prosthesis for aphakia, multifocal  92355 Fitting of spectacle mounted low vision aid; single element  92356 Prosthesis service for aphakia, temporary  92377 Repair and refitting spectacles, except for aphakia experiment  92371 Repair and refitting spectacles, except for aphakia  92371 Repair and refitting spectacles, except for aphakia  92371 Nasal function studies  92352 Positional nystagmus, including gaze  92532 Positional nystagmus test  92533 Calonic vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests)  92544 Optokinetic nystagmus test  92545 Computerized dynamic posturography  92549 Computerized dynamic posturography  92549 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway, including interpretation and report; with motor control test (MCT) and adaptation test (ADT)  92588 Hair Analysis  92695 Evaluation for prescription of non-speech-generating augmentative and alternative communication device including programming and modification  100 Fitting of spectacles and inclusion in additional 30 minutes  101 Cardioassist-method of circulatory assist; external (EECP)		· · · · · · · · · · · · · · · · · · ·	
supervision and direction of fitting, corneal lens for aphakia, both eyes  Modification of contact lens (separate procedure), with medical supervision of adaptation  92326 Replacement of contact lens  Pitting of spectacles, except for aphakia; nonfocal  92341 Fitting of spectacles, except for aphakia, bifocal  92342 Fitting of spectacles, except paphakia, multifocal  92353 Fitting of spectacle prosthesis for aphakia, multifocal  92354 Fitting of spectacle prosthesis for aphakia; multifocal  92355 Fitting of spectacle mounted low vision aid; single element  92356 Fitting of spectacle mounted low vision aid; telescopic  92357 Fitting of spectacle mounted low vision aid; telescopic  92358 Prosthesis service for aphakia; temporary  92370 Repair and refitting spectacles, except for aphakia exporate prosthesis for aphakia ex	02216		
Modification of contact lens (separate procedure), with medical supervision of adaptation  92326 Replacement of contact lens  92340 Fitting of spectacles, except for aphakia; nonfocal  92341 Fitting of spectacles, except for aphakia, bifocal  92342 Fitting of spectacles, except for aphakia, multifocal  92352 Fitting of spectacle prosthesis for aphakia, multifocal  92353 Fitting of spectacle prosthesis for aphakia, multifocal  92354 Fitting of spectacle mounted low vision aid; single element  92355 Fitting of spectacle mounted low vision aid; telescopic  92356 Prosthesis service for aphakia, temporary  92377 Repair and refitting spectacles, except for aphakia  92371 Repair and refitting spectacles, except for aphakia  92512 Nasal function studies  92531 Spontaneous nystagmus, including gaze  92532 Positional nystagmus test  92533 Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests)  9254 Optokinetic nystagmus test  9254 Optokinetic nystagmus test  9254 Optokinetic nystagmus test  9254 Computerized dynamic posturography  9254 Computerized dynamic posturography Source of Source	32310		
supervision of adaptation  92326 Replacement of contact lens  92340 Fitting of spectacles, except for aphakia; nonfocal  92341 Fitting of spectacles, except for aphakia, bifocal  92342 Fitting of spectacles, except for aphakia, multifocal  92352 Fitting of spectacle prosthesis for aphakia, multifocal  92353 Fitting of spectacle prosthesis for aphakia, multifocal  92354 Fitting of spectacle mounted low vision aid; telescopic  92355 Fitting of spectacle mounted low vision aid; telescopic  92356 Prosthesis service for aphakia, temporary  92370 Repair and refitting spectacles, except for aphakia  92371 Repair and refitting spectacles, except for aphakia  92371 Repair and refitting spectacles, except for aphakia  92512 Nasal function studies  92513 Spontaneous nystagmus, including gaze  92523 Coloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests)  92531 Optokinetic nystagmus test  92544 Hyperactivity testing  92548 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway, including interpretation and report; with motor control test (MCT) and adaptation test (ADT)  92588 Hair Analysis  92606 Therapeutic service(s) for the use of non-speech-generating augmentative and alternative communication device  71 Therapeutic service(s) for the use of non-speech-generating augmentative and alternative communication device  92608 Evaluation for prescription of non-speech-generating augmentative and alternative communication device (List separately in addition to code for primary procedure.)  92633 Learning disability evaluation  10 Cardioassist-method of circulatory assist; external (EECP)		supervision and direction or fitting, comeariens for apriaxia, both eyes	
supervision of adaptation  92326 Replacement of contact lens  92340 Fitting of spectacles, except for aphakia; nonfocal  92341 Fitting of spectacles, except for aphakia, bifocal  92342 Fitting of spectacles, except for aphakia, multifocal  92352 Fitting of spectacle prosthesis for aphakia, multifocal  92353 Fitting of spectacle prosthesis for aphakia, multifocal  92354 Fitting of spectacle mounted low vision aid; telescopic  92355 Fitting of spectacle mounted low vision aid; telescopic  92356 Prosthesis service for aphakia, temporary  92370 Repair and refitting spectacles, except for aphakia  92371 Repair and refitting spectacles, except for aphakia  92371 Repair and refitting spectacles, except for aphakia  92512 Nasal function studies  92513 Spontaneous nystagmus, including gaze  92523 Coloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests)  92531 Optokinetic nystagmus test  92544 Hyperactivity testing  92548 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway, including interpretation and report; with motor control test (MCT) and adaptation test (ADT)  92588 Hair Analysis  92606 Therapeutic service(s) for the use of non-speech-generating augmentative and alternative communication device  71 Therapeutic service(s) for the use of non-speech-generating augmentative and alternative communication device  92608 Evaluation for prescription of non-speech-generating augmentative and alternative communication device (List separately in addition to code for primary procedure.)  92633 Learning disability evaluation  10 Cardioassist-method of circulatory assist; external (EECP)	92325	Modification of contact lens (separate procedure) with medical	
P32326 Replacement of contact lens P32340 Fitting of spectacles, except for aphakia, nonfocal P32341 Fitting of spectacles, except for aphakia, bifocal P32342 Fitting of spectacles, except for aphakia, bifocal P32343 Fitting of spectacles, except for aphakia, monofocal P32353 Fitting of spectacle prosthesis for aphakia, multifocal P32353 Fitting of spectacle mounted low vision aid; single element P32355 Fitting of spectacle mounted low vision aid; telescopic P32356 Pitting of spectacle mounted low vision aid; telescopic P32357 Pitting of spectacle mounted low vision aid; telescopic P32358 Prosthesis service for aphakia, temporary P32370 Repair and refitting spectacles, except for aphakia P32371 Repair and refitting spectacles, except for aphakia P32371 Repair and refitting spectacles, except for aphakia P32371 Spontaneous nystagmus, including gaze P32372 Positional nystagmus including gaze P32373 Spontaneous nystagmus test P32374 Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests) P3238 Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests) P3240 Optokinetic nystagmus test P32541 Hyperactivity testing P32542 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT) P32588 Hair Analysis P32605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device P32606 Therapeutic service(s) for the use of non-speech-generating augmentative and alternative communication device P32607 Therapeutic service(s) for the use of non-speech-generating augmentative and alternative communication device P32608 Evaluation for prescription of non-speech-generating augmentative and alternative communication device (acceptage and patients) P32609 Tale patients and patients and pati	32323		
Fitting of spectacles, except for aphakia; nonfocal  92341 Fitting of spectacles, except for aphakia, bifocal  92342 Fitting of spectacles, except for aphakia, multifocal  92352 Fitting of spectacles, except for aphakia, multifocal  92353 Fitting of spectacle prosthesis for aphakia, multifocal  92354 Fitting of spectacle mounted low vision aid; single element  92355 Fitting of spectacle mounted low vision aid; single element  92370 Repair and refitting spectacles, except for aphakia  92371 Repair and refitting spectacles, except for aphakia  92371 Repair and refitting spectacles, except for aphakia  92512 Nasal function studies  92513 Spontaneous nystagmus, including gaze  92524 Positional nystagmus test  92533 Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests)  92544 Cypteractivity testing  92545 Computerized dynamic posturography  92549 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)  92588 Hair Analysis  92606 Therapeutic service(s) for the use of non-speech-generating augmentative and alternative communication device  92606 Evaluation for prescription of non-speech-generating augmentative and alternative communication device  92606 Evaluation for prescription of non-speech-generating augmentative and alternative communication device  92633 Learning disability evaluation  92633 Learning disability evaluation  92634 Learning disability evaluation	02326	·	
92341 Fitting of spectacles, except for aphakia, bifocal 92342 Fitting of spectacles, except for aphakia, multifocal 92352 Fitting of spectacle prosthesis for aphakia, multifocal 92353 Fitting of spectacle prosthesis for aphakia, multifocal 92354 Fitting of spectacle mounted low vision aid; single element 92355 Fitting of spectacle mounted low vision aid; telescopic 92356 Prosthesis service for aphakia, temporary 92370 Repair and refitting spectacles, except for aphakia 92371 Repair and refitting spectacles, except for aphakia 92371 Repair and refitting spectacles, except for aphakia 92512 Nasal function studies 92531 Spontaneous nystagmus, including gaze 92532 Positional nystagmus test 92532 Positional nystagmus test 92534 Optokinetic nystagmus test 92545 Optokinetic nystagmus test 92546 Computerized dynamic posturography 92547 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT) 92588 Hair Analysis 92606 Evaluation for prescription of non-speech-generating augmentative and alternative communication device 92606 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.) 92633 Learning disability evaluation		·	
92342 Fitting of spectacles, except for aphakia, multifocal 92352 Fitting of spectacle prosthesis for aphakia; multifocal 92353 Fitting of spectacle prosthesis for aphakia; multifocal 92354 Fitting of spectacle mounted low vision aid; single element 92355 Fitting of spectacle mounted low vision aid; single element 92356 Fitting of spectacle mounted low vision aid; telescopic 92358 Prosthesis service for aphakia, temporary 92370 Repair and refitting spectacles, except for aphakia 92371 Repair and refitting spectacles, except for aphakia 92371 Repair and refitting spectacles, spectacle prosthesis for aphakia 92512 Nasal function studies 92531 Spontaneous nystagmus, including gaze 92532 Positional nystagmus test 92533 Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests) 92534 Optokinetic nystagmus test 92545 Optokinetic nystagmus test 92546 Computerized dynamic posturography 92549 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT) 92588 Hair Analysis 92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device 92606 Therapeutic service(s) for the use of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.) 92633 Learning disability evaluation 92631 Learning disability evaluation		• • • • • • • • • • • • • • • • • • • •	
92352 Fitting of spectacle prosthesis for aphakia, monofocal 92353 Fitting of spectacle prosthesis for aphakia, multifocal 92354 Fitting of spectacle mounted low vision aid; single element 92355 Fitting of spectacle mounted low vision aid; telescopic 92358 Prosthesis service for aphakia, temporary 92370 Repair and refitting spectacles, except for aphakia 92371 Repair and refitting spectacles, except for aphakia 92371 Repair and refitting spectacles, except for aphakia 92512 Nasal function studies 92531 Spontaneous nystagmus, including gaze 92532 Positional nystagmus test 92533 Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests) 92534 Optokinetic nystagmus test 92544 Hyperactivity testing 92549 Computerized dynamic posturography 92540 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT) 92588 Hair Analysis 92606 Therapeutic service(s) for the use of non-speech-generating augmentative and alternative communication device 92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, including programming and modification 92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.) 92633 Learning disability evaluation			
92353 Fitting of spectacle prosthesis for aphakia; multifocal 92354 Fitting of spectacle mounted low vision aid; single element 92355 Fitting of spectacle mounted low vision aid; telescopic 92368 Prosthesis service for aphakia, temporary 92370 Repair and refitting spectacles, except for aphakia 92371 Repair and refitting spectacles, except for aphakia 92371 Repair and refitting spectacles, spectacle prosthesis for aphakia 92371 Spontaneous nystagmus, including gaze 92531 Spontaneous nystagmus, including gaze 92532 Positional nystagmus test 92532 Positional nystagmus test 92533 Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests) 92534 Optokinetic nystagmus test 92544 Hyperactivity testing 92545 Computerized dynamic posturography 92546 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT) 92588 Hair Analysis 92606 Evaluation for prescription of non-speech-generating augmentative and alternative communication device 192606 Therapeutic service(s) for the use of non-speech-generating augmentative and alternative communication device, including programming and modification 192618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.) 192633 Learning disability evaluation 192671 Cardioassist-method of circulatory assist; external (EECP)			
Fitting of spectacle mounted low vision aid; single element 92355 Fitting of spectacle mounted low vision aid; telescopic 92358 Prosthesis service for aphakia, temporary 92370 Repair and refitting spectacles, except for aphakia 92371 Repair and refitting spectacles, except for aphakia 92372 Nasal function studies 92373 Spontaneous nystagmus, including gaze 92531 Spontaneous nystagmus, including gaze 92532 Positional nystagmus test 92533 Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests) 92534 Optokinetic nystagmus test 92545 Computerized dynamic posturography 92548 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT) 92588 Hair Analysis 92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device 92606 Therapeutic service(s) for the use of non-speech-generating device, including programming and modification 92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.) 92633 Learning disability evaluation			
92355 Fitting of spectacle mounted low vision aid; telescopic 92358 Prosthesis service for aphakia, temporary 92370 Repair and refitting spectacles, except for aphakia 92371 Repair and refitting spectacles, except for aphakia 92371 Repair and refitting spectacles, spectacle prosthesis for aphakia 92371 Spontaneous nystagmus, including gaze 92531 Spontaneous nystagmus, including gaze 92532 Positional nystagmus test 92533 Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests) 92534 Optokinetic nystagmus test 92544 Hyperactivity testing 92545 Computerized dynamic posturography 92549 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT) 92588 Hair Analysis 92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device 92606 Therapeutic service(s) for the use of non-speech-generating device, including programming and modification 92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.) 92633 Learning disability evaluation 92971 Cardioassist-method of circulatory assist; external (EECP)			
92358 Prosthesis service for aphakia, temporary 92370 Repair and refitting spectacles, except for aphakia 92371 Repair and refitting spectacles, except for aphakia 92512 Nasal function studies 92513 Spontaneous nystagmus, including gaze 92532 Positional nystagmus test 92533 Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests) 92534 Optokinetic nystagmus test 92544 Hyperactivity testing 92545 Computerized dynamic posturography 92549 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT) 92588 Hair Analysis 92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device 92606 Therapeutic service(s) for the use of non-speech-generating device, including programming and modification 92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.) 92633 Learning disability evaluation 92971 Cardioassist-method of circulatory assist; external (EECP)			
Repair and refitting spectacles, except for aphakia  92371 Repair and refitting spectacles, spectacle prosthesis for aphakia  92512 Nasal function studies  92531 Spontaneous nystagmus, including gaze  92532 Positional nystagmus test  92533 Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests)  92534 Optokinetic nystagmus test  92545 Optokinetic nystagmus test  92546 Computerized dynamic posturography  92547 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)  92588 Hair Analysis  92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device  92606 Therapeutic service(s) for the use of non-speech-generating device, including programming and modification  92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.)  92633 Learning disability evaluation  92971 Cardioassist-method of circulatory assist; external (EECP)			
Repair and refitting spectacles, spectacle prosthesis for aphakia  92512 Nasal function studies  92531 Spontaneous nystagmus, including gaze  92532 Positional nystagmus test  92533 Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests)  92534 Optokinetic nystagmus test  92544 Hyperactivity testing  92548 Computerized dynamic posturography  92549 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)  92588 Hair Analysis  92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device  92606 Therapeutic service(s) for the use of non-speech-generating device, including programming and modification  92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.)  92633 Learning disability evaluation  92971 Cardioassist-method of circulatory assist; external (EECP)			
92512 Nasal function studies 92531 Spontaneous nystagmus, including gaze 92532 Positional nystagmus test 92533 Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests) 92534 Optokinetic nystagmus test 92549 Computerized dynamic posturography 92549 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT) 92588 Hair Analysis 92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device 92606 Therapeutic service(s) for the use of non-speech-generating device, including programming and modification 92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.) 92633 Learning disability evaluation 92971 Cardioassist-method of circulatory assist; external (EECP)	92371		
92531 Spontaneous nystagmus, including gaze 92532 Positional nystagmus test 92533 Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests) 92534 Optokinetic nystagmus test 92544 Hyperactivity testing 92548 Computerized dynamic posturography 92549 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT) 92588 Hair Analysis 92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device 92606 Therapeutic service(s) for the use of non-speech-generating device, including programming and modification 92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.) 92633 Learning disability evaluation 92971 Cardioassist-method of circulatory assist; external (EECP)			
Positional nystagmus test 92532 Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests) 92534 Optokinetic nystagmus test 92544 Hyperactivity testing 92548 Computerized dynamic posturography 92549 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT) 92588 Hair Analysis 92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device 92606 Therapeutic service(s) for the use of non-speech-generating device, including programming and modification 92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.) 92633 Learning disability evaluation 92971 Cardioassist-method of circulatory assist; external (EECP)	92512	Nasal function studies	
Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes four tests)  92534 Optokinetic nystagmus test  92544 Hyperactivity testing  92548 Computerized dynamic posturography  92549 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)  92588 Hair Analysis  92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device  92606 Therapeutic service(s) for the use of non-speech-generating device, including programming and modification  92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes  (List separately in addition to code for primary procedure.)  92633 Learning disability evaluation  92971 Cardioassist-method of circulatory assist; external (EECP)	92531	Spontaneous nystagmus, including gaze	
constitutes four tests)  92534 Optokinetic nystagmus test  92544 Hyperactivity testing  92548 Computerized dynamic posturography  92549 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)  92588 Hair Analysis  92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device  92606 Therapeutic service(s) for the use of non-speech-generating device, including programming and modification  92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes  (List separately in addition to code for primary procedure.)  92633 Learning disability evaluation  92971 Cardioassist-method of circulatory assist; external (EECP)	92532	Positional nystagmus test	
92534 Optokinetic nystagmus test 92544 Hyperactivity testing 92548 Computerized dynamic posturography 92549 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT) 92588 Hair Analysis 92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device 92606 Therapeutic service(s) for the use of non-speech-generating device, including programming and modification 92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.) 92633 Learning disability evaluation 92971 Cardioassist-method of circulatory assist; external (EECP)	92533	Caloric vestibular test, each irrigation (binaural, bithermal stimulation	
92544 Hyperactivity testing 92548 Computerized dynamic posturography 92549 Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)  92588 Hair Analysis 92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device 92606 Therapeutic service(s) for the use of non-speech-generating device, including programming and modification 92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.) 92633 Learning disability evaluation 92971 Cardioassist-method of circulatory assist; external (EECP)		constitutes four tests)	
Computerized dynamic posturography Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)  Hair Analysis  Evaluation for prescription of non-speech-generating augmentative and alternative communication device  Therapeutic service(s) for the use of non-speech-generating device, including programming and modification  Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes  (List separately in addition to code for primary procedure.)  Learning disability evaluation  Cardioassist-method of circulatory assist; external (EECP)	92534	Optokinetic nystagmus test	
Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)  92588 Hair Analysis  92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device  92606 Therapeutic service(s) for the use of non-speech-generating device, including programming and modification  92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.)  92633 Learning disability evaluation  92971 Cardioassist-method of circulatory assist; external (EECP)	92544		
SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)  92588 Hair Analysis  92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device  92606 Therapeutic service(s) for the use of non-speech-generating device, including programming and modification  92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.)  92633 Learning disability evaluation  92971 Cardioassist-method of circulatory assist; external (EECP)	92548		
sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)  92588 Hair Analysis  92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device  92606 Therapeutic service(s) for the use of non-speech-generating device, including programming and modification  92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes  (List separately in addition to code for primary procedure.)  92633 Learning disability evaluation  92971 Cardioassist-method of circulatory assist; external (EECP)	92549		
interpretation and report; with motor control test (MCT) and adaptation test (ADT)  92588 Hair Analysis  92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device  92606 Therapeutic service(s) for the use of non-speech-generating device, including programming and modification  92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes  (List separately in addition to code for primary procedure.)  92633 Learning disability evaluation  92971 Cardioassist-method of circulatory assist; external (EECP)			
test (ADT)  92588 Hair Analysis  92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device  92606 Therapeutic service(s) for the use of non-speech-generating device, including programming and modification  92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.)  92633 Learning disability evaluation 92971 Cardioassist-method of circulatory assist; external (EECP)			
92588 Hair Analysis  92605 Evaluation for prescription of non-speech-generating augmentative and alternative communication device  92606 Therapeutic service(s) for the use of non-speech-generating device, including programming and modification  92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes  (List separately in addition to code for primary procedure.)  92633 Learning disability evaluation  92971 Cardioassist-method of circulatory assist; external (EECP)			
Evaluation for prescription of non-speech-generating augmentative and alternative communication device  Therapeutic service(s) for the use of non-speech-generating device, including programming and modification  Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.)  Learning disability evaluation  Cardioassist-method of circulatory assist; external (EECP)			
and alternative communication device  Therapeutic service(s) for the use of non-speech-generating device, including programming and modification  P2618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.)  P2633 Learning disability evaluation  P2971 Cardioassist-method of circulatory assist; external (EECP)	92588		
Therapeutic service(s) for the use of non-speech-generating device, including programming and modification  92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.)  92633 Learning disability evaluation 92971 Cardioassist-method of circulatory assist; external (EECP)	92605		
including programming and modification  92618 Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.)  92633 Learning disability evaluation 92971 Cardioassist-method of circulatory assist; external (EECP)			
Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.)  Learning disability evaluation  Cardioassist-method of circulatory assist; external (EECP)	92606	, , , , , , , , , , , , , , , , , , , ,	
and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure.)  92633 Learning disability evaluation 92971 Cardioassist-method of circulatory assist; external (EECP)	222/-		
each additional 30 minutes (List separately in addition to code for primary procedure.)  92633 Learning disability evaluation 92971 Cardioassist-method of circulatory assist; external (EECP)	92618		
(List separately in addition to code for primary procedure.)  92633 Learning disability evaluation  92971 Cardioassist-method of circulatory assist; external (EECP)			
92633 Learning disability evaluation 92971 Cardioassist-method of circulatory assist; external (EECP)			
92971 Cardioassist-method of circulatory assist; external (EECP)			
93024 Ergonovine provocation test			
	93024	Ergonovine provocation test	

93050	Arterial pressure waveform analysis for assessment of central arterial	
	pressures	
93260	Programming device evaluation (in person) with iterative adjustment of	
	the implantable device to test the function of the device and select	
	optimal permanent programmed values with analysis, review and	
	report by a physician or other qualified health care professional;	
	implantable subcutaneous lead defibrillator system	
93261	Interrogation device evaluation (in person) with analysis, review and	
93201	report by a physician or other qualified health care professional,	
	includes connection, recording and disconnection per patient	
	encounter; implantable subcutaneous lead defibrillator system	
	cheduliter, implantable subcutaneous lead delibrillator system	
93278	Signal-averaged electocardiography, with or without ECG	
93356	Myocardial strain imaging using speckle tracking-derived assessment	
	of myocardial mechanics (List separately in addition to codes for	
	echocardiography imaging)	
93702	Bioimpedence spectroscopy extracellular fluid analysis	
93740	Temperature gradient studies	
93770	Determination of venous pressure	
93895	Quantitative carotid intima media thickness and carotid atheroma	
93982	Noninvasive physiologic study of implanted wireless pressure sensor	
	in aneurysmal sac following endovascu- lar repair, complete study	
	including recording, analysis of pressure and waveform tracings,	
	interpretation and report	
93985	Duplex scan of arterial inflow and venous outflow for preoperative	
	vessel assessment prior to creation of hemodialysis access; complete	
	bilateral study	
93986	Duplex scan of arterial inflow and venous outflow for preoperative	
	vessel assessment prior to creation of hemodialysis access; complete	
	unilateral study	
94005	Home ventilator management care plan oversight of a patient (patient	
	not present) in home, domicilary or rest home (e.g., assisted living)	
	requiring review of status, review of laboratories and other studies and	
	revision of orders and respiratory care plan	
04450	Vital agracity total (agravata procedure)	
94150 94669	Vital capacity, total (separate procedure)  Mechanical chest wall oscillation to facilitate lung function, per session	
94009	Mechanical criest wall oscillation to facilitate lung function, per session	
94762	Overnight measurement of oxygen saturation in blood using ear or	
	finger device	
95004	Percutaneous tests (scratch, puncture, prick) with allergenic extracts,	
	immediate type reaction, including test interpretation and report,	
	specify number of tests	
95024	Intracutaneous (intradermal) tests with allergenic extracts, immediate	
	type reaction, including test interpretation and report, specify number	
	of tests	
95027	Intracutaneous (intradermal) tests, sequential and incremental, with	
	allergenic extracts for airborne allergens, immediate type reaction,	
	including test interpretation and report, specify number of tests	
95028	Intracutaneous (intradermal) tests with allergenic extracts, delayed	
	type reaction, including reading, specify number of tests	
05044	ALLEDOV DATOUTECTO. Datab accomplication to all allege	
95044	ALLERGY PATCH TESTS - Patch or application test(s) (specify number of tests)	
95052	Photo patch test(s) (specify number of tests)	
95056	Photo tests	
95060	Ophthalmic mucous membrane tests	
95065	Direct nasal mucous membrane tests	
55555	Direct hasar macoas momerans tosts	

Professional services for allergen immunotherapy not including provision of allergenic extracts; single injection	
Professional services for allergen immunotherapy not including	
Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; single injection	
Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 2 or more injections	
Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; single stinging insect venom	
Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 2 stinging insect venoms	
Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 3 stinging insect venoms	
Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 4 stinging insect venoms	
Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 5 stinging insect venoms	
Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; sensor placement, hook-up, calibration of monitor, patient training, removal of sensor, and printout of recording	
Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; interpretation and report	
Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation and report, 2-12 hours of EEG recording; without video	
Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation and report, 2-12 hours of EEG recording; with video (VEEG)	
Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, each increment of greater than 12 hours, up to 26 hours of EEG recording, interpretation and report after each 24-hour period; without video	
Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, each increment of greater than 12 hours, up to 26 hours of EEG recording, interpretation and report after each 24-hour period; with video (VEEG)	
	provision of allergenic extracts; single injection  Professional services for allergen immunotherapy not including provision of allergenic extracts; 2 or more injections  Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; single injection  Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 2 or more injections  Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; single stinging insect venom  Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 2 stinging insect venoms  Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 3 stinging insect venoms  Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 4 stinging insect venoms  Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional, including provision of allergenic extract; 5 stinging insect venoms  Professional services for allergen immunotherapy in the office or institution of the prescribing physician or other qualified health care professional review of recorded events, and printout of recording physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpreta

95721	Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 36 hours, up to 60 hours of EEG recording, without video	
95722	Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 36 hours, up to 60 hours of EEG recording, with video (VEEG)	
95723	Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 60 hours, up to 84 hours of EEG recording, without video	
95724	Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 60 hours, up to 84 hours of EEG recording, with video (VEEG)	
95725	Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 84 hours of EEG recording, without video	
95726	Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 84 hours of EEG recording, with video (VEEG)	
95782	Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, attended by a technologist	
95783	Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bi-level ventilation, attended by a technologist	
95800	Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (eg, by airflow or peripheral arterial tone), and sleep time	
95801	Sleep study, unattended, simultaneous recording; minimum of heart rate, oxygen saturation, and respiratory analysis (eg, by airflow or peripheral arterial tone)	
95803	Actigraphy Testing	
95805	Multiple sleep latency or maintenance of wakefulness testing, recording, analysis and interpretation of physiological measurements of sleep during multiple trials to assess sleepiness	
95806	Sleep study, unattended, simultaneous recording of, heart rate, oxygen saturation, respiratory airflow, and respiratory effort (eg, thoracoabdominal movement)	
95807	Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended by a technologist	
95808	Polysomnography; any age, sleep staging with 1-3 additional parameters of sleep, attended by a technologist	
95810	Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist	
<u> </u>		<u> </u>

95811	Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist	
95836	Electrocorticogram from an implanted brain neurostimulator pulse generator/transmitter, including recording, with interpretation and written report, up to 30 days	
95976	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional	
95977	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with complex cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional	
95983	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, first 15 minutes face-to-face time with physician or other qualified health care professional	
95990	Refilling and maintenance of implantable pump or reservoir for drug delivery, spinal (intrathecal, epidural) or brain (intraventricular)	
95991	Refilling and maintenance of implantable pump or reservoir for drug delivery, spinal (intrathecal, epidural) or brain (intraventricular); administered by physician	
95992	Canalith repositioning procedure(s) (e.g., epley maneuver semont maneuver) per day	
96000	Comprehensive computer-based motion analysis by video-taping and 3-D kinematics	
96001	Comprehensive computer-based motion analysis by video-taping and 3-D kinematics	
96002	Dynamic surface electromyography, during walking or other functional activities	
96003	Dynamic fine wire electromyography	
96004	Physician review and interpretation of comprehensive computer based motion analysis, dynamic plantar pressure measurements	
96127	Hyperactivity testing	
96156	Health behavior assessment, or re-assessment (ie, health-focused clinical interview, behavioral observations, clinical decision making)	
96158	Health behavior intervention, individual, face-to-face; initial 30 minutes	
96159	Health behavior intervention, individual, face-to-face; each additional 15 minutes (List separately in addition to code for primary service)	

Administration of health risk assessment instrument	
Administration of health risk assessment instrument	
Health behavior intervention, group (2 or more patients), face-to-face; initial 30 minutes	
Health behavior intervention, group (2 or more patients), face-to-face; each additional 15 minutes (List separately in addition to code for primary service)	
Health behavior intervention, family (with the patient present), face-to-face; initial 30 minutes	
Health behavior intervention, family (with the patient present), face-to- face; each additional 15 minutes (List separately in addition to code for primary service)	
Health behavior intervention, family (without the patient present), face-to-face; initial 30 minutes	
Health behavior intervention, family (without the patient present), face- to-face; each additional 15 minutes (List separately in addition to code for primary service)	
Application of on-body injector (includes cannula insertion) for timed subcutaneous injection	
Refilling and maintenance of portable pump	
delivery, systemic (e.g., intravenous, intra- arterial)	
premalignant and/or malignant lesions	
Microscopic examination of hairs plucked or clipped by the examiner (excluding hair collected by the patient) to determine telogen and anagen counts, or structural hair shaft abnormality	
Whole body integumentary photography, for monitoring of high risk patients with dysplastic nevus syndrome or a history of dysplastic nevi, or patients with a personal or familial history of melanoma	
Laser treatment for inflammatory skin disease (psoriasis); total area less than 250 sq cm	
Laser treatment for inflammatory skin disease (psoriasis); 250 sq cm to 500 sq cm	
Laser treatment for inflammatory skin disease (psoriasis); over 500 sq cm	
Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin;	
Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin;	
Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin;	
Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin;	
Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin;	
Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin;	
Therapeutic interventions that focus on cognitive function (eg, attention, memory, reasoning, executive function, problem solving, and/or pragmatic functioning) and compensatory strategies to manage the performance of an activity (eg, managing time or schedules, initiating, organizing, and sequencing tasks), direct (one-on-one) patient contact; initial 15 minutes	
	Health behavior intervention, group (2 or more patients), face-to-face; initial 30 minutes  Health behavior intervention, group (2 or more patients), face-to-face; each additional 15 minutes (List separately in addition to code for primary service)  Health behavior intervention, family (with the patient present), face-to-face; initial 30 minutes  Health behavior intervention, family (with the patient present), face-to-face; each additional 15 minutes (List separately in addition to code for primary service)  Health behavior intervention, family (without the patient present), face-to-face; each additional 15 minutes (List separately in addition to code for primary service)  Health behavior intervention, family (without the patient present), face-to-face; each additional 15 minutes (List separately in addition to code for primary service)  Application of on-body injector (includes cannula insertion) for timed subcutaneous injection  Refilling and maintenance of portable pump  Refilling and maintenance of implantable pump or reservoir for drug delivery, systemic (e.g., intravenous, intra- arterial)  Photodynamic therapy by external application of light to destroy premalignant and/or malignant lesions  Microscopic examination of hairs plucked or clipped by the examiner (excluding hair collected by the patient) to determine telogen and anagen counts, or structural hair shaft abnormality  Whole body integumentary photography, for monitoring of high risk patients with dysplastic nevus syndrome or a history of dysplastic nevi, or patients with a personal or familial history of melanoma  Laser treatment for inflammatory skin disease (psoriasis); total area less than 250 sq cm  Laser treatment for inflammatory skin disease (psoriasis); voer 500 sq cm  Laser treatment for inflammatory skin disease (psoriasis); voer 500 sq cm  Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin;  Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin;  Reflectance confocal micros

97130	Therapeutic interventions that focus on cognitive function (eg, attention, memory, reasoning, executive function, problem solving, and/or pragmatic functioning) and compensatory strategies to manage the performance of an activity (eg, managing time or schedules, initiating, organizing, and sequencing tasks), direct (one-on-one) patient contact; each additional 15 minutes (List separately in addition to code for primary procedure)	
97169	Athletic training evaluation, low complexity, requiring these components: A history and physical activity profile with no comorbidities that affect physical activity; An examination of affected body area and other symptomatic or related systems addressing 1-2 elements from any of the following: body structures, physical activity, and/or participation deficiencies; and Clinical decision making of low complexity using standardized patient assessment instrument and/or measurable assessment of functional outcome. Typically, 15 minutes are spent face-to-face with the patient and/or family.	
97170	Athletic training evaluation, moderate complexity, requiring these components: A medical history and physical activity profile with 1-2 comorbidities that affect physical activity; An examination of affected body area and other symptomatic or related systems addressing a total of 3 or more elements from any of the following: body structures, physical activity, and/or participation deficiencies; and Clinical decision making of moderate complexity using standardized patient assessment instrument and/or measurable assessment of functional outcome. Typically, 30 minutes are spent face-to-face with the patient and/or family.	
97171	Athletic training evaluation, high complexity, requiring these components: A medical history and physical activity profile, with 3 or more comorbidities that affect physical activity; A comprehensive examination of body systems using standardized tests and measures addressing a total of 4 or more elements from any of the following: body structures, physical activity, and/or participation deficiencies; Clinical presentation with unstable and unpredictable characteristics; and Clinical decision making of high complexity using standardized patient assessment instrument and/or measurable assessment of functional outcome. Typically, 45 minutes are spent face-to-face with the patient and/or family.	
97172	Re-evaluation of athletic training established plan of care requiring these components: An assessment of patient's current functional status when there is a documented change; and A revised plan of care using a standardized patient assessment instrument and/or measurable assessment of functional outcome with an update in management options, goals, and interventions. Typically, 20 minutes are spent face-to-face with the patient and/or family.	
97533	Sensory integrative techniques to enhance sensory processing	
97545	Work hardening/conditioning, initial two hours	
97546 97602	Work hardening/conditioning, each additional hour  Removal of devitalized tissue from wound(s), non- selective	
	debridement, without anesthesia (e.g., wet-to- moist dressing, enzymatic, abrasion), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session	
97750	Physical perform test or measurement, w/written report, each 15 min.	
97810	Acupuncture, one or more needles, without electrical stimulation; initial 15 minutes of personal one-on-one contact with the patient	
I	•	

97813	Acupuncture, one or more needles, without electrical stimulation; each additional 15 minutes of personal one- on-one contact with the patient, with re-insertion of needle(s) (list separately in addition to code for primary procedure)  Acupuncture, one or more needles, with electrical stimu- lation; initial 15 minutes of personal one-on-one contact with the patient	
	· · ·	
;	Acupuncture, one or more needles, with electrical stimulation; each additional 15 minutes of personal one- on-one contact with the patient, with re-insertion of needle(s) (list separately in addition to code for primary procedure)	
98925	Chiropractic services/treatment	
	Chiropractic services/treatment	
98927	Chiropractic services/treatment	
98928	Chiropractic services/treatment	
98929	Chiropractic services/treatment	
98940	Chiropractic services/treatment	
98941	Chiropractic services/treatment	
	Chiropractic services/treatment	
	Chiropractic services/treatment	
	Education and training for patient seft-managment by a qualified, nonphysician health care professional using a standardized curriculum, face-to-face with the patient (could include caregiver/family) each 30 minutes; indi- vidual patient	
	Education/training for patient self management by qual, non-MD health care professional w/standard curriculum, face/face w/patient (caregiver, family) each 30 mins.; 2–4 patients	
	Education/training for patient self management by qual, non-MD health care professional w/standard curriculum, face/face w/patient (caregiver, family) each 30 mins.; 5–8 patients	
 	Telephone assessment and management service provided by a qualified nonphysician health care professional to an established patient, parent, or guardian not originating from a related assessment and management service provided within the previous 7 days nor leading to an assessment and management service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion	
 	Telephone assessment and management service provided by a qualified nonphysician health care professional to an established patient, parent, or guardian not originating from a related assessment and management service provided within the previous 7 days nor leading to an assessment and management service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion	
 	Telephone assessment and management service provided by a qualified nonphysician health care professional to an established patient, parent, or guardian not originating from a related assessment and management service provided within the previous 7 days nor leading to an assessment and management service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion	
	Qualified nonphysician health care professional online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes	
	Qualified nonphysician health care professional online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 11-20 minutes	

98972		
00000	Qualified nonphysician health care professional online digital	
00000	evaluation and management service, for an established patient, for up	
00000	to 7 days, cumulative time during the 7 days; 21 or more minutes	
00000	and a day of the fill	
00000		
99000	Handling and/or conveyance of specimen for transfer from the office	
	to a laboratory	
99001	Handling and/or conveyance of specimen for transfer from the patient	
	in other than an office to a laboratory (distance may be indicated)	
	distance may be indicated)	
99002	Handling, conveyance, and/or any other service in con- nection with	
	the implementation of an order involving devices	
99024	Postoperative follow-up visit, included in global service	
99026	Hospital mandated on call srvc, in-hospital, each hour	
99027	Hospital mandated on call srvc, out-of-hospital, each hour	
99051	Services provided in the office during regularly scheduled evening,	
	weekend, or holiday office hours, in addition to basic service	
	Wookena, or heliday emice hedre, in addition to bacic convice	
99053	Services provided 10 p.m.–8 a.m. at a 24-hour facility, in addition to	
	basic service	
99056	Service(s) typically provided in the office, provided out of the office at	
33300	request of patient, in addition to basic service	
00050		
99058	Office services provided on an emergency basis	
99060	Services provided on an emerg basis out of the office which disrupts	
	other scheduled office services in addition to basic service	
00070		
99070	Materials charges	
99071	Educational supplies	
99075	Medical testimony	
99078	Physician or other qualified health care professional qualified by	
33070		
	education, training, licensure/regulation (when applicable) educational	
	services rendered to patients in a group setting (eg, prenatal, obesity,	
	or diabetic instruc- tions)	
99080	Special reports	
99082	· · ·	
	Unusual travel (e.g., transportation and escort of patient)	
99091	Collection and interpretation of physiologic data (e.g., ecg, blood	
	pressure, glucose monitoring) digitally stored and/or transmitted by	
	the patient and/or caregiver to the physician or other qualified health	
	the patient and/or caregiver to the physician or other qualified health care professional, requiring a minimum of 30 minutes	
	the patient and/or caregiver to the physician or other qualified health care professional, requiring a minimum of 30 minutes	
	care professional, requiring a minimum of 30 minutes	
99100		
99100	care professional, requiring a minimum of 30 minutes	
	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70	
99100 99116	care professional, requiring a minimum of 30 minutes	
99116	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia	
	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70	
99116	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia	
99116 99135	Anesthesia complicated by utilization of controlled hypotension	
99116 99135 99140	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)	
99116 99135	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)  Ipecac or similar administration for individual emesis and continued	
99116 99135 99140	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)	
99116 99135 99140	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)  Ipecac or similar administration for individual emesis and continued	
99116 99135 99140 99175	Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)  Ipecac or similar administration for individual emesis and continued observation until stomach adequately emptied of poison	
99116 99135 99140	Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)  Ipecac or similar administration for individual emesis and continued observation until stomach adequately emptied of poison  Physician attendance and supervision of hyperbaric oxygen therapy,	
99116 99135 99140 99175	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)  Ipecac or similar administration for individual emesis and continued observation until stomach adequately emptied of poison  Physician attendance and supervision of hyperbaric oxygen therapy, per session	
99116 99135 99140 99175 99183 99195	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)  Ipecac or similar administration for individual emesis and continued observation until stomach adequately emptied of poison  Physician attendance and supervision of hyperbaric oxygen therapy, per session  Phlebotomy, therapeutic (separate procedure)	
99116 99135 99140 99175	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)  Ipecac or similar administration for individual emesis and continued observation until stomach adequately emptied of poison  Physician attendance and supervision of hyperbaric oxygen therapy, per session	
99116 99135 99140 99175 99183 99195 99199	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)  Ipecac or similar administration for individual emesis and continued observation until stomach adequately emptied of poison  Physician attendance and supervision of hyperbaric oxygen therapy, per session  Phlebotomy, therapeutic (separate procedure)  Unlisted special service, procedure or report	
99116 99135 99140 99175 99183 99195	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)  Ipecac or similar administration for individual emesis and continued observation until stomach adequately emptied of poison  Physician attendance and supervision of hyperbaric oxygen therapy, per session  Phlebotomy, therapeutic (separate procedure)  Unlisted special service, procedure or report  Physician direction of emergency medical systems (ems) emergency	
99116 99135 99140 99175 99183 99195 99199 99288	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)  Ipecac or similar administration for individual emesis and continued observation until stomach adequately emptied of poison  Physician attendance and supervision of hyperbaric oxygen therapy, per session  Phlebotomy, therapeutic (separate procedure)  Unlisted special service, procedure or report  Physician direction of emergency medical systems (ems) emergency care, advanced life support	
99116 99135 99140 99175 99183 99195 99199 99288 99354	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)  Ipecac or similar administration for individual emesis and continued observation until stomach adequately emptied of poison  Physician attendance and supervision of hyperbaric oxygen therapy, per session  Phlebotomy, therapeutic (separate procedure)  Unlisted special service, procedure or report  Physician direction of emergency medical systems (ems) emergency care, advanced life support  Prolonged phys svc in office or opd, face-to-face, first hour	
99116 99135 99140 99175 99183 99195 99199 99288	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)  Ipecac or similar administration for individual emesis and continued observation until stomach adequately emptied of poison  Physician attendance and supervision of hyperbaric oxygen therapy, per session  Phlebotomy, therapeutic (separate procedure)  Unlisted special service, procedure or report  Physician direction of emergency medical systems (ems) emergency care, advanced life support	
99116 99135 99140 99175 99183 99195 99199 99288 99354 99355	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)  Ipecac or similar administration for individual emesis and continued observation until stomach adequately emptied of poison  Physician attendance and supervision of hyperbaric oxygen therapy, per session  Phlebotomy, therapeutic (separate procedure)  Unlisted special service, procedure or report  Physician direction of emergency medical systems (ems) emergency care, advanced life support  Prolonged phys svc in office or opd, face-to-face, first hour  Prolong phys serv in office/op/each additional 30 minutes	
99116 99135 99140 99175 99183 99195 99199 99288 99354	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)  Ipecac or similar administration for individual emesis and continued observation until stomach adequately emptied of poison  Physician attendance and supervision of hyperbaric oxygen therapy, per session  Phlebotomy, therapeutic (separate procedure)  Unlisted special service, procedure or report  Physician direction of emergency medical systems (ems) emergency care, advanced life support  Prolonged phys svc in office or opd, face-to-face, first hour  Prolonged phys serv in office/op/each additional 30 minutes  Prolonged phys serv/in pat/requiring direct (face-to-face) patient	
99116 99135 99140 99175 99183 99195 99199 99288 99354 99355 99356	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)  Ipecac or similar administration for individual emesis and continued observation until stomach adequately emptied of poison  Physician attendance and supervision of hyperbaric oxygen therapy, per session  Phlebotomy, therapeutic (separate procedure)  Unlisted special service, procedure or report  Physician direction of emergency medical systems (ems) emergency care, advanced life support  Prolonged phys svc in office or opd, face-to-face, first hour  Prolonged phys serv/in pat/requiring direct (face-to-face) patient contact	
99116 99135 99140 99175 99183 99195 99199 99288 99354 99355	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)  Ipecac or similar administration for individual emesis and continued observation until stomach adequately emptied of poison  Physician attendance and supervision of hyperbaric oxygen therapy, per session  Phlebotomy, therapeutic (separate procedure)  Unlisted special service, procedure or report  Physician direction of emergency medical systems (ems) emergency care, advanced life support  Prolonged phys svc in office or opd, face-to-face, first hour  Prolonged phys serv/in pat/requiring direct (face-to-face) patient contact  Prolonged phys serv/in pat/requiring direct patient contact, each add'l	
99116 99135 99140 99175 99183 99195 99199 99288 99354 99355 99356	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)  Ipecac or similar administration for individual emesis and continued observation until stomach adequately emptied of poison  Physician attendance and supervision of hyperbaric oxygen therapy, per session  Phlebotomy, therapeutic (separate procedure)  Unlisted special service, procedure or report  Physician direction of emergency medical systems (ems) emergency care, advanced life support  Prolonged phys svc in office or opd, face-to-face, first hour  Prolonged phys serv/in pat/requiring direct (face-to-face) patient contact	
99116 99135 99140 99175 99183 99195 99199 99288 99354 99355 99356	care professional, requiring a minimum of 30 minutes  Anesthesia for patient of extreme age, under one year & over 70  Anesthesia complicated by utilization of total body hypothermia  Anesthesia complicated by utilization of controlled hypotension  Anesthesia complicated by emergency conditions (specify)  Ipecac or similar administration for individual emesis and continued observation until stomach adequately emptied of poison  Physician attendance and supervision of hyperbaric oxygen therapy, per session  Phlebotomy, therapeutic (separate procedure)  Unlisted special service, procedure or report  Physician direction of emergency medical systems (ems) emergency care, advanced life support  Prolonged phys svc in office or opd, face-to-face, first hour  Prolonged phys serv/in pat/requiring direct (face-to-face) patient contact  Prolonged phys serv/in pat/requiring direct patient contact, each add'l	

00250	Drolonged aval 2 mat convince directlin notledd! 20 minutes	
99359	Prolonged eval & mgt serv/non-direct/in pat/add'l 30 minutes	
99360	Phys standby serv/prolonged attend/each 30 minutes	
99366	Medical team conference with interdisciplinary team of health care	
	professionals, face-to-face with patient and/or family, 30 minutes or	
	more, participation by nonphysician qualified health care professional	
99367	Medical team conference with interdisciplinary team of health care	
00001	professionals, patient and/or family not present, 30 minutes or more;	
	participation by physician	
99368	Medical team conference with interdisciplinary team of health care	
33300	professionals, patient and/or family not present, 30 minutes or more;	
	participation by nonphysician qualified health care professional	
	participation by non-physician qualified reduct out of professional	
99415	Prolonged clinical staff service (the service beyond the typical service	
	time) during an evaluation and manage- ment service in the office or	
	outpatient setting, direct patient contact with physician supervision;	
	first hour (list separately in addition to code for outpatient evaluation	
	and management service)	
99416	Prolonged clinical staff service, each additional 30 min- utes	
99421	Online digital evaluation and management service, for an established	
	patient, for up to 7 days, cumulative time during the 7 days; 5-10	
	minutes	
99422	Online digital evaluation and management service, for an established	
	patient, for up to 7 days, cumulative time during the 7 days; 11-20	
	minutes	
99423	Online digital evaluation and management service, for an established	
	patient, for up to 7 days, cumulative time during the 7 days; 21 or	
	more minutes	
99442	Telephone evaluation and management service by a physician or	
	other qualified health care professional who may report evaluation and	
	management services provided to an established patient, parent, or	
	guardian not originating from a related E/M service provided within the	
	previous 7 days nor leading to an E/M service or procedure within the	
	next 24 hours or soonest available appointment; 11-20 minutes of	
	medical discussion	
99443	Telephone evaluation and management service by a physician or	
	other qualified health care professional who may report evaluation and	
	management services provided to an established patient, parent, or	
	guardian not originating from a related E/M service provided within the	
	previous 7 days nor leading to an E/M service or procedure within the	
	next 24 hours or soonest available appointment; 21-30 minutes of	
	medical discussion	
99446	Interprofessional telephone/Internet assessment and management	
	service provided by a consultative physician including a verbal and	
	written report to the patient's treating/requesting physician or other	
	qualified health care professional; 5-10 minutes of medical	
	consultative discussion and review	
99447	Interprofessional telephone/Internet assessment and management	
	service provided by a consultative physician including a verbal and	
	written report to the patient's treating/requesting physician or other	
	qualified health care professional; 11-20 minutes of medical	
	consultative discussion and review	
99448	Interprofessional telephone/Internet assessment and management	
	service provided by a consultative physician including a verbal and	
	written report to the patient's treating/requesting physician or other	
	qualified health care professional; 21-30 minutes of medical	
	consultative discussion and review	

		T
99449	Interprofessional telephone/Internet assessment and management service provided by a consultative physician including a verbal and written report to the patient's treating/requesting physician or other qualified health care professional; 31 minutes or more of medical consultative discussion and review	
99450	Life/disability evaluation	
99455	Work related or medical disability examination by the treating physician that includes: Completion of a medical history commensurate with the patient's condition; Performance of an examination commensurate with the patient's condition; Formulation of a diagnosis, assessment of capabilities and stability, and calculation of impairment; Development of future medical treatment plan; and Completion of necessary documentation/certificates and report.	
99456	Work related or medical disability examination by other than the treating physician that includes: Completion of a medical history commensurate with the patient's condition; Performance of an examination commensurate with the patient's condition; Formulation of a diagnosis, assessment of capabilities and stability, and calculation of impairment; Development of future medical treatment plan; and Completion of necessary documentation/certificates and report.	
99458	Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; each additional 20 minutes (List separately in addition to code for primary procedure)	
99473	Self-measured blood pressure using a device validated for clinical accuracy; patient education/training and device calibration	
99474	Self-measured blood pressure using a device validated for clinical accuracy; separate self-measurements of two readings one minute apart, twice daily over a 30-day period (minimum of 12 readings), collection of data reported by the patient and/or caregiver to the physician or other qualified health care professional, with report of average systolic and diastolic pressures and subsequent communication of a treatment plan to the patient	
99487	Complex chronic care management services, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, establishment or substantial revision of a comprehensive care plan, moderate or high complexity medical decision making; 60 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month	
99489	Complex chronic care management services, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, establishment or substantial revision of a comprehensive care plan, moderate or high complexity medical decision making; 60 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month.; each additional 30 minutes	
30.00	Chronic care management services	<u> </u>

99497	Advance care planning including the explanation and discussion of	
	advance directives such as standard forms (with completion of such	
	forms, when performed), by the physician or other qualified health	
	care professional; first 30 minutes, face-to-face with the patient, family	
	member(s), and/or surrogate	
	member(3), and/or surrogate	
00.400	Advanced to the state of the second section and discussion of	
99498	Advance care planning including the explanation and discussion of	
	advance directives such as standard forms (with completion of such	
	forms, when performed), by the physician or other qualified health	
	care professional; each additional 30 minutes (List separately in	
	addition to code for primary procedure)	
99512	Home visit for hemodialysis	
99600	Unlisted home visit service or procedure	
99605	Medication therapy management service(s) provided by a pharmacist,	
	individual, face-to-face with patient, with assessment and intervention	
	if provided; initial 15 minutes, new patient	
	n promosa, minar no minaros, mon panom	
99606	Medication therapy management service(s) provided by a pharmacist,	
20000	individual, face-to-face with patient, with assessment and intervention	
	if provided; initial 15 minutes, established patient	
	ii provided, iriitai 15 mindles, established patient	
99607	Modication thereby management consider(a) are sided by a share side	
99607	Medication therapy management service(s) provided by a pharmacist,	
	individual, face-to-face with patient, with assessment and intervention	
	if provided; each additional 15 minutes (List separately in addition to	
	code for primary service)	
HCPCS		
A0021	Ambulance service outside state	
A0080	Non-emergency transportation: per mile–volunteer with no personal	
	interest	
A0090	Non-emergency transportation: per mile– vehicle provided by	
	individual w/vested interest	
A0100	Non-emergency transportation	
A0110	Nonemergency transportation and bus, intra- or interstate carrier	
A 0.4.00	Non-constant form of the second state of the s	
A0120	Non-emergency transportation: mini-bus, mountain area transports, or	
10100	other transportation systems	
A0130	Nonemergency transportation: wheelchair van	
A0140	Nonemergency transportation and air travel (private or commercial),	
	intra- or interstate (Fixed wing)	
A0160	Nonemergency transportation: per mile - caseworker or social worker	
A0470	Transportation ancillant parking focal talls, ather	
A0170	Transportation ancillary: parking fees, tolls, other	
A0180	Nonemergency transportation: ancillary: lodging – recipient	
A0190	Nonemergency transportation: ancillary: meals – recipient	
A0200	Nonemergency transportation: ancillary: lodging – escort	
A0210	Nonemergency transportation: ancillary: meals – escort	
A0392	ALS specialized service disposable supplies; defibrillation (to be used	
	only in jurisdictions where defibrillation cannot be performed by BLS	
	ambulances Note: Included in the global ambulance service	
A0394	ALS specialized service disposable supplies; IV drug therapy Note:	
105	Included in the global ambulance service	
A0396	ALS specialized service disposable supplies; esophageal intubation	
	Note: Included in the global ambulance service	
A0398	ALS routine disposable supplies	
	Note: Included in the global ambulance service	
A0420	Ambulance service waiting time (one half-hour)	
A0424	Ambulance service extra attendant	
A0426	Ambulance, advanced life support, nonemergency transport	

A0427	Ambulance coming advanced life cumpert, amorganou transport level	
AU427	Ambulance service, advanced life support, emergency transport, level 1	
A0428	Ambulance, basic life support, nonemergency transport	
A0429	Ambulance service, basic life support, emergency transport	
A0432	Paramedic intercept (PI), rural area, transport furnished by a volunteer	
70402	i aramedie intercept (17), fural area, transport furnished by a volunteer	
A0434	Specialty Care Transport (SCT)	
A0888	Non-covered ambulance mileage, per mile (e.g., for miles traveled	
7.0000	beyond closest appropriate facility)	
A0998	Ambulance response and treatment, no transport	
A0999	Unlisted ambulance service	
A4206	Syringe with needle, sterile, 1cc or less, each	
A4210	Needle-free injection device, each	
A4215	Needle, sterile, any size, each	
A4220	Refill kit implantable fusion pump	
A4226	Supplies for maintenance of insulin infusion pump with dosage rate	
	adjustment using therapeutic continuous glucose sensing, per week	
A4230	Infusion set for external insulin pump, non needle cannula type	
A4231	Infusion set for external insulin pump, needle type	
A4232	Syringe with needle for external insulin pump, sterile, 3 c	
A4233	Replacement batteries for use with medically necessary home blood	
	glucose monitor owned by patient	
A4234	Replacement batteries for use with medically necessary home blood	
	glucose monitor owned by patient	
A4235	Replacement batteries for use with medically necessary home blood	
	glucose monitor owned by patient	
A4236	Replacement batteries for use with medically necessary home blood	
	glucose monitor owned by patient	
A4250	Urine reagent strips/tablets	
A4252	Blood ketone test or reagent strip, each	
A4253	Blood glucose/reagent strips	
A4254	Battery for glucose monitor	
A4255	Glucose monitor platforms	
A4256	Normal, low and high calibrator solution/chips	
A4258	Spring powered device for lancet, each	
A4259	Lancets, per box of 100	
A4262	Temp absorb lacrimal duct implant	
A4263	Perm non-dis lacrimal duct implant	
A4267	Contraceptive supply, condom, male, each	
A4268	Contraceptive supply, condom, female, each	
A4269	Contraceptive supply, spermacide (foam, gel), each	
A4270	Disposable endoscope sheath, each	
A4300	Implantable access catheter (venous, arterial, epidural or peritoneal),	
1 100-	extn	
A4305	Disposable drug delivery system/catheter	
A4306	Disposable drug delivery system/catheter	
A4450	Tape, non-waterproof, per 18 sq. in.	
A4452	Tape, waterproof, per 18 sq. in.	
A4455	Adhesive remover or solvent per ounce	
A4458	Enema bag with tubing	
A4459	Manual pump-operated enema system, includes balloon, catheter and all accessories, reusable, any type	
A 4 4 6 4		
A4461	Surgical dressing holder, non-reusable, each	
A4470	Gravlee jet washer	
A4480	Vabra aspirator	
A4550	Surgical trays	
A4559	Coupling gel or paste, for use with ultrasound device, per oz	
A4563	Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each	
	IDUIND AND AN AUDINES AND AUGESSUITES. ANY LYDE EACH	
A4575	Topical hyperbaric oxygen chamber, disposable	

A4580	Cast supplies	
A4580 A4590	Special casting materials	
A4601	Lithium ion battery for non prosthetic use, replacement	
A4601 A4602	Replacement battery for external infusion pump owned by patient,	
	lithium, 1.5 volt, each	
A4638	Replacement battery for patient-owned ear pulse genera- tor, each	
A4639	Replacement pad for infrared heating pad system, each	
A4641	Radiopharm diagnostic imaging agent noc	
A4649	Surgical supply; miscellaneous	
A4772	Blood glucose test strips	
A4870	Plumbing and/or electrical work for home hemodialysis equipment	
A4890	Contracts, repair and maintenance, for hemodialysis equipment	
A4931	Oral thermometer, reusable, any type, each	
A4932	Rectal thermometer, reusable, any type, each	
A5514	For diabetics only, multiple density insert, made by direct carving with	
	cam technology from a rectified cad model created from a digitized scan of the patient, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each	
A6000	Non-contact wound warming wound cover for use with the non-contact wound warming device	
A6025	Silicone gel sheet, each	
A6257	Transparent film, sterile, 16 sq in or	
A7025	High frequency chest wall oscillation system vest, replacement	
A7026	High frequency chest wall oscillation system hose, replacement	
A8000	less, each dressing	
A8001	Helmet, protective, hard, prefabricated, includes all components and accessories	
A9150	Non-prescription drugs	
A9270	Non-covered item or service	
A9274	External ambulatory insulin delivery system, disposable, each, includes all supplies and accessories	
A9276	Sensor; invasive (e.g., subcutaneous), disposable, for use with interstitial continuous glucose monitoring system, one unit = 1 day supply	
A9275	Disposable home glucose monitor	
A9277	Transmitter; external, for use with interstitial continuous glucose monitoring system	
A9278	External receiver, cgm sys	
A9279	Monitoring feature/device, stand-alone or integrated, any type, includes all accessories, components and electronics, not otherwise classified	
A9280	Alert or alarm device, not otherwise classified	
A9281	Reaching/grabbing device, any type, any length, each	
A9300	Exercise equipment	
A9510	Supply of radiopharmaceutical diagnostic imaging agent, technetium tc99m	
A9700	Supply of injectable contrast material for use in echocardiography	
A9901	Delivery, set up, and/or dispensing service component of another HCPCS code	
B4105	In-line cartridge containing digestive enzyme(s) for enteral feeding, each	
B4187	Omegaven, 10 grams lipids	
	Parent nutr additives	
B4216		
B4216 B4220	Parent nutr supply kit premix	
B4220	Parent nutr supply kit premix	

Brachytherapy source, non-stranded, gold-198, per source Brachytherapy source, non-stranded, high dose rate iridium-192, per source Brachytherapy source, iodine 125, per source Brachytherapy source, non-stranded, non-high dose rate iridium-192,	
source Brachytherapy source, iodine 125, per source	
per source	
Cardioverter Defibrillator, Dual Chamber Implantable	Device donation required
Cardioverter Defibrillator, Single Chamber Implantable	Device donation required
. , , , , , , , , , , , , , , , , , , ,	
issue-to bone (implantable)	
Endoscope, retrograde imaging/illumination colonoscope device (implantable)	
nfusion pump, programmable (implantable)	
Pacemaker, Dual Chamber (implantable)	Device donation required
Pacemaker, Single Chamber (implantable)	Device donation required
ntegrated keratoprothesis	
nterspinous process distraction device (implantable)	
Generator, neurostimulator implantable	
Generator, neurostimulator (implantable), non-rechargeable, with	
-	
, , , , , , , , , , , , , , , , , , , ,	
'	
'	
·	
	Device donation required
· · · · · · · · · · · · · · · · · · ·	
Catheter, pressure-generating, one-way valve, intermittently occlusive	
Probe, image-guided, robotic, waterjet ablation	
Probe, percutaneous lumbar discectomy	
Brachytherapy source, non-stranded, yttrium-90, per source	
Pacemaker, Dual Chamber	Device donation required
Pacemaker, Single Chamber	Device donation required
Pacemaker, Other than Single or Dual	Device donation required
mplantable wireless pulmonary artery pressure sensor with delivery	
Brachytherapy source, non-stranded, High Activity, Iodine-125,	
greater than 2.2 mci (nist), per source	
Brachytherapy linear source, non-stranded, palladium-103, per 1 mm	
Brachytherapy source, non-stranded, Ytterbium-169, per source	
Brachytherapy source, stranded, lodine-125, per source	
, ,,	
Brachytherapy source, non-stranded, Palladium-103, per source	
Brachytherapy source, stranded, Cesium-131, per source	
Brachytherapy source, non-stranded, Cesium-131, per source	
Brachytherapy source, cesium-131 chloride solution, per millicurie	
Brachytherapy planar source, palladium-103, per square millimeter	
Brachytherapy source, stranded, not otherwise specified, per source	
Brachytherapy source, non-stranded, not otherwise specified, per source	
	Catheter, brachytherapy seed administration Orthopedic/device/drug matrix for opposing bone-to-bone or soft issue-to bone (implantable) Endoscope, retrograde imaging/illumination colonoscope device implantable) Infusion pump, programmable (implantable) Pacemaker, Dual Chamber (implantable) Pacemaker, Single Chamber (implantable) Pacemaker, Single Chamber (implantable) Pacemaker, Single Chamber (implantable) Pacemator, neurostimulator implantable) Pacemator, neurostimulator (implantable), non-rechargeable, with Paransvenous sensing and stimulation leads Pacemator, cardiac contractility modulation (implantable) Pacemator, pacemator, cardiac contractility modulation (implantable) Pacemator, pacemator, cardiac contractility modulation (implantable) Pacemator, pacemator, cardiac pacemator, cardiac contractility modulation, pacemator, cardiac pacemator,

00007	Operation of the distriction of the Property o	
C8937	Computer-aided detection, including computer algorithm analysis of	
	breast mri image data for lesion detection/characterization,	
	pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)	
	interpretation (list separately in addition to code for primary procedure)	
C9035	Injection, aripiprazole lauroxil (aristada initio), 1 mg	
C9036	Injection, patisiran, 0.1 mg	
C9037	Injection, risperidone (perseris), 0.5 mg	
C9038	Injection, mogamulizumab-kpkc, 1 mg	
C9039	Injection, plazomicin, 5 mg	
C9054	Injection, lefamulin (xenleta), 1 mg	
C9055	Injection, brexanolone, 1mg	
C9727	Insertion of implants into the soft palate;	
C9733	Nonphthalmic fluorescnet vascular angiography	
C9734	Focused ultrasound ablation/therapeutic intervention, other than uterine leiomyomata, with magnetic reso- nance (MR) guidance	
C9739	Cystourethroscopy, with insertion of transprostatic implant	
C9740	Cystourethroscopy, with insertion of transprostatic implant	
C9751	Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by	
	microwave energy, including fluoroscopic guidance, when performed,	
	with computed tomography acquisition(s) and 3-d rendering, computer-	
	assisted, image-guided navigation, and endobronchial ultrasound	
	(ebus) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node	
	stations or structures and therapeutic intervention(s)	
	stations of ottastares and therapeatte intervention(o)	
C9752	Destruction of intraosseous basivertebral nerve, first two vertebral	
	bodies, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum	
C9753	Destruction of intraosseous basivertebral nerve, each additional	
	vertebral body, including imaging guidance (e.g., fluoroscopy),	
	lumbar/sacrum (list separately in addition to code for primary	
	procedure)	
C9754	Creation of arteriovenous fistula, percutaneous; direct, any site,	
	including all imaging and radiologic supervision and interpretation,	
	when performed and secondary procedures to redirect blood flow (e.g., transluminal balloon angioplasty, coil embolization, when	
	performed)	
C9755	Creation of arteriovenous fistula, percutaneous using magnetic-guided	
09733	arterial and venous catheters and radiofrequency energy, including	
	flow-directing procedures (e.g., vascular coil embolization with	
	radiologic supervision and interpretation, when performed) and	
	fistulogram(s), angiography, venography, and/or ultrasound, with	
	radiologic supervision and interpretation, when performed	
C9757	Laminotomy (hemilaminectomy), with decompression of nerve root(s),	
	including partial facetectomy, foraminotomy and excision of herniated	
	intervertebral disc, and repair of annular defect with implantation of	
	bone anchored annular closure device, including annular defect	
	measurement, alignment and sizing assessment, and image guidance; 1 interspace, lumbar	
00750		
C9758	Blinded procedure for nyha class iii/iv heart failure; transcatheter implantation of interatrial shunt or placebo control, including right heart	
	catheterization, trans-esophageal echocardiography (tee)/intracardiac	
	echocardiography (ice), and all imaging with or without guidance (e.g.,	
	ultrasound, fluoroscopy), performed in an approved investigational	
	device exemption (ide) study	
D0180	Comprehensive periodontal evaluation – new or established patient	
D0250	Extraoral – first film	
D0200	Extraoral - mot mm	

	In	1
D0260	Extraoral – each additional film	
D0277	Vertical bitewings – 7 to 8 films	
D0460	Pulp vitality tests	
D0470	Diagnostic casts	
D1310	Nutritional counseling for control of dental disease	
D1510	Space maintainer – fixed – unilateral	
D1515	Space maintainer – fixed – bilateral	
D1520	Space maintainer – removable – unilateral	
D1525	Space maintainer – removable – bilateral	
D1550	Re-cementation of space maintainer	
D1555	Removal of fixed space maintainer	
D2710	Crown – resin-based composite (indirect)	
D2712	Crown – 3/4 resin-based composite (indirect)	
D2712 D2720	Crown – resin with high noble metal	
	· ·	
D2721 D2722	Crown – resin with predominantly base metal  Crown – resin with noble metal	
	-	
D2740	Crown – porcelain/ceramic substrate	
D2750	Crown – porcelain fused to high noble metal	
D2751	Crown – porcelain fused to predominantly base metal	
D2752	Crown – porcelain fused to noble metal	
D2780	Crown – ¾ cast high noble metal	
D2781	Crown – ¾ cast predominantly base metal	
D2782	Crown – ¾ cast noble metal	
D2791	Crown – full cast predominantly base metal	
D2792	Crown – full cast noble metal	
D2794	Crown – titanium	
D2910	Recement inlay, onlay, or partial coverage restoration	
D2915	Recement cast or prefabricated post and core	
D2931	Prefabricated stainless steel crown – permanent tooth	
D2951	Pin retention – per tooth, in addition to restoration	
D2952	Pin retention – per tooth, in addition to restoration	
D2953	Each additional indirectly fabricated post-same tooth	
D2953 D2954	Prefabricated post and core in addition to crown	
	·	
D2957	Each additional prefabricated post-same tooth	
D4910	Periodontal maintenance (2 in a 12 month period)	
D5670	Replace all teeth and acrylic on cast metal framework (maxillary)	
D5671	Replace all teeth and acrylic on cast metal framework (mandibular)	
D5710	Rebase complete maxillary denture	
D5711	Rebase complete mandibular denture	
D5720	Rebase maxillary partial denture	
D5721	Rebase mandibular partial denture	
D5740	Reline maxillary partial denture (chairside)	
D5741	Reline mandibular partial denture (chairside)	
D5760	Reline maxillary partial denture (laboratory)	
D5761	Reline mandibular partial denture (laboratory)	
D5850	Tissue conditioning, maxillary	
D5851	Tissue conditioning, mandibular	
D6205	Pontic – indirect resin based composite	
D6210	Pontic – cast high noble metal	
D6211	Pontic – cast predominantly base metal	
D6212	Pontic – cast noble metal	
D6214	Pontic – titanium	
D6240	Pontic – porcelain fused to high noble metal	
D6241	Pontic – porcelain fused to predominantly base metal	
D6242	Pontic – porcelain fused to noble metal	
D6250	Pontic – resin with high noble metal	
D6251	Pontic – resin with predominantly base metal	
D6252	Pontic – resin with noble metal	
D6710	Crown – indirect resin-based composite	
D6720	Crown – resin with high noble metal	
D6721	Crown – resin with predominantly base metal	
1116721		

D6722	Crown – resin with noble metal	
D6722 D6750		
	Crown – porcelain fused to high noble metal	
D6751	Crown – porcelain fused to predominantly base metal	
D6752	Crown – porcelain fused to noble metal	
D6780	Crown – ¾ cast high noble metal	
D6781	Crown – ¾ cast predominantly base metal	
D6782	Crown – ¾ cast noble metal	
D6790	Crown – full cast high noble metal	
D6791	Crown – full cast predominantly base metal	
D6792	Crown – full cast noble metal	
D6794	Crown – titanium	
D6970	Post and core in addition to fixed partial denture retainer, indirectly fabricated	
D6972	Prefabricated post and core in addition to fixed partial denture retainer	
D6973	Core build up for retainer, including any pins	
D6976	Each additional cast post – same tooth	
D6977	Each additional prefabricated post – same tooth	
D7511	Incision and drainage of abscess – intraoral soft issue – complicated	
	(includes drainage of multiple fascial spaces)	
D7521	Incision and drainage of abscess – extraoral soft issue – compli- cated	
	(includes drainage of multiple fascial spaces)	
D9110	Palliative (emergency) treatment of dental pain – minor procedure	
D9450	Case presentation, detailed and extensive treatment planning	
D9951	Occlusal adjustment – limited	
E0118	Crutch substitute, lower leg platform, with or without wheels, ea.	
E0162	Sitz bath chair	
E0175	Foot rest use w/commode chair	
E0190	Positioning pillow/cushion	
E0191	Heel/elbow protector ea.	
E0194	Air fluidized bed	
E0200	Heat lamp w/o stand	
E0205	Heat lamp w/stand	
E0210	Electric heat pad std	
E0215	Electric heat pad moist	
E0217	Water circulating heat pad with pump	
E0218	Water circulating cold pad with pump	
E0221	Infrared heating pad system	
E0225	Hydrocollator unit includes pads	
E0231	Non-contact wound warming wound cover for use with the non-contact	
=0.5	wound warming device	
E0232	Warming card for use with non-contact wound device	
E0239	Hydrocollator unit portable	
E0240	Bath/shower chair, with or without wheels, any size	
E0241	Bath tub wall rail ea	
E0242	Bath tub rail floor base	
E0243	Toilet rail ea	
E0244	Raised toilet seat	
E0245	Tub stool or bench	
E0246	Transfer tub rail attachment	
E0247	Transfer bench for tub or toilet with or without commode opening	
E0248	Transfer bench, heavy duty, for tub or toilet with or without commode opening	
E0249	Pad for water circulating heat unit, for replacement only	
E0274	Over-bed table	
E0315	Bed accessory, board, table or support device, any type	
E0435	Portable liquid oxygen system, purchase; includes por- table	
_0-100	container, supply reservoir, flowmeter, humidifier, contents gauge, cannula or mask, tubing and refill adaptor	

E0446	Topical oxygen delivery system, not otherwise specified, includes all	
	supplies and accessories	
E0447	Portable oxygen contents, liquid, 1 month's supply = 1 unit, prescribed	
	amount at rest or nighttime exceeds 4 liters per minute (lpm)	
E0450	Values a contilator	
E0450	Volume ventilator	
E0466	Home ventilator, any type, used with noninvasive interface	
E0467	Home ventilator, multi-function respiratory device, also performs any	
	or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all	
	accessories, components and supplies for all functions	
	accessories, components and supplies for all functions	
E0480	Intropulmonary paraussive ventilation evetem	
E0480	Intrapulmonary percussive ventilation system Intrapulmonary percussive ventilation system and related accessories	
L0401	intrapulmonary percussive ventilation system and related accessories	
E0483	High frequency chest wall oscillation system	
E0486	Oral device/appliance used to reduce upper airway collapsibility,	
	adjustable or non-adjustable, custom fabricated, includes fitting and	
	adjustment	
E0605	Vaporizer room type	
E0607	Home blood glucose monitor	
E0610	Pacemaker monitor self-contained	
E0615	Pacemaker monitor self contained	
E0616	Implantable cardiac event recorder w/memory, activator	
	& programmer	
E0617	External defibrillator with integrated electrocardiogram analysis	
E0625	Patient lift kartop bathroom	
E0627	Seat lift mech in comb lift-chair	
E0629	Sep seat lift mech reimbursed	
E0636	Multipositional patient support system, with integrated lift, patient	
	accessible controls	
E0638	Standing frame/table system, one position (e.g., upright, supine or	
	prone stander), any size including pediatric, with or without wheels	
E0641	Standing frame/table system, mobile (dynamic stander), any size	
	including pediatric	
E0642	Standing frame/table system, mobile (dynamic stander), any size	
	including pediatric	
E0650	Pneumatic compressor, non-segmental home model	
E0651	Pneumatic compressor, segmental home model without calibrated	
=	gradient pressure	
E0652	Pneumatic compressor, segmental home model with calibrated	
F0055	gradient pressure	
E0655	Non-segmental pneumatic appliance for use with pneumatic	
F0656	compressor, half arm	
E0656	Segmental pneumatic appliance for use with pneumatic compressor,	
E0657	trunk	
E0657	Segmental pneumatic appliance for use with pneumatic compressor,	
EOGGO	Non aggregated programatic appliance for use with programatic	
E0660	Non-segmental pneumatic appliance for use with pneumatic	
E0665	compressor, full leg	
E0665	Non-segmental pneumatic appliance for use with pneumatic	
E0666	compressor, full arm  Non-segmental pneumatic appliance for use with pneumatic	
L0000	compressor, half leg	
E0667	Segmental pneumatic appliance for use with pneumatic compressor,	
L0007	full leg	
E0668	Segmental pneumatic appliance for use with pneumatic compressor,	
L0000	full arm	
E0669	Segmental pneumatic appliance for use with pneumatic compressor,	
	half leg	
<u> </u>		

E0670		
1	Segmental pneumatic appliance for use with pneumatic compressor, integrated, 2 full legs and trunk	
E0671	Segmental gradient pressure pneumatic appliance, full leg	
E0672	Segmental gradient pressure pneumatic appliance, full arm	
	Segmental gradient pressure pneumatic appliance, full affiles	
E0673		
E0675	Pneumatic compression device, high pressure, rapid inflation/deflation cycle, for arterial insufficiency (unilateral or bilateral system)	
E0676	Intermittent limb compression device (includes all accessories), not otherwise specified	
E0747	Osteogenesis stimulator, electrical, non-invasive, other than spinal applications	
E0748	Osteogenesis stimulator, electrical, noninvasive, spinal applications	
E0760	Osteogenesis stimulator, low intensity ultrasound, non-invasive	
E0766	Electrical stimulation device used for cancer treatment, includes all accessories, any type	
E0770	Functional electric stim NOS	
E0784	External ambulatory infusion pump, insulin	
E0787	External ambulatory infusion pump, insulin, dosage rate adjustment using therapeutic continuous glucose sensing	
E0935	Continuous passive motion exercise device for use on knee only	
E0700	Safety equipment	
E0744	Neuromuscular stimulator for scoliosis	
E0762	Transcutaneous electrical joint stimulation device system	
E0764	Functional neuromuscular stimulator, used for walking by spinal cord injured	
E0765	FDA-approved nerve stimulator, with replaceable batteries, for treatment of nausea and vomitting	
E0779	Ambulatory infusion pump, mechanical, reusable, for infusion 8 hrs or greater	
E0780	Ambulatory infusion pump, mechanical, reusable, for infusion less than 8 hours	
E0782	Terbutaline therapy - Infusion pump implantable non programmable	
E0783	Terbutaline therapy - Infusion pump system, implantable, programmable	
E0786	Implantable programmable infusion pump, replacement	
E0791	Parent infus pump stationary	
E0983	Manual wheelchair accessory, power add-on to convert manual	
	wheelchair to motorized wheelchair, joystick control	
E0984	Manual wheelchair accessory, power, add-on to convert manual wheelchair to motorized wheelchair, tiller control	
E0986	Manual wheelchair accessory, push activated power assist, each	
E1002	Wheelchair accessory, power seating system, tilt only	
E1003	Wheelchair accessory, power seating system, recline only, without shear reduction	
E1004	Wheelchair accessory, power seating system, recline only, with mechanical shear reduction	
E1005	Wheelchair accessory, power seating system, recline only, with power shear reduction	
E4000	Wheelchair accessory, power seating system, combination tilt and	
E1006		
E1006	recline, without shear reduction  Wheelchair accessory, power seating system, combination tilt and recline, with mechanical shear reduction	

E1009	Wheelchair accessory, addition to power seating system,	
	mechanically linked leg elevation system, including pushrod and leg	
	rest, each	
E1010	Wheelchair accessory, addition to power seating system, power leg	
21010	elevation system, including leg rest, pair	
E1015	Shock absorber for manual wheelchair, each	
E1015	Shock absorber for manual wheelchair, each	
E1017	Heavy duty shock absorber for heavy duty or extra heavy duty manual	
E4040	wheelchair, each	
E1018	Heavy duty shock absorber for heavy duty or extra heavy duty power wheelchair, each	
E1028	Wheelchair accessory, manual swingaway, retractable or removable	
	mounting hardware for joystick, other control interface or positioning	
	accessory	
E1035	Multi-positional patient transfer system, with integrated seat, operated	
	by care giver, patient weight capacity up to and including 300 pounds	
	ay ama gran, panana na granapanny ap na ama mananang ana panana	
E1037	Transport chair, pediatric size	
E1038	Transport chair, podatare size	
E1227	Special height arms for wheelchair	
E1228	Special height arms for wheelchair	
E1230	Power operated vehicle (three- or four-wheel nonhighway) specify	
E1230	brand name and model number	
E4004		
E1231	Wheelchair, pediatric size, tilt-in-space, rigid, adjustable, with seating system	
E1232	Wheelchair, pediatric size, tilt-in-space, folding, adjustable, with	
L 1202	seating system	
E1233	Wheelchair, pediatric size, tilt-in-space, rigid, adjustable, without	
L 1233	seating system	
E4004	<u> </u>	
E1234	Wheelchair, pediatric size, tilt-in-space, folding, adjustable, without seating system	
E400E	Wheelchair, pediatric size, rigid, adjustable, with seating system	
E1235	wheelchair, pediatric size, rigid, adjustable, with seating system	
E1236	Whoolehair podiatric size folding adjustable with coating system	
E1230	Wheelchair, pediatric size, folding, adjustable, with seating system	
F4007	Whoolehair podiatric size rigid adjustable without costing quetom	
E1237	Wheelchair, pediatric size, rigid, adjustable, without seating system	
E4000	Decrease the extension and introduction of extension and extension are extension.	
E1239	Power wheelchair, pediatric size, not otherwise specified	
E1296	Special wheelchair; seat height from floor	
E1297	Special wheelchair; seat depth, by upholstery	
E1298	Special wheelchair; seat depth and/or width, by construction	
E1300	Whirlpool portable (overtub)	
E1310	Whirlpool non-port (built-in)	
E1632	Wearable artificial kidney, each	
E1635	Compact (portable) travel hemodialyzer system	
E1700	Jaw motion rehabilitation system	
E1701	Replacement cushions for jaw motion rehab	
E1702	Replacement measuring scales for jaw motion rehabilitation system,	
	pkg. of 200	
E1703	Replacement measuring scales for jaw motion rehab	
E1800	Dynamic adjustable elbow extension/flexion device, includes soft	
	interface materia	
E1801	Static progressive stretch elbow device, extension and/or flexion, with	
	or without range of motion adjustment, includes all components and	
	accessories	
E1806	Static progressive stretch wrist device, flexion and/or extension, with	
	or without range of motion adjustment, includes all components and	
	accessories	
E1811	Static progressive stretch knee device, extension and/or flexion, with	
	or without range of motion adjustment, includes all components and	
	accessories	
		<u> </u>

	Static progressive stretch ankle device, flexion and/or extension, with	
1	or without range of motion adjustment, includes all components and	
	accessories	
E1818	Static progressive stretch forearm pronation/supination device, with or	
	without range of motion adjustment, includes all components and	
	accessories	
	Replacement soft interface material/cuffs for bi-directional static	
	progressive stretch device	
	Dynamic adjustable shoulder flexion/abduction/rotation device,	
	includes soft interface material	
E1841	Static progressive stretch shoulder device, with or without range of	
	motion adjustment, includes all components and accessories	
1		
E2100	Blood glucose monitor with voice synthesizer	
	Blood glucose monitor with integrated lancing/blood sample	
	0 0 1	
	Pulse generator system for tympanic treatment of inner ear	
	Manual wheelchair accessory, nonstandard seat frame, width greater	
1	than or equal to 20 inches and less than 24 inches	
	Manual wheelchair accessory, nonstandard seat frame width, 24–27	
<u> </u>	inches	
E2203	Manual wheelchair accessory, nonstandard frame depth, 20 to less	
	than 22 inches	
E2204	Manual wheelchair accessory, nonstandard seat frame depth 22 to 25	
	inches	
	Manual wheelchair accessory, handrim without projections (includes	
	ergonomic or contoured), any type, replacement only, each	
1	ergonomic of contoured), any type, replacement only, each	
<u> </u>		
	Wheelchair accessory, crutch and cane holder, each	
E2208	Wheelchair accessory, cylinder tank carrier, each	
E2209	Accessory, arm trough, with or without hand support, each	
E2224	Manual wheelchair accessory, propulsion wheel excludes tire, any	
1	size, each	
E2227	Manual wheelchair accessory, gear reduction drive wheel, each	
1	,,,,	
E2231	Manual wheelchair accessory, solid seat support base (replaces sling	
	seat), includes any type mounting hardware	
	Back, planar, for pediatric size wheelchair including fixed attaching	
	hardware	
	Seat, planar, for pediatric size wheelchair including fixed attaching	
	hardware	
E2293	Back, contoured, for pediatric size wheelchair including fixed attaching	
1	hardware	
E2294	Seat, contoured, for pediatric size wheelchair including fixed attaching	
	hardware	
	Manual wheelchair accessory, for pediatric size wheelchair, dynamic	
	seating frame, allows coordinated movement of multiple positioning	
	features	
	Power wheelchair accessory, electronic connection between	
	wheelchair controller and one power seating system motor, including	
	all related electronics, indicator feature, mechanical function selection	
	switch, and fixed mounting hardware	
E2311	Power wheelchair accessory, electronic connection between	
1	wheelchair controller and two or more power seating system motors,	
1	including all related electronics, indicator feature, mechanical function	
	selection switch, and fixed mounting hardware	
	-	
	Power wheelchair accessory, hand or chin control interface, mini	
E2312	Power wheelchair accessory, hand or chin control interface, mini-	
E2312	Power wheelchair accessory, hand or chin control interface, mini- proportional remote joystick, proportional, including fixed mounting hardware	

E2313 E2321	Dower wheelsheir accessory harness for ungrade to evacadable	
E2321	Power wheelchair accessory, harness for upgrade to expandable	
E2321	controller, including all fasteners, connectors and mounting hardware,	
E2321	each	
E2321	Power wheelchair accessory, hand control interface, remote joystick,	
	nonproportional, including all related electronics, mechanical stop	
	switch, and fixed mounting hardware	
E2322	Power wheelchair accessory, hand control interface, multiple	
LZSZZ		
	mechanical switches, nonproportional, including all related electronics,	
	mechanical stop switch, and fixed mounting hardware	
F0000	Decree wheelshe's access on a felfa fee of the different and a second	
E2323	Power wheelchair accessory, specialty joystick handle for hand control	
	interface, prefabricated	
E2324	Power wheelchair accessory, chin cup for chin control interface	
	,	
=		
E2325	Power wheelchair accessory, sip and puff interface, nonproportional,	
	including all related electronics, mechanical stop switch, and manual	
	swingaway mounting hardware	
F0000		
E2326	Power wheelchair accessory, breath tube kit for sip and puff interface	
L		
E2327	Power wheelchair accessory, head control interface, mechanical,	
]	proportional, including all related electronics, mechanical direction	
I	i i	
I	change switch, and fixed mounting hardware	
1		
E2328	Power wheelchair accessory, head control or extremity control	
E2320	· · · · · · · · · · · · · · · · · · ·	
	interface, electronic, proportional, including all related electronics and	
I	fixed mounting hardware	
F2220	Dower who alabair accessory, board control interface, contact quitab	
E2329	Power wheelchair accessory, head control interface, contact switch	
	mechanism, nonproportional, including all related electronics,	
	mechanical stop switch, mechanical direction change switch, head	
	array, and fixed mounting hardware	
	<u> </u>	
E2330	Power wheelchair accessory, head control interface, proximity switch	
	mechanism, nonproportional, including all related electronics,	
	mechanical stop switch, mechanical direction change switch, head	
	array, and fixed mounting hardware	
E2331	Power wheelchair accessory, attendant control, proportional, including	
	all related electronics and fixed mounting hardware	
	ÿ	
E2340	Power wheelchair accessory, nonstandard seat frame width, 20-23 in.	
	·	
E0044	Device who alshair accessory repretandend and frame width 04.07 in	
E2341	Power wheelchair accessory, nonstandard seat frame width, 24-27 in.	
E2342	Power wheelchair accessory, nonstandard seat frame depth, 20 or 21	
	II.	
	in.	
	Power wheelchair accessory, nonstandard seat frame depth, 22-25	
E2343	in.	
E2343	Int.	
E2343 E2351	Power wheelchair accessory, electronic interface to operate speech	
	Power wheelchair accessory, electronic interface to operate speech	
E2351	Power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface	
	Power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface  Power wheelchair accessory, group 34 sealed lead acid battery, each	
E2351	Power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface  Power wheelchair accessory, group 34 sealed lead acid battery, each (e.g., gel cell, absorbed glass mat)	
E2351	Power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface  Power wheelchair accessory, group 34 sealed lead acid battery, each (e.g., gel cell, absorbed glass mat)	
E2351	Power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface  Power wheelchair accessory, group 34 sealed lead acid battery, each (e.g., gel cell, absorbed glass mat)  Power wheelchair accessory, 22 NF sealed lead acid battery, each	
E2351 E2359 E2361	Power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface  Power wheelchair accessory, group 34 sealed lead acid battery, each (e.g., gel cell, absorbed glass mat)  Power wheelchair accessory, 22 NF sealed lead acid battery, each (eg., gel cell, absorbed glassmat)	
E2351	Power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface  Power wheelchair accessory, group 34 sealed lead acid battery, each (e.g., gel cell, absorbed glass mat)  Power wheelchair accessory, 22 NF sealed lead acid battery, each (eg., gel cell, absorbed glassmat)  Power wheelchair accessory, group 24 sealed lead acid battery, each	
E2351 E2359 E2361	Power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface  Power wheelchair accessory, group 34 sealed lead acid battery, each (e.g., gel cell, absorbed glass mat)  Power wheelchair accessory, 22 NF sealed lead acid battery, each (eg., gel cell, absorbed glassmat)	
E2351  E2359  E2361  E2363	Power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface  Power wheelchair accessory, group 34 sealed lead acid battery, each (e.g., gel cell, absorbed glass mat)  Power wheelchair accessory, 22 NF sealed lead acid battery, each (eg., gel cell, absorbed glassmat)  Power wheelchair accessory, group 24 sealed lead acid battery, each (eg., gel cell, absorbed glassmat)	
E2351 E2359 E2361	Power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface  Power wheelchair accessory, group 34 sealed lead acid battery, each (e.g., gel cell, absorbed glass mat)  Power wheelchair accessory, 22 NF sealed lead acid battery, each (eg., gel cell, absorbed glassmat)  Power wheelchair accessory, group 24 sealed lead acid battery, each (eg., gel cell, absorbed glassmat)  Power wheelchair accessory, U-1 sealed lead acid battery, each (e.g.,	
E2351  E2359  E2361  E2363  E2365	Power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface  Power wheelchair accessory, group 34 sealed lead acid battery, each (e.g., gel cell, absorbed glass mat)  Power wheelchair accessory, 22 NF sealed lead acid battery, each (eg., gel cell, absorbed glassmat)  Power wheelchair accessory, group 24 sealed lead acid battery, each (eg., gel cell, absorbed glassmat)  Power wheelchair accessory, U-1 sealed lead acid battery, each (e.g., gel cell absorbed glassmat)	
E2351  E2359  E2361  E2363	Power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface  Power wheelchair accessory, group 34 sealed lead acid battery, each (e.g., gel cell, absorbed glass mat)  Power wheelchair accessory, 22 NF sealed lead acid battery, each (eg., gel cell, absorbed glassmat)  Power wheelchair accessory, group 24 sealed lead acid battery, each (eg., gel cell, absorbed glassmat)  Power wheelchair accessory, U-1 sealed lead acid battery, each (e.g.,	
E2351  E2359  E2361  E2363  E2365	Power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface  Power wheelchair accessory, group 34 sealed lead acid battery, each (e.g., gel cell, absorbed glass mat)  Power wheelchair accessory, 22 NF sealed lead acid battery, each (eg., gel cell, absorbed glassmat)  Power wheelchair accessory, group 24 sealed lead acid battery, each (eg., gel cell, absorbed glassmat)  Power wheelchair accessory, U-1 sealed lead acid battery, each (e.g., gel cell absorbed glassmat)  Power wheelchair accessory, battery charger, single mode, for use	
E2351  E2359  E2361  E2363  E2365	Power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface  Power wheelchair accessory, group 34 sealed lead acid battery, each (e.g., gel cell, absorbed glass mat)  Power wheelchair accessory, 22 NF sealed lead acid battery, each (eg., gel cell, absorbed glassmat)  Power wheelchair accessory, group 24 sealed lead acid battery, each (eg., gel cell, absorbed glassmat)  Power wheelchair accessory, U-1 sealed lead acid battery, each (e.g., gel cell absorbed glassmat)	
E2351  E2359  E2361  E2363  E2365  E2366	Power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface  Power wheelchair accessory, group 34 sealed lead acid battery, each (e.g., gel cell, absorbed glass mat)  Power wheelchair accessory, 22 NF sealed lead acid battery, each (eg., gel cell, absorbed glassmat)  Power wheelchair accessory, group 24 sealed lead acid battery, each (eg., gel cell, absorbed glassmat)  Power wheelchair accessory, U-1 sealed lead acid battery, each (e.g., gel cell absorbed glassmat)  Power wheelchair accessory, battery charger, single mode, for use with only one battery type, sealed or non sealed, each	
E2351  E2359  E2361  E2363  E2365	Power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface  Power wheelchair accessory, group 34 sealed lead acid battery, each (e.g., gel cell, absorbed glass mat)  Power wheelchair accessory, 22 NF sealed lead acid battery, each (eg., gel cell, absorbed glassmat)  Power wheelchair accessory, group 24 sealed lead acid battery, each (eg., gel cell, absorbed glassmat)  Power wheelchair accessory, U-1 sealed lead acid battery, each (e.g., gel cell absorbed glassmat)  Power wheelchair accessory, battery charger, single mode, for use	
E2351 E2359 E2361 E2363 E2365 E2366	Power wheelchair accessory, electronic interface to operate speech generating device using power wheelchair control interface  Power wheelchair accessory, group 34 sealed lead acid battery, each (e.g., gel cell, absorbed glass mat)  Power wheelchair accessory, 22 NF sealed lead acid battery, each (eg., gel cell, absorbed glassmat)  Power wheelchair accessory, group 24 sealed lead acid battery, each (eg., gel cell, absorbed glassmat)  Power wheelchair accessory, U-1 sealed lead acid battery, each (e.g., gel cell absorbed glassmat)  Power wheelchair accessory, battery charger, single mode, for use with only one battery type, sealed or non sealed, each	

E2370	Power wheelchair component, motor and gear box combination,	
====	replacement only	
E2371	Power wheelchair accessory, group 27 sealed lead acid battery, (eg., Gel cell, absorbed glassmat), each	
E2373	Power wheelchair accessory, hand or chin control interface, compact	
	remote joystick, proportional, including fixed mounting hardware	
E2374	Power wheelchair accessory, hand or chin control interface, standard	
	remote joystick (not including controller), proportional, including all	
	related electronics and fixed mounting hardware, replacement only	
E2375	Power wheelchair accessory, nonexpendable controller, including all	
	related electronics and mounting hardware, replacement only	
E2376	Power wheelchair accessory, expendable controller, including all	
	related electronics and mounting hardware, replacement only	
E2377	Power wheelchair accessory, expandable controller, including all	
	related electronics and mounting hardware, upgraded provided at	
	initial issue	
E2381	Power wheelchair accessory, pneumatic drive wheel tire, any size, replacement only, each	
E2382	Power wheelchair accessory, tube for pneumatic drive wheel tire, any	
	size, replacement only, each	
E2383	Power wheelchair accessory, insert for pneumatic drive wheel tire	
	(removable), any type, any size, replacement only, each	
E2384	Power wheelchair accessory, pneumatic caster tire, any size,	
	replacement only, each	
E2385	Power wheelchair accessory, tube for pneumatic caster tire, any size,	
	replacement only, each	
E2386	Power wheelchair accessory, foam filled drive wheel tire, any size, replacement only, each	
E2387	Power wheelchair accessory, foam filled caster tire, any size,	
	replacement only, each	
E2388	Power wheelchair accessory, foam filled wheel tire, any size,	
	replacement only, each	
E2389	Power wheelchair accessory, foam caster tire, any size, replacement only, each	
E2390	Power wheelchair accessory, caster tire, any size, replacement only,	
	each	
E2391	Power wheelchair accessory, solid (rubber/plastic) caster tire	
F0000	(removable), any size, replacement only, each	
E2392	Power wheelchair accessory, solid (rubber/plastic)caster tire with integrated wheel, any size, replacement only, each	
E2394	Power wheelchair accessory, drive wheel excludes tire, any size,	
	replacement only, each	
E2395	Power wheelchair accessory, caster wheel excludes tire, any size, replacement only, each	
E2396	Power wheelchair, caster fork, any size, replacement only, each	
E2397	Power wheelchair accessory, lithium-based battery, each	
E2398	Wheelchair accessory, dynamic positioning hardware for back	
E2504	Speech generating device, digitized speech, using pre-recorded	
	messages, greater than 20 minutes but less than or equal to 40	
	minutes recording time	
E2506	Speech generating device, digitized speech, using pre-recorded	
	messages, greater than 40 minutes recording time	
E2508	Speech generating device, synthesized speech	
E2510	Speech generating device, synthesized speech	
E2511	Speech generating software program	
	•	·

E2512	Accessory for speech generating device, mounting system	Ι
E2599	Accessory for speech generating device, mounting system  Accessory for speech generating device, not otherwise classified	
	Accessory for speech generaling device, not otherwise diassilled	
E2603	Skin protection wheelchair seat cushion, width less than 22 inches, any depth	
E2604	Skin protection wheelchair seat cushion, width 22 inches or greater, any depth	
E2605	Positioning wheelchair seat cushion, width less than 22 inches, any depth	
E2606	Positioning wheelchair seat cushion, width 22 inches or greater, any depth	
E2607	Skin protection and positioning wheelchair seat cushion, width less than 22 in., any depth	
E2608	Skin protection and positioning wheelchair seat cushion, width 22 in. or greater, any depth	
E2609	Custom fabricated wheelchair seat cushion, any size	
E2610	Wheelchair seat cushion, powered	
E2611	General use wheelchair back cushion, width less than 22 inches, any height, including any type mounting hardware	
E2612	General use wheelchair back cushion, width 22 inches or greater, any height, including any type mounting hardware	
E2613	Positioning wheelchair back cushion, posterior, width less than 22 inches, any height, including any type mounting hardware	
E2614	Positioning wheelchair back cushion, posterior, width 22 inches or greater, any height, including any type mounting hardware	
E2615	Positioning wheelchair back cushion, posterior-lateral, width less than 22 inches, any height, including any type mounting hardware	
E2616	Positioning wheelchair back cushion, posterior-lateral, width 22 inches or greater, any height, including any type mounting hardware	
E2617	Custom fabricated wheelchair back cushion, any size, including any type mounting hardware	
E2619	Replacement cover for wheelchair seat cushion or back cushion, each	
E2620	Positioning wheelchair back cushion, planar back with lateral supports, width less than 22 inches, any height, including any type mounting hardware	
E2621	Positioning wheelchair back cushion, planar back with lateral supports, width 22 inches or greater, any height, including any type mounting hardware	
E2622	Skin protection wheelchair seat cushion, adjustable, width less than 22 inches, any depth	
E2623	Skin protection wheelchair seat cushion, adjustable, width 22 inches or greater, any depth	
E2624	Skin protection and positioning wheelchair seat cushion, adjustable, width less than 22 inches, any depth	
E2625	Skin protection and positioning wheelchair seat cushion, adjustable, width 22 inches or greater, any depth	
E2626	Wheelchair accessory, shoulder elbow, mobile arm support attached to wheelchair, balanced, adjustable	
E2627	Wheelchair accessory, shoulder elbow, mobile arm support attached to wheelchair, balanced, adjustable rancho type	
E2628	Wheelchair accessory, shoulder elbow, mobile arm support attached to wheelchair, balanced, reclining	
E2629	Wheelchair accessory, shoulder elbow, mobile arm support attached to wheelchair, balanced, friction arm support (friction dampening to proximal and distal joints)	

E2630	Wheelchair accessory, shoulder elbow, mobile arm support,	
	monosuspension arm and hand support, overhead elbow forearm	
	hand sling support, yoke type suspension support	
E2631	Wheelchair accessory, addition to mobile arm support, elevating	
	proximal arm	
E2632	Wheelchair accessory, addition to mobile arm support, offset or	
	lateral rocker arm with elastic balance control)	
E2633	Wheelchair accessory, addition to mobile arm support, supinator	
L2033	wheelchair accessory, addition to mobile aim support, supmator	
G0027	Semen analysis; presence and/or motility of sperm excluding huhner	
G0166	External counterpulsation	
G0173	Linear accelerator based stereotactic radiosurgery, complete course of therapy in one session	
G0175	Scheduled interdisciplinary team conference (minimum of three	
00170	exclusive)	
G0068	Professional services for the administration of anti-infective, pain	
	management, chelation, pulmonary hypertension, and/or inotropic	
	infusion drug(s) for each infusion drug administration calendar day in	
	the individual's home, each 15 minutes	
G0069	Professional services for the administration of subcutaneous	
	immunotherapy for each infusion drug administration calendar day in	
	the individual's home, each 15 minutes	
G0070	Professional services for the administration of chemotherapy for each	
	infusion drug administration calendar day in the individual's home,	
	each 15 minutes	
G0071	Payment for communication technology-based services for 5 minutes	
30071	or more of a virtual (non-face-to-face) communication between an	
	rural health clinic (rhc) or federally qualified health center (fqhc)	
	practitioner and rhc or fqhc patient, or 5 minutes or more of remote	
	evaluation of recorded video and/or images by an rhc or fqhc	
	practitioner, occurring in lieu of an office visit; rhc or fqhc only	
	practitioner, occurring in fied of an office visit, the or ight offig	
G0076	Brief (20 minutes) care management home visit for a new patient. for	
	use only in a medicare-approved cmmi model. (services must be	
	furnished within a beneficiary's home, domiciliary, rest home, assisted	
	living and/or nursing facility)	
G0077	Limited (30 minutes) care management home visit for a new patient.	
00077	for use only in a medicare-approved cmmi model. (services must be	
	furnished within a beneficiary's home, domiciliary, rest home, assisted	
	living and/or nursing facility)	
G0078	Moderate (45 minutes) care management home visit for a new patient.	
	for use only in a medicare-approved cmmi model. (services must be	
	furnished within a beneficiary's home, domiciliary, rest home, assisted	
	living and/or nursing facility)	
G0079	Comprehensive (60 minutes) care management home visit for a new	
300,0	patient. for use only in a medicare-approved cmmi model. (services	
	must be furnished within a beneficiary's home, domiciliary, rest home,	
	assisted living and/or nursing facility)	
G0080	Extensive (75 minutes) care management home visit for a new	
	patient. for use only in a medicare-approved cmmi model. (services	
	must be furnished within a beneficiary's home, domiciliary, rest home,	
	assisted living and/or nursing facility)	
G0081	Brief (20 minutes) care management home visit for an existing patient.	
	for use only in a medicare-approved cmmi model. (services must be	
	furnished within a beneficiary's home, domiciliary, rest home, assisted	
	living and/or nursing facility)	
	g allow of floring facility)	

G0082	Limited (30 minutes) care management home visit for an existing patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)	
G0083	Moderate (45 minutes) care management home visit for an existing patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)	
G0084	Comprehensive (60 minutes) care management home visit for an existing patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)	
G0085	Extensive (75 minutes) care management home visit for an existing patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)	
G0086	Limited (30 minutes) care management home care plan oversight. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)	
G0087	Comprehensive (60 minutes) care management home care plan oversight. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)	
G0155	Services of clinical social worker in home health or hospice settings setting, each 15 minutes	
G0176	Activity therapy, such as music, dance, art	
G0186	Destruction of localized lesion of choroid	
G0255	Current preception threshold/sensory nerve conduction test for any limb	
G0269	Placement of occlusive device into either a venous or arterial access site, post-surgical or interventional procedure (e.g., angioseal plug, vascular plug)	
G0279	Diagnostic digital breast tomosynthesis, unilateral or bilateral (List separately in addition to G0204 or G0206)	
G0282	Electrical stimulation, to one or more areas, for wound care	
G0293	Non-covered surgical procedure(s) using conscious sedation, regional, general, or spinal anesthesia in a Medicare-qualifying clinical trial, per day	
G0294	Non-covered surgical procedure(s) using either no anesthesia or local anesthesia only in a Medicare-qualifying clinical trial, per day	
G0295	Electromagnetic stimulation, to one or more areas	
G0302	Pre-operative pulmonary surgery services for preparation for LVRS, complete course of services	
G0303	Pre-operative pulmonary surgery services for preparation for LVRS, 10–15 days of services	
G0304	Pre-operative pulmonary surgery services for preparation for LVRS, one to nine days of service	
G0305	Post-discharge pulmonary surgery services after LVRS, minimum of six days	
G0329	Electromagnetic therapy, to one or more areas for chronic stage III or IV	
G0333	Pharmacy dispensing fee for inhalation drug(s); initial 30-day supply as a beneficiary	
· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·

G0339	Image-guided robotic linear accelerator-based stereotactic	
30339		
	radiosurgery, complete course of therapy in one session or first session of fractionated treatment	
00010		
G0340	Image-guided robotic linear accelerator-based stereotactic	
	radiosurgery, delivery including collimator changes and custom	
	plugging, fractionated treatment, all lesions, per session, second	
	through fifth sessions, maximum five sessions per course of treatment	
G0341	Percutaneous islet cell transplant, includes portal vein catheterization	
	and infusion	
G0342	Laparoscopy for islet cell transplant, includes portal vein	
000.2	catheterization and infusion	
G0343	Laparotomy for islet cell transplant, includes portal vein catheterization	
00040	and infusion	
G0372	Physician service required to establish and document the need for a	
G0372		
00070	power mobility device	
G0378	Hospital observation service, per hour	
G0379	Direct admission of patient for hospital observation care	
G0380	Level 1 hospital emergency department visit provided in a type b	
	emergency department; (the ed must meet at least one of the	
	following requirements: (1) it is licensed by the state in which it is	
	located under applicable state law as an emergency room or	
	emergency department; (2) it is held out to the public (by name,	
	posted signs, advertising, or other means) as a place that provides	
	care for emergency medical conditions on an urgent basis without	
	requiring a previously scheduled appointment; or (3) during the	
	calendar year immediately preceding the calendar year in which a	
	determination under 42 CFR 489.24 is being made, based on a	
	representative sample of patient visits that occurred during that	
	calendar year, it provides at least one-third of all of its outpatient visits	
	for the treatment of emergency medical conditions on an urgent basis	
	without requiring a previously scheduled appointment)	
	without requiring a previously soriedated appointmently	
G0381	Level 2 hospital emergency department visit provided in a type b	
00301	emergency department; (the ed must meet at least one of the	
	following requirements: (1) it is licensed by the state in which it is	
	located under applicable state law as an emergency room or	
	emergency department; (2) it is held out to the public (by name,	
	posted signs, advertising, or other means) as a place that provides	
	care for emergency medical conditions on an urgent basis without	
	requiring a previously scheduled appointment; or (3) during the	
	calendar year immediately preceding the calendar year in which a	
	determination under 42 CFR 489.24 is being made, based on a	
	representative sample of patient visits that occurred during that	
	calendar year, it provides at least one-third of all of its outpatient visits	
	for the treatment of emergency medical conditions on an urgent basis	
	without requiring a previously scheduled appointment)	
	1	

G0382	Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 CFR 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment)	
G0383	Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 CFR 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment)	
G0384	Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 CFR 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment)	
G0390	Trauma response team associated with hospital critical care service	
G0396	Alcohol and/or substance (other than tobacco) abuse structured assessment (e.g., audit, dast), and brief intervention 15–30 minutes	
G0397	Alcohol and/or substance (other than tobacco) abuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes	
G0402	Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of Medicare enrollment	
G0451	Development testing	

G0454	Physician documentation of face-to-face visit for durable medical	
	equipment determination performed by nurse practitioner, physician	
	assistant or clinical nurse specialist	
G0460	Autologous platelet rich plasma for chronic wounds/ ulcers, including	
	phlebotomy, centrifugation, and all other preparatory procedures,	
	administration and dress- ings, per treatment	
G0463	Hospital outpatient clinic visit for assessment and management of a	
	patient	
G0464	Colorectal cancer screening; stool-based DNA and fecal occult	
	hemoglobin (e.g., KRAS, NDRG4 and BMP3)	
G0498	Chemotherapy administration, intravenous infusion technique;	
00.00	initiation of infusion in the office/clinic setting using office/clinic	
	pump/supplies, with continuation of the infusion in the community	
	setting (e.g., home, domicili- ary, rest home or assisted living) using a	
	portable pump provided by the office/clinic, includes follow up office/	
	clinic visit at the conclusion of the infusion	
00010		
G0913	Improvement in visual function achieved within 90 days following	
00044	cataract surgery	
G0914	Patient care survey was not completed by patient	
G0915	Improvement in visual function not achieved within 90 days following	
	cataract surgery	
G0916	Satisfaction with care achieved within 90 days following cataract	
	surgery	
G0917	Patient satisfaction survey was not completed by patient	
G0918	Satisfaction with care not achieved within 90 days following cataract	
	surgery	
G1000	Clinical decision support mechanism applied pathways, as defined by	
	the medicare appropriate use criteria program	
G1001	Clinical decision support mechanism evicore, as defined by the	
	medicare appropriate use criteria program	
G1002	Clinical decision support mechanism medcurrent, as defined by the	
	medicare appropriate use criteria program	
G1003	Clinical decision support mechanism medicalis, as defined by the	
	medicare appropriate use criteria program	
G1004	Clinical decision support mechanism national decision support	
	company, as defined by the medicare appropriate use criteria program	
G1005	Clinical decision support mechanism national imaging associates, as	
	defined by the medicare appropriate use criteria program	
	and the second of the second program	
G1006	Clinical decision support mechanism test appropriate, as defined by	
01000	the medicare appropriate use criteria program	
G1007	Clinical decision support mechanism aim specialty health, as defined	
G 1007	by the medicare appropriate use criteria program	
C1000		
G1008	Clinical decision support mechanism cranberry peak, as defined by	
C4000	the medicare appropriate use criteria program	
G1009	Clinical decision support mechanism sage health management	
	solutions, as defined by the medicare appropriate use criteria program	
04012		
G1010	Clinical decision support mechanism stanson, as defined by the	
	medicare appropriate use criteria program	
G1011	Clinical decision support mechanism, qualified tool not otherwise	
	specified, as defined by the medicare appropriate use criteria program	
G2000	Blinded administration of convulsive therapy procedure, either	
	electroconvulsive therapy (ect, current covered gold standard) or	
	magnetic seizure therapy (mst, non-covered experimental therapy),	
	performed in an approved ide-based clinical trial, per treatment	
	session	
	•	<del>'</del>

G2010	Remote evaluation of recorded video and/or images submitted by an established patient (e.g., store and forward), including interpretation with follow-up with the patient within 24 business hours, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment	
G2011	Alcohol and/or substance (other than tobacco) abuse structured assessment (e.g., audit, dast), and brief intervention, 5-14 minutes	
G2012	Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion	
G2021	Health care practitioners rendering treatment in place (tip)	
G2022	A model participant (ambulance supplier/provider), the beneficiary refuses services covered under the model (transport to an alternate destination/treatment in place)	
G2058	Chronic care management services, each additional 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month (list separately in addition to code for primary procedure). (do not report g2058 for care management services of less than 20 minutes additional to the first 20 minutes of chronic care management services during a calendar month). (use g2058 in conjunction with 99490). (do not report 99490, g2058 in the same calendar month as 99487, 99489, 99491)).	
G2061	Qualified nonphysician healthcare professional online assessment, for an established patient, for up to seven days, cumulative time during the 7 days; 5-10 minutes	
G2062	Qualified nonphysician healthcare professional online assessment service, for an established patient, for up to seven days, cumulative time during the 7 days; 11-20 minutes	
G2063	Qualified nonphysician qualified healthcare professional assessment service, for an established patient, for up to seven days, cumulative time during the 7 days; 21 or more minutes	
G2064	Comprehensive care management services for a single high-risk disease, e.g., principal care management, at least 30 minutes of physician or other qualified health care professional time per calendar month with the following elements: one complex chronic condition lasting at least 3 months, which is the focus of the care plan, the condition is of sufficient severity to place patient at risk of hospitalization or have been the cause of a recent hospitalization, the condition requires development or revision of disease-specific care plan, the condition requires frequent adjustments in the medication regimen, and/or the management of the condition is unusually complex due to comorbidities	

-	-	
G2065	Comprehensive care management for a single high-risk disease services, e.g. principal care management, at least 30 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month with the following elements: one complex chronic condition lasting at least 3 months, which is the focus of the care plan, the condition is of sufficient severity to place patient at risk of hospitalization or have been cause of a recent hospitalization, the condition requires development or revision of disease-specific care plan, the condition requires frequent adjustments in the medication regimen, and/or the management of the condition is unusually complex due to comorbidities	
G2066	Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results	
G2067	Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program)	
G2068	Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)	
G2069	Medication assisted treatment, buprenorphine (injectable); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)	
G2070	Medication assisted treatment, buprenorphine (implant insertion); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)	
G2071	Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)	
G2072	Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)	
G2073	Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)	
G2074	Medication assisted treatment, weekly bundle not including the drug, including substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)	

G2075	Medication assisted treatment, medication not otherwise specified; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program)  Intake activities, including initial medical examination that is a complete, fully documented physical evaluation and initial assessment by a program physician or a primary care physician, or an authorized healthcare professional under the supervision of a program physician qualified personnel that includes preparation of a treatment plan that includes the patient's short-term goals and the tasks the patient must perform to complete the short-term goals; the patient's requirements for education, vocational rehabilitation, and employment; and the medical, psycho- social, economic, legal, or other supportive services that a patient needs, conducted by qualified personnel (provision of	
G2077	the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure  Periodic assessment; assessing periodically by qualified personnel to	
	determine the most appropriate combination of services and treatment (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure	
G2078	Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure	
G2079	Take-home supply of buprenorphine (oral); up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure	
G2080	Each additional 30 minutes of counseling in a week of medication assisted treatment, (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure	
G2081	Patients age 66 and older in institutional special needs plans (snp) or residing in long-term care with a pos code 32, 33, 34, 54 or 56 for more than 90 days during the measurement period	
G2082	Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of up to 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation	
G2083	Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, includes 2 hours post-administration observation	
G2086	Office-based treatment for opioid use disorder, including development of the treatment plan, care coordination, individual therapy and group therapy and counseling; at least 70 minutes in the first calendar month	
G2087	Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 minutes in a subsequent calendar month	

G2088	Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; each additional 30 minutes beyond the first 120 minutes (list separately in addition to code for primary procedure)	
G2089	Most recent hemoglobin a1c (hba1c) level 7.0 to 9.0%	
G2090	Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period	
G2091	Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period	
G2092	Angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) or angiotensin receptor-neprilysin inhibitor (arni) therapy prescribed or currently being taken	
G2093	Documentation of medical reason(s) for not prescribing ace inhibitor or arb or arni therapy (e.g., hypotensive patients who are at immediate risk of cardiogenic shock, hospitalized patients who have experienced marked azotemia, allergy, intolerance, other medical reasons)	
G2094	Documentation of patient reason(s) for not prescribing ace inhibitor or arb or arni therapy (e.g., patient declined, other patient reasons)	
G2095	Documentation of system reason(s) for not prescribing ace inhibitor or arb or arni therapy (e.g., other system reasons)	
G2096	Angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) or angiotensin receptor-neprilysin inhibitor (arni) therapy was not prescribed, reason not given	
G2097	Children with a competing diagnosis for upper respiratory infection within three days of diagnosis of pharyngitis (e.g., intestinal infection, pertussis, bacterial infection, lyme disease, otitis media, acute sinusitis, acute pharyngitis, acute tonsillitis, chronic sinusitis, infection of the pharynx/larynx/tonsils/adenoids, prostatitis, cellulitis, mastoiditis, or bone infections, acute lymphadenitis, impetigo, skin staph infections, pneumonia/gonococcal infections, venereal disease (syphilis, chlamydia, inflammatory diseases [female reproductive organs]), infections of the kidney, cystitis or uti	
G2098	Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period	
G2099	Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period	
G2100	Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period	

C2464	Detients 66 years of any and alder with at least are alsim/s	
G2101	Patients 66 years of age and older with at least one claim/encounter	
	for frailty during the measurement period and either one acute	
	inpatient encounter with a diagnosis of advanced illness or two	
	outpatient, observation, ed or nonacute inpatient encounters on	
	different dates of service with an advanced illness diagnosis during	
	the measurement period or the year prior to the measurement period	
G2102	Dilated retinal eye exam with interpretation by an ophthalmologist or	
	optometrist documented and reviewed	
C2402	•	
G2103	Seven standard field stereoscopic photos with interpretation by an	
	ophthalmologist or optometrist documented and reviewed	
G2104	Eye imaging validated to match diagnosis from seven standard field	
	stereoscopic photos results documented and reviewed	
G2105	Patients age 66 or older in institutional special needs plans (snp) or	
02100	residing in long-term care with pos code 32, 33, 34, 54 or 56 for more	
	than 90 days during the measurement period	
G2106	Patients 66 years of age and older with at least one claim/encounter	
	for frailty during the measurement period and a dispensed medication	
	for dementia during the measurement period or the year prior to the	
	measurement period	
G2107	Patients 66 years of age and older with at least one claim/encounter	
G2107		
	for frailty during the measurement period and either one acute	
	inpatient encounter with a diagnosis of advanced illness or two	
	outpatient, observation, ed or nonacute inpatient encounters on	
	different dates of service with an advanced illness diagnosis during	
	the measurement period or the year prior to the measurement period	
00100		
G2108	Patients age 66 or older in institutional special needs plans (snp) or	
	residing in long-term care with pos code 32, 33, 34, 54 or 56 for more	
	than 90 days during the measurement period	
G2109	Patients 66 years of age and older with at least one claim/encounter	
	for frailty during the measurement period and a dispensed medication	
	for dementia during the measurement period or the year prior to the	
	measurement period	
G2110	Patients 66 years of age and older with at least one claim/encounter	
1	for frailty during the measurement period and either one acute	
1	inpatient encounter with a diagnosis of advanced illness or two	
1	outpatient, observation, ed or nonacute inpatient encounters on	
	different dates of service with an advanced illness diagnosis during	
	the measurement period or the year prior to the measurement period	
	the measurement period of the year prior to the measurement period	
G2112	Patient receiving <=5 mg daily prednisone (or equivalent), or ra	
	activity is worsening, or glucocorticoid use is for less than 6 months	
G2113	Patient receiving >5 mg daily prednisone (or equivalent) for longer	
02113		
	than 6 months, and improvement or no change in disease activity	
G2114	Patients 66-80 years of age with at least one claim/encounter for	
	frailty during the measurement period and a dispensed medication for	
	dementia during the measurement period or the year prior to the	
	measurement period	
C211E	·	
G2115	Patients 66 years of age and older with at least one claim/encounter	
	for frailty during the measurement period and a dispensed medication	
	for dementia during the measurement period or the year prior to the	

G2116	Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period	
G2117	Patients 66-80 years of age with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period	
G2118	Patients 81 years of age and older with a evidence of frailty during the measurement period	
G2119	Within the past 2 years, calcium and/or vitamin d optimization has been ordered or performed	
G2120	Within the past 2 years, calcium and/or vitamin d optimization has not been ordered or performed	
G2121	Psychosis, depression, anxiety, apathy, and impulse control disorder assessed	
G2122	Psychosis, depression, anxiety, apathy, and impulse control disorder not assessed	
G2123	Patients 66-80 years of age and had at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period	
G2124	Patients 66-80 years of age and had at least one claim/encounter for frailty during the measurement period and a dispensed dementia medication	
G2125	Patients 81 years of age and older with evidence of frailty during the measurement period	
G2126	Patients 66 years of age or older and had at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period	
G2127	Patients 66 years of age or older and had at least one claim/encounter for frailty during the measurement period and a dispensed dementia medication	
G2128	Documentation of medical reason(s) for not on a daily aspirin or other antiplatelet (e.g. history of gastrointestinal bleed, intra-cranial bleed, blood disorders, idiopathic thrombocytopenic purpura (itp), gastric bypass or documentation of active anticoagulant use during the measurement period)	
G2129	Procedure-related bp's not taken during an outpatient visit. examples include same day surgery, ambulatory service center, g.i. lab, dialysis, infusion center, chemotherapy	
G2130	Patients age 66 or older in institutional special needs plans (snp) or	
02130	residing in long-term care with pos code 32, 33, 34, 54 or 56 for more than 90 days during the measurement period	

G2132	Patients 66-80 years of age with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period	
G2133	Patients 66-80 years of age with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period	
G2134	Patients 66 years of age or older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period	
G2135	Patients 66 years of age or older with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period	
G2136	Back pain measured by the visual analog scale (vas) at three months (6 ? 20 weeks) postoperatively was less than or equal to 3.0 or back pain measured by the visual analog scale (vas) within three months preoperatively and at three months (6 ? 20 weeks) postoperatively demonstrated an improvement of 5.0 points or greater	
G2137	Back pain measured by the visual analog scale (vas) at three months (6 ? 20 weeks) postoperatively was greater than 3.0 and back pain measured by the visual analog scale (vas) within three months preoperatively and at three months (6 ? 20 weeks) postoperatively demonstrated a change of less than an improvement of 5.0 points	
G2138	Back pain as measured by the visual analog scale (vas) at one year (9 to 15 months) postoperatively was less than or equal to 3.0 or back pain measured by the visual analog scale (vas) within three months preoperatively and at one year (9 to 15 months) postoperatively demonstrated a change of 5.0 points or greater	
G2139	Back pain measured by the visual analog scale (vas) pain at one year (9 to 15 months) postoperatively was greater than 3.0 and back pain measured by the visual analog scale (vas) within three months preoperatively and at one year (9 to 15 months) postoperatively demonstrated a change of less than 5.0	
G2140	Leg pain measured by the visual analog scale (vas) at three months (6 ? 20 weeks) postoperatively was less than or equal to 3.0 or leg pain measured by the visual analog scale (vas) within three months preoperatively and at three months (6 - 20 weeks) postoperatively demonstrated an improvement of 5.0 points or greater	
G2141	Leg pain measured by the visual analog scale (vas) at three months (6 ? 20 weeks) postoperatively was greater than 3.0 and leg pain measured by the visual analog scale (vas) within three months preoperatively and at three months (6 - 20 weeks) postoperatively demonstrated less than an improvement of 5.0 points	

G2142	Functional status measured by the oswestry disability index (odi version 2.1a) at one year (9 to 15 months) postoperatively was less than or equal to 22 or functional status measured by the odi version 2.1a within three months preoperatively and at one year (9 to 15 months) postoperatively demonstrated a change of 30 points or greater	
G2143	Functional status measured by the oswestry disability index (odi version 2.1a) at one year (9 to 15 months) postoperatively was greater than 22 and functional status measured by the odi version 2.1a within three months preoperatively and at one year (9 to 15 months) postoperatively demonstrated a change of less than 30 points	
G2144	Functional status measured by the oswestry disability index (odi version 2.1a) at three months (6 ? 20 weeks) postoperatively was less than or equal to 22 or functional status measured by the odi version 2.1a within three months preoperatively and at three months (6 - 20 weeks) postoperatively demonstrated a change of 30 points or greater	
G2145	Functional status measured by the oswestry disability index (odi version 2.1a) at three months (6 ? 20 weeks) postoperatively was greater than 22 and functional status measured by the odi version 2.1a within three months preoperatively and at three months (6 - 20 weeks) postoperatively demonstrated a change of less than 30 points	
G2146	Leg pain as measured by the visual analog scale (vas) at one year (9 to 15 months) postoperatively was less than or equal to 3.0 or leg pain measured by the visual analog scale (vas) within three months preoperatively and at one year (9 to 15 months) postoperatively demonstrated an improvement of 5.0 points or greater	
G2147	Leg pain measured by the visual analog scale (vas) at one year (9 to 15 months) postoperatively was greater than 3.0 and leg pain measured by the visual analog scale (vas) within three months preoperatively and at one year (9 to 15 months) postoperatively demonstrated less than an improvement of 5.0 points	
G2148	Performance met: multimodal pain management was used	
G2149	Documentation of medical reason(s) for not using multimodal pain management (e.g., allergy to multiple classes of analgesics, intubated patient, hepatic failure, patient reports no pain during pacu stay, other medical reason(s))	
G2150	Performance not met: multimodal pain management was not used	
G2151	Patients with diagnosis of a degenerative neurological condition such as als, ms, parkinson's diagnosed at any time before or during the episode of care	
G2152	Performance met: the residual change score is equal to or greater than 0	
G2153	In hospice or using hospice services during the measurement period	
G2154	Patient received at least one td vaccine or one tdap vaccine between nine years prior to the start of the measurement period and the end of the measurement period	
G2155	Patient had history of at least one of the following contraindications any time during or before the measurement period: anaphylaxis due to tdap vaccine, anaphylaxis due to td vaccine or its components; encephalopathy due to tdap or td vaccination (post tetanus vaccination encephalitis, post diphtheria vaccination encephalitis or post pertussis vaccination encephalitis.)	

Patient did not receive at least one di vaccine or nor tdap vaccine betwen nine years prior to the start of the measurement period and the end of the measurement period; or have history of at least one of the following contratadications any time during or before to to tdap vaccine, anaphylaxis due to to vaccine or its components; encephalopsity, due to tdap or tot vaccination (post tetanus vaccination encephalitis, post diphthenia vaccination oncephalitis or post pertursis vaccination encephalitis).  Patients received both the 13-valent pneumococcal conjugate vaccina and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during the measurement period  G2158  Patient bad prior pneumococcal vaccine adverses reaction any time during or before the measurement period  G2169  Patient did not receive both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period  G2160  Patient did not receive both the 13-valent pneumococcal conjugate vaccine and the 32-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period.  G2160  Patient raceived at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime or or after the patient's 50th birthday before or during the measurement period  G2161  Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  G2162  Patient thad prior adverse reaction caused by zoster vaccine or the vaccine or two doses of the herpes zoster fecombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or howe prior produced to the prior prior to the measurement perior or d			
the end of the measurement period; or have history of at least one of the following contraindations any time during or before to the measurement period; anaphylaxis due to tdap vaccine, anaphylaxis due to td vaccine or its components; ancephallist, post diphtheria vaccination (post tetanus vaccination encephallist, post diphtheria vaccination encephallist or post pertursis vaccination encephallist).  Patients received both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during the measurement period.  G2158 Patient had prior pneumococcal vaccine adverse reaction any time during or before the measurement period waccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period vaccine adverse reaction any time during or before the measurement period vaccine adverse reaction any time during or before the measurement period.  G2160 Patient received at least one dose of the herpes zoster rive vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period.  G2161 Patient did not receive at least one dose of the herpes zoster live vaccine or its components any time during or before the measurement period.  G2162 Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period or have prior adverse reaction caused by zoster vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period and ju	G2156	·	
the following contraindications any time during or before the measurement period: anaphylaxis due to tid vaccination (post telanus vaccination encephalitis or post pertussis vaccination encephalitis.)  Patients received both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during the measurement period  22158 Patient had prior pneumococcal vaccine adverse reaction any time during or before the measurement period vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine adverser reaction any time during or before the measurement period.  22160 Patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period vaccine adverse any time during or before the measurement period vaccine any time during or before the measurement period vaccine any time during or before the measurement period vaccine any time during or before the measurement period vaccine any time during or before or during the measurement period vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period or two doses of the herpes zoster recombinant vaccine (at least 22 days apart) anytime to or or deverse reaction any time during or before the measurement period or the during or before the measurement period or the during or before the measurement period or during the measurement period or during the measurement period or during			
measurement period: anaphylaxis due to tdap vaccine, anaphylaxis due to td vaccine or its components; encephalopathy due to tdap or td vaccination (post tetanus vaccination encephalitis, post diphtheria vaccination encephalitis or post pertussis vaccination encephalitis.)  Patients received both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during the measurement period  G2158 Patient had prior pneumococcal vaccine adverse reaction any time during or before the measurement period  G2159 Patient did not receive both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period, or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period vaccine adverse reaction any time during or before the measurement period vaccine adverse reaction any time during or before the measurement period of the herpes zoster recombinant vaccine (at least 25 days apart) anytime on or after the patients 50th birthday before or during the measurement period  G2160 Patient had prior adverse reaction causad by zoster vaccine or its components any time during or before the measurement period  G2161 Patient had prior adverse reaction asset the patients 50th birthday before or during the measurement period or its components any time during or before the measurement period.  G2162 Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 25 days, apart) anytime on or after the patients 50th birthday before or during the measurement period; or have prior adverse reaction any time before or during the measurement period; or have prior adverse reaction any time before or during the measurement period.  G2163 Patient received an influenza vaccine on or			
due to to vaccination (post teaturus vaccination encephalitis, post diphtheria vaccination (post teaturus vaccination encephalitis) and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during the measurement period  62158 Patient had prior pneumococcal vaccine adverses reaction any time during or before the measurement period  62159 Patient did not receive both the 13-valent pneumococcal conjugate vaccine at least 12 months apart, with the first occurrence adverse reaction any time during or before the measurement period  62159 Patient did not receive both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period, or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period vaccine adverse reaction any time during or before the measurement period vaccine adverse reaction any time during or before the measurement period of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period components any time during or before the measurement period components any time during or before the measurement period of the vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period, or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period, or have prior adverse reaction aused by zoster vaccine or its components any time during or before the measurement period, or have prior adverse reaction any time before or during the measurement period or before the measurement period and june 30 of the measurement period.  62164 Patient had prior influenza vacci			
vaccination (post tetanus vaccination encephalitis, post diphtheria vaccination encephalitis or post pertussis vaccination encephalitis.)  Patients received both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during the measurement period  G2158 Patient and prior pneumococcal vaccine adverse reaction any time during or before the measurement period patient and prior pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period patients are considered vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period, or have prior pneumococcal vaccine adversers reaction any time during or before the measurement period patients of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period  G2161 Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  G2162 Patient did not receive at least one dose of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period, or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period or have prior or during the measurement period or have prior adverse reaction any time before or during the measurement period or between july 1 of the year prior to the measurement period or du			
vaccination encephalitis or post pertussis vaccination encephalitis.)  Patients received both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during the measurement period  G2158 Patient had prior pneumococcal vaccine adverse reaction any time during or before the measurement period  G2159 Patient did not receive both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period. or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period vaccine adverse reaction any time during or before the measurement period to work odses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period  G2160 Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  G2161 Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  G2162 Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period, or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period, or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period, or have prior adverse reaction any time before or during the measurement period and june 30 of the measurement period.  G2163 Patient had prior influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period.  G2164 Pa		due to td vaccine or its components; encephalopathy due to tdap or td	
Patients received both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during the measurement period  G2158  Patient had prior pneumococcal vaccine adverse reaction any time during or before the measurement period  Patient did not receive both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period  G2160  Patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period  G2161  Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  G2162  Patient did not receive at least one dose of the herpes zoster live vaccine or work doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period, or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period, or have prior adverse reaction acused by zoster vaccine or its components any time during or before the measurement period of hor measurement period.  G2163  Patient received an influenza virus vaccine adverse reaction any time before or during the measurement period of the measurement period of the measurement period of vaccine adverse reaction any time before or during the measurement period of vaccine adverse reaction any t		vaccination (post tetanus vaccination encephalitis, post diphtheria	
and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during the measurement period during the measurement period during the measurement period during the first occurrence after the age of 60 before or during measurement period expected at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period.  Patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period.  Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period.  Patient had not receive at least one dose of the herpes zoster rive vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period or before the measurement period are least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period or the components any time during or before the measurement period and june 30 of the measurement period or before the measurement period and june 30 of the measurement period or before the measurement period and june 30 of the measurement period and june 30 of the measurement period adverse reaction any time before or during the measurement period and june 30 of the measurement period adverse reaction any time before or during the measurement period and june 30 of the measurement period adverse reaction any time before or during the measurement period adverse reaction any time before or during the measureme		vaccination encephalitis or post pertussis vaccination encephalitis.)	
and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during the measurement period during the measurement period during the measurement period during the first occurrence after the age of 60 before or during measurement period expected at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period.  Patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period.  Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period.  Patient had not receive at least one dose of the herpes zoster rive vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period or before the measurement period are least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period or the components any time during or before the measurement period and june 30 of the measurement period or before the measurement period and june 30 of the measurement period or before the measurement period and june 30 of the measurement period and june 30 of the measurement period adverse reaction any time before or during the measurement period and june 30 of the measurement period adverse reaction any time before or during the measurement period and june 30 of the measurement period adverse reaction any time before or during the measurement period adverse reaction any time before or during the measureme			
and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during the measurement period during the measurement period during the measurement period during the first occurrence after the age of 60 before or during measurement period expected at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period.  Patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period.  Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period.  Patient had not receive at least one dose of the herpes zoster rive vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period or before the measurement period are least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period or the components any time during or before the measurement period and june 30 of the measurement period or before the measurement period and june 30 of the measurement period or before the measurement period and june 30 of the measurement period and june 30 of the measurement period adverse reaction any time before or during the measurement period and june 30 of the measurement period adverse reaction any time before or during the measurement period and june 30 of the measurement period adverse reaction any time before or during the measurement period adverse reaction any time before or during the measureme			
and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during the measurement period during the measurement period during the measurement period during the first occurrence after the age of 60 before or during measurement period expected at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period.  Patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period.  Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period.  Patient had not receive at least one dose of the herpes zoster rive vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period or before the measurement period are least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period or the components any time during or before the measurement period and june 30 of the measurement period or before the measurement period and june 30 of the measurement period or before the measurement period and june 30 of the measurement period and june 30 of the measurement period adverse reaction any time before or during the measurement period and june 30 of the measurement period adverse reaction any time before or during the measurement period and june 30 of the measurement period adverse reaction any time before or during the measurement period adverse reaction any time before or during the measureme			
months apart, with the first occurrence after the age of 60 before or during the measurement period and integrating the measurement period accine adverse reaction any time during or before the measurement period accine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period decise adverse reaction any time during or before the measurement period of two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period decise and the prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period decise at 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period or its components any time during or before the measurement period or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period or have prior adverse reaction accorded by zoster vaccine or its components any time during or before the measurement period and june 30 of the measurement period or during the measurement period or during the measurement period and june 30 of the measurement period or during the measurement period adverse reaction any time before or during the measurement period and june 30 of the measurement period or during the measurement period or the measurement period or the measurement period or during the vaccine adverse reaction any time before or during the measurement period or the measurement period or the measurement	G2157		
during the measurement period  G2158 Patient had prior pneumococcal vaccine adverse reaction any time during or before the measurement period  G2159 Patient did not receive both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period  G2160 Patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period  G2161 Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  G2162 Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period or heve prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period. The patient's 50th birthday before or during the measurement period on the period prior to the measurement period, or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period on the period prior did period perio		· · · · · · · · · · · · · · · · · · ·	
G2158 Patient had prior pneumococcal vaccine adverse reaction any time during or before the measurement period of during or before them seasurement period or two doses of the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period of two doses of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period  G2161 Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  G2162 Patient did not receive at least one dose of the herpes zoster live vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period:  G2163 Patient did not receive at least one dose of the herpes zoster live vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  G2163 Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period  G2164 Patient did not receive an influenza vaccine adverse reaction any time before or during the measurement period and june 30 of the measurement period adverse reaction any time before or during the measurement period and june 30 of the measurement period and june 30 of the measurement period or during the vac aprior influenza virus vaccine adverse reaction any time before or during the vac prior influenza virus vaccine adverse reaction any time before or during the vac			
during or before the measurement period  Patient did not receive both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period over the vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period  Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  Patient did not receive at least one dose of the herpes zoster live vaccine or its components any time during or before the measurement period vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period; or have prior adverse reaction caused by zoster vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period.  Patient received an influenza virus vaccine adverse reaction any time before or during the measurement period.  Patient that a prior influenza virus vaccine adverse reaction any time before or during the measurement period.  Patient telused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge; patient unable to complete the neck fs prom at admission or discharge; patient unable to complete the neck fs prom at admission or discharge; patient unable to complete the neck fs prom at admission or discharge; patient unable to complete the neck fs prom at admission and/or discharge; patient self-discharge dearly, medical reason  Earlier Performance not met: the residual change score is		during the measurement period	
Patient did not receive both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period  Patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period  Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  G2161 Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period and june 30 of the measurement period  G2163 Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period  G2164 Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period and june 30 of the measurement period.  G2165 Patient did not receive an influenza virus vaccine and june 30 of the measurement period; or did not have a prior influenze virus vaccine adverse reaction any time before or during the measurement period.  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharg	G2158	Patient had prior pneumococcal vaccine adverse reaction any time	
vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period, or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period.  Patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period  Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  Q2162 Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period; or before the measurement period or before the measurement period or before the measurement period or between july 1 of the year prior to the measurement period and june 30 of the measurement period  Q2163 Patient received an influenza virus vaccine adverse reaction any time before or during the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period of upon 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period.  Patient refused to participate at admission and/or discharge; patient upon 40 to the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period.  Patient refused to participate at admission and/or discharge; patient upon 40 to complete the neck fs prom at admission or discharge; patient self-discharged early, medical reason  Patient		during or before the measurement period	
vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period.  Patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period  Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period or before the measurement period are first the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period.  Patient received an influenza virus vaccine adverse reaction any time before or during the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period.  Patient relused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxylecorder is not available; patient self-discharged early, medical reason  Ca167 Performance not met: the residual change score is less than 0  Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricu	G2159	Patient did not receive both the 13-valent pneumococcal conjugate	
least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period.  Patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period.  Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period.  Patient did not receive at least one dose of the herpes zoster live vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period of the measurement period or between july 1 of the year prior to the measurement period and june 30 of the measurement period of the measurement period and june 30 of the measurement period or during the measurement period and june 30 of the measurement period or during the measurement period and june 30 of the measurement period or during the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period.  Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period.  Patient refused to participate at admission and/or discharge patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit,			
before or during measurement period; or have prior pneumococcal vaccine adverse reaction any time during or before the measurement period  Patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period  Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period of the measurement period and june 30 of the measurement period or during the measurement period and june 30 of the measurement period or during the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction and adverse reaction and any time before or during the measurement period and june 30 of the measurement period; or day and the period and june 30 of the measurement pe			
vaccine adverse reaction any time during or before the measurement period			
G2160 Patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period  G2161 Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  G2162 Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period or have prior adverse reaction caused by zoster vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period of during the measurement period and june 30 of the measurement period of during the measurement period and june 30 of the measurement period of the year prior to the measurement period and june 30 of the measurement period or during the measurement period and june 30 of the measurement period or during the measurement period and june 30 of the measurement period, or din oft have a prior influenza virus vaccine adverse reaction any time before or during the measurement period or during the measurement period or during the measurement period or discharge to the participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) == 40% or documentation as normal or mildly depressed left ventricular systolic function			
G2160 Patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period  G2161 Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  G2162 Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period: or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period or before the measurement period  G2163 Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period  G2164 Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period and june 30 of the measurement period  G2165 Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period on the wear prior influenza virus vaccine adverse reaction any time before or during the measurement period and june 30 of the measurement period on the wear prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge; patient unable to complete the neck fs prom at admission or discharge; patient unable to complete the neck fs prom at admission or discharge; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G2168 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function		·	
two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period  Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period or its components any time during or before the measurement period and june 30 of the measurement period or Jatient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period or Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  Patient refused to participate at admission and/or discharge, patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, insulage parrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  Cal Performance not met: the residual change score is less than 0  Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function		F	
two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period  Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period or its components any time during or before the measurement period and june 30 of the measurement period or Jatient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period or Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  Patient refused to participate at admission and/or discharge, patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, insulage parrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  Cal Performance not met: the residual change score is less than 0  Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function			
apart) anytime on or after the patient's 50th birthday before or during the measurement period  G2161 Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  G2162 Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period or between july 1 of the year prior to the measurement period and june 30 of the measurement period or during the measurement period and june 30 of the measurement before or during the measurement period and june 30 of the measurement period or during the measurement period and june 30 of the measurement period or during the measurement period and june 30 of the measurement period or during the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period.  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function	G2160		
the measurement period  Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period and june 30 of the measurement period  Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  Patient did not receive an influenza virus vaccine adverse reaction any time before or during the measurement period and june 30 of the measurement period of the year prior to the measurement period and june 30 of the measurement period		· · · · · · · · · · · · · · · · · · ·	
G2162 Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  G2162 Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period or between july 1 of the year prior to the measurement period and june 30 of the measurement period  G2164 Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2165 Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G2168 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function			
Components any time during or before the measurement period  Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period or between july 1 of the year prior to the measurement period and june 30 of the measurement period  Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function		the measurement period	
Components any time during or before the measurement period  Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period or between july 1 of the year prior to the measurement period and june 30 of the measurement period  Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function			
Components any time during or before the measurement period  Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period or between july 1 of the year prior to the measurement period and june 30 of the measurement period  Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function	G2161	Patient had prior adverse reaction caused by zoster vaccine or its	
G2162 Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  G2163 Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period  G2164 Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2165 Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function			
vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period  Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function			
vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period  Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function	G2162	Patient did not receive at least one dose of the hernes zoster live	
least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  G2163 Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period  G2164 Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2165 Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function	02102		
before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period  Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period  Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function			
reaction caused by zoster vaccine or its components any time during or before the measurement period  Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period  Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function			
or before the measurement period  G2163 Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period  G2164 Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2165 Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function			
G2163 Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period  G2164 Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2165 Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function		· , , , , , , , , , , , , , , , , , , ,	
prior to the measurement period and june 30 of the measurement period  Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function		or before the measurement period	
prior to the measurement period and june 30 of the measurement period  Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function			
G2164 Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2165 Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function	G2163	Patient received an influenza vaccine on or between july 1 of the year	
G2164 Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2165 Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function		prior to the measurement period and june 30 of the measurement	
before or during the measurement period  G2165 Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function			
before or during the measurement period  G2165 Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function	G2164	Patient had a prior influenza virus vaccine adverse reaction any time	
G2165 Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function		l ·	
the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function	G2165	·	
measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function	52.100		
adverse reaction any time before or during the measurement period  G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function			
G2166 Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function			
unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function		davorse reaction any time before or during the measurement period	
unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function	00100		
cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function	G2166		
reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function			
self-discharged early; medical reason  G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function			
G2167 Performance not met: the residual change score is less than 0  G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function			
G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function		self-discharged early; medical reason	
G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function			
G8395 Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function	G2167	Performance not met: the residual change score is less than 0	
normal or mildly depressed left ventricular systolic function			
		· · · · · · · · · · · · · · · · · · ·	
G8396 Left ventricular ejection fraction (LVEF) not performed or documented		and the second s	
Test ventificular ejection fraction (LVLr) not performed of documented	C830e	Left ventricular ejection fraction (LVEE) not performed or decumented	
	90390	Len venincular ejection fraction (LVEF) not performed or documented	

00007	Dilete di secondo a su fina di se successi a suferiore a di se l'indice de come autotica	
G8397	Dilated macular or fundus exam performed, including documentation	
	of the presence or absence of macular edema and level of severity of	
	retinopathy	
G8398	Dilated macular or fundus exam not performed	
G8399	Patient with documented results of a central dual-energy x-ray	
	absorptiometry (dxa) ever being performed	
G8400	Patient with central dual-energy x-ray absorptiometry (dxa) results not	
	documented, reason not given	
G8404	Lower extremity neurological exam performed and documented	
	, , ,	
G8405	Lower extremity neurological exam not performed	
G8410	Footwear evaluation performed and documented	
G8415	Footwear evaluation was not performed	
G8416	Clinician documented that patient was not an eligible candidate for	
00410	footwear evaluation measure	
G8417	BMI is documented above normal parameters and a follow-up plan is	
G6417	documented	
00440		
G8418	BMI is documented below normal parameters and a follow-up plan is	
	documented	
G8419	BMI documented outside normal parameters, no follow-up plan	
	documented, no reason given	
G8420	BMI is documented within normal parameters and no follow-up plan is	
	required	
G8421	BMI not documented and no reason is given	
G8422	BMI not documented, documentation the patient is not eligible for BMI	
	calculation	
G8427	Eligible clinician attests to documenting in the medical record they	
	obtained, updated, or reviewed the patient's current medications	
G8428	Current list of medications not documented as obtained, updated, or	
00.20	reviewed by the eligible clinician, reason not given	
G8430	Eligible clinician attests to documenting in the medical record the	
00430	patient is not eligible for a current list of medications being obtained,	
	updated, or reviewed by the eligible clinician	
G8431		
G6431	Screening for depression is documented as being positive and a	
00400	follow-up plan is documented	
G8432	Depression screening not documented, reason not given	
G8433	Screening for depression not completed, documented reason	
G8442	Pain assessment not documented as being performed, documentation	
	the patient is not eligible for a pain assessment using a standardized	
	tool	
G8450	Beta-blocker therapy prescribed	
G8451	Beta-blocker therapy for lvef < 40% not prescribed for reasons	
	documented by the clinician (e.g., low blood pressure, fluid overload,	
	asthma, patients recently treated with an intravenous positive inotropic	
	agent, allergy, intolerance, other medical reasons, patient declined,	
	other patient reasons, or other reasons attributable to the healthcare	
	system)	
G8452	Beta-blocker therapy not prescribed	
G8465	High or very high risk of recurrence of prostate cancer	
G8473	Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor	
5	blocker (ARB) therapy prescribed	
G8474	Angiotensin converting enzyme (ace) inhibitor or angiotensin receptor	
JU-7/ 7	blocker (arb) therapy not prescribed for reasons documented by the	
	clinician (e.g., allergy, intolerance, pregnancy, renal failure due to ace	
	inhibitor, diseases of the aortic or mitral valve, other medical reasons)	
	or (e.g., patient declined, other patient reasons) or (e.g., lack of drug	
	availability, other reasons attributable to the health care system)	
	availability, other reasons attributable to the fledith care system)	

G8475	Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy not prescribed, reason not given	
G8476	Most recent blood pressure has a systolic measurement of < 140 mmhg and a diastolic measurement of < 90 mmhg	
G8477	Most recent blood pressure has a systolic measurement of >= 140 mmhg and/or a diastolic measurement of >= 90 mmhg	
G8478	Blood pressure measurement not performed or documented, reason not given	
G8482	Influenza immunization administered or previously received	
G8483	Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons)	
G8484	Influenza immunization was not administered, reason not given	
G8506	Patient receiving angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy	
G8509	Pain assessment documented as positive using a standardized tool, follow-up plan not documented, reason not given	
G8510	Screening for depression is documented as negative, a follow-up plan is not required	
G8511	Screening for depression documented as positive, follow-up plan not documented, reason not given	
G8535	Elder maltreatment screen not documented; documentation that patient not eligible for the elder maltreatment screen	
G8536	No documentation of an elder maltreatment screen, reason not given	
G8539	Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies on the date of functional outcome assessment, is documented	
G8540	Functional outcome assessment not documented as being performed, documentation the patient is not eligible for a functional outcome assessment using a standardized tool	
G8541	Functional outcome assessment using a standardized tool not documented, reason not given	
G8542	Functional outcome assessment using a standardized tool is documented; no functional deficiencies identified, care plan not required	
G8543	Documentation of a positive functional outcome assessment using a standardized tool; care plan not documented, reason not given	
G8559	Patient referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation	
G8560	Patient has a history of active drainage from the ear within the previous 90 days	
G8561	Patient is not eligible for the referral for otologic evaluation for patients with a history of active drainage measure	
G8562	Patient does not have a history of active drainage from the ear within the previous 90 days	
G8563	Patient not referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation, reason not given	
G8564	Patient was referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation, reason not specified)	
G8565	Verification and documentation of sudden or rapidly progressive hearing loss	
G8566	Patient is not eligible for the "referral for otologic evaluation for sudden or rapidly progressive hearing loss" measure	

rapidly progressive hearing loss  Ratient was not referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation, reason not given  Ration Prolonged postoperative intubation (> 24 hrs) required  Ration Prolonged postoperative intubation (> 24 hrs) not required  Ration Prolonged postoperative intubation (> 24 hrs) not required  Ration Development of deep sternal wound infection/mediastinitis within 30 days postoperatively  Ration No deep sternal wound infection/mediastinitis  Ration No deep sternal wound infection/mediastinitis  Ration No stroke following isolated CABG surgery  Ration No postoperative renal failure or required dialysis  Restrict No postoperative renal failure or required  Re-exploration required due to mediastinal bleeding with or without tamponade, graft occlusion, valve dysfunction or other cardiac reason  Re-exploration not required due to mediastinal bleeding with or without tamponade, graft occlusion, valve dysfunction or other cardiac reason  Re-exploration not required due to mediastinal bleeding with or without tamponade, graft occlusion, valve dysfunction or other cardiac reason  Re-exploration not required the tomediastinal bleeding with or without tamponade, graft occlusion, valve dysfunction or other cardiac reason  Restrict No service No serv	r _	T	
Patient was not referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation, reason not given	G8567	Patient does not have verification and documentation of sudden or	
training in disorders of the ear) for an ofologic evaluation, reason not given  GRESSE Prolonged postoperative intubation (> 24 hrs) required  GRESTO Prolonged postoperatively  GRESTO Prolonged postoperative renal failure or required dialysis  GRESTO Prolonged Prolo		, ,, ,	
given   G8569	G8568		
Gas698		training in disorders of the ear) for an otologic evaluation, reason not	
Protonged postoperative intubation (> 24 hrs) not required			
G8571 No deep sternal wound infection/mediastinitis within 30 days postoperatively considerable of the con	G8569	Prolonged postoperative intubation (> 24 hrs) required	
days postoperatively  68573 Stroke following isolated CABG surgery  86574 No stroke following isolated CABG surgery  86575 Developed postoperative renal failure or required dialysis  86576 No postoperative renal failure or required dialysis  86577 Re-exploration required due to mediatinal bleeding with or without tamponade, graft occlusion, valve dysfunction or other cardiac reason  86578 Re-exploration required due to mediatinal bleeding with or without tamponade, graft occlusion, valve dysfunction or other cardiac reason  86578 Re-exploration not required due to mediatinal bleeding with or without tamponade, graft occlusion, valve dysfunction or other cardiac reason  86578 Asprin or another antiplatelet therapy used  86599 Asprin or another antiplatelet therapy used  86690 IV I-PA initiated within three hours (<= 180 minutes) of time last known well  86601 IV I-PA not initiated within three hours (<= 180 minutes) of time last known well for reasons documented by clinician  86602 IV I-PA not initiated within three hours (<= 180 minutes) of time last known well for reasons documented by clinician  86602 IV I-PA not initiated within three hours (<= 180 minutes) of time last known well, reason not given  86602 IV I-PA not initiated within three hours (<= 180 minutes) of time last known well, reason not given  86603 IV I-PA not initiated within three hours (<= 180 minutes) of time last known well, reason not given  86604 IV I-PA not initiated within three hours (<= 180 minutes) of time last known well, reason not given  86607 IV I-PA not initiated within three hours (<= 180 minutes) of time last known well or reasons documented by clinician  86608 IV I-PA not initiated within three hours (<= 180 minutes) of time last known well reason not given  86600 IV I-PA not initiated within three hours (<= 180 minutes) of time last known well reason not given  86600 IV I-PA not initiated within three hours (<= 180 minutes) of time last known well reason or given for minutes) of time last known well reason or given for minute	G8570	Prolonged postoperative intubation (> 24 hrs) not required	
Seption   Sept	G8571	Development of deep sternal wound infection/mediastinitis within 30	
Stroke following isolated CABG surgery		days postoperatively	
Septiment   Sept	G8572	No deep sternal wound infection/mediastinitis	
Developed postoperative renal failure or required dialysis	G8573	Stroke following isolated CABG surgery	
G8576   No postoperative renal failure/dialysis not required   G8577   Re-exploration required due to mediastinal bleeding with or without tamponade, graft occlusion, valve dysfunction or other cardiac reason   G8578   Re-exploration not required due to mediastinal bleeding with or without tamponade, graft occlusion, valve dysfunction or other cardiac reason   G8598   Aspirin or another antiplatelet therapy used   G8599   Aspirin or another antiplatelet therapy used   G8600   IV t-PA initiated within three hours (<= 180 minutes) of time last known well   G8601   IV t-PA not initiated within three hours (<= 180 minutes) of time last known well for reasons documented by clinician   G8601   IV t-PA not initiated within three hours (<= 180 minutes) of time last known well for reasons documented by clinician   G8602   IV t-PA not initiated within three hours (<= 180 minutes) of time last known well, reason not given   G8603   IV t-PA not initiated within three hours (<= 180 minutes) of time last known well, reason not given   G8604   IV t-PA not initiated within three hours (<= 180 minutes) of time last known well, reason not given   G8608   Surgical procedure performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, disocated or wrong power iot, retinal detachment, or wound dehiscence)   G8628   Surgical procedure not performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iot, retinal detachment, or wound dehiscence)   G8630   Pharmacologic therapy (other than minerals/vitamins) for osteoporosis prescribed   G8631   Pharmacologic therapy (other than minerals/vitamins) for osteoporosis prescribed   G8632   Risk-adjusted functional status change residual score for the knee successfully calculated and the score was equal to zero (0) or greater than zero (<0)   G8640   Risk-adjusted functional status change residual score for the knee not measured becau	G8574	No stroke following isolated CABG surgery	
Re-exploration required due to mediastinal bleeding with or without tamponade, graft occlusion, valve dysfunction or other cardiac reason  Re-exploration not required due to mediastinal bleeding with or without tamponade, graft occlusion, valve dysfunction or other cardiac reason  Responsation or another antiplatelet therapy used  Aspirin or another antiplatelet therapy used  Aspirin or another antiplatelet therapy not used, reason not given  IV t-PA initiated within three hours (<= 180 minutes) of time last known well  Responsation of the part of the	G8575		
tamponade, graft occlusion, valve dysfunction or other cardiac reason  Re-exploration not required due to mediastinal bleeding with or without tamponade, graft occlusion, valve dysfunction or other cardiac reason  Sesson Aspirin or another antiplatelet therapy used Aspirin or another antiplatelet therapy used Aspirin or another antiplatelet therapy used  Sesson IV t-PA initiated within three hours (<= 180 minutes) of time last known well for reasons documented by clinician  Vt -PA not initiated within three hours (<= 180 minutes) of time last known well for reasons documented by clinician  Vt -PA not initiated within three hours (<= 180 minutes) of time last known well, reason not given  Sesson Vt -PA not initiated within three hours (<= 180 minutes) of time last known well, reason not given  Wt -PA not initiated within three hours (<= 180 minutes) of time last known well, reason not given  Sesson Vt -PA not initiated within 190 days following cataract surgery for major complications (e, g., retained nuclear fragments, endophthalmits, dislocated or wrong power iol, retinal detachment, or wound dehiscence)  Surgical procedure not performed within 30 days following cataract surgery for major complications (e, g., retained nuclear fragments, endophthalmits, dislocated or wrong power iol, retinal detachment, or wound dehiscence)  Surgical procedure not performed within 30 days following cataract surgery for major complications (e, g., retained nuclear fragments, endophthalmits, dislocated or wrong power iol, retinal detachment, or wound dehiscence)  Sesson Paramacologic therapy (other than minierals/vitamins) for osteoporosis prescribed  Risk-adjusted functional status change residual score for the knee successfully calculated and the score was equal to zero (0) or greater than zero (-0)  Risk-adjusted functional status change residual score for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow by status survey near discharge, reason not given  Risk-adju	G8576	No postoperative renal failure/dialysis not required	
Re-exploration not required due to mediastinal bleeding with or without tamponade, graft occlusion, valve dysfunction or other cardiac reason  68598 Aspirin or another antiplatelet therapy used  68599 Aspirin or another antiplatelet therapy used  68600 IV t-PA initiated within three hours (<= 180 minutes) of time last known well  68601 IV t-PA not initiated within there hours (<= 180 minutes) of time last known well for reasons documented by clinician  68602 IV t-PA not initiated within there hours (<= 180 minutes) of time last known well for reasons documented by clinician  68602 IV t-PA not initiated within three hours (<= 180 minutes) of time last known well for reasons documented by clinician  68602 IV t-PA not initiated within three hours (<= 180 minutes) of time last known well, reason not given  68603 Surgical procedure performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)  68608 Surgical procedure not performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)  68633 Pharmacologic therapy (other than minierals/vitamins) for osteoporosis prescribed  68635 Pharmacologic therapy for osteoporosis was not prescribed, reason not given  68647 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was equal to zero (0) or greater than zero (-0)  68650 Risk-adjusted functional status change residual score for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  68651 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (-0)  68652 Risk-adjusted functional status change residual score	G8577	Re-exploration required due to mediastinal bleeding with or without	
tamponade, graft occlusion, valve dysfunction or other cardiac reason		tamponade, graft occlusion, valve dysfunction or other cardiac reason	
tamponade, graft occlusion, valve dysfunction or other cardiac reason			
Aspirin or another antiplatelet therapy used  Aspirin or another antiplatelet therapy not used, reason not given    VI-PA initiated within three hours (<= 180 minutes) of time last known well   VI-PA not initiated within three hours (<= 180 minutes) of time last known well for reasons documented by clinician   VI-PA not initiated within three hours (<= 180 minutes) of time last known well reason not given    VI-PA not initiated within three hours (<= 180 minutes) of time last known well, reason not given   VI-PA not initiated within three hours (<= 180 minutes) of time last known well, reason not given	G8578	Re-exploration not required due to mediastinal bleeding with or without	
Aspirin or another antiplatelet therapy not used, reason not given    Reference   Referenc		tamponade, graft occlusion, valve dysfunction or other cardiac reason	
Aspirin or another antiplatelet therapy not used, reason not given    Reference   Referenc			
Aspirin or another antiplatelet therapy not used, reason not given    Vt-PA initiated within three hours (<= 180 minutes) of time last known well	G8598	Aspirin or another antiplatelet therapy used	
IV t-PA initiated within three hours (<= 180 minutes) of time last known well	<b>-</b>		
Known well			
Known well	G8600	IV t-PA initiated within three hours (<= 180 minutes) of time last	
known well for reasons documented by clinician    Nt-PA not initiated within three hours (<= 180 minutes) of time last known well, reason not given    Surgical procedure performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)    Surgical procedure not performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)    G8633   Pharmacologic therapy (other than minierals/vitamins) for osteoporosis prescribed   G8633   Pharmacologic therapy (other than minierals/vitamins) for osteoporosis prescribed   G8634   Risk-adjusted functional status change residual score for the knee successfully calculated and the score was equal to zero (0) or greater than zero (<0)    G8648   Risk-adjusted functional status change residual score for the knee successfully calculated and the score was less than zero (<0)    G8650   Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given    G8651   Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (<0)    G8652   Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)    G8654   Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)    G8654   Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)    Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)			
known well for reasons documented by clinician    Nt-PA not initiated within three hours (<= 180 minutes) of time last known well, reason not given    Surgical procedure performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)    Surgical procedure not performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)    G8633   Pharmacologic therapy (other than minierals/vitamins) for osteoporosis prescribed   G8633   Pharmacologic therapy (other than minierals/vitamins) for osteoporosis prescribed   G8634   Risk-adjusted functional status change residual score for the knee successfully calculated and the score was equal to zero (0) or greater than zero (<0)    G8648   Risk-adjusted functional status change residual score for the knee successfully calculated and the score was less than zero (<0)    G8650   Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given    G8651   Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (<0)    G8652   Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)    G8654   Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)    G8654   Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)    Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)	G8601	IV t-PA not initiated within three hours (<= 180 minutes) of time last	
Vt-PA not initiated within three hours (<= 180 minutes) of time last known well, reason not given		· · · · · · · · · · · · · · · · · · ·	
known well, reason not given  Surgical procedure performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)  Surgical procedure not performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)  G8633 Pharmacologic therapy (other than minierals/vitamins) for osteoporosis prescribed  G8635 Pharmacologic therapy for osteoporosis was not prescribed, reason not given  G8647 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8648 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was less than zero (<0)  G8650 Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8651 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8652 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  G8654 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  G8654 Risk-adjusted functional status change residual scores for the hip successfully calculated and the score was less than zero (<0)  G8654 Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,	G8602	·	
Surgical procedure performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)  Surgical procedure not performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)  G8633 Pharmacologic therapy (other than minierals/vitamins) for osteoporosis prescribed  G8635 Pharmacologic therapy for osteoporosis was not prescribed, reason not given  G8647 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8648 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was less than zero (<0)  G8650 Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8651 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8652 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8654 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)		· · · · · · · · · · · · · · · · · · ·	
surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)  G8628 Surgical procedure not performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)  G8633 Pharmacologic therapy (other than minierals/vitamins) for osteoporosis prescribed  G8635 Pharmacologic therapy for osteoporosis was not prescribed, reason not given  G8647 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8648 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was less than zero (<0)  G8650 Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8651 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8652 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  G8654 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  G8654 Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,	G8627		
endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)  Surgical procedure not performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)  G8633 Pharmacologic therapy (other than minierals/vitamins) for osteoporosis prescribed  G8635 Pharmacologic therapy for osteoporosis was not prescribed, reason not given  G8647 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8648 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was less than zero (<0)  G8650 Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8651 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8652 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  G8654 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)			
Surgical procedure not performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)    Pharmacologic therapy (other than minierals/vitamins) for osteoporosis prescribed   Pharmacologic therapy for osteoporosis was not prescribed, reason not given   Risk-adjusted functional status change residual score for the knee successfully calculated and the score was equal to zero (0) or greater than zero (>0)    Risk-adjusted functional status change residual score for the knee successfully calculated and the score was less than zero (<0)   Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given    Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)    Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)    Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)    Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)    Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)    Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)			
surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)  G8633 Pharmacologic therapy (other than minierals/vitamins) for osteoporosis prescribed  G8635 Pharmacologic therapy for osteoporosis was not prescribed, reason not given  G8647 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8648 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was less than zero (<0)  G8650 Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8651 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8652 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  G8654 Risk-adjusted functional status change residual score for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,			
surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)  G8633 Pharmacologic therapy (other than minierals/vitamins) for osteoporosis prescribed  G8635 Pharmacologic therapy for osteoporosis was not prescribed, reason not given  G8647 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8648 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was less than zero (<0)  G8650 Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8651 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8652 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  G8654 Risk-adjusted functional status change residual score for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,	G8628	Surgical procedure not performed within 30 days following cataract	
endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)  G8633 Pharmacologic therapy (other than minierals/vitamins) for osteoporosis prescribed  G8635 Pharmacologic therapy for osteoporosis was not prescribed, reason not given  G8647 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8648 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was less than zero (<0)  G8650 Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8651 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8652 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  G8654 Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,			
Wound dehiscence)  G8633 Pharmacologic therapy (other than minierals/vitamins) for osteoporosis prescribed  G8635 Pharmacologic therapy for osteoporosis was not prescribed, reason not given  G8647 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8648 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was less than zero (<0)  G8650 Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8651 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8652 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  G8654 Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,			
osteoporosis prescribed  G8635 Pharmacologic therapy for osteoporosis was not prescribed, reason not given  G8647 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8648 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was less than zero (<0)  G8650 Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8651 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8652 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  G8654 Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,			
osteoporosis prescribed  G8635 Pharmacologic therapy for osteoporosis was not prescribed, reason not given  G8647 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8648 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was less than zero (<0)  G8650 Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8651 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8652 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  G8654 Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,	G8633	Pharmacologic therapy (other than minierals/vitamins) for	
Pharmacologic therapy for osteoporosis was not prescribed, reason not given	00000	9 ,, ,	
not given  Risk-adjusted functional status change residual score for the knee successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the knee successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,	G8635	· · · · · ·	
Risk-adjusted functional status change residual score for the knee successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the knee successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the hip successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,	00000		
successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8648 Risk-adjusted functional status change residual score for the knee successfully calculated and the score was less than zero (<0)  G8650 Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8651 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8652 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  G8654 Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,	G8647	ĕ	
than zero (>0)  Risk-adjusted functional status change residual score for the knee successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,	00011		
Risk-adjusted functional status change residual score for the knee successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the hip successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,			
Successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,	G8648	` '	
G8650 Risk-adjusted functional status change residual scores for the knee not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8651 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  G8652 Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  G8654 Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,	30070		
not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,		1	
not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,	G8650	Risk-adjusted functional status change residual scores for the knee	
intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,	30000		
reason not given  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,		·	
Risk-adjusted functional status change residual score for the hip successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,			
successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,	G8651	<u> </u>	
than zero (>0)  Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,	30031		
Risk-adjusted functional status change residual score for the hip successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,			
successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,	C96F2		
G8654 Risk-adjusted functional status change residual scores for the hip not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,	G0052		
measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,		successivily calculated and the score was less than zero (<0)	
measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge,	C0654	Disk adjusted functional status above assistant assess for the later as	
intake on admission and/or follow up status survey near discharge,	G8654		
Todoott Hot given			
		roadon not given	

ankle successfully calculated and the score was equal to zero (0) or greater than zero ( > 0)  G8656 Risk-adjusted functional status change residual scores for the foot or ankle successfully calculated and the score was less than zero (< 0)  G8658 Risk-adjusted functional status change residual scores for the foot or ankle not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8659 Risk-adjusted functional status change residual score for the lumbar impairment successfully calculated and the score was equal to zero (0) or greater than zero ( > 0)  G8660 Risk-adjusted functional status change residual score for the lumbar impairment successfully calculated and the score was less than zero ( < 0)  G8661 Risk-adjusted functional status change residual score for the lumbar impairment not provided the score was less than zero ( < 0)  G8662 Risk-adjusted functional status change residual scores for the lumbar impairment not measured because the patient did not complete foto's status survey near discharge, patient not appropriate  G8662 Risk-adjusted functional status change residual scores for the lumbar impairment not measured because the patient did not complete foto's status survey, near discharge, reason on given  G8663 Risk-adjusted functional status change residual score for the shoulder successfully calculated and the score was equal to zero (0) or greater than zero ( > 0)  G8664 Risk-adjusted functional status change residual score for the shoulder successfully calculated and the score was equal to zero (0) or greater than zero ( > 0)  G8666 Risk-adjusted functional status change residual scores for the shoulder successfully calculated and the score was equal to zero (0) or greater than zero ( > 0)  G8667 Risk-adjusted functional status change residual scores for the elbow, wrist or hand successfully calculated and the score was equal to zero (0) or greater than zero ( > 0)  G8668 Risk-adjusted functional status			
ankle successfully calculated and the score was less than zero (< 0)  Risk-adjusted functional status change residual scores for the toot or ankle not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the lumbar impairment successfully calculated and the score was equal to zero (o)  Risk-adjusted functional status change residual score for the lumbar impairment successfully calculated and the score was less than zero (< 0)  Risk-adjusted functional status change residual scores for the lumbar impairment successfully calculated and the score was less than zero (< 0)  Risk-adjusted functional status change residual scores for the lumbar impairment not measured because the patient did not complete foto's status survey near discharge, patient not appropriate status survey near discharge, patient not appropriate status survey near discharge, as a discharge,	G8655		
ankle not measured because the patient did not complete foto's functional inake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the lumbar impairment successfully calculated and the score was equal to zero (0) or greater than zero (<0)  Risk-adjusted functional status change residual score for the lumbar impairment successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the lumbar impairment successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the lumbar impairment not measured because the patient did not complete foto's status survey near discharge, patient not appropriate  Risk-adjusted functional status change residual scores for the lumbar impairment not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the shoulder successfully calculated and the score was equal to zero (0) or greater than zero (<0)  Risk-adjusted functional status change residual score for the shoulder successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the shoulder successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual score for the shoulder successfully calculated and the score was sequal to zero (0) or greater than zero (<0)  Risk-adjusted functional status change residual score for the elbow, wrist or hand successfully calculated and the score was sequal to zero (0) or greater than zero (<0)  Risk-adjusted functional status change residual score for the elbow, wrist or hand successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual score for the neck, cranium, mandblo, thoracic spine, ri	G8656		
impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)  Risk-adjusted functional status change residual score for the lumbar impairment successfully calculated and the score was less than zero (4 o)  Risk-adjusted functional status change residual scores for the lumbar impairment successfully calculated and the score was less than zero Risk-adjusted functional status change residual scores for the lumbar impairment not measured because the patient did not complete foto's status survey near discharge, patient not appropriate  Risk-adjusted functional status change residual scores for the lumbar impairment not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8663 Risk-adjusted functional status change residual score for the shoulder successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the shoulder successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual score for the shoulder not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the elbow, wrist or hand successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the elbow, wrist or hand successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual score for the elbow, wrist or hand successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, this, or other general orthopaedic impairment successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted func	G8658	ankle not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given	
impairment successfully calculated and the score was less than zero (< 0)  (5 0)  (8661 Risk-adjusted functional status change residual scores for the lumbar impairment not measured because the patient did not complete foto's status survey near discharge, patient not appropriate  Risk-adjusted functional status change residual scores for the lumbar impairment not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8663 Risk-adjusted functional status change residual score for the shoulder successfully calculated and the score was equal to zero (0) or greater than zero (<0)  G8664 Risk-adjusted functional status change residual score for the shoulder successfully calculated and the score was less than zero (<0)  G8666 Risk-adjusted functional status change residual scores for the shoulder successfully calculated and the score was less than zero (<0)  G8667 Risk-adjusted functional status change residual scores for the shoulder not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8667 Risk-adjusted functional status change residual score for the elbow, wrist or hand successfully calculated and the score was equal to zero (0) or greater than zero (<0)  G8668 Risk-adjusted functional status change residual score for the elbow, wrist or hand successfully calculated and the score was less than zero (<0)  G8670 Risk-adjusted functional status change residual score for the elbow, wrist or hand not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8671 Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, fibs, or other general orthopaedic impairment successfully calculated and the score was less than zero (<0) or greater than zero (<0) or greater than zero (<0) or greater than	G8659	impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)	
impairment not measured because the patient did not complete foto's status survey near discharge, patient not appropriate  Risk-adjusted functional status change residual scores for the lumbar impairment not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8663 Risk-adjusted functional status change residual score for the shoulder successfully calculated and the score was equal to zero (0) or greater than zero (<0)  G8664 Risk-adjusted functional status change residual score for the shoulder successfully calculated and the score was less than zero (<0)  G8666 Risk-adjusted functional status change residual scores for the shoulder not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8667 Risk-adjusted functional status change residual score for the elbow, with or hand successfully calculated and the score was equal to zero (0) or greater than zero (<0)  G8668 Risk-adjusted functional status change residual score for the elbow, with or hand successfully calculated and the score was less than zero (<0)  G8669 Risk-adjusted functional status change residual score for the elbow, with or hand successfully calculated and the score was less than zero (<0)  G8670 Risk-adjusted functional status change residual scores for the elbow, with or hand not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8671 Risk-adjusted functional status change residual scores for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was equal to zero (0) or greater than zero (<0)  G8672 Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score	G8660	impairment successfully calculated and the score was less than zero	
impairment not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  38663 Risk-adjusted functional status change residual score for the shoulder successfully calculated and the score was equal to zero (0) or greater than zero (<0)  38664 Risk-adjusted functional status change residual score for the shoulder successfully calculated and the score was less than zero (<0)  38666 Risk-adjusted functional status change residual scores for the shoulder successfully calculated and the score was less than zero (<0)  38667 Risk-adjusted functional status change residual scores for the shoulder shoulder not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  38667 Risk-adjusted functional status change residual score for the elbow, wrist or hand successfully calculated and the score was equal to zero (0) or greater than zero (<0)  38668 Risk-adjusted functional status change residual score for the elbow, wrist or hand successfully calculated and the score was less than zero (<0)  38670 Risk-adjusted functional status change residual scores for the elbow, wrist or hand not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  38671 Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was equal to zero (0) or greater than zero (<0)  38672 Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was less than zero (<0)  38674 Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment not measure	G8661	impairment not measured because the patient did not complete foto's	
successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the shoulder successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the shoulder not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the elbow, wrist or hand successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the elbow, wrist or hand successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the elbow, wrist or hand not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual scores for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not	G8662	impairment not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near	
Successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the shoulder not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the elbow, wrist or hand successfully calculated and the score was equal to zero (0) or greater than zero (<0)  Risk-adjusted functional status change residual score for the elbow, wrist or hand successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the elbow, wrist or hand not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was equal to zero (0) or greater than zero (<0)  Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual scores for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given	G8663	successfully calculated and the score was equal to zero (0) or greater	
shoulder not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the elbow, wrist or hand successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the elbow, wrist or hand successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the elbow, wrist or hand not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)  Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was less than zero (< 0)  Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8694  Left ventricular ejection fraction (lvef) < 40%	G8664		
wrist or hand successfully calculated and the score was equal to zero (0) or greater than zero (>0)  Risk-adjusted functional status change residual score for the elbow, wrist or hand successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the elbow, wrist or hand not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)  Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was less than zero (< 0)  Risk-adjusted functional status change residual scores for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Left ventricular ejection fraction (Ivef) < 40%	G8666	shoulder not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near	
wrist or hand successfully calculated and the score was less than zero (<0)  Risk-adjusted functional status change residual scores for the elbow, wrist or hand not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)  Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was less than zero (< 0)  Risk-adjusted functional status change residual scores for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Reservative decided and the score was less than zero (< 0)	G8667	wrist or hand successfully calculated and the score was equal to zero	
wrist or hand not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)  Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was less than zero (< 0)  Risk-adjusted functional status change residual scores for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8694  Left ventricular ejection fraction (lvef) < 40%	G8668	wrist or hand successfully calculated and the score was less than zero	
cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)  Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was less than zero (< 0)  Risk-adjusted functional status change residual scores for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8694  Left ventricular ejection fraction (lvef) < 40%	G8670	wrist or hand not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey	
cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was less than zero (< 0)  G8674 Risk-adjusted functional status change residual scores for the neck, cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8694 Left ventricular ejection fraction (lvef) < 40%	G8671	cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was equal to zero	
cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given  G8694 Left ventricular ejection fraction (Ivef) < 40%	G8672	cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment successfully calculated and the score was less than zero	
		cranium, mandible, thoracic spine, ribs, or other general orthopaedic impairment not measured because the patient did not complete foto's functional intake on admission and/or follow up status survey near discharge, reason not given	
G8696 Antithromhotic therapy prescribed at discharge	G8694	Left ventricular ejection fraction (lvef) < 40%	
20000 printing mode incrept proteined at discharge	G8696	Antithrombotic therapy prescribed at discharge	

G8697	Antithrombotic therapy not prescribed for documented reasons (e.g.,	
	patient had stroke during hospital stay, patient expired during inpatient	
	stay, other medical reason(s)); (e.g., patient left against medical	
	advice, other patient reason(s))	
G8698	Antithrombotic therapy was not prescribed at discharge, reason not	
	given	
00700		
G8708	Patient not prescribed or dispensed antibiotic	
G8709	Patient prescribed or dispensed antibiotic for documented medical	
	reason(s) (e.g., intestinal infection, pertussis, bacterial infection, lyme	
	disease, otitis media, acute sinusitis, acute pharyngitis, acute	
	tonsillitis, chronic sinusitis, infection of the	
	pharynx/larynx/tonsils/adenoids, prostatitis, cellulitis, mastoiditis, or	
	bone infections, acute lymphadenitis, impetigo, skin staph infections,	
	pneumonia/gonococcal infections, venereal disease (syphilis,	
	chlamydia, inflammatory diseases (female reproductive organs)),	
	infections of the kidney, cystitis or uti, and acne)	
G8710	Patient prescribed or dispensed antibiotic	
G8711	Prescribed or dispensed antibiotic	
G8712	Antibiotic not prescribed or dispensed	
	·	
G8721	Pt category (primary tumor), pn category (regional lymph nodes), and	
	histologic grade were documented in pathology report	
G8722	Documentation of medical reason(s) for not including the pt category,	
00722		
	the pn category or the histologic grade in the pathology report (e.g., re-	
	excision without residual tumor; non-carcinomasanal canal)	
G8723	Charles a site is other than anotomic location of primary tumor	
	Specimen site is other than anatomic location of primary tumor	
G8724	Pt category, pn category and histologic grade were not documented in	
	the pathology report, reason not given	
G8730	Pain assessment documented as positive using a standardized tool	
00730		
	and a follow-up plan is documented	
G8731	Pain assessment using a standardized tool is documented as	
	negative, no follow-up plan required	
G8732	No documentation of pain assessment, reason not given	
G8733	Elder maltreatment screen documented as positive and a follow-up	
	plan is documented	
G8734	Elder maltreatment screen documented as negative, no follow-up	
00.01	required	
	·	
G8735	Elder maltreatment screen documented as positive, follow-up plan not	
	documented, reason not given	
G8749	Absence of signs of melanoma (cough, dyspnea, tenderness,	
30. 40		
	localized neurologic signs such as weakness, jaundice or any other	
	sign suggesting systemic spread) or absence of symptoms of	
	melanoma (pain, paresthesia, or any other symptom suggesting the	
	possibility of systemic spread of melanoma)	
G8752	Most recent systolic blood pressure < 140 mmhg	
G8753	Most recent systolic blood pressure >= 140 mmhg	
G8754	Most recent diastolic blood pressure < 90 mmhg	
	Ţ	
G8755	Most recent diastolic blood pressure >= 90 mmhg	
G8756	No documentation of blood pressure measurement, reason not given	
G8783	Normal blood pressure reading documented, follow-up not required	
30103	rionnal blood pressure reading documented, follow-up not required	
G8785	Blood pressure reading not documented, reason not given	
G8797	Specimen site other than anatomic location of esophagus	

G8807	Trans-abdominal or trans-vaginal ultrasound not performed for reasons documented by clinician (e.g., patient has visited the ED	
	multiple times within 72 hours, patient has a documented intrauterine pregnancy [IUP])	
00000		
G8808	Performance of trans-abdominal or trans-vaginal ultrasound not ordered, reason not given (e.g., patient has visited the ED multiple	
	• • • • • • • • • • • • • • • • • • • •	
	times with no documentation of a trans-abdominal or trans-vaginal	
	ultrasound within ED or from referring eligible professional)	
G8809	Rh-immunoglobulin (RHOGAM) ordered	
G8810	Rh-immunoglobulin (RHOGAM) not ordered for reasons documented	
	by clinician (e.g., patient had prior documented receipt of RHOGAM	
	within 12 weeks, patient refusal)	
G8811	Documentation rh-immunoglobulin (RHOGAM) was not ordered,	
	reason not given	
G8815	Documented reason in the medical records for why the statin therapy	
	was not prescribed (i.e., lower extremity bypass was for a patient with	
	non-artherosclerotic disease)	
G8816	Statin medication prescribed at discharge	
G8817	Statin therapy not prescribed at discharge, reason not given	
G8818	Patient discharge to home no later than post-operative day #7	
G8825	Patient not discharged to home by post-operative day #7	
G8826	Patient discharge to home no later than post-operative day #2	
•	following EVAR	
G8833	Patient not discharged to home by post-operative day #2 following	
	Evar	
G8834	Patient discharged to home no later than post-operative day #2	
	following CEA	
G8838	Patient not discharged to home by post-operative day #2 following	
00000	CEA	
G8839	Sleep apnea symptoms assessed, including presence or absence of	
00000	snoring and daytime sleepiness	
G8840	Documentation of reason(s) for not documenting an assessment of	
G0040	sleep symptoms (e.g., patient didn't have initial daytime sleepiness,	
	patient visited between initial testing and initiation of therapy)	
	patient visited between initial testing and initiation of therapy)	
G8841	Close appea symptoms not accessed reason not given	
G8842	Sleep apnea symptoms not assessed, reason not given	
G0042	Apnea hypopnea index (AHI) or respiratory disturbance index (RDI)	
00040	measured at the time of initial diagnosis	
G8843	Documentation of reason(s) for not measuring an apnea hypopnea	
	index (AHI) or a respiratory disturbance index (RDI) at the time of	
	initial diagnosis (e.g., psychiatric disease, dementia, patient declined,	
	financial, insurance coverage, test ordered but not yet completed)	
G8844	Apnea hypopnea index (AHI) or respiratory disturbance index (RDI)	
	not measured at the time of initial diagnosis, reason not given	
G8845	Positive airway pressure therapy prescribed	
G8846	Moderate or severe obstructive sleep apnea (apnea hypopnea index	
	(AHI) or respiratory disturbance index (RDI) of 15 or greater)	
G8849	Documentation of reason(s) for not prescribing positive airway	
	pressure therapy (e.g., patient unable to tolerate, alternative therapies	
	use, patient declined, financial, insurance coverage)	
G8850	Positive airway pressure therapy not prescribed, reason not given	
20000	. 35 3 sirray product thorapy not produition, roughly not given	
G8851	Objective measurement of adherence to positive airway pressure	
-000 i	therapy, documented	
G8852		
U000Z	Positive airway pressure therapy prescribed	

G8854	Documentation of reason(s) for not objectively measuring adherence to positive airway pressure therapy (e.g., patient didn't bring data from continous positive airway pressure [CPAP], therapy not yet initiated, not available on machine)	
G8855	Objective measurement of adherence to positive airway pressure	
	therapy not performed, reason not given	
G8856	Referral to a physician for an otologic evaluation performed	
G8857	Patient is not eligible for the referral for otologic evaluation measure (e.g., patients who are already under the care of a physician for acute or chronic dizziness)	
G8858	Referral to a physician for an otologic evaluation not performed, reason not given	
G8863	Patients not assessed for risk of bone loss, reason not given	
G8864	Pneumococcal vaccine administered or previously received	
G8865	Documentation of medical reason(s) for not administering or previously receiving pneumococcal vaccine (e.g., patient allergic reaction, potential adverse drug reaction)	
G8866	Documentation of patient reason(s) for not administering or previously receiving pneumococcal vaccine (e.g., patient refusal)	
G8867	Pneumococcal vaccine not administered or previously received, reason not given	
G8869	Patient has documented immunity to Hepatitis B and is receiving a first course of anti-TNF therapy	
G8872	Excised tissue evaluated by imaging intraoperatively to confirm successful inclusion of targeted lesion	
G8873	Patients with needle localization specimens which are not amenable to intraoperative imaging such as mri needle wire localization, or targets which are tentatively identified on mammogram or ultrasound which do not contain a biopsy marker but which can be verified on intraoperative inspection or pathology (e.g., needle biopsy site where the biopsy marker is remote from the actual biopsy site)	
G8874	Excised tissue not evaluated by imaging intraoperatively to confirm successful inclusion of targeted lesion	
G8875	Clinician diagnosed breast cancer preoperatively by a minimally invasive biopsy method	
G8876	Documentation of reason(s) for not performing minimally invasive biopsy to diagnose breast cancer preoperatively (e.g., lesion too close to skin, implant, chest wall, etc., lesion could not be adequately visualized for needle biopsy, patient condition prevents needle biopsy [weight, breast thickness, etc.], duct excision without imaging abnormality, prophylactic mastectomy, reduction mammoplasty, excisional biopsy performed by another physician)	
G8877	Clinician did not attempt to achieve the diagnosis of breast cancer preoperatively by a minimally invasive biopsy method, reason not given	
G8878	Sentinel lymph node biopsy procedure performed	
G8879	Clinically node negative (t1n0m0 or t2n0m0) invasive breast cancer	
G8880	Documentation of reason(s) sentinel lymph node biopsy not performed (e.g., reasons could include but not limited to; non-invasive cancer, incidental discovery of breast cancer on prophylactic mastectomy, incidental discovery of breast cancer on reduction mammoplasty, pre-operative biopsy proven lymph node (In) metastases, inflammatory carcinoma, stage 3 locally advanced cancer, recurrent invasive breast cancer, patient refusal after informed consent)	
G8881	Stage of breast cancer is greater than t1n0m0 or t2n0m0	
G8882	Sentinel lymph node biopsy procedure not performed, reason not given	

-	T	
G8883	Biopsy results reviewed, communicated, tracked and documented	
G8884	Clinician documented reason that patient's biopsy results were not reviewed	
G8885	Biopsy results not reviewed, communicated, tracked or documented	
G8907	Patient documented not to have experienced any of the following events: a burn prior to discharge; a fall within the facility; wrong site/side/patient/procedure/implant event; or a hospital transfer or hospital admission upon discharge from the facility	
G8908	Patient documented to have received a burn prior to discharge	
G8909	Patient documented not to have received a burn prior to discharge	
G8910	Patient documented to have experienced a fall within ASC	
G8911	Patient documented not to have experienced a fall within Ambulatory Surgical Center	
G8912	Patient documented to have experienced a wrong site, wrong side, wrong patient, wrong procedure or wrong implant event	
G8913	Patient documented not to have experienced a wrong site, wrong side, wrong patient, wrong procedure or wrong implant event	
G8914	Patient documented to have experienced a hospital transfer or hospital admission upon discharge from ASC	
G8915	Patient documented not to have experienced a hospital transfer or hospital admission upon discharge from ASC	
G8916	Patient with preoperative order for IV antibiotic surgical site infection (SSI) prophylaxis, antibiotic initiated on time	
G8917	Patient with preoperative order for IV antibiotic surgical site infection (SSI) prophylaxis, antibiotic not initiated on time	
G8918	Patient without preoperative order for IV antibiotic surgical site infection (SSI) prophylaxis	
G8923	Left ventricular ejection fraction (LVEF) < 40% or documentation of moderately or severely depressed left ventricular systolic function	
G8924	Spirometry test results demonstrate fev1/fvc < 70%, fev < 60% predicted and patient has copd symptoms (e.g., dyspnea, cough/sputum, wheezing)	
G8925	Spirometry test results demonstrate fev1 >= 60% fev1/fvc >= 70%, predicted or patient does not have copd symptoms	
G8926	Spirometry test not performed or documented, reason not given	
G8934	Left ventricular ejection fraction (LVEF) <40% or documentation of moderately or severely depressed left ventricular systolic function	
G8935	Clinician prescribed angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy	
G8936	Clinician documented that patient was not an eligible candidate for angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy (eg, allergy, intolerance, pregnancy, renal failure due to ace inhibitor, diseases of the aortic or mitral valve, other medical reasons) or (eg, patient declined, other patient reasons) or (eg, lack of drug availability, other reasons attributable to the health care system)	
G8937	Clinician did not prescribe angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy, reason not given	
G8938	BMI is documented as being outside of normal limits, follow-up plan is not documented, documentation the patient is not eligible	

G8939	Pain assessment documented as positive, follow-up plan not documented, documentation the patient is not eligible	
G8941	Elder maltreatment screen documented as positive, follow-up plan not	
	documented, documentation the patient is not eligible	
G8942	Functional outcomes assessment using a standardized tool is	
	documented within the previous 30 days and care plan, based on	
	identified deficiencies on the date of the functional outcome assessment, is documented	
G8944	AJCC melanoma cancer Stage 0 through IIC melanoma	
G8946	Minimally invasive biopsy method attempted but not diagnostic of	
	breast cancer (e.g., high risk lesion of breast such as atypical ductal	
	hyperplasia, lobular neoplasia, atypical lobular hyperplasia, lobular	
	carcinoma in situ, atypical columnar hyperplasia, flat epithelial atypia,	
	radial scar, complex sclerosing lesion, papillary lesion, or any lesion with spindle cells)	
	with apinule cella)	
G8947	One or more neuropsychiatric symptoms	
G8950	Pre-hypertensive or hypertensive blood pressure reading documented,	
	and the indicated follow-up is documented	
G8952	Pre-hypertensive or hypertensive blood pressure reading documented, indicated fallow up not desumented, reason not given	
	indicated follow-up not documented, reason not given	
G8955	Most recent assessment of adequacy of volume management	
	documented	
G8956	Patient receiving maintenance hemodialysis in an outpatient dialysis facility	
G8958	Assessment of adequacy of volume management not documented, reason not given	
G8959	Clinician treating major depressive disorder communicates to clinician	
	treating comorbid condition	
G8960	Clinician treating major depressive disorder did not communicate to	
	clinician treating comorbid condition, reason not given	
G8961	Cardiac stress imaging test primarily performed on low-risk surgery	
	patient for preoperative evaluation within 30 days preceding this	
00000	surgery	
G8962	Cardiac stress imaging test performed on patient for any reason including those who did not have low risk surgery or test that was	
	performed more than 30 days preceding low risk surgery	
	performed meno than do days proceding for not dargery	
G8963	Cardiac stress imaging performed primarily for monitoring of	
	asymptomatic patient who had PCI within 2 years	
G8964	Cardiac stress imaging test performed primarily for any other reason	
	than monitoring of asymptomatic patient who had PCI within 2 years (e.g., symptomatic patient, patient greater than 2 years since PCI,	
	initial evaluation, etc)	
G8965	Cardiac stress imaging test primarily performed on low CHD risk	
	patient for initial detection and risk assessment	
G8966	Cardiac stress imaging test performed on symptomatic or higher than	
	low CHD risk patient or for any reason other than initial detection and risk assessment	
G8967	Warfarin or another oral anticoagulant that is FDA approved	
	prescribed	
G8968	Documentation of medical reason(s) for not prescribing warfarin or	
	another oral anticoagulant that is fda approved for the prevention of	
	thromboembolism (e.g., allergy, risk of bleeding, other medical reasons)	
G8969	Documentation of patient reason(s) for not prescribing warfarin or	
	another oral anticoagulant that is FDA approved (e.g., economic,	
	social, and/or religious impediments, noncompliance patient refusal,	
	other patient reasons)	

00000		
G8970	No risk factors or one moderate risk factor for thromboembolism	
G8971	Warfarin or another oral anticoagulant that is FDA approved not	
000=0	prescribed, reason not given	
G8972	One or more high risk factors for thromboembolism or more than one moderate risk factor for thromboembolism	
G8973	Most recent hemoglobin (hgb) level < 10 g/dl	
G8974	Hemoglobin level measurement not documented, reason not given	
00074	Training about 100 contract that decounterized, reason 100 given	
G8975	Documentation of medical reason(s) for patient having a hemoglobin	
	level < 10 g/dl (e.g., patients who have non-renal etiologies of anemia	
	[e.g., sickle cell anemia or other hemoglobinopathies, hypersplenism,	
	primary bone marrow disease, anemia related to chemotherapy for	
	diagnosis of malignancy, postoperative bleeding, active bloodstream	
	or peritoneal infection], other medical reasons)	
G8976	Most recent hemoglobin (hgb) level >= 10 g/dl	
G9001	Coordinated care fee, initial rate	
G9002	Coordinated care fee, maintenance rate	
G9003	Coordinated care fee, risk adjusted high, initial	
G9004	Coordinated care fee, risk adjusted low, initial	
G9005	Coordinated care fee, risk adjusted maintenance	
G9006	Coordinated care fee, home monitoring	
G9007	Coordinated care fee, scheduled team conference	
G9008	Coordinated care fee, physician coordinated care oversight services	
	71 7	
G9009	Coordinated care fee, risk adjusted maintenance, level 3	
G9010	Coordinated care fee, risk adjusted maintenance, level 4	
G9011	Coordinated care fee, risk adjusted maintenance, level 5	
G9012	Other specified case management service not elsewhere classified	
G9013	ESRD Demo Basic Bundle Level I	
G9013 G9014	ESRD Demo Basic Bundle Level I ESRD Demo Expanded Bundle including venous access and related services	
	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in	
G9014	ESRD Demo Expanded Bundle including venous access and related services	
G9014	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]	
G9014 G9016	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the	
G9014 G9016	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]	
G9014 G9016	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-	
G9014 G9016 G9050	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)	
G9014 G9016 G9050	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing	
G9014 G9016 G9050	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a Medicare-	
G9014 G9016 G9050	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing	
G9014 G9016 G9050 G9051	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a Medicare-approved demonstration project)	
G9014 G9016 G9050	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a Medicare-approved demonstration project)	
G9014 G9016 G9050 G9051	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and	
G9014 G9016 G9050 G9051	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy	
G9014 G9016 G9050 G9051	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy might be considered in the future (for use in a Medicare-approved	
G9014 G9016 G9050 G9051	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)	
G9014 G9016 G9050 G9051	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; expectant management of patient	
G9014 G9016 G9050 G9051	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; expectant management of patient with evidence of cancer for whom no cancer directed therapy is being	
G9014 G9016 G9050 G9051	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; expectant management of patient with evidence of cancer for whom no cancer directed therapy is being administered or arranged at present; cancer directed therapy might be	
G9014 G9016 G9050 G9051	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; expectant management of patient with evidence of cancer for whom no cancer directed therapy is being administered or arranged at present; cancer directed therapy might be considered in the future (for use in a Medicare-approved	
G9014 G9016 G9050 G9051 G9052	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; expectant management of patient with evidence of cancer for whom no cancer directed therapy is being administered or arranged at present; cancer directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)	
G9014 G9016 G9050 G9051	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; expectant management of patient with evidence of cancer for whom no cancer directed therapy is being administered or arranged at present; cancer directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; supervising, coordinating or	
G9014 G9016 G9050 G9051 G9052	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; expectant management of patient with evidence of cancer for whom no cancer directed therapy is being administered or arranged at present; cancer directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; supervising, coordinating or managing care of patient with terminal cancer or for whom other	
G9014 G9016 G9050 G9051 G9052	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; expectant management of patient with evidence of cancer for whom no cancer directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; supervising, coordinating or managing care of patient with terminal cancer or for whom other medical illness prevents further cancer treatment; includes symptom	
G9014 G9016 G9050 G9051 G9052	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; expectant management of patient with evidence of cancer for whom no cancer directed therapy is being administered or arranged at present; cancer directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; supervising, coordinating or managing care of patient with terminal cancer or for whom other medical illness prevents further cancer treatment; includes symptom management, end-of-life care planning, management of palliative	
G9014 G9016 G9050 G9051 G9052	ESRD Demo Expanded Bundle including venous access and related services  Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [Demo project code only]  Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; expectant management of patient with evidence of cancer for whom no cancer directed therapy might be considered in the future (for use in a Medicare-approved demonstration project)  Oncology; primary focus of visit; supervising, coordinating or managing care of patient with terminal cancer or for whom other medical illness prevents further cancer treatment; includes symptom	

00		
G9055	Oncology; primary focus of visit; other, unspecified service not	
	otherwise listed (for use in a Medicare-approved demonstration	
	project)	
G9056	Oncology; practice guidelines; management adheres to guidelines (for	
	use in a Medicare-approved demonstration project)	
G9057	Oncology; practice guidelines; management differs from guidelines as	
	a result of patient enrollment in an institutional review board approved	
	clinical trial (for use in a Medicare-approved demonstration project)	
	ominoar that (for use in a wedisare approved demonstration project)	
00050		
G9058	Oncology; practice guidelines; management differs from guidelines	
	because the treating physician disagrees with guideline	
	recommendations (for use in a Medicare-approved demonstration	
	project)	
G9059	Oncology; practice guidelines; management differs from guidelines	
	because the patient, after being offered treatment consistent with	
	guidelines, has opted for alternative treatment or management,	
	including no treatment (for use in a Medicare-approved demonstration	
	project)	
G9060	Oncology; practice guidelines; management differs from guidelines for	
3000	reason(s) associated with patient comorbid illness or performance	
	status not factored into guidelines (for use in a Medicare-approved	
	demonstration project)	
00001	1 , ,	
G9061	Oncology; practice guidelines; patient's condition not addressed by	
	available guidelines (for use in a Medicare-approved demonstration	
	project)	
G9062	Oncology; practice guidelines; management differs from guidelines for	
	other reason(s) not listed (for use in a Medicare-approved	
	demonstration project)	
G9063	Oncology; disease status; limited to non-small cell lung cancer; extent	
	of disease initially established as stage I (prior to neo-adjuvant	
	therapy, if any) with no evidence of disease progression, recurrence,	
	or metastases (for use in a Medicare-approved demonstration project)	
	or motacidos (for dos in a modicare approved demonstration project)	
C0064	Oncology, disease status, limited to non-amplifical lung concert system	
G9064	Oncology; disease status; limited to non-small cell lung cancer; extent	
	of disease initially established as stage II (prior to neo-adjuvant	
	therapy, if any) with no evidence of disease progression, recurrence,	
	or metastases (for use in a Medicare-approved demonstration project)	
G9065	Oncology; disease status; limited to non-small cell lung cancer; extent	
	of disease initially established as stage III a (prior to neo-adjuvant	
	therapy, if any) with no evidence of disease progression, recurrence,	
	or metastases (for use in a Medicare-approved demonstration project)	
G9066	Oncology; disease status; limited to non-small cell lung cancer; stage	
00000	III B- IV at diagnosis, metastatic, locally recurrent, or progressive (for	
	use in a Medicare-approved demonstration project)	
	add in a modicale approved demonstration projecti	
00007	Once le mundiage de la constant de l	
G9067	Oncology; disease status; limited to non-small cell lung cancer; extent	
	of disease unknown, staging in progress, or not listed (for use in a	
	Medicare-approved demonstration project)	
G9068	Oncology; disease status; limited to small cell and combined small	
	cell/non-small cell; extent of disease initially established as limited	
	with no evidence of disease progression, recurrence, or metastases	
	(for use in a Medicare-approved demonstration project)	
	, , , , , , , , , , , , , , , , , , , ,	
G9069	Oncology: disease status: small call lung concer limited to small call	
G9009	Oncology; disease status; small cell lung cancer, limited to small cell	
	and combined small cell/non-small cell; extensive stage at diagnosis,	
	metastatic, locally recurrent, or progressive (for use in a Medicare-	
	approved demonstration project)	

G9070	Oncology; disease status; small cell lung cancer, limited to small cell and combined small cell/non-small; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)	
G9071	Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; stage I or stage IIA-IIB; or T3, N1, M0; and ER and/or PR positive; with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	
G9072	Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; stage I, or stage IIA-IIB; or T3, N1, M0; and ER and PR negative; with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	
G9073	Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; stage IIIA-IIIB; and not T3, N1, M0; and ER and/or PR positive; with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	
G9074	Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; stage IIIA-IIIB; and not T3, N1, M0; and ER and PR negative; with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	
G9075	Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project)	
G9077	Oncology; disease status; prostate cancer, limited to adenocarcinoma as predominant cell type; T1-T2C and Gleason 2-7 and PSA < or equal to 20 at diagnosis with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	
G9078	Oncology; disease status; prostate cancer, limited to adenocarcinoma as predominant cell type; T2 or T3A Gleason 8-10 or PSA > 20 at diagnosis with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	
G9079	Oncology; disease status; prostate cancer, limited to adenocarcinoma as predominant cell type; T3B-T4, any N; any T, N1 at diagnosis with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	
G9080	Oncology; disease status; prostate cancer, limited to adenocarcinoma; after initial treatment with rising PSA or failure of PSA decline (for use in a Medicare-approved demonstration project)	
G9083	Oncology; disease status; prostate cancer, limited to adenocarcinoma; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)	
G9084	Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T1-3, N0, M0 with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	

G9085	Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T4, N0, M0 with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	
G9086	Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T1-4, N1-2, M0 with no evidence of disease progression, recurrence, or metastases (for use in a Medicareapproved demonstration project)	
G9087	Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive with current clinical, radiologic, or biochemical evidence of disease (for use in a Medicare-approved demonstration project)	
G9088	Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive without current clinical, radiologic, or biochemical evidence of disease (for use in a Medicare-approved demonstration project)	
G9089	Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)	
G9090	Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T1-2, N0, M0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	
G9091	Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T3, N0, M0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	
G9092	Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T1-3, N1-2, M0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence or metastases (for use in a Medicare-approved demonstration project)	
G9093	Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as T4, any N, M0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	
G9094	Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project)	
G9095	Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)	

G9096	Oncology; disease status; esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; extent of disease initially established as T1-T3, N0-N1 or NX (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicareapproved demonstration project)	
G9097	Oncology; disease status; esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; extent of disease initially established as t4, any n, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)	
G9098	Oncology; disease status; esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project)	
G9099	Oncology; disease status; esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)	
G9100	Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; post R0 resection (with or without neoadjuvant therapy) with no evidence of disease recurrence, progression, or metastases (for use in a Medicare-approved demonstration project)	
G9101	Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; post R1 or R2 resection (with or without neoadjuvant therapy) with no evidence of disease progression, or metastases (for use in a Medicare-approved demonstration project)	
G9102	Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; clinical or pathologic M0, unresectable with no evidence of disease progression, or metastases (for use in a Medicare-approved demonstration project)	
G9103	Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; clinical or pathologic M1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project)	
G9104	Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)	
G9105	Oncology; disease status; pancreatic cancer, limited to adenocarcinoma as predominant cell type; post R0 resection without evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)	
G9106	Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; post R1 or R2 resection with no evidence of disease progression, or metastases (for use in a Medicare-approved demonstration project)	
G9107	Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; unresectable at diagnosis, M1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project)	

G9103 Oncology, disease status; pancreatic cancer, limited to adenocarriomes, extend of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)  G9109 Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, phanyx and laynx with squamous cell as predominant cell type; extent of disease initially established as T1-T2 and N0, M0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  G9110 Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, phanyx and larynx with squamous cell as predominant cell type; extent of disease initially established as T3-4 and/or N1-3. M0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  G9111 Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, phanyx and larynx with squamous cell as predominant cell type; with at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project)  G9112 Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, phanyx and larynx with squamous cell as predominant cell type; water of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)  G9113 Oncology; disease status; ovarian cancer, limited to epithelial cancer; particular to cancers and provided control or cancers of oral cavity, phanyx and larynx with squamous cell as predominant cell type; exent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)  G9113 Oncology; disease status; ovarian cancer, limited to epithelial cancer; particular projects and provided control projects of the particular cancer; particular projects and provided demonstration project)  G9114 Oncology;			
oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease initially established as 11-12 and No. Mo (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicareapproved demonstration project)  Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease initially established as 13-4 and/or N1-3, M0 (prior to neo-adjuvant therapy, if any) with ne evidence of disease progression, recurrence, or metastases (for use in a Medicareapproved demonstration project)  Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project)  Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)  Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)  Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage IA-B (grade 2-3); or stage IC (all grades); or stage II: without evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage IA-B (grade 2-3); or stage IC (all grades); or stage II: without evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  Oncology; disease status; ovarian cancer	G9108	adenocarcinoma; extent of disease unknown, staging in progress, or	
oral cavity, pharynx and larynx with squamous cell as predominant cell type: extent of disease initially established as T3-4 and/or N1-3, M0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  G9111 Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project)  G9112 Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)  G9113 Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage IA-B (grade 1) without evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  G9114 Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage IA-B (grade 2-3); or stage IC (all grades); or stage II; without evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  G9115 Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage III-IV; without evidence of progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  G9116 Oncology; disease status; ovarian cancer, limited to epithelial cancer; evidence of disease progression, or recurrence, and/or platinum resistance (for use in a Medicare-approved demonstration project)  G9120 Oncology; disease status; ovarian cancer, limited to epithelial cancer; evidence of disease progression, or recurrence, and/or platinum resistance (for use in a Medicare-approved demonstration project)  G9121 Oncology; disease status; chronic myelogenous leu	G9109	oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease initially established as T1-T2 and N0, M0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-	
oral cavify, pharynx and larynx with squamous cell as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project)  G9112 Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)  G9113 Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage IA-B (grade 1) without evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  G9114 Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage IA-B (grade 2-3); or stage IC (all grades); or stage II; without evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  G9115 Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage III-IV; without evidence of progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  G9116 Oncology; disease status; ovarian cancer, limited to epithelial cancer; evidence of disease progression, or recurrence, and/or platinum resistance (for use in a Medicare-approved demonstration project)  G9116 Oncology; disease status; ovarian cancer, limited to epithelial cancer; evidence of disease progression, or recurrence, and/or platinum resistance (for use in a Medicare-approved demonstration project)  G9127 Oncology; disease status; ovarian cancer, limited to epithelial cancer; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)  G9128 Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; chronic phiadelphia chromosome positive and/or BCR-ABL positive; accelerated phase not in hematologic, cytog	G9110	oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease initially established as T3-4 and/or N1-3, M0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-	
oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)  G9113 Oncology, disease status; ovarian cancer, limited to epithelial cancer; pathologic stage IA-B (grade 1) without evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  G9114 Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage IA-B (grade 2-3); or stage IC (all grades); or stage II; without evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  G9115 Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage III-IV; without evidence of progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  G9116 Oncology; disease status; ovarian cancer, limited to epithelial cancer; evidence of disease progression, or recurrence, and/or platinum resistance (for use in a Medicare-approved demonstration project)  G9117 Oncology; disease status; ovarian cancer, limited to epithelial cancer; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)  G9120 Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; chronic phase not in hematologic, cytogenetic, or molecular remission (for use in a Medicare-approved demonstration project)	G9111	oral cavity, pharynx and larynx with squamous cell as predominant cell type; M1 at diagnosis, metastatic, locally recurrent, or progressive (for	
pathologic stage IA-B (grade 1) without evidence of disease progression, recurrence, or metastases (for use in a Medicareapproved demonstration project)  Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage IA-B (grade 2-3); or stage IC (all grades); or stage II; without evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage III-IV; without evidence of progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  G9116 Oncology; disease status; ovarian cancer, limited to epithelial cancer; evidence of disease progression, or recurrence, and/or platinum resistance (for use in a Medicare-approved demonstration project)  G9117 Oncology; disease status; ovarian cancer, limited to epithelial cancer; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)  G9123 Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; chronic phase not in hematologic, cytogenetic, or molecular remission (for use in a Medicare-approved demonstration project)  G9124 Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; accelerated phase not in hematologic cytogenetic, or molecular	G9112	oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease unknown, staging in progress, or not listed (for	
pathologic stage IA-B (grade 2-3); or stage IC (all grades); or stage II; without evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  G9115 Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage III-IV; without evidence of progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  G9116 Oncology; disease status; ovarian cancer, limited to epithelial cancer; evidence of disease progression, or recurrence, and/or platinum resistance (for use in a Medicare-approved demonstration project)  G9117 Oncology; disease status; ovarian cancer, limited to epithelial cancer; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)  G9123 Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; chronic phase not in hematologic, cytogenetic, or molecular remission (for use in a Medicare-approved demonstration project)  G9124 Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; accelerated phase not in hematologic cytogenetic, or molecular	G9113	pathologic stage IA-B (grade 1) without evidence of disease progression, recurrence, or metastases (for use in a Medicare-	
pathologic stage III-IV; without evidence of progression, recurrence, or metastases (for use in a Medicare-approved demonstration project)  G9116 Oncology; disease status; ovarian cancer, limited to epithelial cancer; evidence of disease progression, or recurrence, and/or platinum resistance (for use in a Medicare-approved demonstration project)  G9117 Oncology; disease status; ovarian cancer, limited to epithelial cancer; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)  G9123 Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; chronic phase not in hematologic, cytogenetic, or molecular remission (for use in a Medicare-approved demonstration project)  G9124 Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; accelerated phase not in hematologic cytogenetic, or molecular	G9114	pathologic stage IA-B (grade 2-3); or stage IC (all grades); or stage II; without evidence of disease progression, recurrence, or metastases	
evidence of disease progression, or recurrence, and/or platinum resistance (for use in a Medicare-approved demonstration project)  G9117 Oncology; disease status; ovarian cancer, limited to epithelial cancer; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)  G9123 Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; chronic phase not in hematologic, cytogenetic, or molecular remission (for use in a Medicare-approved demonstration project)  G9124 Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; accelerated phase not in hematologic cytogenetic, or molecular	G9115	pathologic stage III-IV; without evidence of progression, recurrence, or	
extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)  G9123 Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; chronic phase not in hematologic, cytogenetic, or molecular remission (for use in a Medicare-approved demonstration project)  G9124 Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; accelerated phase not in hematologic cytogenetic, or molecular	G9116	evidence of disease progression, or recurrence, and/or platinum	
Philadelphia chromosome positive and/or BCR-ABL positive; chronic phase not in hematologic, cytogenetic, or molecular remission (for use in a Medicare-approved demonstration project)  G9124 Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; accelerated phase not in hematologic cytogenetic, or molecular	G9117	extent of disease unknown, staging in progress, or not listed (for use	
Philadelphia chromosome positive and/or BCR-ABL positive; accelerated phase not in hematologic cytogenetic, or molecular	G9123	Philadelphia chromosome positive and/or BCR-ABL positive; chronic phase not in hematologic, cytogenetic, or molecular remission (for use	
	G9124	Philadelphia chromosome positive and/or BCR-ABL positive; accelerated phase not in hematologic cytogenetic, or molecular	

G9125	Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; blast phase not in hematologic, cytogenetic, or molecular remission (for use in a Medicare-approved demonstration project)	
G9126	Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or BCR-ABL positive; in hematologic, cytogenetic, or molecular remission (for use in a Medicare-approved demonstration project)	
G9128	Oncology; disease status; limited to multiple myeloma, systemic disease; smoldering, stage I (for use in a Medicare-approved demonstration project)	
G9129	Oncology; disease status; limited to multiple myeloma, systemic disease; stage II or higher (for use in a Medicare-approved demonstration project)	
G9130	Oncology; disease status; limited to multiple myeloma, systemic disease; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)	
G9131	Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a Medicare-approved demonstration project)	
G9132	Oncology; disease status; prostate cancer, limited to adenocarcinoma; hormone-refractory/androgen-independent (e.g., rising PSA on anti-androgen therapy or post-orchiectomy); clinical metastases (for use in a Medicare-approved demonstration project)	
G9133	Oncology; disease status; prostate cancer, limited to adenocarcinoma; hormone-responsive; clinical metastases or M1 at diagnosis (for use in a Medicare-approved demonstration project)	
G9134	Oncology; disease status; non-Hodgkin's lymphoma, any cellular classification; stage I, II at diagnosis, not relapsed, not refractory (for use in a Medicare-approved demonstration project)	
G9135	Oncology; disease status; non-Hodgkin's lymphoma, any cellular classification; stage III, IV, not relapsed, not refractory (for use in a Medicare-approved demonstration project)	
G9136	Oncology; disease status; non-Hodgkin's lymphoma, transformed from original cellular diagnosis to a second cellular classification (for use in a Medicare-approved demonstration project)	
G9137	Oncology; disease status; non-Hodgkin's lymphoma, any cellular classification; relapsed/refractory (for use in a Medicare-approved demonstration project)	
G9138	Oncology; disease status; non-Hodgkin's lymphoma, any cellular classification; diagnostic evaluation, stage not determined, evaluation of possible relapse or non-response to therapy, or not listed (for use in a Medicare-approved demonstration project)	
G9139	Oncology; disease status; chronic myelogenous leukemia, limited to Philadelphia chromosome positive and/or Bcr-Abl positive; extent of disease unknown, staging in progress, not listed (for use in a Medicare-approved demonstration project)	
G9140	Frontier extended stay clinic demonstration; for a patient stay in a clinic approved for the CMS demonstration project	
G9143	Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)	

G9147	Outpatient intravenous insulin treatment (oivit) either pulsatile or	
	continuous, by any means, guided by the results of measurements	
	for: respiratory quotient, and/or, urine urea nitrogen (uun), and/or,	
	arterial, venous or cap- illary glucose, and/or potassium concentration	
G9148	National committee for quality assurance—level 1 medical home	
G9149	National committee for quality assurance—level 2 medical home	
G9150	National committee for quality assurance—level 3 medical home	
	' '	
G9151	Mapcp demonstration - state provided services	
G9152	Mapop demonstration - community health teams	
G9153	Mapop demonstration - physician incentive pool	
G9156	Evaluation for wheelchair requiring face-to-face visit with physician	
G9187	Bundled payments for care improvement initiative home visit for	
00107	patient assessment performed by a qualified health care professional	
	for individuals not considered homebound including, but not limited to,	
	assessment of safety, falls, clinical status, fluid status, medication	
	reconciliation/management, patient compliance with orders/plan of	
	care, performance of activities of daily living, appropriateness of care	
	setting; (for use only in the meidcare-approved bundled payments for	
	care improvement initiative); may not be billed for a 30-day period	
	covered by a transitional care management code	
	, °	
G9188	Beta-blocker therapy not prescribed, reason not given	
G9189	Beta-blocker therapy prescribed or currently being taken	
G9190	Documentation of medical reason(s) for not prescribing beta-blocker	
00100	therapy (eg, allergy, intolerance, other medical reasons)	
	thorapy (eg, allergy, inteleration, ethor medical reasons)	
00101		
G9191	Documentation of patient reason(s) for not prescribing beta-blocker	
	therapy (eg, patient declined, other patient reasons)	
G9192	Documentation of system reason(s) for not prescribing beta-blocker	
	therapy (eg, other reasons attributable to the health care system)	
G9196	Documentation of medical reason(s) for not ordering a first or second	
03130	generation cephalosporin for antimicrobial prophylaxis (e.g., patients	
	enrolled in clinical trials, patients with documented infection prior to	
	surgical procedure of interest, patients who were receiving antibiotics	
	more than 24 hours prior to surgery [except colon surgery patients	
	taking oral prophylactic antibiotics], patients who were receiving	
	antibiotics within 24 hours prior to arrival [except colon surgery	
	patients taking oral prophylactic antibiotics], other medical reason(s))	
00407	Designmentation of audor for first on several research in section	
G9197	Documentation of order for first or second generation cephalosporin	
	for antimicrobial prophylaxis	
G9198	Order for first or second generation cephalosporin for antimicrobial	
	prophylaxis was not documented, reason not given	
G9212	Dsm-ivtm criteria for major depressive disorder documented at the	
	initial evaluation	
G0212		
G9213	Dsm-iv-tr criteria for major depressive disorder not documented at the	
	initial evaluation, reason not otherwise specified	
G9223	Pneumocystis jiroveci pneumonia prophylaxis prescribed within 3	
	months of low cd4+ cell count below 500 cells/mm3 or a cd4	
	months of low out i och oddit below ood ochs/mino of a out	
G9225	percentage below 15%  Foot exam was not performed, reason not given	

G9226 Foot examination performed (includes inspection, sensory exam with 10-g m of the following: vibration using 128-h ankle reflexes, or vibration perception report when all of the 3 components ankle reflexes, or vibration perception report when all of the 3 components ankle reflexes, or vibration perception report when all of the 3 components ankle reflexes, or vibration perception report when all of the 3 components ankle reflexes, or vibration perception report when all of the 3 components ankle reflexes (report when results are present for a godding gonorrhea, and syphilis so (patient refusal is the only allowed exit (report when results are present for a godding gonorrhea, and syphilis so (patient refusal is the only allowed exit (report when results are present for a godding gonorrhea, and syphilis so (patient refusal is the only allowed exit (report when results are present for a godding the measurement period condition for any depressive disclinician treating comorbid condition for patient is unable to communicate the condition; the patient is unwilling to comorbid condition; or the patient is unorbid patient followed by reporting nephrology system reasons)  G9239 Documentation of reasons for patient hemodialysis with a catheter as the material patient followed by reporting nephrology system reasons)  G9240 Patient whose mode of vascular accemaintenance hemodialysis is initiated godding goddin	
G9228 Chlamydia, gonorrhea and syphilis so (report when results are present for a G9229 Chlamydia, gonorrhea, and syphilis so (patient refusal is the only allowed exc G9230 Chlamydia, gonorrhea, and syphilis no Chlamydia,	onofilament plus testing any one z tuning fork, pinprick sensation, threshold, and pulse exam;
G9229 Chlamydia, gonorrhea, and syphilis so (patient refusal is the only allowed extended and syphilis not compared to the patient period of the patient is unwilling to comprehe the modialysis with a catheter as the modial patient followed by reporting nephrolosystem reasons)  G9240 Patient whose mode of vascular accemaintenance hemodialysis is initiated of system reasons)  G9241 Patient whose mode of vascular accemaintenance hemodialysis is initiated of the 24 month measurement period between medical visits  G9247 Patient did not have at least one medical visits  G9248 Documentation of patient pain brough hours from initial assessment  G9250 Documentation of patient discharged operative day 2 following cas  G9250 Documentation of patient discharged operative day 2 following cas  G9257 Documentation of patient death follow G9257 Documentation of patient the death follow G9257 Documentation of patient stroke follow	
(patient refusal is the only allowed exc.)  G9230 Chlamydia, gonorrhea, and syphilis n.  G9231 Documentation of end stage renal distransplant before or during the measuduring the measurement period.  G9232 Clinician treating major depressive disclinician treating comorbid condition for patient is unable to communicate the condition; the patient is unwilling to comorbid condition; or the patient is unodition, or any other specified patient hemodialysis with a catheter as the medical reasons, patient declined and patient followed by reporting nephrolosystem reasons)  G9240 Patient whose mode of vascular accemaintenance hemodialysis is initiated.  G9241 Patient whose mode of vascular accemaintenance hemodialysis is initiated.  G9242 Documentation of viral load equal to coviral load not performed.  G9243 Documentation of viral load less than Patient did not have at least one medical visits.  G9246 Patient had at least one medical visits month measurement period, with a medical visits.  G9250 Documentation of patient pain brough hours from initial assessment.  G9251 Documentation of patient with pain now within 48 hours from initial assessment.  G9253 Documentation of patient discharged operative day 2 following cas.  G9256 Documentation of patient death follow.  G9257 Documentation of patient stroke follow.	
G9231 Documentation of end stage renal distransplant before or during the measurement period G9232 Clinician treating major depressive disclinician treating comorbid condition for patient is unable to communicate the condition; the patient is unwilling to comorbid condition; or the patient is unodition, or any other specified patient hemodialysis with a catheter as the material patient has a maturing avf/avg, timeled medical reasons, patient declined avfort patient followed by reporting nephrolosystem reasons)  G9240 Patient whose mode of vascular accemaintenance hemodialysis is initiated patient whose mode of vascular accemaintenance hemodialysis is initiated patient whose mode of vascular accemaintenance hemodialysis is initiated patient whose mode of vascular accemaintenance hemodialysis is initiated patient whose mode of vascular accemaintenance hemodialysis is initiated patient whose mode of vascular accemaintenance hemodialysis is initiated viral load not performed G9242 Documentation of viral load less than G9243 Documentation of viral load less than G9246 Patient did not have at least one medical visits G9247 Patient had at least one medical visits G9247 Patient had at least one medical visit month measurement period, with a medical visits G9250 Documentation of patient pain brough hours from initial assessment G9251 Documentation of patient discharged operative day 2 following cas G9253 Documentation of patient discharged operative day 2 following cas G9255 Documentation of patient death follow G9257 Documentation of patient stroke following cas	
transplant before or during the measurduring the measurement period  G9232 Clinician treating major depressive disclinician treating comorbid condition in patient is unable to communicate the condition; the patient is unwilling to excomorbid condition; or the patient is undition, or any other specified patient hemodialysis with a catheter as the material patient has a maturing avf/avg, timeledical reasons, patient declined avf patient followed by reporting nephrologystem reasons)  G9240 Patient whose mode of vascular accemaintenance hemodialysis is initiated patient whose mode of vascular accemaintenance hemodialysis is initiated. G9241 Patient whose mode of vascular accemaintenance hemodialysis is initiated. G9242 Documentation of viral load equal to eviral load not performed. G9243 Documentation of viral load less than G9246 Patient did not have at least one medion of the 24 month measurement period between medical visits. G9247 Patient had at least one medical visit month measurement period, with a medical visits. G9250 Documentation of patient pain brough hours from initial assessment. G9251 Documentation of patient discharged operative day 2 following cas. G9255 Documentation of patient discharged operative day 2 following cas. G9256 Documentation of patient death follow. G9257 Documentation of patient stroke follow.	
clinician treating comorbid condition for patient is unable to communicate the condition; the patient is unwilling to comorbid condition; or the patient is undition, or any other specified patient condition, or any other specified patient patient hemodialysis with a catheter as the material patient has a maturing avf/avg, time-I medical reasons, patient declined avfort patient followed by reporting nephrologystem reasons)  G9240 Patient whose mode of vascular accemaintenance hemodialysis is initiated patient whose mode of vascular accemaintenance hemodialysis is initiated. Patient whose mode of vascular accemaintenance hemodialysis is initiated. Documentation of viral load equal to coviral load not performed. Documentation of viral load less than Patient did not have at least one medical viral had at least one medical visits. Patient had at least one medical visit month measurement period, with a medical visits. Patient had at least one medical visit month measurement period, with a medical visits. Patient had at least one medical visit month measurement pain brough hours from initial assessment. Documentation of patient discharged operative day 2 following cas. G9256 Documentation of patient discharged operative day 2 following cas. G9257 Documentation of patient death follow. G9257 Documentation of patient stroke follow.	
hemodialysis with a catheter as the matient has a maturing avf/avg, timeledical reasons, patient declined avf patient followed by reporting nephrolosystem reasons)  G9240 Patient whose mode of vascular accemaintenance hemodialysis is initiated Patient whose mode of vascular accemaintenance hemodialysis is initiated Documentation of viral load equal to a viral load not performed Documentation of viral load less than Patient did not have at least one medion of the 24 month measurement period between medical visits Patient had at least one medical visits Patient had at least one medical visits Month measurement period, with a matien of patient pain brough hours from initial assessment Documentation of patient with pain now within 48 hours from initial assessment G9251 Documentation of patient discharged operative day 2 following cas G9256 Documentation of patient death follow G9257 Documentation of patient teath follow G9257 Documentation of patient stroke follow	or specified patient reason (e.g., diagnosis of a comorbid ommunicate the diagnosis of a naware of the comorbid
G9240 Patient whose mode of vascular accermaintenance hemodialysis is initiated G9241 Patient whose mode of vascular accermaintenance hemodialysis is initiated G9242 Documentation of viral load equal to overal load not performed G9243 Documentation of viral load less than G9246 Patient did not have at least one mediof the 24 month measurement period between medical visits G9247 Patient had at least one medical visit month measurement period, with a medical visits G9250 Documentation of patient pain brough hours from initial assessment G9251 Documentation of patient discharged operative day 2 following cas G9256 Documentation of patient death follow G9257 Documentation of patient death follow G9257 Documentation of patient stroke follow	ode of vascular access (e.g., mited trial of hemodialysis, other /avg, other patient reasons,
G9241 Patient whose mode of vascular accemaintenance hemodialysis is initiated Documentation of viral load equal to oviral load not performed G9243 Documentation of viral load less than G9246 Patient did not have at least one med of the 24 month measurement period between medical visits G9247 Patient had at least one medical visit month measurement period, with a medical visits G9250 Documentation of patient pain brough hours from initial assessment G9251 Documentation of patient with pain now within 48 hours from initial assessment G9254 Documentation of patient discharged operative day 2 following cas G9255 Documentation of patient death follow G9257 Documentation of patient teath follow G9257 Documentation of patient stroke follow	
G9242 Documentation of viral load equal to over viral load not performed G9243 Documentation of viral load less than G9246 Patient did not have at least one med of the 24 month measurement period between medical visits G9247 Patient had at least one medical visit month measurement period, with a medical visits G9250 Documentation of patient pain brough hours from initial assessment G9251 Documentation of patient with pain now within 48 hours from initial assessment G9254 Documentation of patient discharged operative day 2 following cas G9255 Documentation of patient death follow G9257 Documentation of patient stroke follows	ss is not a catheter at the time
G9246 Patient did not have at least one med of the 24 month measurement period between medical visits  G9247 Patient had at least one medical visit month measurement period, with a medical visits  G9250 Documentation of patient pain brough hours from initial assessment  G9251 Documentation of patient with pain now within 48 hours from initial assessment  G9254 Documentation of patient discharged operative day 2 following cas  G9255 Documentation of patient discharged operative day 2 following cas  G9256 Documentation of patient death follow G9257 Documentation of patient stroke follow	
G9246 Patient did not have at least one med of the 24 month measurement period between medical visits  G9247 Patient had at least one medical visit month measurement period, with a medical visits  G9250 Documentation of patient pain brough hours from initial assessment  G9251 Documentation of patient with pain now within 48 hours from initial assessment  G9254 Documentation of patient discharged operative day 2 following cas  G9255 Documentation of patient discharged operative day 2 following cas  G9256 Documentation of patient death follow G9257 Documentation of patient stroke follow	200 copies/ml
month measurement period, with a medical visits  G9250 Documentation of patient pain brough hours from initial assessment  G9251 Documentation of patient with pain now within 48 hours from initial assessment  G9254 Documentation of patient discharged operative day 2 following cas  G9255 Documentation of patient discharged operative day 2 following cas  G9256 Documentation of patient death follow G9257 Documentation of patient stroke follow	ical visit in each 6 month period
hours from initial assessment  G9251 Documentation of patient with pain no within 48 hours from initial assessment  G9254 Documentation of patient discharged operative day 2 following cas  G9255 Documentation of patient discharged operative day 2 following cas  G9256 Documentation of patient death follow  G9257 Documentation of patient stroke follow	
within 48 hours from initial assessment G9254 Documentation of patient discharged operative day 2 following cas G9255 Documentation of patient discharged operative day 2 following cas G9256 Documentation of patient death following G9257 Documentation of patient stroke following cas	t to a comfortable level within 48
operative day 2 following cas  G9255 Documentation of patient discharged operative day 2 following cas  G9256 Documentation of patient death follow  G9257 Documentation of patient stroke follow	
G9255 Documentation of patient discharged operative day 2 following cas G9256 Documentation of patient death follow G9257 Documentation of patient stroke follow	
G9257 Documentation of patient stroke follow	to home no later than post
·	
COOFO Decomposite of periods studies fellow	ing cas
G9258 Documentation of patient stroke follow	
G9259 Documentation of patient survival and	ving cas
G9260 Documentation of patient death follow	ving cas ving cea
G9261 Documentation of patient survival and	ving cas ving cea l absence of stroke following cas

G9262 Documentation of patient death in the aaa repair G9263 Documentation of patient survival in endovascular aaa repair G9264 Documentation of patient receiving negreater than or equal to 90 days with reasons (e.g., other medical reasons patient reasons) G9265 Patient receiving maintenance hemoto 90 days with a catheter as the moto 90 days without a catheter as the G9267 Documentation of patient with one or within 30 days G9268 Documentation of patient with one or days G9269 Documentation of patient without one	the hospital following  naintenance hemodialysis for a catheter for documented , patient declined avf/avg, other  dialysis for greater than or equal de of vascular access  dialysis for greater than or equal mode of vascular access  more complications or mortality  more complications within 90  e or more complications and
endovascular aaa repair  G9264 Documentation of patient receiving n greater than or equal to 90 days with reasons (e.g., other medical reasons patient reasons)  G9265 Patient receiving maintenance hemo to 90 days with a catheter as the mo  G9266 Patient receiving maintenance hemo to 90 days without a catheter as the  G9267 Documentation of patient with one or within 30 days  G9268 Documentation of patient with one or days  G9269 Documentation of patient without one	naintenance hemodialysis for a catheter for documented patient declined avf/avg, other dialysis for greater than or equal de of vascular access dialysis for greater than or equal mode of vascular access  more complications or mortality more complications within 90 e or more complications and
greater than or equal to 90 days with reasons (e.g., other medical reasons patient reasons)  G9265 Patient receiving maintenance hemoto 90 days with a catheter as the moto 90 days without a catheter as the G9267 Documentation of patient with one or within 30 days  G9268 Documentation of patient with one or days  G9269 Documentation of patient without one	a catheter for documented patient declined avf/avg, other  dialysis for greater than or equal de of vascular access  dialysis for greater than or equal mode of vascular access  more complications or mortality  more complications within 90  e or more complications and
to 90 days with a catheter as the mo  G9266 Patient receiving maintenance hemo to 90 days without a catheter as the  G9267 Documentation of patient with one or within 30 days  G9268 Documentation of patient with one or days  G9269 Documentation of patient without one	dialysis for greater than or equal mode of vascular access  more complications or mortality  more complications within 90  e or more complications and
to 90 days without a catheter as the  G9267 Documentation of patient with one or within 30 days  G9268 Documentation of patient with one or days  G9269 Documentation of patient without one	mode of vascular access  more complications or mortality  more complications within 90  e or more complications and
within 30 days  G9268 Documentation of patient with one or days  G9269 Documentation of patient without one	more complications within 90 e or more complications and
days  G9269 Documentation of patient without one	e or more complications and
· ·	
without mortality within 30 days	e or more complications within 90
G9270 Documentation of patient without one days	<u> </u>
G9273 Blood pressure has a systolic value of 90	
G9274 Blood pressure has a systolic value of 90 or systolic value < 140 and diasto 140 and diastolic value < 90	
G9275 Documentation that patient is a curre	ent non-tobacco user
G9276 Documentation that patient is a curre G9277 Documentation that the patient is on	
has documentation of a valid contrai aspirin/anti-platelet; contraindications coagulant use, allergy to aspirin or a gastrointestinal bleed and bleeding cexceptions documented by the physically aspirin or anti-platelet are acceptional inflammatory agents, documented risuncontrolled hypertension defined as gastroesophageal reflux)	ndication or exception to sexceptions include anti- nti-platelets, history of lisorder; additionally, the following cian as a reason for not taking otable (use of non-steroidal anti- sk for drug interaction,
G9278 Documentation that the patient is no regimen	t on daily aspirin or anti-platelet
G9279 Pneumococcal screening performed vaccination received prior to discharge	ge
G9280 Pneumococcal vaccination not adminot specified	
G9281 Screening performed and documenta indicated/patient refusal	
G9282 Documentation of medical reason(s) type or nsclc-nos classification with a for other purposes in a patient with a cancer or other documented medical	an explanation (e.g., biopsy taken history of non-small cell lung
G9283 Non small cell lung cancer biopsy an documents classification into specific nsclc-nos with an explanation	c histologic type or classified as
G9284 Non small cell lung cancer biopsy an not document classification into spectors in sclc-nos with an explanation	cific histologic type or classified as
G9285 Specimen site other than anatomic loas non small cell lung cancer	ocation of lung or is not classified

G9286	And the factor of a contract of the contract o	
	Antibiotic regimen prescribed within 10 days after onset of symptoms	
G9287	Antibiotic regimen not prescribed within 10 days after onset of symptoms	
G9288	Documentation of medical reason(s) for not reporting the histological	
G9200		
	type or nsclc-nos classification with an explanation (e.g., a solitary	
	fibrous tumor in a person with a history of non-small cell carcinoma or	
	other documented medical reasons)	
G9289	Non small cell lung cancer biopsy and cytology specimen report	
	documents classification into specific histologic type or classified as	
	nsclc-nos with an explanation	
G9290	Non small cell lung cancer biopsy and cytology specimen report does	
00200	not document classification into specific histologic type or classified as	
	1 - 11	
	nsclc-nos with an explanation	
G9291	Specimen site other than anatomic location of lung, is not classified	
	as non small cell lung cancer or classified as nsclc-nos	
G9292	Documentation of medical reason(s) for not reporting pt category and	
	a statement on thickness and ulceration and for pt1, mitotic rate (e.g.,	
	negative skin biopsies in a patient with a history of melanoma or other	
	documented medical reasons)	
00000	· · · · · · · · · · · · · · · · · · ·	
G9293	Pathology report does not include the pt category and a statement on	
	thickness and ulceration and for pt1, mitotic rate	
G9294	Pathology report includes the pt category and a statement on	
	thickness and ulceration and for pt1, mitotic rate	
G9295	Specimen site other than anatomic cutaneous location	
G9296	Patients with documented shared decision-making including	
00200	discussion of conservative (non-surgical) therapy (e.g., NSAIDs,	
	analgesics, weight loss, exercise, injections) prior to the procedure	
	analycolos, weight 1033, exercise, injections) prior to the procedure	
~~~~		
G9297	Shared decision-making including discussion of conservative (non-	
	surgical) therapy (e.g., NSAIDs, analgesics, weight loss, exercise,	
	injections) prior to the procedure, not documented, reason not given	
G9298		
G9298	injections) prior to the procedure, not documented, reason not given  Patients who are evaluated for venous thromboembolic and	
G9298	injections) prior to the procedure, not documented, reason not given  Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g.,	
	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)	
	injections) prior to the procedure, not documented, reason not given  Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and	
	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure	
	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason	
	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure	
G9299	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason	
G9299	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)	
G9299	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)  Documentation of medical reason(s) for not completely infusing the	
G9299 G9300	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)  Documentation of medical reason(s) for not completely infusing the prophylactic antibiotic prior to the inflation of the proximal tourniquet (e.g., a tourniquet was not used)	
G9299 G9300	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)  Documentation of medical reason(s) for not completely infusing the prophylactic antibiotic prior to the inflation of the proximal tourniquet (e.g., a tourniquet was not used)  Patients who had the prophylactic antibiotic completely infused prior to	
G9299 G9300 G9301	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)  Documentation of medical reason(s) for not completely infusing the prophylactic antibiotic prior to the inflation of the proximal tourniquet (e.g., a tourniquet was not used)  Patients who had the prophylactic antibiotic completely infused prior to the inflation of the proximal tourniquet	
G9299 G9300 G9301	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)  Documentation of medical reason(s) for not completely infusing the prophylactic antibiotic prior to the inflation of the proximal tourniquet (e.g., a tourniquet was not used)  Patients who had the prophylactic antibiotic completely infused prior to the inflation of the proximal tourniquet	
G9299 G9300 G9301 G9302	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)  Documentation of medical reason(s) for not completely infusing the prophylactic antibiotic prior to the inflation of the proximal tourniquet (e.g., a tourniquet was not used)  Patients who had the prophylactic antibiotic completely infused prior to the inflation of the proximal tourniquet  Prophylactic antibiotic not completely infused prior to the inflation of the proximal tourniquet, reason not given	
G9299 G9300 G9301 G9302	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)  Documentation of medical reason(s) for not completely infusing the prophylactic antibiotic prior to the inflation of the proximal tourniquet (e.g., a tourniquet was not used)  Patients who had the prophylactic antibiotic completely infused prior to the inflation of the proximal tourniquet  Prophylactic antibiotic not completely infused prior to the inflation of the proximal tourniquet, reason not given  Operative report does not identify the prosthetic implant specifications	
G9299 G9300 G9301 G9302	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)  Documentation of medical reason(s) for not completely infusing the prophylactic antibiotic prior to the inflation of the proximal tourniquet (e.g., a tourniquet was not used)  Patients who had the prophylactic antibiotic completely infused prior to the inflation of the proximal tourniquet  Prophylactic antibiotic not completely infused prior to the inflation of the proximal tourniquet, reason not given  Operative report does not identify the prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the	
G9299 G9300 G9301 G9302	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)  Documentation of medical reason(s) for not completely infusing the prophylactic antibiotic prior to the inflation of the proximal tourniquet (e.g., a tourniquet was not used)  Patients who had the prophylactic antibiotic completely infused prior to the inflation of the proximal tourniquet  Prophylactic antibiotic not completely infused prior to the inflation of the proximal tourniquet, reason not given  Operative report does not identify the prosthetic implant specifications	
G9299 G9300 G9301 G9302	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)  Documentation of medical reason(s) for not completely infusing the prophylactic antibiotic prior to the inflation of the proximal tourniquet (e.g., a tourniquet was not used)  Patients who had the prophylactic antibiotic completely infused prior to the inflation of the proximal tourniquet  Prophylactic antibiotic not completely infused prior to the inflation of the proximal tourniquet, reason not given  Operative report does not identify the prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the	
G9299 G9300 G9301 G9302 G9303	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)  Documentation of medical reason(s) for not completely infusing the prophylactic antibiotic prior to the inflation of the proximal tourniquet (e.g., a tourniquet was not used)  Patients who had the prophylactic antibiotic completely infused prior to the inflation of the proximal tourniquet  Prophylactic antibiotic not completely infused prior to the inflation of the proximal tourniquet, reason not given  Operative report does not identify the prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the prosthetic implant and the size of each prosthetic implant, reason not given	
G9299 G9300 G9301 G9302 G9303	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)  Documentation of medical reason(s) for not completely infusing the prophylactic antibiotic prior to the inflation of the proximal tourniquet (e.g., a tourniquet was not used)  Patients who had the prophylactic antibiotic completely infused prior to the inflation of the proximal tourniquet  Prophylactic antibiotic not completely infused prior to the inflation of the proximal tourniquet, reason not given  Operative report does not identify the prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the prosthetic implant and the size of each prosthetic implant, reason not given  Operative report identifies the prosthetic implant specifications	
G9299 G9300 G9301 G9302 G9303	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)  Documentation of medical reason(s) for not completely infusing the prophylactic antibiotic prior to the inflation of the proximal tourniquet (e.g., a tourniquet was not used)  Patients who had the prophylactic antibiotic completely infused prior to the inflation of the proximal tourniquet  Prophylactic antibiotic not completely infused prior to the inflation of the proximal tourniquet, reason not given  Operative report does not identify the prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the prosthetic implant and the size of each prosthetic implant, reason not given  Operative report identifies the prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the	
G9299 G9300 G9301 G9302 G9303	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)  Documentation of medical reason(s) for not completely infusing the prophylactic antibiotic prior to the inflation of the proximal tourniquet (e.g., a tourniquet was not used)  Patients who had the prophylactic antibiotic completely infused prior to the inflation of the proximal tourniquet  Prophylactic antibiotic not completely infused prior to the inflation of the proximal tourniquet, reason not given  Operative report does not identify the prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the prosthetic implant and the size of each prosthetic implant, reason not given  Operative report identifies the prosthetic implant specifications	
G9298 G9299 G9300 G9301 G9302 G9303 G9304	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)  Documentation of medical reason(s) for not completely infusing the prophylactic antibiotic prior to the inflation of the proximal tourniquet (e.g., a tourniquet was not used)  Patients who had the prophylactic antibiotic completely infused prior to the inflation of the proximal tourniquet  Prophylactic antibiotic not completely infused prior to the inflation of the proximal tourniquet, reason not given  Operative report does not identify the prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the prosthetic implant and the size of each prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the prosthetic implant and the size of each prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the prosthetic implant and the size of each prosthetic implant implant of the prosthetic implant and the size of each prosthetic implant	
G9299 G9300 G9301 G9302 G9303 G9304	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)  Documentation of medical reason(s) for not completely infusing the prophylactic antibiotic prior to the inflation of the proximal tourniquet (e.g., a tourniquet was not used)  Patients who had the prophylactic antibiotic completely infused prior to the inflation of the proximal tourniquet  Prophylactic antibiotic not completely infused prior to the inflation of the proximal tourniquet, reason not given  Operative report does not identify the prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the prosthetic implant and the size of each prosthetic implant, reason not given  Operative report identifies the prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the	
G9299 G9300 G9301 G9302 G9303	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)  Documentation of medical reason(s) for not completely infusing the prophylactic antibiotic prior to the inflation of the proximal tourniquet (e.g., a tourniquet was not used)  Patients who had the prophylactic antibiotic completely infused prior to the inflation of the proximal tourniquet  Prophylactic antibiotic not completely infused prior to the inflation of the proximal tourniquet, reason not given  Operative report does not identify the prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the prosthetic implant and the size of each prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the prosthetic implant and the size of each prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the prosthetic implant and the size of each prosthetic implant implant of the prosthetic implant and the size of each prosthetic implant	
G9299 G9300 G9301 G9302 G9303 G9304	Patients who are evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., history of DVT, PE, MI, arrhythmia and stroke)  Patients who are not evaluated for venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure including (e.g., history of DVT, PE, MI, arrhythmia and stroke, reason not given)  Documentation of medical reason(s) for not completely infusing the prophylactic antibiotic prior to the inflation of the proximal tourniquet (e.g., a tourniquet was not used)  Patients who had the prophylactic antibiotic completely infused prior to the inflation of the proximal tourniquet  Prophylactic antibiotic not completely infused prior to the inflation of the proximal tourniquet, reason not given  Operative report does not identify the prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the prosthetic implant and the size of each prosthetic implant, reason not given  Operative report identifies the prosthetic implant specifications including the prosthetic implant manufacturer, the brand name of the prosthetic implant and the size of each prosthetic implant on the prosthetic implant and the size of each prosthetic implant.	

005		
G9307	No return to the operating room for a surgical procedure, for	
	complications of the principal operative procedure, within 30 days of	
	the principal operative procedure	
G9308	Unplanned return to the operating room for a surgical procedure, for	
	complications of the principal operative procedure, within 30 days of	
	the principal operative procedure	
G9309	No unplanned hospital readmission within 30 days of principal	
	procedure	
G9310	Unplanned hospital readmission within 30 days of principal procedure	
G9311	No surgical site infection	
G9312	Surgical site infection	
G9313	Amoxicillin, with or without clavulanate, not prescribed as first line	
	antibiotic at the time of diagnosis for documented reason (eg, cystic	
	fibrosis, immotile cilia disorders, ciliary dyskinesia, immune deficiency,	
	prior history of sinus surgery within the past 12 months, and anatomic	
	abnormalities, such as deviated nasal septum, resistant organisms,	
	allergy to medication, recurrent sinusitis, chronic sinusitis, or other reasons)	
	,	
G9314	Amoxicillin, with or without clavulanate, not prescribed as first line	
	antibiotic at the time of diagnosis, reason not given	
G9315	Documentation amoxicillin, with or without clavulanate, prescribed as	
	a first line antibiotic at the time of diagnosis	
G9316	Documentation of patient-specific risk assessment with a risk	
	calculator based on multi-institutional clinical data, the specific risk	
	calculator used, and communication of risk assessment from risk	
	calculator with the patient or family	
G9317	Documentation of patient-specific risk assessment with a risk	
	calculator based on multi-institutional clinical data, the specific risk	
	calculator used, and communication of risk assessment from risk	
	calculator with the patient or family not completed	
G9318	Imaging study named according to standardized nomenclature	
G9319	Imaging study not named according to standardized nomenclature,	
	reason not given	
G9321	Count of previous ct (any type of ct) and cardiac nuclear medicine	
	(myocardial perfusion) studies documented in the 12-month period	
	prior to the current study	
G9322	Count of previous ct and cardiac nuclear medicine (myocardial	
	perfusion) studies not documented in the 12-month period prior to the	
	current study, reason not given	
G9326	Ct studies performed not reported to a radiation dose index registry	
	that is capable of collecting at a minimum all necessary data	
	elements, reason not given	
G9327	Ct studies performed reported to a radiation dose index registry that is	
	capable of collecting at a minimum all necessary data elements	
G9329	DICOM format image data available to non-affiliated external	
	healthcare facilities or entities on a secure, media free, reciprocally	
	searchable basis with patient authorization for at least a 12-month	
	period after the study not documented in final report, reason not given	
G9340	Final report documented that DICOM format image data available to	
	non-affiliated external healthcare facilities or entities on a secure,	
	media free, reciprocally searchable basis with patient authorization for	
	at least a 12-month period after the study	
G9341	Search conducted for prior patient CT studies completed at non-	
	affiliated external healthcare facilities or entities within the past 12-	
	months and are available through a secure, authorized, media-free,	
	shared archive prior to an imaging study being performed	
	1	

Search not conducted prior to an imaging study being performed for prior parient CT studies completed at non-filliated external healthcare facilities or entities within the past 12-months and are available through a secure, authorized, media-free, shared archive, reason not given  G8344 Due to system reasons search not conducted for DICOM format images for prior patient CT imaging studies completed at non-affiliated external healthcare facilities or entities within the past 12 months that are available through a secure, authorized, media-free, shared archive (e.g., no-affiliated destinal healthcare facilities or entities within the past 12 months that are available through a secure, authorized, media-free, shared archive (e.g., no-affiliated destinal healthcare facilities or entities within the past 12 months that are available through a secure, authorized, media-free, shared archive (e.g., no-affiliated destinal healthcare facilities or entities does not have archival sibilities from gain and patients of the patients of diagnosis for documented reasons (e.g., persons with sustilis symptomic listents of the patients of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 30 days after the date of diagnosis or documental reasons (e.g., patients with complications, second or to barroard or received within 90 days after the date of dia			
prior patient CT studies completed at non-affiliated external healthcare facilities or entities within the past 12-months and are available through a secure, authorized, media-free, shared archive, reason not given  39344 Due to system reasons search not conducted for DICOM format images for prior patient CT imaging studies completed at non-affiliated external healthcare facilities or entities within the past 12 months that are available through a secure, authorized, media-free, shared archive (e.g., non-affiliated external healthcare facilities or entities does not have archival abilities through a shared archival system)  39345 Pollow-up recommendations documented according to recommended guidelines for incidentally detected pulmonary nodules (e.g., follow-up CT imaging studies needed or flat in collow-up in needed) based at a militimum on nodule size and patient risk factors  39347 Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not gliven  39348 CT scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (e.g. persons with sinustis symptoms lasting at least 7 to 10 days, antibiotic resistance, immunocompronised, recurrent sinustis, such fontal sinustis, acute sphenoid sinustis, periorbital celulitis, or other medical)  39349 Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis  39350 Ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis or foeceived within 90 days after the date of diagnosis or received within 90 days after the date of diagnosis or ordered or received within 90 days after the date of diagnosis or obscriptions or the paranasal sinuses ordered or received within 90 days after the date of the paranasal sinuses or	G9342	Search not conducted prior to an imaging study being performed for	
facilities or entities within the past 12-months and are available through a secure, authorized, media free, shared archive, reason not given  3344 Due to system ressons search not conducted for DICOM format images for prior patient CT imaging studies completed an on-affiliated element healthcare facilities or entities within the past 12 months that are available through a secure, authorized, media-free, shared archive (e.g., no-affiliated external healthcare facilities or entities does not have archival abilities through a shared archival system)  59345 Follow-up recommendations documented according to recommended guidelines for incidentally detected pulmonary nodules (e.g., follow-up CT imaging studies needed or that no follow-up is needed) based at a minimum on nodule size and patient risk factors  69347 Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not given  69348 CI scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (e.g. persons with sinusitis symptoms lasting at least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinusitis, acute frontal sinusitis, acute sphenoid sinusitis, periorbiat acliulisis, or other medical)  69349 Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis  69350 CI scan of the paranasal sinuses not ordered at the time of diagnosis or received within 28 days after date of diagnosis  69351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  69352 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given within 90 days after the date of diagnosis, reason not given detected by a day after the date of diagnosis or documented reasons (e.g. patients with complications, second ct obtained prior to surgery, other medical reasons)  69		, , , , , , , , , , , , , , , , , , , ,	
through a secure, authorized, media-free, shared archive, reason not given  3344  Due to system reasons search not conducted for DICOM format impose for prior patient CT maging studies completed at non-affiliated external healthcare facilities or entities within the past 12 months that are available through a secure, authorized, media-free, shared archive (e.g., non-affiliated external healthcare facilities or entities does not have archival abilities through a shared archival system)  Follow-up recommendations documented according to recommended guidelines for incidentally detected pulmonary nodules (e.g., follow-up CT imaging audies needed or that no follow-up is needed) based at a minimum on nodule size and patient risk factors  Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not given  G9347  Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not given  CI scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (eg., persons with sinusitis symptoms lasting at least 7 to 10 days, antibotic resistance, immunocompromised, recurrent sinusitis, actual replaced in the situation of the complex of the situation of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 90 days after days on the paranasal sinuses ordered or received within 90 days after the date of diagnosis or received within 90 days after the date of diagnosis for documented reasons (eg., patients with complications, second ct obtained prior to surgery, other medical reasons)  G9350  More than one of scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg., patients with complications, second ct obtained prior to surgery, other med			
given  Due to system reasons search not conducted for DICOM format images for prior patient CT imaging studies completed at non-difficited external healthcare facilities or entities within the past 12 months that are available through a secure, authorized, media-free, shared archive (e.g., non-diffiliated external healthcare facilities or entities does not have archival abilities through a shared archival system)  Follow-up recommendations documented according to recommended guidelines for incidentally detected pulmonary nodules (e.g., follow-up CT imaging studies needed or that no follow-up is needed) based at a minimum on nodule size and patient risk factors  Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not given  G9348 CI scan of the paranesal sinuses ordered at the time of diagnosis for documented reasons (eg., persons with sinusitis symptoms lasting at least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinusitis, acute frontal sinusitis, acute sphenoid sinusitis, periorital cellulitis, or other medical)  G9349 Documentation of at scan of the paranesal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis  G9350 CI scan of the paranesal sinuses not ordered at the time of diagnosis or received within 28 days after date of diagnosis  G9351 More than one of scan of the paranesal sinuses ordered or received within 90 days after diagnosis.  G9352 More than one of scan of the paranesal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  G9353 More than one of scan of the paranesal sinuses ordered or received within 90 days after the date of diagnosis.  G9354 More than one of scan of the paranesal sinuses ordered or received within 90 days after the date of diagnosis.  G9355 Elective delivery or early induction performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education not pe			
Due to system reasons search not conducted for DICOM format images for prior patient CT maging studies completed at non-affiliated external healthcare facilities or entities within the past 12 months that are available through a secure, authorized, maderfiere, Shared archive (e.g., non-affiliated external healthcare facilities within the past 12 months that are available through a secure, authorized, maderfiere, Shared archive (e.g., non-affiliated external healthcare facilities or entities does not have archival abilities through a shared archival system)  Follow-up recommendations documented according to recommended guidelines for incidentally detected pulmonary nodules (e.g., follow-up CT imaging studies needed or that no follow-up is needed) based at a minimum on nodule size and patient risk factors  G8347 Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not given  G848 CI scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (e.g. persone with insults) symptoms tasting at least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinusisis, acute fornial sinusities, speniorbital cellulitis, or other medical)  G9349 Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis  G9350 CI scan of the paranasal sinuses not devel or received within 90 days after the date of diagnosis or received within 28 days after date of diagnosis  G9351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis reason not given with such as the strend of the paranasal sinuses ordered or received within 90 days after the date of diagnosis reason not given because of the paranasal sinuses ordered or received within 90 days after the date of diagnosis reason not given because of the paranasal sinuses ordered or preceived within 90 days after the date of diagnosis reason not given b			
images for prior patient CT imaging studies completed at non-affiliated external healthcare facilities or entities within the past 12 months that are available through a secure, authorized, media-free, shared archive (e.g., non-affiliated external healthcare facilities or entities does not have archival abilities through a shared archival system)  Follow-up recommendations documented according to recommended guidelines for incidentally detected pulmonary nodules (e.g., follow-up CT imaging studies needed or that no follow-up is needed) based at a minimum on nodule size and patient risk factors  Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not given  Ct scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (e.g. persons with sinusitis symptoms fashing at least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinusitis, sculer fortal sinusitis, sourior spheniod sinusitis, periorbial cellulitis, or other medical)  Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis  Gasso  Ct scan of the paranasal sinuses not ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 90 days after date of diagnosis or received within 90 days after date of diagnosis or dered or received within 90 days after date of diagnosis received within 90 days after date of diagnosis received within 90 days after date of diagnosis reson to give a stream or a ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis reson to give a days after date of diagnosis or decommented reasons (e.g. patients with complications, second of obtained prior to surgery, other medical reasons)  Gasso  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis reson not given to surgery, other medical reasons)  Gasso  E		given	
images for prior patient CT imaging studies completed at non-affiliated external healthcare facilities or entities within the past 12 months that are available through a secure, authorized, media-free, shared archive (e.g., non-affiliated external healthcare facilities or entities does not have archival abilities through a shared archival system)  Follow-up recommendations documented according to recommended guidelines for incidentally detected pulmonary nodules (e.g., follow-up CT imaging studies needed or that no follow-up is needed) based at a minimum on nodule size and patient risk factors  Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not given  Ct scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (e.g. persons with sinusitis symptoms fashing at least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinusitis, sculer fortal sinusitis, sourior spheniod sinusitis, periorbial cellulitis, or other medical)  Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis  Gasso  Ct scan of the paranasal sinuses not ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 90 days after date of diagnosis or received within 90 days after date of diagnosis or dered or received within 90 days after date of diagnosis received within 90 days after date of diagnosis received within 90 days after date of diagnosis reson to give a stream or a ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis reson to give a days after date of diagnosis or decommented reasons (e.g. patients with complications, second of obtained prior to surgery, other medical reasons)  Gasso  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis reson not given to surgery, other medical reasons)  Gasso  E	G9344	Due to system reasons search not conducted for DICOM format	
external healthcare facilities or entities within the past 12 months that are available through a seure, authorized, media-free, shared archive (e.g., non-arfiliated external healthcare facilities or entities does not have archival abilities through a shared archival system)  Follow-up recommendations documented according to recommended guidelines for incidentally detected pulmonary nodules (e.g., follow-up C T imaging studies needed or that no follow-up is needed) based at a minimum on nodule size and patient risk factors  Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not given  G9347 Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not given  G9348 Ct scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (e.g. persons with sinusitis symptoms lasting at least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinusitis, acute frontal sinusitis, acute sphenoid sinusitis, periorbital cellulitis, or other medical)  G9349 Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis  G9350 Ct scan of the paranasal sinuses not ordered at the time of diagnosis or received within 28 days after date of diagnosis  G9360 More than one ct scan of the paranasal sinuses ordered or received within 30 days after the date of diagnosis, reason not given  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis or documented reasons (e.g. patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 Ose ct scan or not ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis or documented reasons)  G		·	
are available through a secure, authorized, media-free, shared archive (e.g., non-affiliated external healthcare facilities or entities does not have archival abilities through a shared archival system)  Follow-up recommendations documented according to recommended guidelines for incidentally detected pulmonary nodules (e.g., follow-up CT imaging studies needed or that not follow-up is needed) based at a minimum on nodule size and patient risk factors  Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not given  G9346 C scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (eg. persons with sinusitis symptoms lasting at least 7 to 10 days, ambibotic resistance, immunocompromised, recurrent sinusitis, acute frontal sinusitis, acute sphenoid sinusitis, perioribital cellulitis, or other medical)  G9349 Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 30 days after date of diagnosis.  G9350 Oct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis.  G9351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg. patients with complications, second of obtained prior to surgery, other medical reasons)  G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons  G9355 Elective delivery or early induction not performed  G9356 Post-partum screenings, evaluations and education performed  G9357 Post-partum screenings, evaluations and edu			
(e.g., non-affiliated external healthcare facilities or entities does not have archival abilities through a shared archival system)  Follow-up recommendations documented according to recommended guidelines for incidentally detected pulmonary nodules (e.g., follow-up CT imaging studies needed or that no follow-up is needed) based at a minimum on nodule size and patient risk factors  G3347  Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not glyen  Ct scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (e.g. persons with sinushis symptoms lasting at least 7 to 10 days, arbibiotic resistance, immunocompromised, recurrent sinusitis, acute frontal sinushis, acute sphenoid sinushis, periorbital cellulitis, or other medical, periorbital cellulitis, or other medical)  G3349  Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 20 days after date of diagnosis or received within 20 days after date of diagnosis or received within 30 days after date of diagnosis rother or received within 30 days after the date of diagnosis rother dorn received within 30 days after the date of diagnosis rother dorn received within 30 days after the date of diagnosis for documented reasons (e.g. patients with complications, second ct obtained prior to surgery, other medical reasons)  G3351  More than one ct scan of the paranasal sinuses ordered or received within 30 days after the date of diagnosis for documented reasons (e.g. patients with complications, second ct obtained prior to surgery, other medical reasons)  G3353  Post-partum screenings, evaluations and education performed  G3364  G3369  Documentation of negative or managed positive th screen with further evidence that the is not active within one year of patient visit e		·	
feology and a politic strough a shared archival system)  Follow-up recommendations documented according to recommended guidelines for incidentally detected pulmonary nodules (e.g., follow-up CT imaging studies needed or that no follow-up is needed) based at a minimum on nodule size and patient risk factors  Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, resson not given  G9348  Ct scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (eg, persons with sinusitis symptoms lasting at least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinusitis, soute frontal sinusitis, acute sphenoid sinusitis, periorbital cellulitis, or other medical)  G9349  Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 190 days after diagnosis or received within 90 days after diagnosis or received within 90 days after diagnosis or received within 90 days after diagnosis.  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given within 90 days after the date of diagnosis, reason not given within 90 days after the date of diagnosis for documented reasons (eg, patients with complications, second ct obtained prior to surgery, other medical reasons)  G9353  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis and education performed  G9364  G9365  Elective delivery or early induction not performed  G9366  G9366  One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis or documented reasons  G9367  Post-partum screenings, evaluations and education performed  Post-partum screenings, evaluations and education performed  Post-partum screenings, evalua			
G9345 Follow-up recommendations documented according to recommended guidelines for incidentally detected pulmonary nodules (e.g., follow-up CT imaging studies needed or that no follow-up is needed) based at a minimum on nodule size and patient risk factors  G9347 Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not glyan  G1 Ct scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (eg., persons with sinushis symptoms lasting at least 7 to 10 days, artibiotic resistance, immunocompromised, recurrent sinusitis, acute frontal sinushis, acute sphenoid sinushis, periorbital collution, or other medical, periorbital collution, or other medical sinushis, acute sphenoid sinushis, periorbital collution, or other medical received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 30 days after diagnosis  G9350 Ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis redeforment or received within 90 days after the date of diagnosis redeforment or received within 90 days after the date of diagnosis for documented reasons (eg., patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis of documented reasons (eg., patients with complications, second ct obtained prior to surgery, other medical reasons)  G9356 Elective delivery or early induction not performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education performed  G9369 Documentation of negative or managed positive th screen with furthe		(e.g., non-affiliated external healthcare facilities or entities does not	
guidelines for incidentally detected pulmonary nodules (e.g., follow-up CT imaging studies needed or that no follow-up is needed) based at a minimum on nodule size and patient risk factors  Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not given  Cl scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (eg. persons with sinusitis symptoms lasting at least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinusitis, acute frontal sinusitis, acute sphenoid sinusitis, perioribial cellulitis, or other medical, or other medical cellulitis, acute sphenoid sinusis is, perioribial cellulitis, or other medical cellulitis, acute sphenoid sinusis or cellulitis, perioribial cellulitis, or other medical cellulitis, acute sphenoid sinusis or received within 28 days after date of diagnosis or received within 90 days after diagnosis or received within 90 days after diagnosis.  Gasto More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  Gasto More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg. patents with complications, second ct obtained prior to surgery, other medical reasons)  Gasto Cl cascan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis in the date of diagnosis or documented reasons (eg. patents with complications, second ct obtained prior to surgery, other medical reasons)  Gasto		have archival abilities through a shared archival system)	
guidelines for incidentally detected pulmonary nodules (e.g., follow-up CT imaging studies needed or that no follow-up is needed) based at a minimum on nodule size and patient risk factors  Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not given  G348  C1 scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (eg., persons with sinusitis symptoms lasting at least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinusitis, acute forntal sinusitis, acute sphenoid sinusitis, periorbidal cellulitis, or other medical, periorbidal cellulitis, or other medical cellulitis, and the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 90 days after diagnosis.  G3551  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  G3553  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg., patients with complications, second ct obtained prior to surgery, other medical reasons)  G3564  G357  One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis for documented reasons (eg., patients with complications, second ct obtained prior to surgery, other medical reasons)  G357  One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis for documentation of residucion not performed  G357  Post-partum screenings, evaluations and edu			
guidelines for incidentally detected pulmonary nodules (e.g., follow-up CT imaging studies needed or that no follow-up is needed) based at a minimum on nodule size and patient risk factors  Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not given  G348  C1 scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (eg., persons with sinusitis symptoms lasting at least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinusitis, acute forntal sinusitis, acute sphenoid sinusitis, periorbidal cellulitis, or other medical, periorbidal cellulitis, or other medical cellulitis, and the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 90 days after diagnosis.  G3551  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  G3553  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg., patients with complications, second ct obtained prior to surgery, other medical reasons)  G3564  G357  One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis for documented reasons (eg., patients with complications, second ct obtained prior to surgery, other medical reasons)  G357  One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis for documentation of residucion not performed  G357  Post-partum screenings, evaluations and edu			
CT imaging studies needed or that no follow-up is needed) based at a minimum on nodule size and patient risk factors  Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not given  G3348 Ct scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (e.g. persons with sinusitis symptoms lasting at least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinusitis, acute frontal sinusitis, acute sphenoid sinusitis, periorbital cellulitis, or other medical)  Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis  Ct scan of the paranasal sinuses not ordered at the time of diagnosis or received within 28 days after date of diagnosis  G3350 Ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  G3353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (e.g. patients with complications, second ct obtained prior to surgery, other medical reasons)  G3351 More than one ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis for documented reasons (e.g. patients with complications, second ct obtained prior to surgery, other medical reasons)  G3353 Elective delivery or early induction performed  G3356 Elective delivery or early induction performed  G3357 Post-partum screenings, evaluations and education performed  G3358 Elective delivery or early induction performed  G3359 Post-partum screenings, evaluations and education performed  G3360 No documentation of negative or managed positive th screen with further evidence that to is not active within one year of patient visit  No documentation of negative or managed positive th screen  Medical indication for inductio	G9345		
minimum on nodule size and patient risk factors  Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not given  G348 CI scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (eg., persons with sinusitis symptoms lasting at least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinusitis, acute frontal sinusitis, acute sphenoid sinusitis, periorbidal cellulitis, or other medical)  G349 Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 90 days after diagnosis  G351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis  G352 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  G353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg, patients with complications, second ct obtained prior to surgery, other medical reasons)  G354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G355 Elective delivery or early induction not performed  G356 Elective delivery or early induction performed  G357 Post-partum screenings, evaluations and education performed  G358 Post-partum screenings, evaluations and education not performed  G359 Documentation of negative or managed positive tb screen  M6dical indication for induction (eg., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, fetal conditions complicating regressions.		guidelines for incidentally detected pulmonary nodules (e.g., follow-up	
Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not given  G9348		CT imaging studies needed or that no follow-up is needed) based at a	
Follow-up recommendations not documented according to recommended guidelines for incidentally detected pulmonary nodules, reason not given  G9348 Ct scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (eg. persons with sinusitis symptoms lasting at least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinusitis, acute frontal sinusitis, ammunocompromised, recurrent sinusitis, acute frontal sinusitis, acute sphenoid sinusitis, periorbital cellulitis, or other medical)  G9349 Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 30 days after diagnosis or received within 90 days after diagnosis or diagnosis or received within 90 days after diagnosis or diagnosis, reason not given  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg. patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or not ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis or occumented reasons (eg. patients with complications, second ct obtained prior to surgery, other medical reasons)  G9355 Elective delivery or early induction of performed  G9356 Post-partum screenings, evaluations and education performed  G9357 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that the is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  Medical indication for induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclamps		minimum on nodule size and patient risk factors	
recommended guidelines for incidentally detected pulmonary nodules, reason not given  G9348 Ct scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (eg, persons with sinusitis symptoms lasting at least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinusitis, acute frontal sinusitis, acute sphenoid sinusitis, periorbital cellutitis, or other medical)  G9349 Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 90 days after diagnosis.  G9350 More than one ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis.  G9352 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given within 90 days after the date of diagnosis, reason not given within 90 days after the date of diagnosis for documented reasons (eg, patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis.  G9355 Elective delivery or early induction performed  G9356 Post-partum screenings, evaluations and education performed  G9357 Post-partum screenings, evaluations and education not performed  G9360 No documentation of negative or managed positive tb screen with further evidence that the is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  G9361 Medical indication for induction [eq., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, (e.g., hemorrhage an		'	
recommended guidelines for incidentally detected pulmonary nodules, reason not given  G9348 Ct scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (eg, persons with sinusitis symptoms lasting at least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinusitis, acute frontal sinusitis, acute sphenoid sinusitis, periorbital cellutitis, or other medical)  G9349 Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 90 days after diagnosis.  G9350 More than one ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis.  G9352 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given within 90 days after the date of diagnosis, reason not given within 90 days after the date of diagnosis for documented reasons (eg, patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis.  G9355 Elective delivery or early induction performed  G9356 Post-partum screenings, evaluations and education performed  G9357 Post-partum screenings, evaluations and education not performed  G9360 No documentation of negative or managed positive tb screen with further evidence that the is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  G9361 Medical indication for induction [eq., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, (e.g., hemorrhage an	C0247	Follow up recommendations not decrimented according to	
reason not given  G9348 Ct scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (eg, persons with sinusitis symptoms lasting at least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinusitis, acute frontal sinusitis, acute sphenoid sinusitis, periorbital cellulitis, or other medical)  G9349 Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 90 days after date of diagnosis  G9351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  More than one of scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason do tobtained prior to surgery, other medical reasons)  G9353  One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359  Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360  No documentation of negative or managed positive tb screen with further evidence that the is not active within one year of patient patient visit  G9361  No documentation of negat	G9347		
G9348 Ct scan of the paranasal sinuses ordered at the time of diagnosis for documented reasons (eg, persons with sinusitis symptoms lasting at least 7 to 10 days, antibiotic resistance, immuncompromised, recurrent sinusitis, acute frontal sinusitis, acute sphenoid sinusitis, periorbital cellulitis, or other medical)  G9349 Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis  G9350 Ct scan of the paranasal sinuses not ordered at the time of diagnosis or received within 90 days after diagnosis  G9351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis  G9352 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg, patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or not scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education not performed  G9358 Post-partum screenings, evaluations and education not performed  G9369 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  Medical indication for induction [documentation of reason(s) for elective delivery or early induction preformage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnanc		, , , , , , , , , , , , , , , , , , , ,	
documented reasons (eg., persons with sinustits symptoms lasting at least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinustits, acute frontal sinustits, acute sphenoid sinustits, periorbital cellulitis, or other medical)  G9349 Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 90 days after date of diagnosis  G9351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis or diagnosis or deceived within 90 days after diagnosis or diagnosis, reason not given  G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  G9354 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg. patients with complications, second ct obtained prior to surgery, other medical reasons)  G9355 Defective delivery or early induction of the paranasal sinuses ordered within 90 days after the date of diagnosis days after the date of diagnosis  G9356 Elective delivery or early induction not performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that to is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  Medical indication for induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-permature or prolonged, matemal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial])		reason not given	
documented reasons (eg., persons with sinustits symptoms lasting at least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinustits, acute frontal sinustits, acute sphenoid sinustits, periorbital cellulitis, or other medical)  G9349 Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 90 days after diagnosis  G9351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis or diagnosis or deceived within 90 days after the date of diagnosis, reason not given  G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  G9354 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg. patients with complications, second ct obtained prior to surgery, other medical reasons)  G9355 Defective delivery or early induction of performed  G9356 Elective delivery or early induction not performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  Medical indication for induction [documentation of reason(s) for elective delivery (e-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]	G9348	Ct scan of the paranasal sinuses ordered at the time of diagnosis for	
least 7 to 10 days, antibiotic resistance, immunocompromised, recurrent sinusitis, acute frontal sinusitis, acute sphenoid sinusitis, periorbital cellulitis, or other medical)  G9349 Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis  G9350 Ct scan of the paranasal sinuses not ordered at the time of diagnosis or received within 28 days after date of diagnosis  G9351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis  G9352 More than one ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis  G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg., patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G9355 Elective delivery or early induction performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)	· <del>-</del>		
recurrent sinusitis, acute frontal sinusitis, acute sphenoid sinusitis, periorbital cellulitis, or other medical)  G9349 Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 90 days after diagnosis  G9351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg., patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  Medical indication for induction (e.g., hemorrhage and placental complications, hypertension, precclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, letal conditions complicating pregnancy/delivery, letal conditions complicating pregnancy/delivery, letal conditions complicating pregnancy/delivery, letal pregnancy, prior uterine surgery, or participation in clinical triall)			
Decumentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 90 days after diagnosis  G9351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg., patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, tetal pregnancy, prior uterine surgery, or participation in clinical trial)]			
G9349 Documentation of a ct scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 28 days after date of diagnosis or received within 90 days after diagnosis  G9351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis on diagnosis or deceived within 90 days after the date of diagnosis, reason not given  G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg., patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis of diagnosis for documented reasons (eg., patients with complications, second ct obtained prior to surgery, other medical reasons)  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, precelampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, letal conditions complications hyperancy or participation in clinical trial)]		· ·	
time of diagnosis or received within 28 days after date of diagnosis G9350 Ct scan of the paranasal sinuses not ordered at the time of diagnosis or received within 28 days after date of diagnosis G9351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis G9352 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg, patients with complications, second ct obtained prior to surgery, other medical reasons) G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis G9355 Elective delivery or early induction not performed G9356 Elective delivery or early induction performed G9357 Post-partum screenings, evaluations and education performed G9358 Post-partum screenings, evaluations and education not performed G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit G9360 No documentation for negative or managed positive tb screen G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, precelampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fatal conditions complicating pregnancy/delivery, fatal conditions complicating pregnancy/delivery, fatal conditions complication in clinical trial)] G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection		periorbital cellulitis, or other medical)	
time of diagnosis or received within 28 days after date of diagnosis G9350 Ct scan of the paranasal sinuses not ordered at the time of diagnosis or received within 28 days after date of diagnosis G9351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis G9352 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg, patients with complications, second ct obtained prior to surgery, other medical reasons) G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis G9355 Elective delivery or early induction not performed G9356 Elective delivery or early induction performed G9357 Post-partum screenings, evaluations and education performed G9358 Post-partum screenings, evaluations and education not performed G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit G9360 No documentation for negative or managed positive tb screen G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, precelampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fatal conditions complicating pregnancy/delivery, fatal conditions complicating pregnancy/delivery, fatal conditions complication in clinical trial)] G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection			
time of diagnosis or received within 28 days after date of diagnosis G9350 Ct scan of the paranasal sinuses not ordered at the time of diagnosis or received within 28 days after date of diagnosis G9351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis G9352 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg, patients with complications, second ct obtained prior to surgery, other medical reasons) G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis G9355 Elective delivery or early induction not performed G9356 Elective delivery or early induction performed G9357 Post-partum screenings, evaluations and education performed G9358 Post-partum screenings, evaluations and education not performed G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit G9360 No documentation for negative or managed positive tb screen G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, precelampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fatal conditions complicating pregnancy/delivery, fatal conditions complicating pregnancy/delivery, fatal conditions complication in clinical trial)] G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection	G9349	Documentation of a ct scan of the paranasal sinuses ordered at the	
G9350 Ct scan of the paranasal sinuses not ordered at the time of diagnosis or received within 28 days after date of diagnosis  G9351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis  More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  G9352 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg, patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fate pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection			
or received within 28 days after date of diagnosis  G9351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis  G9352 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg, patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis for documented reasons (eg patients with complications, second ct obtained prior to surgery, other medical reasons)  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, precelampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, felat conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical triall)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection		unite of diagnosis of received within 25 days after date of diagnosis	
or received within 28 days after date of diagnosis  G9351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis  G9352 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg, patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis for documented reasons (eg patients with complications, second ct obtained prior to surgery, other medical reasons)  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, precelampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, felat conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical triall)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection			
G9351 More than one ct scan of the paranasal sinuses ordered or received within 90 days after diagnosis  G9352 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg, patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive the screen with further evidence that the is not active within one year of patient visit  G9360 No documentation of negative or managed positive the screen  Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection	G9350		
within 90 days after diagnosis G9352 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg, patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection		or received within 28 days after date of diagnosis	
within 90 days after diagnosis G9352 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg, patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection	G9351	More than one ct scan of the paranasal sinuses ordered or received	
More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis, reason not given  G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg. patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection			
within 90 days after the date of diagnosis, reason not given  G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg, patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, [ate pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection	C0353		
G9353 More than one ct scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis for documented reasons (eg., patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, fetal pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection	G9352		
within 90 days after the date of diagnosis for documented reasons (eg, patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection		within 90 days after the date of diagnosis, reason not given	
within 90 days after the date of diagnosis for documented reasons (eg, patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection			
(eg, patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, tetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection	G9353	More than one ct scan of the paranasal sinuses ordered or received	
(eg, patients with complications, second ct obtained prior to surgery, other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, tetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection		within 90 days after the date of diagnosis for documented reasons	
other medical reasons)  G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive to screen with further evidence that to is not active within one year of patient visit  G9360 No documentation of negative or managed positive to screen  G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection			
G9354 One ct scan or no ct scan of the paranasal sinuses ordered within 90 days after the date of diagnosis  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection			
days after the date of diagnosis  G9355 Elective delivery or early induction not performed  G9356 Elective delivery or early induction performed  G9357 Post-partum screenings, evaluations and education performed  G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection	00054	,	
G9355 Elective delivery or early induction not performed G9356 Elective delivery or early induction performed G9357 Post-partum screenings, evaluations and education performed G9358 Post-partum screenings, evaluations and education not performed G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection	G9354		
G9356 Elective delivery or early induction performed G9357 Post-partum screenings, evaluations and education performed G9358 Post-partum screenings, evaluations and education not performed G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection		days after the date of diagnosis	
G9357 Post-partum screenings, evaluations and education performed G9358 Post-partum screenings, evaluations and education not performed G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection	G9355	Elective delivery or early induction not performed	
G9357 Post-partum screenings, evaluations and education performed G9358 Post-partum screenings, evaluations and education not performed G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection	G9356	Elective delivery or early induction performed	
G9358 Post-partum screenings, evaluations and education not performed  G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection			
G9359 Documentation of negative or managed positive tb screen with further evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection			
evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection	2000	- 11- parameter services, or a salar for and oddodnor not portonnod	
evidence that tb is not active within one year of patient visit  G9360 No documentation of negative or managed positive tb screen  Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection	COSEO	Documentation of pogetive or managed positive the server with fruit and	
G9360 No documentation of negative or managed positive tb screen  G9361 Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection	Gassa		
Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection		evidence that to is not active within one year of patient visit	
Medical indication for induction [documentation of reason(s) for elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection			
elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection	G9360	No documentation of negative or managed positive tb screen	
elective delivery (c-section) or early induction (e.g., hemorrhage and placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection	G9361		
placental complications, hypertension, preeclampsia and eclampsia, rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection		•	
rupture of membranes-premature or prolonged, maternal conditions complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection			
complicating pregnancy/delivery, fetal conditions complicating pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection			
pregnancy/delivery, late pregnancy, prior uterine surgery, or participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection			
participation in clinical trial)]  G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection			
G9364 Sinusitis caused by, or presumed to be caused by, bacterial infection			
		participation in clinical trial)]	
	G0364	Sinusitis caused by or presumed to be caused by bacterial infection	
G9365 One high-risk medication ordered	03304	Tomasias caused by, or presumed to be caused by, bacterial infection	
G9365 One high-risk medication ordered			
	G9365	One high-risk medication ordered	

G9366	One high-risk medication not ordered	
G9367	One high-risk medication not ordered  At least two different high-risk medications ordered	
G9368	At least two different high-risk medications ordered  At least two different high-risk medications not ordered	<del> </del>
G9380	Patient offered assistance with end of life issues during the	
	measurement period	
G9381	Documentation of medical reason(s) for not offering assistance with end of life issues (e.g., patient in hospice care, patient in terminal phase) during the measurement period	
G9382	Patient not offered assistance with end of life issues during the measurement period	
G9383	Patient received screening for HCV infection within the 12 month reporting period	
G9384	Documentation of medical reason(s) for not receiving annual screening for hcv infection (e.g., decompensated cirrhosis indicating advanced disease [i.e., ascites, esophageal variceal bleeding, hepatic encephalopathy], hepatocellular carcinoma, waitlist for organ transplant, limited life expectancy, other medical reasons)	
G9385	Documentation of patient reason(s) for not receiving annual screening for hcv infection (e.g., patient declined, other patient reasons)	
G9386	Screening for HCV infection not received within the 12 month reporting period, reason not given	
G9389	Unplanned rupture of the posterior capsule requiring vitrectomy during cataract surgery	
G9390	No unplanned rupture of the posterior capsule requiring vitrectomy during cataract surgery	
G9393	Patient with an initial phq-9 score greater than nine who achieves remission at twelve months as demonstrated by a twelve month (+/-30 days) phq-9 score of less than five	
G9394	Patient who had a diagnosis of bipolar disorder or personality disorder, death, permanent nursing home resident or receiving hospice or palliative care any time during the measurement or assessment period	
G9395	Patient with an initial phq-9 score greater than nine who did not achieve remission at twelve months as demonstrated by a twelve month (+/- 30 days) phq-9 score greater than or equal to five	
G9396	Patient with an initial phq-9 score greater than nine who was not assessed for remission at twelve months (+/- 30 days)	
G9399	Documentation in the patient record of a discussion between the physician/clinician and the patient that includes all of the following: treatment choices appropriate to genotype, risks and benefits, evidence of effectiveness, and patient preferences toward the outcome of the treatment	
G9400	Documentation of medical or patient reason(s) for not discussing treatment options; medical reasons: patient is not a candidate for treatment due to advanced physical or mental health comorbidity (including active substance use); currently receiving antiviral treatment; successful antiviral treatment (with sustained virologic response) prior to reporting period; other documented medical reasons; patient reasons: patient unable or unwilling to participate in the discussion or other patient reasons	
G9401	No documentation of a discussion in the patient record of a discussion between the physician or other qualfied healthcare professional and the patient that includes all of the following: treatment choices appropriate to genotype, risks and benefits, evidence of effectiveness, and patient preferences toward treatment	
G9402	Patient received follow-up on the date of discharge or within 30 days after discharge	

	-	
G9403	Clinician documented reason patient was not able to complete 30 day	
	follow-up from acute inpatient setting discharge (e.g., patient death	
	prior to follow-up visit, patient non-compliant for visit follow-up)	
	prior to rollow up viole, patient from compliant for viole rollow up,	
G9404	Patient did not receive follow-up on the date of discharge or within 30	
	days after discharge	
G9405	Patient received follow-up within 7 days from discharge	
G9406	Clinician documented reason patient was not able to complete 7 day	
03400	•	
	follow-up from acute inpatient setting discharge (i.e patient death prior	
	to follow-up visit, patient non-compliance for visit follow-up)	
G9407	Patient did not receive follow-up on or within 7 days after discharge	
G9408	Patients with cardiac tamponade and/or pericardiocentesis occurring	
G9400		
	within 30 days	
G9409	Patients without cardiac tamponade and/or pericardiocentesis	
	occurring within 30 days	
G9410	Patient admitted within 180 days, status post CIED implantation,	
	replacement, or revision with an infection requiring device removal or	
	surgical revision	
00111	S .	
G9411	Patient not admitted within 180 days, status post CIED implantation,	
	replacement, or revision with an infection requiring device removal or	
	surgical revision	
G9412	Patient admitted within 180 days, status post CIED implantation,	
	replacement, or revision with an infection requiring device removal or	
	surgical revision	
	=	
G9413	Patient not admitted within 180 days, status post CIED implantation,	
	replacement, or revision with an infection requiring device removal or	
	surgical revision	
G9414	Patient had one dose of meningococcal vaccine on or between the	
00111	patient's 11th and 13th birthdays	
G9415		
G9415	Patient did not have one dose of meningococcal vaccine on or	
	between the patient's 11th and 13th birthdays	
G9416	Patient had one tetanus, diphtheria toxoids and acellular pertussis	
	vaccine (tdap) on or between the patient's 10th and 13th birthdays	
G9417	Patient did not have one tetanus, diphtheria toxoids and acellular	
05417	pertussis vaccine (tdap) on or between the patient's 10th and 13th	
	birthdays	
G9418	Primary non-small cell lung cancer biopsy and cytology specimen	
	report documents classification into specific histologic type or	
	classified as NSCLC-NOS with an explanation	
	·	
C0440	Decumentation of medical reason(s) for not including the history	
G9419	Documentation of medical reason(s) for not including the histological	
	type or nsclc-nos classification with an explanation (e.g., biopsy taken	
	for other purposes in a patient with a history of primary non-small cell	
	lung cancer or other documented medical reasons)	
G9420	Specimen site other than anatomic location of lung or is not classified	
55720	as primary non-small cell lung cancer	
00.45.1	. ,	
G9421	Primary non-small cell lung cancer biopsy and cytology specimen	
	report does not document classification into specific histologic type or	
	classified as NSCLC-NOS with an explanation	
G9422	Primary lung carcinoma resection report documents pt category, pn	
G3422		
	category and for non-small cell lung cancer, histologic type	
	(squamous cell carcinoma, adenocarcinoma and not nsclc-nos)	
1		

T =		
G9423	Documentation of medical reason for not including pt category, pn	
	category and histologic type [for patient with appropriate exclusion	
	criteria (e.g., metastatic disease, benign tumors, malignant tumors	
	other than carcinomas, inadequate surgical specimens)]	
	otilei tilati carcillottias, illauequate surgical specifiens)]	
G9424	Specimen site other than anatomic location of lung, or classified as	
	nsclc-nos	
G9425	Primary lung carcinoma resection report does not document pt	
00420		
	category, pn category and for non-small cell lung cancer, histologic	
	type (squamous cell carcinoma, adenocarcinoma)	
G9426	Improvement in median time from ED arrival to initial ED oral or	
	parenteral pain medication administration performed for ED admitted	
	patients	
C0407	•	
G9427	Improvement in median time from ED arrival to initial ED oral or	
	parenteral pain medication administration not performed for ED	
	admitted patients	
G9428	Pathology report includes the pt category and a statement on	
	thickness and ulceration and for pt1, mitotic rate	
00400	, ,	
G9429	Documentation of medical reason(s) for not including pt category and	
	a statement on thickness and ulceration and for pt1, mitotic rate (e.g.,	
	negative skin biopsies in a patient with a history of melanoma or other	
	documented medical reasons)	
C0420	,	<del> </del>
G9430	Specimen site other than anatomic cutaneous location	
G9431	Pathology report does not include the pt category and a statement on	
	thickness and ulceration and for pt1, mitotic rate	
G9432	Asthma well-controlled based on the act, c-act, acg, or atag score and	
00.02	results documented	
00404		
G9434	Asthma not well-controlled based on the ACT, C-ACT, ACQ, or ATAQ	
	score, or specified asthma control tool not used, reason not given	
G9448	Patients who were born in the years 1945?1965	
G9449		
<u> </u>	History of receiving blood transfusions prior to 1992	
G9450	History of injection drug use	
G9451	Patient received one-time screening for HCV infection	
G9452	Documentation of medical reason(s) for not receiving one-time	
	screening for HCV infection (e.g., decompensated cirrhosis indicating	
	advanced disease [ie, ascites, esophageal variceal bleeding, hepatic	
	encephalopathy], hepatocellular carcinoma, waitlist for organ	
	transplant, limited life expectancy, other medical reasons)	
G9453	Documentation of patient reason(s) for not receiving one-time	
03400	, , , , , , , , , , , , , , , , , , , ,	
	screening for HCV infection (e.g., patient declined, other patient	
	reasons)	
G9454	One-time screening for HCV infection not received within 12 month	
	reporting period and no documentation of prior screening for HCV	
	infection, reason not given	
00.4==	9	
G9455	Patient underwent abdominal imaging with ultrasound, contrast	
	enhanced ct or contrast mri for hcc	
G9456	Documentation of medical or patient reason(s) for not ordering or	
	performing screening for hcc. medical reason: comorbid medical	
	conditions with expected survival < 5 years, hepatic decompensation	
	and not a candidate for liver transplantation, or other medical reasons;	
	patient reasons: patient declined or other patient reasons (e.g., cost of	
	tests, time related to accessing testing equipment)	
004==	<u> </u>	
G9457	Patient did not undergo abdominal imaging and did not have a	
	documented reason for not undergoing abdominal imaging in the	
	reporting period	
	!	<del></del>

G9450 Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, assistance with or referral to external smoking or tobacco use, assistance with or referral to external smoking or tobacco use cessation program) if identified as a tobacco user assistance with or referral to external smoking or tobacco use cessation program) if identified as a tobacco user assistance of tobacco user assistance of the program of the prog	_		
quit smoking or tobacco use, assistance with or referral to external smoking or tobacco use, assistance with or referral to external smoking or tobacco use sessation support programs, or current enrollment in smoking or tobacco use dessation program) if identified as a tobacco user  G9460 Currently a tobacco non-user  G9460 Tobacco assessment or tobacco cessation intervention not performed, reason not given  G9468 Patent not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9469 Patients who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9470 Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (IDXA) not ordered or documented  G9473 Services performed by chaplain in the hospice setting, each 15 minutes  G9474 Services performed by other counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by other counselor in the hospice setting, each 15 minutes  G9477 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9478 Services performed by care coordinator in the hospice setting, each 15 minutes  G9479 Services performed by care coordinator in the hospice setting, each 15 minutes  G9479 Services performed by care coordinator in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  R89480 Admission to medicare care choice model program (mccm)  R89490 Admission to medicare car	G9458	Patient documented as tobacco user and received tobacco cessation	
quit smoking or tobacco use, assistance with or referral to external smoking or tobacco use, assistance with or referral to external smoking or tobacco use sessation support programs, or current enrollment in smoking or tobacco use dessation program) if identified as a tobacco user  G9460 Currently a tobacco non-user  G9460 Tobacco assessment or tobacco cessation intervention not performed, reason not given  G9468 Patent not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9469 Patients who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9470 Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (IDXA) not ordered or documented  G9473 Services performed by chaplain in the hospice setting, each 15 minutes  G9474 Services performed by other counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by other counselor in the hospice setting, each 15 minutes  G9477 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9478 Services performed by care coordinator in the hospice setting, each 15 minutes  G9479 Services performed by care coordinator in the hospice setting, each 15 minutes  G9479 Services performed by care coordinator in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  R89480 Admission to medicare care choice model program (mccm)  R89490 Admission to medicare car		intervention (must include at least one of the following: advice given to	
smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco cessation program) if identified as a tobacco user cessation program) if identified as a construction of the co		quit smoking or tohacco use, counseling on the benefits of quitting	
smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user.  G9469			
in smoking or tobacco use cessation program) if identified as a tobacco user  G9469 Currently a tobacco non-user  G9460 Tobacco assessment or tobacco cessation intervention not performed, reason not given  Patient not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9469 Patients who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9470 Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (DXA) not ordered or documented  G9473 Services performed by chaplain in the hospice setting, each 15 minutes  G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by other counselor in the hospice setting, each 15 minutes  G9477 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by undergound the program (mccm)  G9480 Admission to medicare care choice model program (mccm)  G9480 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused the patient or the family or both, usually, the presenting problem(s) and the needs of the patient or the family or both, usually, the presenting problem(s) and the needs of the patient or			
Company   Currently a tobacco non-user		smoking or tobacco cessation support programs, or current enrollment	
G9459 Currently a tobacco non-user G9460 Tobacco assessment or tobacco cessation intervention not performed, reason not given G9468 Patient not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills G9469 Patients who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills G9470 Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (DXA) not ordered or documented G9473 Services performed by chaplain in the hospice setting, each 15 minutes G9474 Services performed by other counselor in the hospice setting, each 15 minutes G9475 Services performed by volunteer in the hospice setting, each 15 minutes G9476 Services performed by volunteer in the hospice setting, each 15 minutes G9476 Services performed by other counselor in the hospice setting, G9476 Services performed by volunteer in the hospice setting, G9476 Services performed by volunteer in the hospice setting, G9476 Services performed by volunteer in the hospice setting, G9476 Services performed by other qualified therapist in the hospice setting, G9476 Services performed by other qualified pharmacist in the hospice setting, G9476 Services performed by other qualified pharmacist in the hospice setting, G9477 Services performed by other qualified pharmacist in the hospice setting, G9478 Services performed by other qualified pharmacist in the hospice setting, G9479 Services performed by other qualified pharmacist in the hospice setting, G9470 Services performed by other qualified pharmacist in the hospice setting, G9470 Serv		in smoking or tobacco use cessation program) if identified as a	
G9459 Currently a tobacco non-user G9460 Tobacco assessment or tobacco cessation intervention not performed, reason not given G9468 Patient not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills G9469 Patients who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills G9470 Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (DXA) not ordered or documented G9473 Services performed by chaplain in the hospice setting, each 15 minutes G9474 Services performed by other counselor in the hospice setting, each 15 minutes G9475 Services performed by volunteer in the hospice setting, each 15 minutes G9476 Services performed by volunteer in the hospice setting, each 15 minutes G9476 Services performed by other counselor in the hospice setting, G9476 Services performed by volunteer in the hospice setting, G9476 Services performed by volunteer in the hospice setting, G9476 Services performed by volunteer in the hospice setting, G9476 Services performed by other qualified therapist in the hospice setting, G9476 Services performed by other qualified pharmacist in the hospice setting, G9476 Services performed by other qualified pharmacist in the hospice setting, G9477 Services performed by other qualified pharmacist in the hospice setting, G9478 Services performed by other qualified pharmacist in the hospice setting, G9479 Services performed by other qualified pharmacist in the hospice setting, G9470 Services performed by other qualified pharmacist in the hospice setting, G9470 Serv		tobacco user	
G9460 Tobacco assessment or tobacco cessation intervention not performed, reason not given G9468 Patient not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills G9469 Patients who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills G9470 Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone or greater for all fills or a single prescription equating to 600 mg prednisone or greater for all fills G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (DXA) not ordered or documented G9473 Services performed by chaplain in the hospice setting, each 15 minutes G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes G9475 Services performed by other counselor in the hospice setting, each 15 minutes G9476 Services performed by volunteer in the hospice setting, each 15 minutes G9477 Services performed by volunteer in the hospice setting, each 15 minutes G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes G9479 Services performed by other qualified pharmacist in the hospice setting, each 15 minutes G9480 Admission to medicare care choice model program (mccm) G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination, and straightforward medical decision making, furnished in real time using interactive audio and video technology, counseling and coordination of care with other physicians, other qua			
G9460 Tobacco assessment or tobacco cessation intervention not performed, reason not given G9468 Patient not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills G9469 Patients who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills G9470 Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone or greater for all fills or a single prescription equating to 600 mg prednisone or greater for all fills G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (DXA) not ordered or documented G9473 Services performed by chaplain in the hospice setting, each 15 minutes G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes G9475 Services performed by other counselor in the hospice setting, each 15 minutes G9476 Services performed by volunteer in the hospice setting, each 15 minutes G9477 Services performed by volunteer in the hospice setting, each 15 minutes G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes G9479 Services performed by other qualified pharmacist in the hospice setting, each 15 minutes G9480 Admission to medicare care choice model program (mccm) G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination, and straightforward medical decision making, furnished in real time using interactive audio and video technology, counseling and coordination of care with other physicians, other qua			
performed, reason not given   Patient not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills	G9459	Currently a tobacco non-user	
Patient not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills	G9460	Tobacco assessment or tobacco cessation intervention not	
Patient not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills		performed, reason not given	
mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9469 Patients who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9470 Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (DXA) not ordered or documented  G9473 Services performed by chaplain in the hospice setting, each 15 minutes  G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by oulunteer in the hospice setting, each 15 minutes  G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology, counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the pat	C0468	, ,	
or a single prescription equating to 600 mg prednisone or greater for all fills  G9469 Patients who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9470 Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (DXA) not ordered or documented  G9473 Services performed by chaplain in the hospice setting, each 15 minutes  G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by volunteer in the hospice setting, each 15 minutes  G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by care coordinator in the hospice setting, each 15 minutes  G9479 Services performed by dualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified therapist in the hospice setting, each 15 minutes  G9479 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medicar decision making, furnished in real time using interactive audio and video technology, counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both via real time, audio and	03400		
all fills  G9469 Patients who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9470 Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (DXA) not ordered or documented  G9473 Services performed by chaplain in the hospice setting, each 15 minutes  G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by care coordinator in the hospice setting, each 15 minutes  G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by care coordinator in the hospice setting, each 15 minutes  G9479 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology, counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both via real time, audio and			
G9469 Patients who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9470 Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (DXA) not ordered or documented  G9473 Services performed by chaplain in the hospice setting, each 15 minutes  G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by volunteer in the hospice setting, each 15 minutes  G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by care coordinator in the hospice setting, each 15 minutes  G9479 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, turnished in real time using interactive audio and video technology, counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both via real time, audio and		or a single prescription equating to 600 mg prednisone or greater for	
than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9470 Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (IDXA) not ordered or documented  G9473 Services performed by chaplain in the hospice setting, each 15 minutes  G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by volunteer in the hospice setting, each 15 minutes  G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by care coordinator in the hospice setting, each 15 minutes  G9479 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology; counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both, usually, the presenting problem(s) are self limited or minor, typically, 10 minutes are spent with the patient or family or both via real time, audio and		all fills	
than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9470 Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (IDXA) not ordered or documented  G9473 Services performed by chaplain in the hospice setting, each 15 minutes  G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by volunteer in the hospice setting, each 15 minutes  G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by care coordinator in the hospice setting, each 15 minutes  G9479 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology; counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both, usually, the presenting problem(s) are self limited or minor, typically, 10 minutes are spent with the patient or family or both via real time, audio and	G9469	Patients who have received or are receiving corticosteroids greater	
consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (DXA) not ordered or documented  G9473 Services performed by chaplain in the hospice setting, each 15 minutes  G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by volunteer in the hospice setting, each 15 minutes  G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology, counseling and coordination of care with other physicians, other qualified health care professionals or aggencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both, usually, the presenting problem(s) are self limited or minor, typically, 10 minutes are spent with the patient or family or both via real time, audio and	30-100		
prednisone or greater for all fills  G9470 Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (DXA) not ordered or documented  G9473 Services performed by chaplain in the hospice setting, each 15 minutes  G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by volunteer in the hospice setting, each 15 minutes  G9477 Services performed by valunteer in the hospice setting, each 15 minutes  G9478 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9480 Admission to medicare care choice model program (mccm)  Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology, counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both, usually, the presenting problem(s) are self limited or minor, typically, 10 minutes are spent with the patient or family or both via real time, audio and			
Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (DXA) not ordered or documented  G9473 Services performed by chaplain in the hospice setting, each 15 minutes  G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by volunteer in the hospice setting, each 15 minutes  G9477 Services performed by volunteer in the hospice setting, each 15 minutes  G9478 Services performed by care coordinator in the hospice setting, each 15 minutes  G9479 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9480 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology, counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both, usually, the presenting problem(s) are spent with the patient or to thir problem, and on the problem			
mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (DXA) not ordered or documented  G9473 Services performed by chaplain in the hospice setting, each 15 minutes  G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by volunteer in the hospice setting, each 15 minutes  G9477 Services performed by valunteer in the hospice setting, each 15 minutes  G9478 Services performed by care coordinator in the hospice setting, each 15 minutes  G9479 Services performed by qualified therapist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both usually, the presenting problem(s) are spent with the patient or family or both via real time, audio and		prednisone or greater for all fills	
mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills  G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (DXA) not ordered or documented  G9473 Services performed by chaplain in the hospice setting, each 15 minutes  G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by volunteer in the hospice setting, each 15 minutes  G9477 Services performed by valunteer in the hospice setting, each 15 minutes  G9478 Services performed by care coordinator in the hospice setting, each 15 minutes  G9479 Services performed by qualified therapist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both usually, the presenting problem(s) are spent with the patient or family or both via real time, audio and	G9470	Patients not receiving corticosteroids greater than or equal to 10	
or a single prescription equating to 600 mg prednisone or greater for all fills  G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (DXA) not ordered or documented  G9473 Services performed by chaplain in the hospice setting, each 15 minutes  G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by volunteer in the hospice setting, each 15 minutes  G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology, counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and			
all fills  G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (DXA) not ordered or documented  G9473 Services performed by chaplain in the hospice setting, each 15 minutes  G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by volunteer in the hospice setting, each 15 minutes  G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by care coordinator in the hospice setting, each 15 minutes  G9479 Services performed by qualified therapist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and			
G9471 Within the past 2 years, central dual-energy x-ray absorptiometry (DXA) not ordered or documented G9473 Services performed by chaplain in the hospice setting, each 15 minutes G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes G9475 Services performed by other counselor in the hospice setting, each 15 minutes G9476 Services performed by volunteer in the hospice setting, each 15 minutes G9477 Services performed by care coordinator in the hospice setting, each 15 minutes G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes G9479 Services performed by qualified therapist in the hospice setting, each 15 minutes G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes G9480 Admission to medicare care choice model program (mccm) G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology, counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor, typically, 10 minutes are spent with the patient or family or both via real time, audio and			
(DXA) not ordered or documented  G9473 Services performed by chaplain in the hospice setting, each 15 minutes  G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by volunteer in the hospice setting, each 15 minutes  G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor, typically, 10 minutes are spent with the patient or family or both via real time, audio and		all fills	
G9473 Services performed by chaplain in the hospice setting, each 15 minutes G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes G9475 Services performed by other counselor in the hospice setting, each 15 minutes G9476 Services performed by volunteer in the hospice setting, each 15 minutes G9477 Services performed by care coordinator in the hospice setting, each 15 minutes G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes G9480 Admission to medicare care choice model program (mccm) G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor, typically, 10 minutes are spent with the patient or family or both via real time, audio and	G9471	Within the past 2 years, central dual-energy x-ray absorptiometry	
G9473 Services performed by chaplain in the hospice setting, each 15 minutes G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes G9475 Services performed by other counselor in the hospice setting, each 15 minutes G9476 Services performed by volunteer in the hospice setting, each 15 minutes G9477 Services performed by care coordinator in the hospice setting, each 15 minutes G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes G9480 Admission to medicare care choice model program (mccm) G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor, typically, 10 minutes are spent with the patient or family or both via real time, audio and			
minutes  G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by volunteer in the hospice setting, each 15 minutes  G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology, counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both, usually, the presenting problem(s) are self limited or minor, typically, 10 minutes are spent with the patient or family or both via real time, audio and	G9473		
G9474 Services performed by dietary counselor in the hospice setting, each 15 minutes  G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by volunteer in the hospice setting, each 15 minutes  G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology, counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both, usually, the presenting problem(s) are self limited or minor, typically, 10 minutes are spent with the patient or family or both via real time, audio and	03473		
G9475 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by volunteer in the hospice setting, each 15 minutes  G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and	001=1		
G9476 Services performed by other counselor in the hospice setting, each 15 minutes  G9476 Services performed by volunteer in the hospice setting, each 15 minutes  G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and	G9474		
minutes  G9476 Services performed by volunteer in the hospice setting, each 15 minutes  G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and		15 minutes	
minutes  G9476 Services performed by volunteer in the hospice setting, each 15 minutes  G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and	G9475	Services performed by other counselor in the hospice setting, each 15	
minutes  G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and			
minutes  G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and	G9476	Services performed by volunteer in the hospice setting, each 15	
G9477 Services performed by care coordinator in the hospice setting, each 15 minutes  G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and	00470		
G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and	001==		
G9478 Services performed by other qualified therapist in the hospice setting, each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  G9481 Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and	G9477		
each 15 minutes  G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and		15 minutes	
G9479 Services performed by qualified pharmacist in the hospice setting, each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and	G9478	Services performed by other qualified therapist in the hospice setting,	
each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and		each 15 minutes	
each 15 minutes  G9480 Admission to medicare care choice model program (mccm)  Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and	G9479	Services performed by qualified pharmacist in the hospice setting	
G9480 Admission to medicare care choice model program (mccm)  Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and	30713	, , , , , , , , , , , , , , , , , , , ,	
Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and	C0400		
patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and		• • • • • • • • • • • • • • • • • • • •	
joint replacement model, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and	G9481		
problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and		patient for use only in the medicare-approved comprehensive care for	
problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and		joint replacement model, which requires these 3 key components: a	
straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and			
interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and		, ,	
care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and			
agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and			
and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and		· · · · · · · · · · · · · · · · · · ·	
presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and		agencies are provided consistent with the nature of the problem(s)	
presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and		and the needs of the patient or the family or both. usually, the	
are spent with the patient or family or both via real time, audio and			
		, , , , , , , , , , , , , , , , , , , ,	
video intercommunications technology			
		video intercommunications technology	

G9482	Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: an expanded problem focused history; an expanded problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology	
G9483	Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a detailed history; a detailed examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate severity. typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology	
G9484	Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology	
G9485	Remote in-home visit for the evaluation and management of a new patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology	

G9486	Remote in-home visit for the evaluation and management of an established patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires at least 2 of the following 3 key components: a problem focused history; a problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology	
G9487	Remote in-home visit for the evaluation and management of an established patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires at least 2 of the following 3 key components: an expanded problem focused history; an expanded problem focused examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology	
G9488	Remote in-home visit for the evaluation and management of an established patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires at least 2 of the following 3 key components: a detailed history; a detailed examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology	
G9489	Remote in-home visit for the evaluation and management of an established patient for use only in the medicare-approved comprehensive care for joint replacement model, which requires at least 2 of the following 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology	

G9490	Comprehensive care for joint replacement model, home visit for patient assessment performed by clinical staff for an individual not considered homebound, including, but not necessarily limited to patient assessment of clinical status, safety/fall prevention, functional status/ambulation, medication reconciliation/management, compliance with orders/plan of care, performance of activities of daily living, and ensuring beneficiary connections to community and other services. (for use only in the medicare-approved cjr model); may not be billed for a 30 day period covered by a transitional care management code	
G9496	Documentation of reason for not detecting adenoma(s) or other neoplasm. (e.g., neoplasm detected is only diagnosed as traditional serrated adenoma, sessile serrated polyp, or sessile serrated adenoma	
G9497	Received instruction from the anesthesiologist or proxy prior to the day of surgery to abstain from smoking on the day of surgery	
G9498	Antibiotic regimen prescribed	
G9500	Radiation exposure indices, or exposure time and number of fluorographic images in final report for procedures using fluoroscopy, documented	
G9501	Radiation exposure indices, or exposure time and number of fluorographic images not documented in final report for procedure using fluoroscopy, reason not given	
G9502	Documentation of medical reason for not performing foot exam (i.e., patients who have had either a bilateral amputation above or below the knee, or both a left and right amputation above or below the knee before or during the measurement period)	
G9503	Patient taking tamsulosin hydrochloride	
G9504	Documented reason for not assessing hepatitis b virus (hbv) status (e.g. patient not receiving a first course of anti-tnf therapy, patient declined) within one year prior to first course of anti-tnf therapy	
G9505	Antibiotic regimen prescribed within 10 days after onset of symptoms for documented medical reason	
G9506	Biologic immune response modifier prescribed	
G9507	Documentation that the patient is on a statin medication or has documentation of a valid contraindication or exception to statin medications; contraindications/exceptions that can be defined by diagnosis codes include pregnancy during the measurement period, active liver disease, rhabdomyolysis, end stage renal disease on dialysis and heart failure; provider documented contraindications/exceptions include breastfeeding during the measurement period, woman of child-bearing age not actively taking birth control, allergy to statin, drug interaction (hiv protease inhibitors, nefazodone, cyclosporine, gemfibrozil, and danazol) and intolerance (with supporting documentation of trying a statin at least once within the last 5 years or diagnosis codes for myostitis or toxic myopathy related to drugs)	
G9508	Documentation that the patient is not on a statin medication	
G9509	Remission at twelve months as demonstrated by a twelve month (+/-30 days) phq-9 score of less than 5	
G9510	Remission at twelve months not demonstrated by a twelve month (+/-30 days) phq-9 score of less than five; either phq-9 score was not assessed or is greater than or equal to 5	
G9511	Index date phq-9 score greater than 9 documented during the twelve month denominator identification period	
G9512	Individual had a pdc of 0.8 or greater	
G9513	Individual did not have a pdc of 0.8 or greater	

G9514	Patient required a return to the operating room within 90 days of surgery	
G9515	Patient did not require a return to the operating room within 90 days of	
	surgery	
G9516	Patient achieved an improvement in visual acuity, from their	
00547	preoperative level, within 90 days of surgery	
G9517	Patient did not achieve an improvement in visual acuity, from their preoperative level, within 90 days of surgery, reason not given	
G9518	Documentation of active injection drug use	
G9519	Patient achieves final refraction (spherical equivalent) +/- 0.5 diopters of their planned refraction within 90 days of surgery	
G9520	Patient does not achieve final refraction (spherical equivalent) +/- 0.5 diopters of their planned refraction within 90 days of surgery	
G9521	Total number of emergency department visits and inpatient hospitalizations less than two in the past 12 months	
G9522	Total number of emergency department visits and inpatient hospitalizations equal to or greater than two in the past 12 months or patient not screened, reason not given	
G9523	Patient discontinued from hemodialysis or peritoneal dialysis	
G9524	Patient was referred to hospice care	
G9525	Documentation of patient reason(s) for not referring to hospice care (e.g., patient declined, other patient reasons)	
G9526	Patient was not referred to hospice care, reason not given	
G9529	Patient with minor blunt head trauma had an appropriate indication(s) for a head ct	
G9530	Patient presented within 24 hours of a minor blunt head trauma with a gcs score of 15 and had a head ct ordered for trauma by an emergency care provider	
G9531	Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, pregnancy, or is currently taking an antiplatelet medication including: asa/dipyridamole, clopidogrel, prasugrel, ticlopidine, ticagrelor or cilstazol)	
G9532	Patient's head injury occurred greater than 24 hours before presentation to the emergency department, or has a gcs score less than 15 or does not have a gcs score documented, or had a head ct for trauma ordered by someone other than an emergency care provider, or was ordered for a reason other than trauma	
G9533	Patient with minor blunt head trauma did not have an appropriate indication(s) for a head ct	
G9537	Documentation of system reason(s) for ordering an advanced brain imaging study (i.e., needed as part of a clinical trial; other clinician ordered the study)	
G9539	Intent for potential removal at time of placement	
G9540	Patient alive 3 months post procedure	
G9541	Filter removed within 3 months of placement	
G9542	Documented re-assessment for the appropriateness of filter removal within 3 months of placement	
G9543	Documentation of at least two attempts to reach the patient to arrange a clinical re-assessment for the appropriateness of filter removal within 3 months of placement	
G9544	Patients that do not have the filter removed, documented re- assessment for the appropriateness of filter removal, or documentation of at least two attempts to reach the patient to arrange a clinical re-assessment for the appropriateness of filter removal within 3 months of placement	
G9547	Incidental finding: liver lesion <= 0.5 cm, cystic kidney lesion < 1.0 cm or adrenal lesion <= 1.0 cm	
G9548	Final reports for abdominal imaging studies with follow-up imaging recommended	

G9549	Documentation of medical reason(s) that follow-up imaging is	
ĺ	indicated (e.g., patient has a known malignancy that can metastasize,	
ĺ	other medical reason(s) such as fever in an immunocompromised	
	patient)	
G9550	Final reports for abdominal imaging studies with follow-up imaging not	
G9550		
	recommended	
G9551	Final reports for abdominal imaging studies without an incidentally	
ĺ	found lesion noted: liver lesion <= 0.5 cm, cystic kidney lesion < 1.0	
ĺ	cm or adrenal lesion <= 1.0 cm noted or no lesion found	
ĺ		
G9552	Incidental thyroid nodule < 1.0 cm noted in report	
G9553	Prior thyroid disease diagnosis	
G9554	Final reports for ct, cta, mri or mra of the chest or neck or ultrasound	
	of the neck with follow-up imaging recommended	
G9555	Documentation of medical reason(s) for recommending follow up	
ĺ	imaging (e.g., patient has multiple endocrine neoplasia, patient has	
ĺ	cervical lymphadenopathy, other medical reason(s))	
ĺ		
COFFC	Final reports for at ata mri ar mre of the about or needs or ultrescound	
G9556	Final reports for ct, cta, mri or mra of the chest or neck or ultrasound	
	of the neck with follow-up imaging not recommended	
G9557	Final reports for ct, cta, mri or mra studies of the chest or neck or	
ĺ	ultrasound of the neck without an incidentally found thyroid nodule <	
ĺ	1.0 cm noted or no nodule found	
G9558		
G9558	Patient treated with a beta-lactam antibiotic as definitive therapy	
G9559	Documentation of medical reason(s) for not prescribing a beta-lactam	
ĺ	antibiotic (e.g., allergy, intolerance to beta-lactam antibiotics)	
ĺ		
G9560	Patient not treated with a beta-lactam antibiotic as definitive therapy,	
03300	reason not given	
00504	· ·	
G9561	Patients prescribed opiates for longer than six weeks	
G9562	Patients who had a follow-up evaluation conducted at least every	
	three months during opioid therapy	
G9563	Patients who did not have a follow-up evaluation conducted at least	
ĺ	every three months during opioid therapy	
G9573	Remission at six months as demonstrated by a six month (+/-30 days)	
000.0	phq-9 score of less than five	
G9574	Remission at six months not demonstrated by a six month (+/-30	
G9374	•	
ĺ	days) phq-9 score of less than five; either phq-9 score was not	
	assessed or is greater than or equal to five	
G9577	Patients prescribed opiates for longer than six weeks	
G9578	Documentation of signed opioid treatment agreement at least once	
1	during opioid therapy	
00555	No documentation of signed an opioid treatment agreement at least	
(19570		
G9579		
	once during opioid therapy	
G9580	once during opioid therapy  Door to puncture time of less than 2 hours	
	once during opioid therapy	
G9580	once during opioid therapy  Door to puncture time of less than 2 hours	
G9580	once during opioid therapy  Door to puncture time of less than 2 hours	
G9580 G9582	once during opioid therapy  Door to puncture time of less than 2 hours  Door to puncture time of greater than 2 hours, no reason given	
G9580 G9582 G9583	once during opioid therapy  Door to puncture time of less than 2 hours  Door to puncture time of greater than 2 hours, no reason given  Patients prescribed opiates for longer than six weeks  Patient evaluated for risk of misuse of opiates by using a brief	
G9580 G9582 G9583	once during opioid therapy  Door to puncture time of less than 2 hours  Door to puncture time of greater than 2 hours, no reason given  Patients prescribed opiates for longer than six weeks  Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient	
G9580 G9582 G9583 G9584	once during opioid therapy  Door to puncture time of less than 2 hours  Door to puncture time of greater than 2 hours, no reason given  Patients prescribed opiates for longer than six weeks  Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy	
G9580 G9582 G9583	once during opioid therapy  Door to puncture time of less than 2 hours  Door to puncture time of greater than 2 hours, no reason given  Patients prescribed opiates for longer than six weeks  Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy  Patient not evaluated for risk of misuse of opiates by using a brief	
G9580 G9582 G9583 G9584	once during opioid therapy  Door to puncture time of less than 2 hours  Door to puncture time of greater than 2 hours, no reason given  Patients prescribed opiates for longer than six weeks  Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy  Patient not evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient not	
G9580 G9582 G9583 G9584	once during opioid therapy  Door to puncture time of less than 2 hours  Door to puncture time of greater than 2 hours, no reason given  Patients prescribed opiates for longer than six weeks  Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy  Patient not evaluated for risk of misuse of opiates by using a brief	
G9580 G9582 G9583 G9584	once during opioid therapy  Door to puncture time of less than 2 hours  Door to puncture time of greater than 2 hours, no reason given  Patients prescribed opiates for longer than six weeks  Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy  Patient not evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient not	
G9580 G9582 G9583 G9584	once during opioid therapy  Door to puncture time of less than 2 hours  Door to puncture time of greater than 2 hours, no reason given  Patients prescribed opiates for longer than six weeks  Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy  Patient not evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient not interviewed at least once during opioid therapy  Pediatric patient with minor blunt head trauma classified as low risk	
G9580 G9582 G9583 G9584 G9585	once during opioid therapy  Door to puncture time of less than 2 hours  Door to puncture time of greater than 2 hours, no reason given  Patients prescribed opiates for longer than six weeks  Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy  Patient not evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient not interviewed at least once during opioid therapy  Pediatric patient with minor blunt head trauma classified as low risk according to the pecarn prediction rules	
G9580 G9582 G9583 G9584	once during opioid therapy  Door to puncture time of less than 2 hours  Door to puncture time of greater than 2 hours, no reason given  Patients prescribed opiates for longer than six weeks  Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy  Patient not evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient not interviewed at least once during opioid therapy  Pediatric patient with minor blunt head trauma classified as low risk according to the pecarn prediction rules  Patient presented within 24 hours of a minor blunt head trauma with a	
G9580 G9582 G9583 G9584 G9585	once during opioid therapy  Door to puncture time of less than 2 hours  Door to puncture time of greater than 2 hours, no reason given  Patients prescribed opiates for longer than six weeks  Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy  Patient not evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient not interviewed at least once during opioid therapy  Pediatric patient with minor blunt head trauma classified as low risk according to the pecarn prediction rules	
G9580 G9582 G9583 G9584 G9585	once during opioid therapy  Door to puncture time of less than 2 hours  Door to puncture time of greater than 2 hours, no reason given  Patients prescribed opiates for longer than six weeks  Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy  Patient not evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient not interviewed at least once during opioid therapy  Pediatric patient with minor blunt head trauma classified as low risk according to the pecarn prediction rules  Patient presented within 24 hours of a minor blunt head trauma with a gcs score of 15 and had a head ct ordered for trauma by an	

G9595	Patient has documentation of ventricular shunt, brain tumor,	
	coagulopathy, including thrombocytopenia	
G9596	Pediatric patient's head injury occurred greater than 24 hours before	
	presentation to the emergency department, or has a gcs score less	
	than 15 or does not have a gcs score documented, or had a head ct	
	for trauma ordered by someone other than an emergency care	
	provider, or was ordered for a reason other than trauma	
G9597	Pediatric patient with minor blunt head trauma not classified as low	
	risk according to the pecarn prediction rules	
G9598	Aortic aneurysm 5.5 - 5.9 cm maximum diameter on centerline	
	formatted ct or minor diameter on axial formatted ct	
G9599	Aortic aneurysm 6.0 cm or greater maximum diameter on centerline	
	formatted ct or minor diameter on axial formatted ct	
G9600	Symptomatic aaas that required urgent/emergent (non-elective) repair	
G9601	Patient discharge to home no later than post-operative day #7	
G9602	Patient not discharged to home by post-operative day #7	
G9603	Patient survey score improved from baseline following treatment	
G9604	Patient survey results not available	
G9605	Patient survey score did not improve from baseline following treatment	
G9606	Intraoperative cystoscopy performed to evaluate for lower tract injury	
00000	minuspolario ejerescopi periorinea le eralacio isi iener ilactiju.ij	
G9607	Documented medical reasons for not performing intraoperative	
	cystoscopy (e.g., urethral pathology precluding cystoscopy, any	
	patient who has a congenital or acquired absence of the urethra)	
G9608	Intraoperative cystoscopy not performed to evaluate for lower tract	
	injury	
G9609	Documentation of an order for anti-platelet agents	
G9610	Documentation of medical reason(s) in the patient's record for not ordering anti-platelet agents	
G9611	Order for anti-platelet agents was not documented in the patient's	
G9612	record, reason not given	
G9012	Photodocumentation of one or more cecal landmarks to establish a complete examination	
G9613	Documentation of post-surgical anatomy (e.g., right hemicolectomy,	
00011	ileocecal resection, etc.)	
G9614	No photodocumentation of cecal landmarks to establish a complete examination	
G9615	Preoperative assessment documented	
G9616	Documentation of reason(s) for not documenting a preoperative	
	assessment (e.g., patient with a gynecologic or other pelvic	
	malignancy noted at the time of surgery)	
G9617	Preoperative assessment not documented, reason not given	
G9618	Documentation of screening for uterine malignancy or those that had	
G9618		
G9618 G9620	Documentation of screening for uterine malignancy or those that had an ultrasound and/or endometrial sampling of any kind	
	Documentation of screening for uterine malignancy or those that had	
	Documentation of screening for uterine malignancy or those that had an ultrasound and/or endometrial sampling of any kind  Patient not screened for uterine malignancy, or those that have not	
	Documentation of screening for uterine malignancy or those that had an ultrasound and/or endometrial sampling of any kind  Patient not screened for uterine malignancy, or those that have not had an ultrasound and/or endometrial sampling of any kind, reason	
G9620	Documentation of screening for uterine malignancy or those that had an ultrasound and/or endometrial sampling of any kind  Patient not screened for uterine malignancy, or those that have not had an ultrasound and/or endometrial sampling of any kind, reason not given  Patient identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method and	
G9620	Documentation of screening for uterine malignancy or those that had an ultrasound and/or endometrial sampling of any kind  Patient not screened for uterine malignancy, or those that have not had an ultrasound and/or endometrial sampling of any kind, reason not given  Patient identified as an unhealthy alcohol user when screened for	
G9620	Documentation of screening for uterine malignancy or those that had an ultrasound and/or endometrial sampling of any kind  Patient not screened for uterine malignancy, or those that have not had an ultrasound and/or endometrial sampling of any kind, reason not given  Patient identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method and received brief counseling  Patient not identified as an unhealthy alcohol user when screened for	
G9620 G9621	Documentation of screening for uterine malignancy or those that had an ultrasound and/or endometrial sampling of any kind  Patient not screened for uterine malignancy, or those that have not had an ultrasound and/or endometrial sampling of any kind, reason not given  Patient identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method and received brief counseling	
G9620 G9621 G9622	Documentation of screening for uterine malignancy or those that had an ultrasound and/or endometrial sampling of any kind  Patient not screened for uterine malignancy, or those that have not had an ultrasound and/or endometrial sampling of any kind, reason not given  Patient identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method and received brief counseling  Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method	
G9620 G9621	Documentation of screening for uterine malignancy or those that had an ultrasound and/or endometrial sampling of any kind  Patient not screened for uterine malignancy, or those that have not had an ultrasound and/or endometrial sampling of any kind, reason not given  Patient identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method and received brief counseling  Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method  Documentation of medical reason(s) for not screening for unhealthy	
G9620 G9621 G9622	Documentation of screening for uterine malignancy or those that had an ultrasound and/or endometrial sampling of any kind  Patient not screened for uterine malignancy, or those that have not had an ultrasound and/or endometrial sampling of any kind, reason not given  Patient identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method and received brief counseling  Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method	

00004	Detication to a second for subscript, a least of a second consistency	
G9624	Patient not screened for unhealthy alcohol screening using a	
	systematic screening method or patient did not receive brief	
COGOE	counseling, reason not given	
G9625	Patient sustained bladder injury at the time of surgery or discovered	
00000	subsequently up to 1 month post-surgery	
G9626	Documented medical reason for not reporting bladder injury (e.g.,	
	gynecologic or other pelvic malignancy documented, concurrent	
	surgery involving bladder pathology, injury that occurs during urinary incontinence procedure, patient death from non-medical causes not	
	related to surgery, patient died during procedure without evidence of	
	bladder injury)	
G9627	Patient did not sustain bladder injury at the time of surgery nor	
00000	discovered subsequently up to 1 month post-surgery	
G9628	Patient sustained bowel injury at the time of surgery or discovered	
_	subsequently up to 1 month post-surgery	
G9629	Documented medical reasons for not reporting bowel injury (e.g.,	
	gynecologic or other pelvic malignancy documented, planned (e.g.,	
	not due to an unexpected bowel injury) resection and/or re-	
	anastomosis of bowel, or patient death from non-medical causes not	
	related to surgery, patient died during procedure without evidence of	
	bowel injury)	
G9630	Patient did not sustain a bowel injury at the time of surgery nor	
	discovered subsequently up to 1 month post-surgery	
G9631	Patient sustained ureter injury at the time of surgery or discovered	
	subsequently up to 1 month post-surgery	
G9632	Documented medical reasons for not reporting ureter injury (e.g.,	
	gynecologic or other pelvic malignancy documented, concurrent	
	surgery involving bladder pathology, injury that occurs during a urinary	
	incontinence procedure, patient death from non-medical causes not	
	related to surgery, patient died during procedure without evidence of	
	ureter injury)	
G9633	Patient did not sustain ureter injury at the time of surgery nor	
	discovered subsequently up to 1 month post-surgery	
G9634	Health-related quality of life assessed with tool during at least two	
	visits and quality of life score remained the same or improved	
G9635	Health-related quality of life not assessed with tool for documented	
	reason(s) (e.g., patient has a cognitive or neuropsychiatric impairment	
	that impairs his/her ability to complete the hrqol survey, patient has	
	the inability to read and/or write in order to complete the hrqol	
	questionnaire)	
G9636	Health-related quality of life not assessed with tool during at least two	
	visits or quality of life score declined	
G9637	Final reports with documentation of one or more dose reduction	
	techniques (e.g., automated exposure control, adjustment of the ma	
	and/or kv according to patient size, use of iterative reconstruction	
	technique)	
G9638	Final reports without documentation of one or more dose reduction	
	techniques (e.g., automated exposure control, adjustment of the ma	
	and/or kv according to patient size, use of iterative reconstruction	
	technique)	
G9639	Major amputation or open surgical bypass not required within 48 hours	
	of the index endovascular lower extremity revascularization procedure	
G9640	Documentation of planned hybrid or staged procedure	
G9641	Major amputation or open surgical bypass required within 48 hours of	
	the index endovascular lower extremity revascularization procedure	
	,	
	I I	
G9642	Current smokers (e.g., cigarette, cigar, pine, e-cigarette or marijuana)	
G9642	Current smokers (e.g., cigarette, cigar, pipe, e-cigarette or marijuana)	
9642	Current smokers (e.g., cigarette, cigar, pipe, e-cigarette or marijuana)  Elective surgery	

G9644	Patients who abstained from smoking prior to anesthesia on the day of surgery or procedure	
G9645	Patients who did not abstain from smoking prior to anesthesia on the	
00010	day of surgery or procedure	
G9646	Patients with 90 day mrs score of 0 to 2	
G9647	Patients in whom mrs score could not be obtained at 90 day follow-up	
G9648	Patients with 90 day mrs score greater than 2	
G9649	Psoriasis assessment tool documented meeting any one of the specified benchmarks (e.g., (pga; 6-point scale), body surface area (bsa), psoriasis area and severity index (pasi) and/or dermatology life quality index) (dlqi))	
G9651	Psoriasis assessment tool documented not meeting any one of the specified benchmarks (e.g., (pga; 6-point scale), body surface area (bsa), psoriasis area and severity index (pasi) and/or dermatology life quality index) (dlqi)) or psoriasis assessment tool not documented	
G9654	Monitored anesthesia care (mac)	
G9655	A transfer of care protocol or handoff tool/checklist that includes the required key handoff elements is used	
G9656	Patient transferred directly from anesthetizing location to pacu	
G9658	A transfer of care protocol or handoff tool/checklist that includes the required key handoff elements is not used	
G9659	Patients greater than 85 years of age who did not have a history of colorectal cancer or valid medical reason for the colonoscopy, including: iron deficiency anemia, lower gastrointestinal bleeding, crohn's disease (i.e., regional enteritis), familial adenomatous polyposis, lynch syndrome (i.e., hereditary non-polyposis colorectal cancer), inflammatory bowel disease, ulcerative colitis, abnormal finding of gastrointestinal tract, or changes in bowel habits	
G9660	Documentation of medical reason(s) for a colonoscopy performed on a patient greater than 85 years of age (e.g., last colonoscopy incomplete, last colonoscopy had inadequate prep, iron deficiency anemia, lower gastrointestinal bleeding, crohn's disease (i.e., regional enteritis), familial history of adenomatous polyposis, lynch syndrome (i.e., hereditary non-polyposis colorectal cancer), inflammatory bowel disease, ulcerative colitis, abnormal finding of gastrointestinal tract, or changes in bowel habits)	
G9661	Patients greater than 85 years of age who received a routine colonoscopy for a reason other than the following: an assessment of signs/symptoms of gi tract illness, and/or the patient is considered high risk, and/or to follow-up on previously diagnosed advance lesions	
G9662	Previously diagnosed or have an active diagnosis of clinical ascvd	
G9663	Any fasting or direct ldl-c laboratory test result = 190 mg/dl	
G9664	Patients who are currently statin therapy users or received an order	
0000=	(prescription) for statin therapy	
G9665	Patients who are not currently statin therapy users or did not receive an order (prescription) for statin therapy	
G9666	The highest fasting or direct ldl-c laboratory test result of 70-189 mg/dl in the measurement period or two years prior to the beginning of the measurement period	
G9674	Patients with clinical ascvd diagnosis	
G9675	Patients who have ever had a fasting or direct laboratory result of ldl-c = 190 mg/dl	

G9676	Patients aged 40 to 75 years at the beginning of the measurement	
	period with type 1 or type 2 diabetes and with an Idl-c result of 70?189	
	ļ, , , , , , , , , , , , , , , , , , ,	
	mg/dl recorded as the highest fasting or direct laboratory test result in	
	the measurement year or during the two years prior to the beginning	
	of the measurement period	
	'	
G9678	Oncology care model (ocm) monthly enhanced oncology services	
	(meos) payment for ocm enhanced services. g9678 payments may	
	only be made to ocm practitioners for ocm beneficiaries for the	
	furnishment of enhanced services as defined in the ocm participation	
	agreement	
G9679	This code is for onsite acute care treatment of a nursing facility	
	resident with pneumonia; may only be billed once per day per	
	beneficiary	
G9680	This code is for onsite acute care treatment of a nursing facility	
	resident with chf; may only be billed once per day per beneficiary	
	,,,,,,,	
G9681	This code is for onsite acute care treatment of a resident with copd or	
	asthma; may only be billed once per day per beneficiary	
G9682	This code is for the onsite acute care treatment a nursing facility	
G9002	9 ,	
	resident with a skin infection; may only be billed once per day per	
	beneficiary	
H2016	Comprehensive community support services, per diem	
J0725	Injection, Chorionic Gonadotropin, Per 1,000 Usp Units	
	·	
J0178	Injection, Aflibercept 1 mg	
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized	
	(e.g. liquid), 500 mg	
J1557	Injection, immune globulin, (gammaplex), intravenous, non-lyophilized	
31337		
	(e.g., liquid), 500 mg	
J1559	Injection, immune globulin (hizentra), 100 mg	
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized	
	(e.g., liquid), 500 mg	
J1566	Injection, immune globulin, intravenous, lyophilized (e.g., powder), not	
31200		
	otherwise specified, 500 mg	
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized	
	(e.g., liquid), 500 mg	
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g.,	
31309		
	liquid), 500 mg	
J1572	Injection, immune globulin, (flebogamma/flebogamma dif),	
	intravenous, non-lyophilized (e.g., liquid), 500 mg	
J1599	Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid),	
3 1333		
	not otherwise specified, 500 mg	
J1610	Injection, glucagon HCL, per 1mg	
J1620	Injection, Gonadorelin Hydrochloride, Per 100 Mcg	
J1815	Injection, insulin, per 5 units	
J1817	Insuline for administration through DME per 50 units (insulin pump)	
31017	misume for administration through Divic per 50 units (insulin pump)	
J2323	Injection, natalizumab, 1 mg	
J2778	INJECTION RANIBIZUMAB 0.1 MG	
J3300	INJ TRIAMCINOLONE ACETONIDE PF	
	INJ TRIAMCINOLONE ACETONIDE	
J3301		
J3355	Injection, urofollotropin, 75IU	
J3396	INJECTION VERTEPORFIN 0.1 MG	
J3490	Unclassified drugs (when used for the reimbursement of prescription	
	oral antidiabetes agents)	
10570	- '	<del> </del>
J3570	Laetrile Therapy	
J3590	Unclassified biologics	
J7312	INJ DEXAMETH INTRAVIT IMPL 0.1	
J9199	Injection, gemcitabine hydrochloride (infugem), 200 mg	PPAP
J9309	Injection, polatuzumab vedotin-piiq, 1 mg	PPAP
		LLA
K0005	Ultralightweight wheelchair	

K0010	Standard-weight frame motorized/power wheelchair	
K0011	Standard-weight frame motorized/power wheelchair with	
	programmable control parameters for speed adjustment, tremor	
	dampening, acceleration control and braking	
K0012	Lightweight portable motorized/power wheelchair	
K0013	Custom motorized/power wheelchair base	
K0014	Other motorized/power wheelchair base	
K0065	Spoke protectors, each	
K0098	Drive belt for power wheelchair	
K0733	Power wheelchair accessory, 12 to 24 amp hour sealed lead acid	
110700	battery, each	
K0455	Infusion pump used for uninterrupted administration of epoprostenol	
K0553	Supply allowance for therapeutic continuous glucose monitor (CGM), includes all supplies and accessories, 1 month supply = 1 Unit Of Service	
K0554	Receiver (monitor), dedicated, for use with therapeutic glucose continuous monitor system	
K0601	Replacement battery for external infusion pump owned by patient, silver	
K0602	Replacement battery for external infusion pump owned by patient, silver	
K0603	Replacement battery for external infusion pump owned by patient, alkaline	
K0604	Replacement battery for external infusion pump owned by patient, lith.	
K0605	Replacement battery for external infusion pump owned by patient, lith.	
K0669	Wheelchair accessory, wheelchair seat or back cushion, does not meet specific code criteria or no written coding verification from DME PDAC	
K0740	Repair or nonroutine service for oxygen equipment requiring the skill of a technician, labor component, per 15 minutes	
K0800	Power operated vehicle, group 1 standard, patient weight capacity up to and including 300 pounds	
K0801	Power operated vehicle, group 1 heavy duty, patient weight capacity, 301 to 450 pounds	
K0802	Power operated vehicle, group 1 heavy duty, patient weight capacity 451 to 600 pounds	
K0806	Powered operated vehicle, group 2 standard, patient weight capacity up to and including 300 pounds	
K0807	K0807: Power operated vehicle, group 2 heavy duty, patient weight capacity 301 to 450 pounds	
K0808	K0808: Power operated vehicle, group 2 very heavy duty, patient weight capacity 451 to 600 pounds	
K0812	Power operated vehicle, not otherwise classified	
K0813	Power wheelchair, group 1 standard, portable, sling/solid seat and back, patient weight capacity up to and including 300 pounds	
K0814	Power wheelchair, group 1 standard, portable, captain's chair, patient weight capacity up to and including 300 pounds	
K0815	Power wheelchair, group 1 standard, portable, sling/solid seat and back, patient weight capacity up to and including 300 pounds	
K0816	Power wheelchair, group 1 standard, captain's chair, patient weight capacity up to and including 300 pounds	
K0820	Power wheelchair, group 2 standard, portable, sling/solid seat/back, patient weight capacity up to and including 300 pounds	
K0821	Power wheelchair, group 2 standard, portable, captain's chair, patient weight capacity up to and including 300 pounds	

K0822	Power wheelchair, group 2 standard, sling/solid seat/back, patient weight capacity up to and including 300 pounds	
K0823	Power wheelchair, group 2 standard, captain's chair, patient weight	
	capacity up to and including 300 pounds	
K0824	Power wheelchair, group 2 heavy duty, sling/solid seat and back,	
K0825	patient weight capacity 301 to 450 pounds  Power wheelchair, group 2 heavy duty, captain's chair, patient weight	
110020	capacity 301 to 450 pounds	
K0826	Power wheelchair, group 2 very heavy duty, sling/solid seat/back,	
	patient weight capacity 451 to 600 pounds	
K0827	Power wheelchair, group 2 very heavy duty, captain's chair, patient weight capacity 451 to 600 pounds	
K0828	Power wheelchair, group 2 extra very heavy duty, sling/solid seat/back, patient weight capacity 601 pounds or more	
K0829	Power wheelchair, group 2 extra heavy duty, captain's chair, patient	
	weight capacity 601 pounds or more	
K0835	Power wheelchair, group 2 standard, single power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds	
K0836	Power wheelchair, group 2 standard, single power option, captain's	
	chair, patient weight capacity up to and including 300 pounds	
K0837	Power wheelchair, group 2 heavy duty, single power option, sling/solid	
	seat/back, patient weight capacity 301 to 450 pounds	
K0838	Power wheelchair, group 2 heavy duty, single power option, captain's	
	chair, patient weight capacity 301 to 450 pounds	
K0839	Power wheelchair, group 2 very heavy duty, single power option, sling/solid seat/back, patient weight capacity 451 to 600 pounds	
K0840	Power wheelchair, group 2 very heavy duty, single power option,	
1.0010	sling/solid seat/back, patient weight capacity 601 pounds or more	
K0841	Power wheelchair, group 2 standard, multiple power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds	
K0842	Power wheelchair, group 2 standard, multiple power option, captain's	
	chair, patient weight capacity up to and including 300 pounds	
K0843	Power wheelchair, group 2 heavy duty, multiple power option,	
	sling/solid seat/back, patient weight capacity 301 to 450 pounds	
K0848	Power wheelchair, group 3 standard, sling/solid seat/back, patient weight capacity up to and including 300 pounds	
K0849	Power wheelchair, group 3 standard, captain's chair, patient weight	
KUSEU	capacity up to and including 300 pounds	
K0850	Power wheelchair, group 3 heavy duty, sling/solid seat/back, patient weight capacity 301 to 450 pounds	
K0851	Power wheelchair, group 3 heavy duty, captain's chair, patient weight capacity 301 to 450 pounds	
K0852	Power wheelchair, group 3 very heavy duty, sling/solid seat/back,	
	patient weight capacity 451 to 600 pounds	
K0853	Power wheelchair, group 3 very heavy duty, captain's chair, patient weight capacity 451 to 600 pounds	
K0854	Power wheelchair, group 3 extra heavy duty, sling/solid seat/back, patient weight capacity 601 pounds or more	
K0855	Power wheelchair, group 3 extra heavy duty, captain's chair, patient weight capacity 601 pounds or more	
K0856	Power wheelchair, group 3 standard, single power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds	
	boarback, patient weight capacity up to and including 500 pourids	
	<del></del>	

K0857	Power wheelchair, group 3 standard, single power option, captain's	
	chair, patient weight capacity up to and including 300 pounds	
K0858	Power wheelchair, group 3 heavy duty, single power option, sling/solid	
	seat/back, patient weight capacity 301 to 450 pounds	
K0859	Power wheelchair, group 3 heavy duty, single power option, captain's	
	chair, patient weight capacity 301 to 450 pounds	
K0860	Power wheelchair, group 3 very heavy duty, single power option,	
	sling/solid seat/back, patient weight capacity 451 to 600 pounds	
K0861	Power wheelchair, group 3 standard, multiple power option, sling/solid	
	seat/back, patient weight capacity up to and including 300 pounds	
K0862	Power wheelchair, group 3 heavy duty, multiple power option,	
	sling/solid seat/back, patient weight capacity 301 to 450 pounds	
K0863	Power wheelchair, group 3 very heavy duty, multiple power option,	
	sling/solid seat/back, patient weight capacity 451 to 600 pounds	
K0864	Power wheelchair, group 3 extra heavy duty, multiple power option,	
	sling/solid seat/back, patient weight capacity 601 pounds or more	
K0868	Power wheelchair, group 4 standard, sling/solid seat/back, patient	
	weight capacity up to and including 300 pounds	
K0869	Power wheelchair, group 4 standard, captain's chair, patient weight capacity up to and including 300 pounds	
K0870	Power wheelchair, group 4 heavy duty, sling/solid seat/back, patient	
	weight capacity 301 to 450 pounds	
K0871	Power wheelchair, group 4 very heavy duty, sling/solid seat/back, patient weight capacity 451 to 600 pounds	
K0877	Power wheelchair, group 4 standard, single power option, sling/solid	
	seat/back, patient weight capacity up to and including 300 pounds	
K0878	Power wheelchair, group 4 standard, single power option, captain's	
	chair, patient weight capacity up to and including 300 pounds	
K0879	Power wheelchair, group 4 heavy duty, single power option, sling/solid	
	seat/back, patient weight capacity 301 to 450 pounds	
K0880	Power wheelchair, group 4 very heavy duty, single power option,	
	sling/solid seat/back, patient weight capacity 451 to 600 pounds	
K0884	Power wheelchair, group 4 standard, multiple power option, sling/solid	
	seat/back, patient weight capacity up to and including 300 pounds	
K0885	Power wheelchair, group 4 standard, multiple power option, captain's	
10000	chair, patient weight capacity up to and including 300 pounds	
K0886	Power wheelchair, group 4 heavy duty, multiple power option,	
1.0000	sling/solid seat/back, patient weight capacity 301 to 450 pounds	
K0890	Power wheelchair, group 5 pediatric, single power option, sling/solid	
	seat/back, patient weight capacity up to and including 125 pounds	
K0891	Power wheelchair, group 5 pediatric, multiple power option, sling/solid	
	seat/back, patient weight capacity up to and including 125 pounds	
K0898	Power wheelchair, not otherwise classified	
K0899	Power mobility device, or does not meet criteria	
K1001	Electronic positional obstructive sleep apnea treatment, with sensor,	
	includes all components and accessories, any type	

1// 000	To	T
K1002	Cranial electrotherapy stimulation (ces) system, includes all supplies	
1// 000	and accessories, any type	
K1003	Whirlpool tub, walk-in, portable	
K1004	Low frequency ultrasonic diathermy treatment device for home use, includes all components and accessories	
K1005	Disposable collection and storage bag for breast milk, any size, any type, each	
L0220	Thoracic rib belt custom made	
L0452	TLSO, flexible, provides trunk support, upper thoracic region, produces intracavitary pressure to reduce load on the intervertebral disks with rigid stays or panel(s), includes shoulder straps and closures, custom fabricated	
L0460	TLSO, triplanar control, modular segmented spinal system, two rigid plastic shells, posterior extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, anterior extends from the symphysis pubis to the sternal notch, soft liner, restricts gross trunk motion in the sagittal, coronal, and transverse planes, lateral strength is provided by overlapping plastic and stabilizing closures, includes straps and closures, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise	
L0480	TLSO, triplanar control, one piece rigid plastic shell without interface liner, with multiple straps and closures, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to sternal notch, anterior or posterior opening, restricts gross trunk motion in sagittal, coronal, and transverse planes, includes a carved plaster or cad-cam model, custom fabricated	
L0482	TLSO, triplanar control, one piece rigid plastic shell with interface liner, multiple straps and closures, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to sternal notch, anterior or posterior opening, restricts gross trunk motion in sagittal, coronal, and transverse planes, includes a carved plaster or cad-cam model, custom fabricated	
L0484	TLSO, triplanar control, two piece rigid plastic shell without interface liner, with multiple straps and closures, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to sternal notch, lateral strength is enhanced by overlapping plastic, restricts gross trunk motion in the sagittal, coronal, and transverse planes, includes a carved plaster or cad-cam model, custom fabricated	
L0486	TLSO, triplanar control, two piece rigid plastic shell with interface liner, multiple straps and closures, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to sternal notch, lateral strength is enhanced by overlapping plastic, restricts gross trunk motion in the sagittal, coronal, and transverse planes, includes a carved plaster or CAD-CAM model, custom fabricated	
L1945	IDEO and ExoSym Energy Storing AFO	
L2006	Knee ankle foot device, any material, single or double upright, swing and/or stance phase microprocessor control with adjustability, includes all components (e.g., sensors, batteries, charger), any type activation, with or without ankle joint(s), custom fabricated	
L2190	Waist/gait belt	

1.0040	Taire of a second second	
L2210	Additions to lower extremity orthosis, dorsiflexion assist	
L2232	Addition to lower extremity orthosis, rocker bottom for total contact	
	ankle foot orthosis, for custom fabricated orthosis only	
L2250	Addition to lower extremity, foot plate, molded to patient model, stirrup	
	attachment	
L2270	Additions to lower extremity orthosis, varus/valgus T-strap	
L2275	Additions to lower extremity orthosis, varus/valgus correction	
L2280	Addition to lower extremity, molded inner boot	
L2320	Addition to lower extremity, non-molded lacer, for custom fabricated	
	orthosis only	
L2330	Addition to lower extremity, lacer molded to patient model, for custom	
	fabricated orthosis only	
L2340	Addition to lower extremity, pre-tibial shell, molded to patient model	
L2350	Addition to lower extremity, prosthetic type, (BK) socket, molded to	
	patient model	
L2385	Addition to lower extremity orthosis, straight knee joint	
L2387	Addition to lower extremity, polycentric knee joint, for custom	
	fabricated knee ankle foot orthosis, each joint	
L2405	Additions to straight knee or offset knee, drop lock	
L2510	Addition to lower extremity, thigh/weight bearing, quadri-lateral brim,	
	molded to patient model	
L2520	Addition to lower extremity, thigh/weight bearing, quadri-lateral brim,	
	custom fitted	
L2525	Addition to lower extremity, thigh/weight bearing, ischial	
	containment/narrow M-L brim, molded to patient model	
L2526	Addition to lower extremity, thigh/weight bearing, ischial	
	containment/narrow M-L brim, custom fitted	
L2540	Addition to lower extremity, thigh/weight bearing, lacer, molded to	
	patient model	
L2627	Addition to lower extremity, pelvic control, plastic, molded to patient	
1.0755	model, reciprocating hip joint and cables	
L2755	Addition to lower extremity orthosis, high strength, lightweight	
	material, all hybrid lamination/prepreg composite, per segment, for custom fabricated orthosis only	
1.0705	,	
L2795	Additions to lower extremity orthesis, knee control	
L2800	Addition to lower extremity orthosis, knee control, knee cap, medial or	
	lateral pull, for use with custom fabricated orthosis only	
L2820	Addition to lower pytromity outhoris, poft interface for molded plactic	
L2020	Addition to lower extremity orthosis, soft interface for molded plastic,	
1 2020	below knee section  Addition to lower extremity orthosis, soft interface for molded plastic,	
L2830	above knee section	
L2861	Addition to lower extremity joint, knee or ankle, concentric adjustable	
L2001	torsion style mechanism for custom fabricated orthotics only	
	torsion style mechanism for eastern labilicated offilolies only	
L2999	Lower extremity orthosis, NOS	
L3170	Foot plastic heel stabilizer	
L3201	Ortho shoe Oxford infant	
L3201	Ortho shoe Oxford fillall	
L3203	Ortho shoe Oxford junior	
L3204	Ortho shoe hightop infant	
L3206	Ortho shoe hightop child	
L3207	Ortho shoe hightop junior	
L3215	Ortho shoes ladies Oxford	
L3216	Ortho shoes ladies depth inlay	
L3217	Ortho shoes ladies hightop	
L3219	Ortho shoes mens Oxford	
L3221	Ortho shoes mens depth inlay	
L3222	Ortho shoes mens hightop	
L3230	Orthopedic footwear, custom shoe, depth inlay, each	
	, ,	<u> </u>

L3250	Orthopedic footwear, custom molded shoe, removable inner mold,	
	prosthetic shoe, each	
L3251	Foot, shoe molded to patient model, silicone shoe, each	
L3252	Foot, shoe molded to patient model, silicone shoe, each	
L3253	Foot, molded shoe Plastazote (or similar) custom fitted, each	
L3254	Non-standard size or width	
L3255	Non-standard size or length	
L3257	Orthopedic footwear, additional charge for split size	
L3300	Lift elevation heel	
L3320	Lift elevation heel & sole	
L3330	Lift elevation metal extension	
L3332	Lift elevation inside shoe	
L3340	Heel wedge sach	
L3350	Heel wedge	
L3360	Sole wedge outside sole	
L3370	Sole wedge between sole	
L3380	Clubfoot wedge	
L3390	Outflare wedge	
L3999	Upper limb orthosis, NOS	
L3400	Metatarsal bar wedge rocker	
L3400 L3410	Metatarsal bar wedge rocker  Metatarsal bar wedge betw sole	
L3410 L3420		
L3420 L3430	Full sole & heel wedge betw sole	
	Heel counter plastic reinforced  Heel counter leather reinforced	
L3440		
L3450	Heel sach cushion type	
L3455	Heel new leather std	
L3460	Heel new rubber std	
L3465	Heel thomas w/wedge	
L3470	Heel thomas extended to ball	
L3480	Heel pad & depression spur	
L3485	Heel pad removable spur	
L3500	Orthopedic shoe addition, insole, leather	
L3510	Orthopedic shoe addition, insole, rubber	
L3520	Orthopedic shoe addition, insole, felt covered w/leather	
L3530	Orthopedic shoe addition, sole, half	
L3540	Orthopedic shoe addition, sole, full	
L3550	Orthopedic shoe addition, toe tap, standard	
L3560	Orthopedic shoe addition, toe tap, horseshoe	
L3570	Orthopedic shoe addition, special extension to instep (leather w/eyelets)	
L3580	Orthopedic shoe addition, convert instep to Velcro closure	
L3590	Orthopedic shoe addition, convert firm shoe counter to soft counter	
L3595	Orthopedic shoe addition, march bar	
L3649	Orthopedic shoe, modification, addition or transfer, not otherwise specified	
L3671	Shoulder orthosis, shoulder joint design, without joints, may include soft interface, straps, custom fabricated, includes fitting and	
L3672	adjustment Shoulder orthosis, abduction positioning (airplane design), thoracic	
	component and support bar, without joints, custom fabricated	
L3673	Shoulder orthosis, abduction positioning (airplane design), thoracic component and support bar, includes nontorsion joint/turnbuckle, custom fabricated	
L3674	Shoulder orthosis, abduction positioning (airplane design), thoracic component and support bar, with or without nontorsion joints/turnbuckle, custom fabricated	
L3677	Shoulder orthosis, shoulder joint design, without joints, customized to fit a specific patient by an individual with expertise	
L3702	Elbow orthosis, without joints, custom fabricated	
	LEIDON OLLIODIO, WILIOUL JOHNO, DUGIOHI IADHUAIGU	

L3720	Elbow orthosis, double upright with forearm/arm cuffs, free motion,	
	custom fabricated	
L3730	Elbow orthosis, double upright with forearm/arm cuffs,	
1 2740	extension/flexion assist, custom fabricated  Elbow orthosis, double upright with forearm/arm cuffs, adjustable	
L3740	position lock with active control, custom fabricated	
L3763	Elbow wrist hand orthosis, rigid, without joints, custom fabricated	
	, , ,	
L3764	Elbow wrist hand orthosis, includes one or more nontorsion joints,	
	elastic bands, turnbuckles, may include soft interface, straps, custom	
L3765	fabricated, includes fitting and adjustment  Elbow wrist hand finger orthosis, rigid, without joints, custom	
L3703	fabricated	
L3766	Elbow wrist hand finger orthosis, includes one or more nontorsion joints, elastic bands, turnbuckles, custom fabricated	
L3800	Wrist hand finger orthosis, short opponens, no attachments, custom fabricated	
L3805	Wrist hand finger orthosis, long opponens, no attachments, custom fabricated	
L3806	Wrist hand finger orthosis, includes one or more nontorsion joint(s), turnbuckles, elastic bands/springs, custom fabricated	
L3807	Wrist hand finger orthosis, without joint(s), customized to fit a specific patient by an individual with expertise	
L3808	Wrist hand finger orthosis, rigid without joints, custom fabricated	
L3891	Addition to upper extremity joint, wrist or elbow, concentric adjustable torsion style mechanism for custom fabricated orthotics only, each	
L3900	Wrist hand finger orthosis, dynamic flexor hinge, reciprocal wrist extension/flexion, finger flexion/extension, wrist or finger driven, custom fabricated	
L3901	Wrist hand finger orthosis, dynamic flexor hinge, reciprocal wrist extension/flexion, finger flexion/extension, cable driven, custom fabricated	
L3902	Wrist hand finger orthosis, external powered, compressed gas, custom fabricated	
L3904	Wrist hand finger orthosis, external powered	
L3905	Wrist hand orthosis, includes one or more nontorsion joints, elastic bands, turnbuckles, custom fabricated	
L3906	Wrist hand orthosis, without joints, custom fabricated	
L3907	Wrist hand orthosis, wrist gauntlet with thumb spica, custom fabricated	
L3913	Hand finger orthosis, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment	
L3915	Wrist hand orthosis, includes one or more nontorsion joints, elastic bands, turnbuckles, customized to fit a specific patient by an individual with expertise	
L3917	Hand orthosis, metacarpal fracture orthosis, customized to fit a specific patient by an individual with expertise	
L3919	Hand orthosis, without joints, custom fabricated	
L3921	Hand finger orthosis, includes one or more nontorsion joints, elastic bands, turnbuckles, custom fabricated	
L3923	Hand finger orthosis, without joints, may include soft interface, straps, customized to fit a specific patient by an individual with expertise	
L3929	Hand finger orthosis, includes one or more nontorsion joints, elastic bands, turnbuckles, customized to fit a specific patient by an individual with expertise	
L3933	Finger orthosis, without joints, custom fabricated	•

L3935	Finger orthosis, nontorsion joint, may include soft interface, custom	
L3961	fabricated, includes fitting and adjustment  Shoulder elbow wrist hand orthosis, shoulder cap design, without	
L3301	joints, custom fabricated	
L3963	Shoulder elbow wrist hand orthosis, molded shoulder, arm, forearm	
	and wrist, with articulating elbow joint, custom fabricated	
L3967	Shoulder elbow wrist hand orthosis, abduction positioning (airplane	
	design), thoracic component and support bar, without joints, custom	
L3971	fabricated  Shoulder allow write hand orthogic aboutles can design includes and	
L3971	Shoulder elbow wrist hand orthosis, shoulder cap design, includes one or more nontorsion joints, elastic bands, turnbuckles, custom	
	fabricated	
L3973	Shoulder elbow wrist hand orthosis, abduction positioning (airplane	
	design), thoracic component and support bar, custom fabricated	
L3975	Shoulder elbow wrist hand finger orthosis, shoulder cap design,	
	without joints, custom fabricated	
L3976	Shoulder elbow wrist hand finger orthosis, abduction positioning	
	(airplane design), thoracic component and support bar, without joints, custom fabricated	
L3977	Shoulder elbow wrist hand finger orthosis, shoulder cap design,	
L3311	includes one or more nontorsion joints, elastic bands, turnbuckles,	
	custom fabricated	
L3978	Shoulder elbow wrist hand finger orthosis, abduction positioning	
	(airplane design), thoracic component and support bar, includes one	
	or more nontorsion joints, elastic bands, turnbuckles, custom	
	fabricated	
L3985	Upper extremity fracture orthosis, forearm, hand with wrist hinge,	
L3986	custom fabricated  Upper extremity fracture orthosis, combination of humeral,	
L3900	radius/ulnar, wrist, (example - Colles' fracture), custom fabricated	
	radias anal, whot, (example Golles Hastars), castom rashoated	
L4020	Replace quadrilateral socket brim, molded to patient model	
L4030	Replace quadrilateral socket brim, custom fitted	
L4040	Replace molded thigh lacer, for custom fabricated orthosis only	
L4045	Replace non-molded thigh lacer, for custom fabricated orthosis only	
21010	Tropiado fiori molada angir lador, for dadiom ladificatoa dialectic diny	
L4050	Replace molded calf lacer, for custom fabricated orthosis only	
L4055	Replace non-molded calf lacer, for custom fabricated orthosis only	
L4396	Static or dynamic ankle foot orthosis, including soft interface material,	
	adjustable for fit, for positioning, customized to fit a specific patient by an individual with expertise	
L4631	Ankle foot orthosis, walking boot type, varus/valgus correction, rocker	
L4031	bottom, anterior tibial shell, soft interface, custom fabricated	
	,	
L5000	Partial foot, shoe insert with longitudinal arch, toe filler	
L5010	Partial foot, molded socket, ankle height, with toe filler	
L5020	Partial foot, molded socket, tibial tubercle height, with toe filler	
L5050	Ankle, Symes, molded socket, SACH foot	
L5060	Ankle, Symes, metal frame, molded leather socket, articulated ankle/foot	
L5100	Below knee, molded socket, shin, SACH foot	
L5105	Below knee, plastic socket, joints and thigh lacer, SACH foot	
L5150	Knee disarticulation (or through knee), molded socket, external knee	
	joints, shin, SACH foot	
L5160	Knee disarticulation (or through knee), molded socket, bent knee	
	configuration, external knee joints, shin, SACH foot	
L5200	Above knee, molded socket, single axis constant friction knee, shin,	
	SACH foot	

L5210	Above knee, short prosthesis, no knee joint ('stubbies'), with foot blocks, no ankle joints, each
L5220	Above knee, short prosthesis, no knee joint ('stubbies'), with articulated ankle/foot, dynamically aligned, each
L5230	Above knee, for proximal femoral focal deficiency, constant friction knee, shin, SACH foot
L5250	Hip disarticulation, Canadian type, molded socket, hip joint, single axis
L5270	constant friction knee, shin, SACH foot  Hip disarticulation, tilt table type, molded socket, locking hip joint,
L5280	single axis constant friction knee, shin, SACH foot  Hemipelvectomy, Canadian type, molded socket, hip joint, single axis
L5300	constant friction knee, shin, SACH foot  Below knee, molded socket, SACH foot, endoskeletal system,
	including soft cover and finishing
L5301	Below knee, molded socket, shin, SACH foot, endoskeletal system
L5310	Knee disarticulation (or through knee), molded socket, SACH foot endoskeletal system
L5311	Knee disarticulation (or through knee), molded socket, external knee joints, shin, SACH foot, endoskeletal system
L5312	Knee disarticulation molded socket, single axis knee pylon sach foot endoskeletal system
L5320	Above knee, molded socket, open end, SACH foot, endoskeletal system, single axis knee, including soft cover and finishing
L5321	Above knee, molded socket, open end, SACH foot, endoskeletal system, single axis knee
L5330	Hip disarticulation, Canadian type, molded socket, endoskeletal system, hip joint, single axis knee, SACH foot, including soft cover and finishing
L5331	Hip disarticulation, Canadian type, molded socket, endoskeletal system, hip joint, single axis knee, SACH foot
L5340	Hemipelvectomy, Canadian type, molded socket, endoskeletal system, hip joint, single axis knee, SACH foot, including soft cover and finishing
L5341	Hemipelvectomy, Canadian type, molded socket, endoskeletal system, hip joint, single axis knee, SACH foot
L5400	Immediate post surgical or early fitting, application of initial rigid dressing, including fitting, alignment, suspension, and one cast change, below knee
L5410	Immediate post surgical or early fitting, application of initial rigid dressing, including fitting, alignment, suspension, below knee, each additional cast change and realignment
L5420	Immediate post surgical or early fitting, application of initial rigid dressing, including fitting, alignment, suspension, and one cast change 'AK' or knee disarticulation
L5430	Immediate post surgical or early fitting, application of initial rigid dressing, including fitting, alignment, suspension, 'AK' or knee disarticulation, each additional cast change and realignment
L5450	Immediate post surgical or early fitting, application of non-weight bearing rigid dressing, below knee
L5460	Immediate post surgical or early fitting, application of non-weight bearing rigid dressing, above knee
L5500	Initial, below knee 'ptb' type socket, non-alignable system, pylon, no cover, SACH foot, plaster socket, direct formed
L5505	Initial, above knee - knee disarticulation, ischial level socket, non- alignable system
L5510	Preparatory, below knee 'ptb' type socket, non-alignable system, pylon, no cover, SACH foot, plaster socket, molded to model

L5520	Preparatory, below knee 'ptb' type socket, non-alignable system,	
	pylon, no cover, SACH foot, thermoplastic or equal, direct formed	
	pylon, no dovor, externious, anomopiadad or equal, anoderennous	
L5530	Preparatory, below knee 'ptb' type socket, non-alignable system,	
	pylon, no cover, SACH foot, thermoplastic or equal, molded to model	
	,, , , , , , , , , , , , , , , , , , , ,	
L5535	Preparatory, below knee 'ptb' type socket nonalignable system, no	
	cover, SACH foot, prefabricated	
L5540	Preparatory, below knee 'ptb' type socket nonalignable system, pylon,	
L3340		
	no cover, SACH foot, laminated socket, molded to model	
L5560	Preparatory, above knee- knee disarticulation, ischial level socket,	
L0000		
	non-alignable system, pylon, no cover, SACH foot, plaster socket,	
	molded to model	
L5570	Preparatory, above knee- knee disarticulation, ischial level socket,	
20070	· · · · · · · · · · · · · · · · · · ·	
	non-alignable system, pylon, no cover, SACH foot, thermoplastic or	
	equal, direct formed	
L5580	Preparatory, above knee- knee disarticulation, ischial level socket,	
	non-alignable system, pylon, no cover, SACH foot, thermoplastic or	
	equal, molded to model	
L5585	Preparatory, above knee- knee disarticulation, ischial level socket,	
	non-alignable system, pylon, no cover, SACH foot, prefabricated	
	Tion alignable system, pylon, no cover, o'Aor rioot, prefabilitated	
L5590	Preparatory, above knee- knee disarticulation, ischial level socket,	
	non-alignable system, pylon, no cover, SACH foot, laminated socket	
	There alignable by storm, pyron, the seven, or territoot, farininated section	
L5595	Preparatory, hip disarticulation-hemipelvectomy, pylon, no cover,	
	SACH foot, thermoplastic or equal, molded to patient model	
	error, monoplastic or equal, molacula to patient mouse	
L5600	Preparatory, hip disarticulation-hemipelvectomy, pylon, no cover,	
1		
1 5610	SACH foot, laminated socket, molded to patient model	
L5610	SACH foot, laminated socket, molded to patient model Hydracadence system	
L5610 L5611	SACH foot, laminated socket, molded to patient model	
	SACH foot, laminated socket, molded to patient model Hydracadence system	
	SACH foot, laminated socket, molded to patient model  Hydracadence system  Addition to lower extremity, endoskeletal system, above knee-knee	
L5611	SACH foot, laminated socket, molded to patient model  Hydracadence system  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control	
	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee	
L5611	SACH foot, laminated socket, molded to patient model  Hydracadence system  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control	
L5611	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee	
L5611 L5613	SACH foot, laminated socket, molded to patient model  Hydracadence system  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control	
L5611	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee	
L5611 L5613	SACH foot, laminated socket, molded to patient model  Hydracadence system  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control	
L5611 L5613	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee	
L5613	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control	
L5611 L5613	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee,	
L5614 L5616	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control	
L5613	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee,	
L5614 L5616 L5617	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit	
L5614 L5616 L5617 L5618	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes	
L5611 L5613 L5614 L5616 L5617 L5618 L5620	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee	
L5614 L5616 L5617 L5618	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes	
L5611 L5613 L5614 L5616 L5617 L5618 L5620	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee	
L5614 L5616 L5617 L5618 L5620 L5722	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee  Knee-shin pneumatic swing	
L5611 L5613 L5614 L5616 L5617 L5618 L5620 L5722 L5724	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee  Knee-shin pneumatic swing  Single axis, fluid swing phase control	
L5611 L5613 L5614 L5616 L5617 L5618 L5620 L5722 L5724 L5726	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee  Knee-shin pneumatic swing  Single axis, fluid swing phase control Single axis, external joints fluid swing phase control	
L5611 L5613 L5614 L5616 L5617 L5618 L5620 L5722 L5724	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee  Knee-shin pneumatic swing  Single axis, fluid swing phase control	
L5611 L5613 L5614 L5616 L5617 L5618 L5620 L5722 L5724 L5726 L5728	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee  Knee-shin pneumatic swing  Single axis, fluid swing phase control  Single axis, fluid swing and stance phase control	
L5611 L5613 L5614 L5616 L5617 L5618 L5620 L5722 L5724 L5726 L5728 L5629	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee  Knee-shin pneumatic swing  Single axis, fluid swing phase control Single axis, fluid swing and stance phase control Addition to lower extremity, below knee, acrylic socket	
L5611 L5613 L5614 L5616 L5617 L5618 L5620 L5722 L5724 L5726 L5728 L5629 L5629 L5630	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee  Knee-shin pneumatic swing  Single axis, fluid swing phase control Single axis, fluid swing and stance phase control Addition to lower extremity, below knee, acrylic socket Symes type expandable wall socket	
L5611 L5613 L5614 L5616 L5617 L5618 L5620 L5722 L5724 L5726 L5728 L5629	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee  Knee-shin pneumatic swing  Single axis, fluid swing phase control Single axis, fluid swing and stance phase control Addition to lower extremity, below knee, acrylic socket	
L5611 L5613 L5614 L5616 L5617 L5618 L5620 L5722 L5724 L5726 L5728 L5629 L5629 L5630 L5631	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee  Knee-shin pneumatic swing  Single axis, fluid swing phase control Single axis, fluid swing and stance phase control Addition to lower extremity, below knee, acrylic socket Symes type expandable wall socket Above knee disarticulated acrylic socket	
L5611 L5613 L5614 L5616 L5617 L5618 L5620 L5722 L5724 L5726 L5728 L5629 L5630 L5631 L5632	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee  Knee-shin pneumatic swing  Single axis, fluid swing phase control Single axis, fluid swing and stance phase control Addition to lower extremity, below knee, acrylic socket Symes type expandable wall socket Above knee disarticulated acrylic socket Symes type 'PTB' brim design socket	
L5611 L5613 L5614 L5616 L5617 L5618 L5620 L5722 L5724 L5726 L5728 L5629 L5630 L5631 L5632 L5634	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee  Knee-shin pneumatic swing  Single axis, fluid swing phase control Single axis, fluid swing and stance phase control Addition to lower extremity, below knee, acrylic socket Symes type expandable wall socket Above knee disarticulated acrylic socket Symes type poster opening socket	
L5611 L5613 L5614 L5616 L5617 L5618 L5620 L5722 L5724 L5726 L5728 L5629 L5630 L5631 L5632 L5634 L5636	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee  Knee-shin pneumatic swing  Single axis, fluid swing phase control  Single axis, fluid swing and stance phase control Addition to lower extremity, below knee, acrylic socket  Symes type expandable wall socket  Above knee disarticulated acrylic socket  Symes type PTB' brim design socket  Symes type poster opening socket  Symes type medial opening socket	
L5611 L5613 L5614 L5616 L5617 L5618 L5620 L5722 L5724 L5726 L5728 L5629 L5630 L5631 L5632 L5634	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee  Knee-shin pneumatic swing  Single axis, fluid swing phase control Single axis, fluid swing and stance phase control Addition to lower extremity, below knee, acrylic socket Symes type expandable wall socket Above knee disarticulated acrylic socket Symes type poster opening socket	
L5611 L5613 L5614 L5616 L5617 L5618 L5620 L5722 L5724 L5726 L5728 L5629 L5630 L5631 L5632 L5634 L5636 L5637	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee Knee-shin pneumatic swing  Single axis, fluid swing phase control Single axis, fluid swing and stance phase control Addition to lower extremity, below knee, acrylic socket Symes type expandable wall socket Above knee disarticulated acrylic socket Symes type poster opening socket Symes type medial opening socket Below knee total contact	
L5611  L5613  L5614  L5616  L5617  L5618  L5620  L5722  L5724  L5726  L5728  L5629  L5630  L5631  L5632  L5634  L5636  L5637  L5638	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee Knee-shin pneumatic swing  Single axis, fluid swing phase control Single axis, fluid swing and stance phase control Addition to lower extremity, below knee, acrylic socket Symes type expandable wall socket Above knee disarticulated acrylic socket Symes type poster opening socket Symes type poster opening socket Below knee total contact Below knee leather socket	
L5611  L5613  L5614  L5616  L5617  L5618  L5620  L5722  L5724  L5726  L5728  L5629  L5630  L5631  L5632  L5634  L5636  L5637  L5638  L5639	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee Knee-shin pneumatic swing  Single axis, fluid swing phase control Single axis, external joints fluid swing phase control Addition to lower extremity, below knee, acrylic socket Symes type expandable wall socket Above knee disarticulated acrylic socket Symes type poster opening socket Symes type medial opening socket Below knee total contact Below knee leather socket Below knee wood socket	
L5611  L5613  L5614  L5616  L5617  L5618  L5620  L5722  L5724  L5726  L5728  L5629  L5630  L5631  L5632  L5634  L5636  L5637  L5638	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee Knee-shin pneumatic swing  Single axis, fluid swing phase control Single axis, fluid swing and stance phase control Addition to lower extremity, below knee, acrylic socket Symes type expandable wall socket Above knee disarticulated acrylic socket Symes type poster opening socket Symes type poster opening socket Below knee total contact Below knee leather socket	
L5611  L5613  L5614  L5616  L5617  L5618  L5620  L5722  L5724  L5726  L5728  L5629  L5630  L5631  L5632  L5634  L5636  L5637  L5638  L5639	SACH foot, laminated socket, molded to patient model Hydracadence system Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with friction swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with hydraulic swing phase control  Addition to lower extremity, endoskeletal system, above knee-knee disarticulation, 4 bar linkage, with pneumatic swing phase control  Addition to lower extremity, endoskeletal system, above knee, universal multiplex system, friction swing phase control  Addition to lower extremity, quick change self-aligning unit Addition to lower extremity, test socket, Symes Addition to lower extremity, test socket, below knee Knee-shin pneumatic swing  Single axis, fluid swing phase control Single axis, external joints fluid swing phase control Addition to lower extremity, below knee, acrylic socket Symes type expandable wall socket Above knee disarticulated acrylic socket Symes type poster opening socket Symes type medial opening socket Below knee total contact Below knee leather socket Below knee wood socket	

1.5040	It the flexible income and at external frame.	<del></del>
L5643	Hip flexible inner socket external frame	
L5644	Above knee wood socket	
L5645	Above knee flexible inner socket external frame	
L5646	Below knee air cushion socket	
L5647	Below knee suction socket	
L5648	Above knee air cushion socket	
L5649	Ischial containment/narrow M-L socket	
L5650	Total contact above knee disarticulation socket	
L5651	Above knee, flexible inner socket external frame	
L5652	Suction suspension, above knee or knee disarticulation socket	
L5653	Knee disarticulation expand wall socket	
L5654	Socket insert, Symes, (Kemblo, Pelite, Aliplast, Plastazote or equal)	
L5655	Socket insert below knee	
L5656	Socket insert knee disarticulation	
L5658	Socket insert above knee	
L5660	Socket insert, Symes, silicone gel or equal	
L5661	Socket insert, multi-durometer Symes	
	·	
L5662	Socket insert, below knee, silicone gel or equal	+
L5663	Socket insert, knee disarticulation, silicone gel or equal	<del> </del>
L5664	Socket insert, above knee, silicone gel or equal	
L5665	Multi-durometer below knee	
L5666	Below knee cuff suspension	
L5667	Below knee/above knee, socket insert, suction suspension with	
	locking mechanism	
L5668	Addition to lower extremity, below knee, molded distal cushion	
L5669	Below knee/above knee, socket insert, suction suspension without	
	locking mechanism	
L5670	Below knee, molded supracondylar suspension ('PTS' or similar)	
L5671	Addition to lower extremity, below knee/above knee suspension	
	locking mechanism	
L5672	Below knee removable medial brim suspension	
L5673	Socket insert w locking mechanism	
L5674	Below knee, suspension sleeve	
L5675	Below knee, suspension sleeve, heavy duty	
L5676	Below knee joints single axis, pair	
		+
L5677	Below knee joints polycentric, pair	
L5678	Below knee joint covers, pair	
L5679	Socket insert w/o locking mechanism	
L5680	Below knee, thigh lacer, non-molded	
L5681	Below knee/above knee, with or without locking mechanism	
L5682	Below knee, thigh lacer, gluteal/ischial, molded	
L5683	Initial custom socket insert	
L5684	Below knee fork strap	
L5686	Below knee back check	†
L5688	Below knee waist belt webbing	<u> </u>
L5690	Below knee waist belt webbing  Below knee waist belt padded and lined	
	·	<u> </u>
II EGOO		
L5692	Above knee pelvic control belt light	
L5694	Above knee pelvic control belt padded and lined	
L5694 L5695	Above knee pelvic control belt padded and lined Above knee sleeve suspension neoprene or equal	
L5694 L5695 L5696	Above knee pelvic control belt padded and lined Above knee sleeve suspension neoprene or equal Above knee disarticulation pelvic joint	
L5694 L5695 L5696 L5697	Above knee pelvic control belt padded and lined Above knee sleeve suspension neoprene or equal Above knee disarticulation pelvic joint Above knee disarticulation pelvic band	
L5694 L5695 L5696 L5697 L5698	Above knee pelvic control belt padded and lined Above knee sleeve suspension neoprene or equal Above knee disarticulation pelvic joint	
L5694 L5695 L5696 L5697	Above knee pelvic control belt padded and lined Above knee sleeve suspension neoprene or equal Above knee disarticulation pelvic joint Above knee disarticulation pelvic band	
L5694 L5695 L5696 L5697 L5698	Above knee pelvic control belt padded and lined Above knee sleeve suspension neoprene or equal Above knee disarticulation pelvic joint Above knee disarticulation pelvic band Above knee disarticulation Silesian bandage	
L5694 L5695 L5696 L5697 L5698 L5699 L5700	Above knee pelvic control belt padded and lined Above knee sleeve suspension neoprene or equal Above knee disarticulation pelvic joint Above knee disarticulation pelvic band Above knee disarticulation Silesian bandage Shoulder harness	
L5694 L5695 L5696 L5697 L5698 L5699 L5700 L5701	Above knee pelvic control belt padded and lined Above knee sleeve suspension neoprene or equal Above knee disarticulation pelvic joint Above knee disarticulation pelvic band Above knee disarticulation Silesian bandage Shoulder harness Replace socket below knee Replace socket above knee	
L5694 L5695 L5696 L5697 L5698 L5699 L5700 L5701 L5702	Above knee pelvic control belt padded and lined Above knee sleeve suspension neoprene or equal Above knee disarticulation pelvic joint Above knee disarticulation pelvic band Above knee disarticulation Silesian bandage Shoulder harness Replace socket below knee Replace socket above knee Replace socket hip	
L5694 L5695 L5696 L5697 L5698 L5699 L5700 L5701	Above knee pelvic control belt padded and lined Above knee sleeve suspension neoprene or equal Above knee disarticulation pelvic joint Above knee disarticulation pelvic band Above knee disarticulation Silesian bandage Shoulder harness Replace socket below knee Replace socket above knee Replace socket hip Ankle, Symes, molded to patient model, socket without solid ankle	
L5694 L5695 L5696 L5697 L5698 L5699 L5700 L5701 L5702 L5703	Above knee pelvic control belt padded and lined Above knee sleeve suspension neoprene or equal Above knee disarticulation pelvic joint Above knee disarticulation pelvic band Above knee disarticulation Silesian bandage Shoulder harness Replace socket below knee Replace socket above knee Replace socket hip Ankle, Symes, molded to patient model, socket without solid ankle cushion heel (SACH) foot, replacement only	
L5694 L5695 L5696 L5697 L5698 L5699 L5700 L5701 L5702 L5703	Above knee pelvic control belt padded and lined Above knee sleeve suspension neoprene or equal Above knee disarticulation pelvic joint Above knee disarticulation pelvic band Above knee disarticulation Silesian bandage Shoulder harness Replace socket below knee Replace socket above knee Replace socket hip Ankle, Symes, molded to patient model, socket without solid ankle cushion heel (SACH) foot, replacement only Custom shape cover below knee	
L5694 L5695 L5696 L5697 L5698 L5699 L5700 L5701 L5702 L5703	Above knee pelvic control belt padded and lined Above knee sleeve suspension neoprene or equal Above knee disarticulation pelvic joint Above knee disarticulation pelvic band Above knee disarticulation Silesian bandage Shoulder harness Replace socket below knee Replace socket above knee Replace socket hip Ankle, Symes, molded to patient model, socket without solid ankle cushion heel (SACH) foot, replacement only	

L5707	Custom shape cover hip disarticulation	
L5710	Knee-shin exoskeletal single axis manual lock	
L5711	Knee-shin exoskeletal manual lock ultra	
L5712	Knee-shin exoskeletal friction swing and stance phase control	
L5714	Knee-shin exoskeletal variable friction	
L5716	Knee-shin exoskeletal mechanical stance phase lock	
L5718	Knee-shin exoskeletal friction swing and stance phase control	
207.10	Turios orian oxecitorical motion owing and started privace control	
L5780	Single axis, pneumatic/hydra pneumatic swing phase control	
L5781	Addition to lower limb prosthesis, vacuum pump, residual limb volume management and moisture evacuation system	
L5782	Addition to lower limb prosthesis, vacuum pump, residual limb volume management and moisture evacuation system, heavy duty	
L5785	Exoskeletal below knee, ultra-light material	
L5790	Exoskeletal above knee, ultra-light material	
L5795	Exoskeletal hip ultra-light material	
L5814	Endoskeletal knee-shin hydraulic swing phase control	
L5822	Endoskeletal knee-shin pneumatic swing, friction stance phase control	
L5824	Endoskeletal knee-shin fluid swing phase control	
L5826	Single axis, hydraulic swing phase control, with miniature high activity frame	
L5828	Endoskeletal knee-shin fluid swing and stance phase control	
L5830	Endoskeletal knee-shin pneumatic/swing phase control	
L5840	4-bar linkage or multiaxial, pneumatic swing phase control	
L5846	Knee-shin system, microprocessor control feature, swing phase only	
L5810	Endoskeletal knee-shin manual lock	
L5811	Endoskeletal knee-shin manual lock ultra	
L5812	Endoskeletal knee-shin friction swing and stance phase control (safety knee)	
L5816	Endoskeletal knee-shin mechanical stance phase control	
L5818	Endoskeletal knee-shin friction swing and stance phase control	
L5845	Knee-shin system stance flexion feature	
L5847	Knee-shin system, microprocessor control feature, stance phase	
L5848	Add to endoskeletal knee-shin, hydraulic	
L5850	Endoskeletal above knee or hip disarticulation, knee extension assist	
L5855	Mechanical hip extension assist	
L5856	Addition to lower extremity prosthesis, endoskeletal knee shin system,	
	microprocessor control feature, swing and stance phase	
L5857	Addition to lower extremity prosthesis, endoskeletal knee shin system, microprocessor control feature, swing phase only	
L5858	Addition to lower extremity prosthesis, endoskeletal knee shin system, microprocessor control feature, stance phase only, includes electronic sensor(s), any type	
L5910	Endoskeletal below knee alignable system	
L5920	Endoskeletal above knee or hip disarticulation, alignable system	
L5925	Above knee manual lock	
_		

L5930	High activity know frama	
	High activity knee frame	
L5940	Addition, endoskeletal system, below knee, ultra-light material	
L5950	Addition, endoskeletal system, above knee, ultra-light material	
L5960	Addition, endoskeletal system, hip disarticulation, ultra-light material	
L5961	Addition, endoskeletal system, polycentric hip joint, pneumatic or hydraulic control	
L5962	Addition, endoskeletal system, below knee, flexible protective outer surface covering system	
L5964	Addition, endoskeletal system, above knee, flexible protective outer surface covering system	
L5966	Addition, endoskeletal system, hip disarticulation, flexible protective outer surface covering system	
L5968	All lower extremity prosthesis, multiaxial ankle	
L5969	Addition, endoskeletal ankle-foot or ankle system, power assist,	
L5970	All lower extremity prostheses, foot, external keel, SACH foot	
L5971	All lower extremity prosthesis, solid ankle cushion heel (SACH) foot, replacement only	
L5972	All lower extremity prostheses, flexible keel foot (Safe, Sten, Bock Dynamic or equal)	
L5973	Endoskeletal ankle foot system, microprocessor	
L5974	All lower extremity prostheses, foot, single axis ankle/foot	
L5975	All lower extremity prosthesis, combination single axis ankle and	
	flexible keel foot	
L5976	All lower extremity prostheses, energy storing foot (Seattle Carbon Copy II or equal)	
L5978	All lower extremity prostheses, foot, multi-axial ankle/foot	
L5979	All lower extremity prostheses, multi-axial ankle, dynamic response foot, one piece system	
L5980	All lower extremity prostheses, flex foot system	
L5981	All lower extremity prostheses, flex-walk system or equal	
L5982	All exoskeletal lower extremity prostheses, axial rotation unit	
L5984	All endoskeletal lower extremity prosthesis, axial rotation unit, with or without adjustability	
L5985	All endoskeletal lower extremity prostheses, dynamic prosthetic pylon	
L5986	All lower extremity prostheses, multi-axial rotation unit	
L5987	All lower extremity prostheses, shank foot system with vertical loading	
20007	pylon	
L5988	Addition to lower extremity prosthesis, vertical shock reducing pylon feature	
L5989	Addition to lower extremity prosthesis, endoskeletal system, pylon with integrated electronic force sensors	
L5990	Addition to lower extremity prosthesis, user adjustable heel height	
L5993	Addition to lower extremity prosthesis, heavy duty feature, foot only	
L5994	Addition to lower extremity prosthesis, heavy duty feature, knee only	
L5995	Addition to lower extremity prosthesis, heavy duty feature, other than foot or knee	
L5999	Lower extremity prosthesis, not otherwise specified	
L6000	Partial hand, thumb remaining	
L6010	Partial hand, little and/or ring finger remaining	
L6020	Partial hand, no finger remaining	
L6025	Transcarpal/partial hand disarticulation	
L6026	Transcarpal/metacarpal or partial had disarticulation prosthesis	
<u> </u>		

L6050	Wrist disarticulation, molded socket, flexible elbow hinges, triceps pad	
L6055	Wrist disarticulation, molded socket with expandable interface	
L6100	Below elbow, molded socket, flexible elbow hinge	
L6110	Below elbow, molded socket, (muenster or northwestern suspension types)	
L6120	Below elbow, molded double wall split socket, step-up hinges, half cuff	
L6130	Below elbow, molded double wall split socket, stump activated locking hinge	
L6200	Elbow disarticulation, molded socket, outside locking hinge, forearm	
L6205	Elbow disarticulation, molded socket with expandable interface	
L6250	Above elbow, molded double wall socket	
L6300	Shoulder disarticulation, molded socket	
L6310	Shoulder disarticulation, passive restoration (complete prosthesis)	
L6320	Shoulder disarticulation, passive restoration (shoulder cap only)	
L6350	Interscapular thoracic, molded socket	
L6360	Interscapular thoracic, passive restoration (complete prosthesis)	
L6370	Interscapular thoracic, passive restoration (shoulder cap only)	
L6380	Immediate post surgical or early fitting, wrist disarticulation or below elbow	
L6382	Immediate post surgical or early fitting, elbow disarticulation or above elbow	
L6384	Immediate post surgical or early fitting, shoulder disarticulation or interscapular thoracic	
L6386	Immediate post surgical or early fitting, each additional cast change and realignment	
L6388	Immediate post surgical or early fitting, application of rigid dressing only	
L6400	Below elbow, molded socket, endoskeletal system	
L6450	Elbow disarticulation, molded socket	
L6500	Above elbow, molded socket	
L6550	Shoulder disarticulation, molded socket, endoskeletal system	
L6570	Interscapular thoracic, molded socket, endoskeletal system	
L6580	Preparatory, wrist disarticulation or below elbow, molded to patient model	
L6582	Preparatory, wrist disarticulation or below elbow, direct formed	
L6584	Preparatory, elbow disarticulation or above elbow, molded to patient model	
L6586	Preparatory, elbow disarticulation or above elbow, direct formed	
L6588	Preparatory, shoulder disarticulation or interscapular thoracic, molded to patient model	
L6590	Preparatory, shoulder disarticulation or interscapular thoracic, direct formed	
L6600	Upper extremity additions, polycentric hinge	
L6605	Upper extremity additions, single pivot hinge	
L6610	Upper extremity additions, flexible metal hinge	
L6611	Addition to upper extremity prosthesis, external powered	
L6615	Upper extremity addition, disconnect locking wrist unit	
L6616	Upper extremity addition, additional disconnect insert	
L6620	Upper extremity addition, flexion/extension wrist unit	
L6621	Upper extremity prosthesis addition, flexion/extension wrist with or without friction, for use with external powered terminal device	

L6623	Upper extremity addition, spring assisted rotational wrist unit	
L6624	Flexion/extension and rotation wrist unit	
L6625		
	Upper extremity addition, rotation wrist unit with cable lock	
L6628	Quick disconnect hook adapter, Otto Bock or equal	
L6629	Lamination collar w/ coupling piece	
L6630	Stainless steel any wrist	
L6632	Latex suspension sleeve each	
L6635	Lift assist for elbow	
L6637	Nudge control elbow lock	
L6638	Upper extremity additions, electric locking	
L6639	Upper extremity additions, heavy duty feature, any elbow	
L6640	Upper extremity additions, shoulder abduction joint	
L6641	Upper extremity addition, excursion amplifier, pully type	
L6642	Upper extremity addition, excursion amplifier, lever type	
L6645	Upper extremity addition, shoulder flexion-abduction joint	
L6646	Upper extremity, shoulder joint	
L6647	Upper extremity, shoulder lock mechanism, body powered actuator	
L6648	Upper extremity, shoulder lock mechanism, external powered actuator	
L6650	Upper extremity addition, shoulder universal joint	
L6655	Upper extremity addition, standard control cable	
L6660	Upper extremity addition, heavy duty control cable	
L6665	Upper extremity addition, teflon or equal cable lining	
L6670	Upper extremity addition, hook to hand	
L6672	Upper extremity addition, harness, chest or shoulder	
L6675	Upper extremity addition, harness, single cable design	
L6676	Upper extremity addition, harness, dual cable design	
L6677	Upper extremity addition, harness, triple control, simultaneous	
20077	operation of terminal device and elbow	
L6680	Upper extremity addition, test socket, wrist disarticulation or below elbow	
L6682	Upper extremity addition, test socket, elbow disarticulation or above elbow	
L6684	Upper extremity addition, test socket, shoulder disarticulation or interscapular thoracic	
L6686	Upper extremity addition, suction socket	
L6687	Upper extremity addition, frame type socket, below elbow or wrist	
1.0000	disarticulation	
L6688	Upper extremity addition, frame type socket, above elbow or elbow disarticulation	
L6689	Upper extremity addition, frame type socket, shoulder disarticulation	
L6690	Upper extremity addition, frame type socket, interscapular-thoracic	
L6691	Upper extremity addition, removable insert	
L6692	Upper extremity addition, silicone gel insert or equal	
L6693	Upper extremity addition, locking elbow	
L6694	Elbow socket insert use with lock	
L6695	Elbow socket insert use without lock	
L6696	Custom elbow socket insert for congenital or atypical traumatic amputee	
L6697	Custom elbow socket insert not for congenital or atypical traumatic amputee	
L6698	Below/above elbow lock mechanism	
L6700	Terminal device, hook, Dorrance, model #3	
L6703	Terminal device, passive hand/mitt	
L6704	Terminal device, passive haramint  Terminal device, sport/recreational/work attachment, any material, any	
	size	
L6705	Terminal device, hook, Dorrance, model #5	

1.0700		
L6706	Terminal device mechanical hook voluntary opening	
L6707	Terminal device mechanical hook voluntary closing	
L6708	Terminal device mechanical hand voluntary opening	
L6709	Terminal device mechanical hand voluntary closing	
L6710	Terminal device, hook, Dorrance model #5X	
L6711	Pediatric terminal device, hook voluntary opening	
L6712	Pediatric terminal device, hook voluntary closing	<del>-</del>
L6713	Terminal device, hand voluntary opening	<del> </del>
L6714	Terminal device, hand voluntary opening  Terminal device, hand voluntary closing	+
	, ,	
L6715	Terminal device, multiple articulation digit includes motor(s) initial	
	issue or replacement	
L6720	Terminal device, hook, Dorrance model #6	
L6721	Terminal device, hook or hand voluntary opening	
L6722	Hook or hand voluntary closing	
L6725	Terminal device, hook, Dorrance model #7	
L6730	Terminal device, hook, Dorrance model #7LO	
L6735	Terminal device, hook, Dorrance model #8	<del>-</del>
L6740	Terminal device, hook, Dorrance model #8X	
L6745	Terminal device, hook, Dorrance model #88X	+
	·	
L6750	Terminal device, hook, Dorrance model #10P	+
L6755	Terminal device, hook, Dorrance model #10X	
L6765	Terminal device, hook, Dorrance model #12P	
L6770	Terminal device, hook, Dorrance model #99X	
L6775	Terminal device, hook, Dorrance model #555	
L6780	Terminal device, hook, Dorrance model #SS555	
L6790	Terminal device, hook-Accu hook	
L6795	Terminal device, hook-2 load	+
L6800	Terminal device, hook-APRL VC	-
L6805	,	_
	Terminal device, modifier wrist unit	
L6806	Terminal device, hook, TRS Grip	
L6807	Terminal device, hook, Grip	
L6808	Terminal device, hook, TRS Adept	
L6809	Terminal device, hook, TRS Super Sport	
L6810	Terminal device, pincher tool	
L6825	Terminal device, hand, Dorrance, VO	
L6830	Terminal device, hand, APRL, VC	7
L6835	Terminal device, hand, Sierra	
L6840	Terminal device, hand, Becker Imperial	+
		_
L6845	Terminal device, hand, Becker Lock Grip	
L6850	Terminal device, hand, Becker Plylite	
L6855	Terminal device, hand, Robin-Aids, VO	
L6860	Terminal device, hand, Robin-Aids, VO soft	
L6865	Terminal device, hand, passive hand	
L6867	Terminal device, hand, Detroit Infant Hand	
L6868	Terminal device, hand, passive infant hand	
L6870	Terminal device, hand, child mitt	7
L6872	Terminal device, hand, NYU child hand	-
L6873		+
	Terminal device, hand, mechanical infant hand	-
L6875	Terminal device, hand, Bock, VC	
L6880	Electric hand, switch or myoelectric controlled	
L6881	Automatic grasp feature, addition to upper limb electric prosthetic terminal device	
L6882	Microprocessor control feature	
L6883	Replacement socket, below elbow/wrist disarticulation, molded to	1
	patient model, for use with or without external power	
L6884	Replacement socket, above elbow disarticulation, molded to patient model, for use with or without external power	
L6885	Replacement socket, shoulder disarticulation/interscapular thoracic,	+
L0000	molded to patient model, for use with or without external power	
	Indiaca to patient model, for use with or without external power	
L6890	Production glove	
L6895	Custom glove	
		•

		<del></del>
L6900	Hand restoration thumb/1 finger	
L6905	Hand restoration multiple fingers	
L6910	Hand restoration no fingers	
L6915	Hand restoration replacement glove	
L6920	Wrist disarticulation switch control	
L6925	Wrist disarticulation myoelectronic control	
L0323	What disarticulation myociccitonic control	
1.0000	Delevi elkevi evitek eestrel	
L6930	Below elbow switch control	
L6935	Below elbow myoelectronic control	
L6940	Elbow disarticulation switch	
L6945	Elbow disarticulation myoelectronic control	
L6950	Above elbow switch control	
L6955	Above elbow myoelectronic control	
L6960	Shoulder disarticulation switch control	
L6965	Shoulder disarticulation myoelectronic	
L6970	Interscapular-thoracic switch control	
L6975	Interscapular-thoracic myoelectronic control	
L7007	Adult electric hand	+
L7008	Pediatric electric hand	
L7009	Adult electric hook	
L7010	Electronic hand, Otto Bock, switch controlled	
L7015	Electronic hand, System Teknik, switch controlled	
L7020	Electronic greifer, Otto Bock, switch controlled	
L7025	Electronic hand, Otto Bock, myoelectronically controlled	
L7030	Electronic hand, System Teknik, myoelectronically controlled	
L7035	Electronic greifer, Otto Bock, myoelectronically controlled	
L7040	Prehensile actuator, switch controlled	
L7045	Electric hook, pediatric	
L7170	Electronic elbow, Hosmer switch	
L7170	Electronic elbow, microprocessor sequential control	+
	· · · · · · · · · · · · · · · · · · ·	
L7181	Electronic elbow, microprocessor simultaneous control	
L7185	Electronic elbow, adolescent	
L7186	Electronic elbow, child	
L7190	Elbow adolescent myoelectronically controlled	
L7191	Elbow child myoelectronically controlled	
L7259	Electronic wrist rotator, any type	
L7260	Electronic wrist rotator, Otto Bock	
L7261	Electronic wrist rotator, Utah arm	
	,	
L7266	Servo control, Sleeper	†
L7272	Analogue control, UNB or equal	
L7274	Proportional control, 6-12 volt	+
		+
L7360	Six volt battery, Otto bock or equal	
L7362	Battery charger, six volt, Otto Bock	
L7364	Twelve volt battery, Utah	
L7366	Battery charger, twelve volt, each	
L7367	Lithium ion battery, replacement	
L7368	Lithium ion battery charger replacement only	
L7400	Addition to upper extremity prosthesis, below elbow/wrist	
	disarticulation, ultra light material (titanium, carbon fiber or equal)	
L7401	Addition to upper extremity prosthesis, above elbow disarticulation,	
''	ultra light material (titanium, carbon fiber or equal)	
L7402	Addition to upper extremity prosthesis, shoulder	+
L1402		
	disarticulation/interscapular thoracic, ultra light material (titanium,	
	carbon fiber or equal)	
L7403	Addition to upper extremity prosthesis, below elbow/wrist	
	disarticulation, acrylic material	
L7404	Addition to upper extremity prosthesis, above elbow disarticulation,	
<u> </u>	acrylic material	
		<del></del>

L7405	Addition to upper extremity prosthesis, shoulder	
	disarticulation/interscapular thoracic, acrylic material	
L7499	Upper extremity prosthesis, not otherwise specified	
L7500	Repair of prosthetic device, hourly rate	
L7510	Repair of prosthetic device, repair or replace minor parts	
L7510	Repair prosthetic device, labor component	
L7600	Prosthetic donning sleeve, any material, each	
L7611	Terminal device, hook, mechanical, voluntary opening, pediatric	
L7612	Terminal device, hook, mechanical, voluntary closing, pediatric	
L7613	Terminal device, hand, mechanical, voluntary opening, pediatric	
L7614	Terminal device, hand, mechanical, voluntary closing, pediatric	
L7621	Terminal device, hook or hand, mechanical, voluntary opening	
L7622	Terminal device, hook or hand, mechanical, voluntary opening	
	, ,	
L7900	Vacuum erection system	
L7902	Tension ring, vacuum erection device	
L8000	Breast prosthesis, mastectomy bra, without integrated breast	
	prosthesis form, any size, any type	
L8001	Breast prosthesis, mastectomy bra, with integrated breast prosthesis	
	form, unilateral, any size, any type	
L8002	Breast prosthesis, mastectomy bra, with integrated breast prosthesis	
	form, bilateral, any size, any type	
L8010	Breast prosthesis, mastectomy	
	, ,	
L8015	External breast prosthesis garment	
L8020	Breast prosthesis, mastectomy	
L8030	Breast prosthesis, silicone or with or without adhesive	
L8031	Breast prosthesis, silicone or equal w/integral adhesive	
L8032	Nipple prosthesis, reusable any type each	
L8033	Nipple prosthesis, custom fabricated, reusable, any material, any type,	
	each	
L8035	Custom breast prosthesis, post mastectomy	
L8039	Breast prosthesis, not otherwise specified	
L8040	Nasal prosthesis, provide by a non-physician	
L8041	Midfacial prosthesis, provided by a non-physician	
L8042	Orbit prosthesis, provided by a non-physician	
L8043	Upper/facial prosthesis, provided by a non-physician	
L8044	Hemi-facial prosthesis, provided by a non-physician	
L8045	Auricular prosthesis, provided by a non-physician	
L8046	Partial facial prosthesis, provided by a non-physician	
L8047	Nasal septal prosthesis, provided by a non-physician	
L8048	Unspecified maxillo-facial prosthesis, provided by a non-physician	
L8049	Repair or modification of maxillofacial prosthesis, provided by a non-	
20040	physician	
1.0400	, ,	
L8400	Prosthetic sheath, below knee	
L8410	Prosthetic sheath, above knee	
L8415	Prosthetic sheath, upper limb	
L8417	Prosthetic sheath/sock, include a gel cushion layer, below knee or	
<u> </u>	above knee	
L8420	Prosthetic sock, multiple ply, below knee	
L8430	Prosthetic sock, multiple ply, above knee	
L8435	Prosthetic sock, multiple ply, upper limb	
L8440	Prosthetic shrinker, below knee	
L8460	Prosthetic shrinker, above knee	
		1
L8465	Prosthetic shrinker, upper limb	
L8470	Prosthetic sock, single ply, below knee	
L8480	Prosthetic sock, single ply, above knee	
L8485	Prosthetic sock, single ply, upper limb	
L8490	Addition to prosthetic sheath/sock, air seal suction retention system	
L8499	Unlisted procedure for miscellaneous prosthetic services	
L8500	Artificial larynx, any type	
	J 7 J J	,

	Autiticial law year manifestation .	
L8505	Artificial larynx replacement battery	
L8507	Tracheo-esophageal voice prosthesis	
L8509	Tracheo-esophageal voice prosthesis	
L8510	Voice amplifier	
L8511	Insert for indwelling tracheoesophageal prosthesis, with or without	
	valve	
L8512	Gelatin capsules for use with tracheoesophageal voice prosthesis	
L8513	Tracheoesophageal voice prosthesis, cleaning devise	
L8514	Replacement tracheoesophageal puncture dilator	
L8515	Gelatin capsule, application device for tracheoesophageal voice prosthesis	
L8605	Injectable bulking agent	
L8607	Injectable bulking agent	
L8608	Miscellaneous external component, supply or accessory for use with the argus ii retinal prosthesis system	
L8609	Artificial cornea	
L8610	Ocular implant	
L8613	Ossicular implant	
L8614		
L8615	Cochlear device/system	
L8015	Headset/headpiece for use w/cochlear implant device, replacement	
L8616	Microphone for use w/cochlear implant device replacement	
L8617	Transmitting coil for use w/cochlear implant device replacement	
L8618	Transmitter cable for use w/cochlear implant device replacement	
L8619	Cochlear implant, external speech processor, integrated replacement	
L8620	Lithium ion battery for use with cochlear implant device	
L8621	Zinc air battery for use with cochlear implant device, replacement, each	
L8622	Alkaline battery for use with cochlear implant device	
L8623	Lithium ion battery for use with cochlear implant device speech	
	processor, other than ear level, replacement, each	
L8624	Lithium ion battery for use with cochlear implant device speech processor, ear level, replacement, each	
L8627	Cochlear implant, external speech processor, component replacement	
L8628	Cochlear implant, external controller component, replacement	
L8629	Transmitting coil for use w/cochlear implant device replacement	
L8690	Auditory osseointegrated device, includes all internal and external	
	components	
L8691	Auditory osseointegrated device, external sound processor, replacement	
L8692	Auditory osseointegrated device includes headband or other means of external attachment	
L8693	Auditory osseointegrated device abutment any length, replacement only	
L8695	External recharge system for battery, replacement only	
L8696	Antenna (external) for use with implantable diaphragmatic/phrenic	
L8698	nerve stimulation device  Miscellaneous component, supply or accessory for use with total	
1 0600	artificial heart system	
L8699	Prosthetic implant, not otherwise specified	
L8701	Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated	

hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated  Orthotic and prosthetic supply, accessory, and/or service component of another HCPCS "t" code  M0075 Cellular therapy  M01000 Intragastric hypothermia using gastric freezing  M0300 IV chelation therapy (chemical endaterectiony)  M0300 IV chelation therapy (chemical endaterectiony)  M0301 Fabric wrapping of abdominal aneurysm  M1106 The start of an episode of care documented in the medical record  M1107 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1108 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1109 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1110 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1111 The start of an episode of care documented in the medical record  M1111 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time befror or during the episode of care  M1111 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1111 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1111 Ongoing care not indicated, patient discharged after only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1111 Ongoing care no			
Lisado Orthotic and prosthetic supply, accessory, and/or service component of another HCPCS "L'code M0076 Poliotherapy M0100 Intragastric hypothermia using gastric freezing M1100 Intragastric hypothermia using gastric freezing M1100 Intragastric hypothermia using gastric freezing M1101 Fabric wrapping of abdominal aneuryam M1106 The start of an episode of care documented in the medical record M1107 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care M1108 Orgoning care not indicated, patient seen only 1:2 visits (e.g., home program only, referred to another provider or facility, consultation only) M1109 Orgoning care not indicated, patient seen only 1:2 visits (e.g., home program only, referred to another provider or facility, consultation only) M1109 Orgoning care not indicated, patient discharged after only 1:2 visits (e.g., home program only, referred to another provider or facility, consultation only) M1101 Orgoning care not indicated, patient discharged early and seen only 1:2 visits (e.g., financial or surgery or hospitalized M1110 Orgoning care not indicated, patient self-discharged early and seen only 1:2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown) M1111 The start of an episode of care documented in the medical record M1112 Ocumentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care M1111 Orgoning care not indicated, patient self-discharged early and seen only 1:2 visits (e.g., financial or insurance reasons, transportation only) M1111 Orgoning care not indicated, patient discharged after only 1:2 visits due to specific medical events, documented in the medical record that make the transment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized M1110 Orgoning care not indic	L8702	Powered upper extremity range of motion assist device, elbow, wrist,	
United and prosthetic supply, accessory, and/or service component of another HCPCS 'L' code  M0075 Cellust thrarpy Protothorapy M0076 Protothorapy M00776 Protothorapy M00776 Protothorapy M00776 Protothorapy M00776 Protothorapy M00776 Protothorapy M00777		hand, finger, single or double upright(s), includes microprocessor,	
United and prosthetic supply, accessory, and/or service component of another HCPCS 'L' code  M0075 Cellust thrarpy Protothorapy M0076 Protothorapy M00776 Protothorapy M00776 Protothorapy M00776 Protothorapy M00776 Protothorapy M00776 Protothorapy M00777		sensors, all components and accessories, custom fabricated	
of another HCPCS 1" code  M0076  Poliotherapy  M0076  Poliotherapy  M0076  Poliotherapy  M0076  Poliotherapy  IV chelation therapy (chemical endanterectomy)  M0001  Fabric wrapping of addominal aneuryam  M1106  This stan of an epsode of care documented in the medical record  M1107  Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1108  Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1109  Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized or problems, or reason unknown)  M1110  Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., hrancial or insurance reasons, transportation problems, or reason unknown)  M1111  The stant of an episode of care documented in the medical record  M1112  Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113  Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114  Ongoing care not indicated, patient self-discharged after only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1113  Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1116  The stant of an episode of care documented in the medical record that ma			
of another HCPCS 1" code  M0076  Poliotherapy  M0076  Poliotherapy  M0076  Poliotherapy  M0076  Poliotherapy  IV chelation therapy (chemical endanterectomy)  M0001  Fabric wrapping of addominal aneuryam  M1106  This stan of an epsode of care documented in the medical record  M1107  Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1108  Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1109  Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized or problems, or reason unknown)  M1110  Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., hrancial or insurance reasons, transportation problems, or reason unknown)  M1111  The stant of an episode of care documented in the medical record  M1112  Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113  Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114  Ongoing care not indicated, patient self-discharged after only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1113  Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1116  The stant of an episode of care documented in the medical record that ma	1 0000	Orthotic and proethetic supply accessory and/or service component	
M0076 Pototherapy M0100 Intragestric hypothermia using gastric freezing M0101 Fabric wrapping of abdominal aneurysm M1106 The start of an episode of care documented in the medical record M1107 Documentation stating patient has a diagnosis of a degenerative eneurological condition such as als, ms. or parkinson's diagnosed at any time before or during the episode of care M1108 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only) M1109 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medicial events, documented in the medical record that make the treatment episode inpossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized M1110 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown) M1111 The start of an episode of care documented in the medical record M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms. or parkinson's diagnosed at arry time before or during the episode of care M1113 Ongoing care not indicated, patient discharged after only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only) M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment peisode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized M1110 Ongoing care not indicated, patient self-discharged after only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only) M1119 Ongoing care n	L9900		
M0076 Integrated by the content of t	140075		
M0100 Intragastric hypothermia using gastric freezing M0300 IV betalton therapy (chemical endaterectory) M0301 Fabric wrapping of abdominal aneurysm M1107 The start of an episode of care documented in the medical record M1107 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care M1108 Ongoing care not indicated, patient discharged after only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only) M1109 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized M1110 Ongoing care not indicated, patient self-discharged aerly and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown) M1111 The start of an episode of care documented in the medical record M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only) M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized or scheduled for scheduled for surgery or ho			
M0301			
Millon			
M1106 The start of an episode of care documented in the medical record  M1107 Documentation stating patient has a diagnosis of a degenerative neurological condition such as alls, ms, or parkinson's diagnosed at any time before or during the episode of care  M1108 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1109 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1110 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1111 The start of an episode of care documented in the medical record  M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as alls, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Occumentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient self-discharged fair only 1-2 visits (e.g., home pr		77	
M1107 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care program only, referred to another provider or facility, consultation only)  M1108 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1109 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1110 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1111 The start of an episode of care documented in the medical record  M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, ref		Fabric wrapping of abdominal aneurysm	
neurological condition such as alls, ms, or parkinson's diagnosed at any time before or during the episode of care  M1108 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1109 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1110 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1111 The start of an episode of care documented in the medical record  M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program on	M1106	The start of an episode of care documented in the medical record	
neurological condition such as alls, ms, or parkinson's diagnosed at any time before or during the episode of care  M1108 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1109 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1110 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1111 The start of an episode of care documented in the medical record  M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program on			
Amit time before or during the episode of care  Mitolo  Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  Mitolo  Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  Mittl  Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  Mittl  Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  Mittl  Ongoing care not indicated, patient seen only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  Mittl  Ongoing care not indicated, patient self-discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  Mittl  Ongoing care not indicated, patient self-discharged arry and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  Mittl  Ongoing care not indicated, patient self-discharged arry and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  Mittl  Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  Ongoing care not indicated, patient self-discha	M1107	Documentation stating patient has a diagnosis of a degenerative	
M1108 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1109 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1110 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1111 The start of an episode of care documented in the medical record  M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Oncumentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care documented in the medical record  M1110 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1110 Ongoing car		neurological condition such as als, ms, or parkinson's diagnosed at	
program only, referred to another provider or facility, consultation only)  M1109 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1110 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1111 The start of an episode of care documented in the medical record  M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1116 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M119 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)		any time before or during the episode of care	
program only, referred to another provider or facility, consultation only)  M1109 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1110 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1111 The start of an episode of care documented in the medical record  M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1116 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M119 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)			
program only, referred to another provider or facility, consultation only)  M1109 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1110 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1111 The start of an episode of care documented in the medical record  M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1116 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M119 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)	M1108	Ongoing care not indicated, patient seen only 1-2 visits (e.g., home	
M1109 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1110 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1111 The start of an episode of care documented in the medical record  M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient seen only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., fi			
due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1110 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1111 The start of an episode of care documented in the medical record  M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M116 The start of an episode of care documented in the medical record  M117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M119 Ongoing care not indicated, patient discharged after only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M119 Ongoing care not indicated, patient discharged after only 1-2 visits (e.g., home program only, referred to another provider or facility consultation only)		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1110 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1111 The start of an episode of care documented in the medical record  M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M116 The start of an episode of care documented in the medical record  M117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M119 Ongoing care not indicated, patient discharged after only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M119 Ongoing care not indicated, patient discharged after only 1-2 visits (e.g., home program only, referred to another provider or facility consultation only)	M1109	Ongoing care not indicated, natient discharged after only 1-2 visits	
make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1110 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1111 The start of an episode of care documented in the medical record  M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or			
hospitalized or scheduled for surgery or hospitalized  M1110 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1111 The start of an episode of care documented in the medical record  M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M116 The start of an episode of care documented in the medical record  M117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M110 Ongoing care not indicated, patient self-discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized			
M1110 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1111 The start of an episode of care documented in the medical record  M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M116 The start of an episode of care documented in the medical record  M117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation			
only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1111 The start of an episode of care documented in the medical record  M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation		Thospitalized of scrieduled for surgery of Hospitalized	
only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1111 The start of an episode of care documented in the medical record  M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation			
M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M116 The start of an episode of care documented in the medical record  M117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation	M1110		
M1111 The start of an episode of care documented in the medical record  M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M116 The start of an episode of care documented in the medical record  M117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation			
M1112 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation		·	
neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M116 The start of an episode of care documented in the medical record  M117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation	M1111	The start of an episode of care documented in the medical record	
neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M116 The start of an episode of care documented in the medical record  M117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation			
any time before or during the episode of care  M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation	M1112	Documentation stating patient has a diagnosis of a degenerative	
M1113 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation		neurological condition such as als, ms, or parkinson's diagnosed at	
program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation		any time before or during the episode of care	
program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation			
program only, referred to another provider or facility, consultation only)  M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation	M1113	Ongoing care not indicated, patient seen only 1-2 visits (e.g., home	
M1114 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation			
due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation			
due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation	M1114	Ongoing care not indicated natient discharged after only 1-2 visits	
make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation	l		
hospitalized or scheduled for surgery or hospitalized  M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation			
M1115 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation			
only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation		Thospitalized of softedured for surgery of Hospitalized	
only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation	M4445	On the second of the first and the second of	
problems, or reason unknown)  M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation	M1115		
M1116 The start of an episode of care documented in the medical record  M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation		· · · · · · · · · · · · · · · · · · ·	
M1117 Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation			
neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation	M1116	The start of an episode of care documented in the medical record	
neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation			
any time before or during the episode of care  M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation	M1117	Documentation stating patient has a diagnosis of a degenerative	
M1118 Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation		neurological condition such as als, ms, or parkinson's diagnosed at	
program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation		any time before or during the episode of care	
program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation			
program only, referred to another provider or facility, consultation only)  M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation	M1118	Ongoing care not indicated, patient seen only 1-2 visits (e.g., home	
M1119 Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation			
due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation			
due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation	M1119	Ongoing care not indicated, patient discharged after only 1-2 visits	
make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation			
hospitalized or scheduled for surgery or hospitalized  M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation			
M1120 Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation			
only 1-2 visits (e.g., financial or insurance reasons, transportation		,	
only 1-2 visits (e.g., financial or insurance reasons, transportation	M1120	Ongoing care not indicated, nationt self-discharged early and seen	
	IVI I I Z U		
proviotio, or reason unitrown			
		problems, or reason uninflowing	

M1121	The start of an episode of care documented in the medical record	
M1122	Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care	
M1123	Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)	
M1124	Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery	
M1125	Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)	
M1126	The start of an episode of care documented in the medical record	
M1127	Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care	
M1128	Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)	
M1129	Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery	
M1130	Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)	
M1131	Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care	
M1132	Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)	
M1133	Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery	
M1134	Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown	
M1135	The start of an episode of care documented in the medical record	
M1136	The start of an episode of care documented in the medical record	
M1137	Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care	
M1138	Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only)	

M1139	Ongoing care not indicated, patient self-discharged early and seen	
	only 1-2 visits (e.g., financial or insurance reasons, transportation	
	problems, or reason unknown)	
14440		
M1140	Ongoing care not indicated, patient discharged after only 1-2 visits	
	due to specific medical events, documented in the medical record that	
	make the treatment episode impossible such as the patient becomes	
	hospitalized or scheduled for surgery for surgery or hospitalized	
M1141	Functional status was not measured by the oxford knee score (oks) at	
	one year (9 to 15 months) postoperatively	
M1142	Emergent cases	
M1143	Initiated episode of rehabilitation therapy, medical, or chiropractic care	
	for neck impairment	
M1144	Ongoing care not indicated, patient seen only 1-2 visits (e.g., home	
IVI I 144		
	program only, referred to another provider or facility, consultation only	
P2028	Cephalin floculation, blood	
P2029	Congo red, blood	
P2031	Hair analysis	
P2033	Thymol turbidity, blood	
P2038	Mucoprotein, blood (seromucoid) (medical necessity procedure)	
P9099	Blood component or product not otherwise classified	
Q0115	Post-coital direct, qualitative examinations of vaginal or cervical	
QUIIS	•	
	mucous	
Q0510	Pharmacy supply fee for initial immunosuppressive drug(s), first	
	month following transplant	
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or	
	immunosuppressive drug(s); for the first prescription in a 30-day	
	period	
	ı.	
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or	
	immunosuppressive drug(s); for a subsequent prescription in a 30-day	
	period	
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	
Q0514	Pharmacy dispensing fee for inhalation drug(s); per 90 days	
Q2042	Tisagenlecleucel, up to 600 million car-positive viable t cells, including	
	leukapheresis and dose preparation procedures, per therapeutic dose	
Q2026	Injection, Radiesse, 0.1ml	
Q2028		
	Injection, Sculptra, 0.5mg	
Q2052	Services, supplies and accessories used in the home under the	
	medicare intravenous immune globulin (ivig) demonstration	
Q3001	Radioelements for brachytherapy, any type, each	
Q3031	Collagen skin test	
Q4082	Drug or biological, not otherwise classified, part b drug competitive	
Q700Z	acquisition program (cap)	
0.4	, , , , , , , , , , , , , , , , , , , ,	
Q4100	Skin substitutes, not otherwise specified	
Q4101	Apligraf, per square centimeter	
Q4102	Oasis wound matrix, per sq cm	
Q4104	Integra bilayer matrix wound dressing (bmwd), per square centimeter	
0.4405	Into any demand as a second Construction (Add)	
Q4105	Integra dermal regeneration template (drt), per square centimeter	
Q4106	Dermagraft, per square centimeter	
Q4107	Graftjacket, per square centimeter	
Q4108	Integra matrix, per sq cm	
Q4116	Alloderm, per square centimeter	
Q4121	TheraSkin, per square centimeter	
Q4124	Oasis ultra tri-layer wound matrix, per square centimeter	<u> </u>
Q4128	FlexHd, Allopatch HD, or Matrix HD per square centimeter	
Q4183	Surgigraft, per square centimeter	
Q4184	Cellesta, per square centimeter	
Q4185	Cellesta flowable amnion (25 mg per cc); per 0.5 cc	

Q4186	Epifix, per square centimeter	
Q4187	Epicord, per square centimeter	
Q4188	Amnioarmor, per square centimeter	
Q4189	Artacent ac, 1 mg	
Q4190	Artacent ac, per square centimeter	
Q4191	Restorigin, per square centimeter	
Q4192	Restorigin, 1 cc	
Q4193	Coll-e-derm, per square centimeter	
Q4194	Novachor, per square centimeter	
Q4195	Puraply, per square centimeter	
Q4196	Puraply am, per square centimeter	
Q4197	Puraply xt, per square centimeter	
Q4198	Genesis amniotic membrane, per square centimeter	
Q4200	Skin te, per square centimeter	
Q4201	Matrion, per square centimeter	
Q4202	Keroxx (2.5g/cc), 1cc	
Q4203	Derma-gide, per square centimeter	
Q4204		
	Xwrap, per square centimeter	
Q5001	Hospice or home health care provided in patient's home/residence	
Q5002	Hospice or home health care provided in assisted living facility	
Q5003	Hospice care provided in nursing long-term care facility (LTC) or non-	
	skilled nursing facility (NF)	
Q5004	Hospice care provided in skilled nursing facility (SNF)	
Q5005	Hospice care provided in inpatient hospital	
Q5006	Hospice care provided in inpatient hospice facility	
Q5007	Hospice care provided in long-term care facility	
Q5007 Q5009	Hospice or home health care provided in place not otherwise specified	
Q5009	(NOS)	
Q9958	High osmolar contrast material, up to 149 mg./ml. iodine concentration, per ml.	
Q9959	High osmolar contrast material, 150–199 mg./ml. iodine concentration,	
40000	per ml.	
Q9960	High osmolar contrast material, 200–249 mg./ml. iodine concentration,	
Q9900	per ml.	
00004		
Q9961	High osmolar contrast material, 250–299 mg./ml. iodine concentration, per ml.	
Q9962	High osmolar contrast material, 300–349 mg./ml. iodine concentration,	
	per ml.	
Q9963	High osmolar contrast material, 350–399 mg./ml. iodine concentration,	
Q3303	per ml.	
00064	·	
Q9964	High osmolar contrast material, 400 or greater mg./ml. iodine	
	concentration, per ml.	
Q9965	Low osmolar contrast material, 100-199 or greater mg./ml. iodine	
	concentration, per ml.	
Q9966	Low osmolar contrast material, 100-199 or greater mg./ml. iodine	
	concentration, per ml.	
Q9967	Low osmolar contrast material	
Q9968	Injection, non-radioactive, non-contrast	
R0070	Transportation of portable x-ray	
R0075	Transportation of portable x-ray	
	Transportation of portable EKG	
R0076		
S0122	Injection, menotropins, 75 IU	
S0126	Injection, follitropin alfa, 75 IU	
S0208	Paramedic intercept, hospital-based ALS service (non-voluntary), non-transport	
S0215	Non-emergency transportation; mileage, per mile	
S0621	Routine ophthalmological examination including refraction; established	
00000	patient	
S0620	Routine ophthalmological examination including refraction; new	
	patient	
S1030	Continuous noninvasive glucose monitoring device, purchase	
S1031	Continuous noninvasive glucose monitoring device, rental	
	·	

S1034	Artificial pancreas device system (i.e., low glucose suspend (LGS)	
	feature)	
S1040	Cranial remolding orthosis, pediatric, rigid, with soft interface material,	
	custom fabricated, includes fitting and adjustment(s)	
S2053	Transplant – small intestine/liver	
S2054	Transplant – multivisceral	
S2055	Harvesting of donor multivisceral organs, with preparation and	
	maintenance of allografts; from cadaver donor	
S2060	Lobar lung transplantation	
S2061	Donor lobectomy (lung) for transplantation, living donor	
S2065	Simultaneous pancreas kidney transplantation	
S2102	Islet cell tissue transplant from pancreas; allogeneic	
S2103	Adrenal tissue transplant to brain	
S2142	Transplant – bone marrow	
S2152	Transplant – multivisceral	
S3840	DNA analysis for germline mutations of the RET proto-oncogene for	
03040	susceptibility to multiple endocrine neoplasia type 2	
S3841	Genetic testing for retinoblastoma	
S3842	Genetic testing for von Hippel-Lindau disease	
S3844	DNA analysis for the connexin 26 gene (GJB2) for susceptibility to	
	congenital, profound deafness	
S3845	Genetic testing for alpha-thalassemia	
S3846	Genetic testing for hemoglobin E beta-thalassemia	
S3850	Genetic testing for sickle cell anemia	
S3852	DNA analysis for APOE epsilon 4 allele for susceptibility to	
00002	Alzheimer's disease	
S3853	Genetic testing for myotonic muscular dystrophy	
S3854	Oncotype DX - gene expression profiling panel for use in the	
	management of breast cancer	
S3855	Genetic testing for detection of mutations in the presenilin - 1 gene	
S3861	Genetic testing, sodium channel, voltage-gated, type V, alpha subunit (SCN5A) and variants for suspected Brugada syndrome	
S3865	Comprehensive gene sequence analysis for hypertrophic cardiomyopathy	
S3866	Genetic analysis for a specific gene mutation for hypertrophic	
	cardiomyopathy (HCM) in an individual with a known HCM mutation in the family	
S0128	Injection, follitropin beta, 75 IU	
S4011	In vitro fertilization; including but not limited to identification and	
- ' -	incubation of mature oocytes, fertilization with sperm, incubation of	
	embryo(s), and subsequent visualization for determination of	
	development	
S4013	Complete cycle, gamete intrafallopian transfer (GIFT), case rate	
S4014	Complete cycle, zygote intrafallopian transfer (ZIFT), case rate	
S4015	Complete in vitro fertilization cycle, not otherwise specified, case rate	
S4016	Frozen in vitro fertilization cycle, case rate	
S4017	Incomplete cycle, treatment cancelled prior to stimulation, case rate	
O-1017	missimplete eyele, treatment cancelled prior to stillidation, case late	
S4018	Frozen embryo transfer procedure cancelled before transfer, case rate	
S4020	In vitro fertilization procedure cancelled before aspiration, case rate	
S4021	In vitro fertilization procedure cancelled after aspiration, case rate	
S4021	, , , , , , , , , , , , , , , , , , ,	
S4021 S4022 S4023	In vitro fertilization procedure cancelled after aspiration, case rate  Assisted oocyte fertilization, case rate  Donor egg cycle, incomplete, case rate	

S4025	Donor services for in vitro fertilization (sperm or embryo), case rate	
04020	bollor services for in vitro fertilization (sperm of embryo), case rate	
S4026	Procurement of donor sperm from sperm bank	
S4027	Storage of previously frozen embryos	
S4028)	Microsurgical epididymal sperm aspiration (MESA	
S4030	Sperm procurement and cryopreservation services; initial visit	
S4031	Sperm procurement and cryopreservation services; subsequent visit	
S4035	Stimulated intrauterine insemination (IUI), case rate	
S4037	Cryopreserved embryo transfer, case rate	
S4040	Monitoring and storage of cryopreserved embryos, per 30 days	
S4042	Management of ovulation induction (interpretation of diagnostic tests	
	and studies, nonface-to-face medical management of the patient), per	
	cycle	
S5035	Home infusion therapy, routine service of infusion device (e.g., pump	
	maintenance)	
S5036	Home infusion therapy, repair of infusion device (e.g., pump repair)	
0=100		
S5108	Home care training to home care client, per 15 minutes	
S5109	Home care training to home care client, per session	
S5110 S5111	Home care training, family; per 15 minutes  Home care training, family; per session	
S5111	Home care training, non-family; per 15 minutes	
S5116	Home care training, non-family; per 13 minutes  Home care training, non-family; per session	
	Home health respiratory therapy, initial evaluation	
S5180 S5181	Home health respiratory therapy, NOS, per diem	
S5550	Insulin rapid 5 u	
S5551	Insulin most rapid 5 units	
S5552	Insulin intermediate acting 5 units	
S5553	Insulin long acting 5 units	
S5560	Insulin reuse pen 1.5 ml	
S5561	Insulin reuse pen 1.5 ml	
S5565	Insulin cartridge for use in insulin delivery device other than pump;	
00000	150 units	
S5566	Insulin cartridge for use in insulin delivery device other than pump;	
00000	300 units	
S5570	Insulin disposable pen 1.5 ml	
S5571	Insulin disposable pen 3 ml	
S8270	Enuesis monitors	
S8490	100 insulin syringes	
S9061	Home administration of aerosolized drug therapy (e.g., pentamidine);	
	administrative services, professional pharmacy services, care	
	coordination, all necessary supplies and equipment (drugs and	
	nursing visits coded separately), per diem	
S9098	Home visit, phototherapy services (e.g., bili-lite), including equipment	
	rental, nursing services, blood draw, supplies, and other services, per	
	diem	
S9122	Home health aide or certified nurse assistant, providing care in the	
	home; per hour	
S9126	Hospice care, in the home, per diem	
S9127	Social work visit, in the home, per diem	
S9208	Home management of preterm labor, including administrative	
	services, professional pharmacy services, care coordination, and all	
	necessary supplies or equipment (drugs and nursing visits coded	
	separately), per diem (do not use this code with any home infusion per	
	diem code)	

S9209	Home management of preterm premature rupture of membranes (PPROM), including administrative services, professional pharmacy services, care coordination, and all necessary supplies or equipment (drugs and nursing visits coded separately), per diem (do not use this code with any home infusion per diem code)	
S9211	Home management of gestational hypertension, includes administrative services, professional pharmacy services, care coordination and all necessary supplies and equipment (drugs and nursing visits coded separately); per diem (do not use this code with any home infusion per diem code)	
S9212	Home management of postpartum hypertension, includes administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with any home infusion per diem code)	
S9213	Home management of preeclampsia, includes administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing services coded separately); per diem (do not use this code with any home infusion per diem code)	
S9214	Home management of gestational diabetes, includes administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately); per diem (do not use this code with any home infusion per diem code)	
S9325	Home infusion therapy, pain management infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, (drugs and nursing visits coded separately), per diem (do not use this code with S9326, S9327 or S9328)	
S9326	Home infusion therapy, continuous (twenty-four hours or more) pain management infusion; administrative services, professional pharmacy services, care coordination and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	
S9327	Home infusion therapy, intermittent (less than twenty-four hours) pain management infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	
S9328	Home infusion therapy, implanted pump pain management infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	
S9329	Home infusion therapy, chemotherapy infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with S9330 or S9331)	
S9330	Home infusion therapy, continuous (twenty-four hours or more) chemotherapy infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	
S9331	Home infusion therapy, intermittent (less than twenty-four hours) chemotherapy infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	

S9336	Home infusion therapy, continuous anticoagulant infusion therapy (e.g., heparin), administrative services, professional pharmacy services, care coordination and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	
S9338	Home infusion therapy, immunotherapy, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	
S9345	Home infusion therapy, anti-hemophilic agent infusion therapy (e.g., factor viii); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	
S9346	Home infusion therapy, alpha-1-proteinase inhibitor (e.g., Prolastin); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	
S9347	Home infusion therapy, uninterrupted, long-term, controlled rate intravenous or subcutaneous infusion therapy (e.g., epoprostenol); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	
S9348	Home infusion therapy, sympathomimetic/inotropic agent infusion therapy (e.g., dobutamine); administrative services, professional pharmacy services, care coordination, all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	
S9351	Home infusion therapy, continuous or intermittent anti-emetic infusion therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and visits coded separately), per diem	
S9353	Home infusion therapy, continuous insulin infusion therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	
S9355	Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	
S9357	Home infusion therapy, enzyme replacement intravenous therapy; (e.g., imiglucerase); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	
S9359	Home infusion therapy, anti-tumor necrosis factor intravenous therapy; (e.g., infliximab); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	
S9361	Home infusion therapy, diuretic intravenous therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	
S9363	Home infusion therapy, anti-spasmotic therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	

S9364	Home infusion therapy, total parenteral nutrition (TPN); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem (do not use with home infusion codes S9365-S9368 using daily volume scales)	
S9365	Home infusion therapy, total parenteral nutrition (TPN); one liter per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem	
S9366	Home infusion therapy, total parenteral nutrition (TPN); more than one liter but no more than two liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem	
S9367	Home infusion therapy, total parenteral nutrition (TPN); more than two liters but no more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem	
S9368	Home infusion therapy, total parenteral nutrition (TPN); more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem	
S9370	Home therapy, intermittent anti-emetic injection therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	
S9538	Home transfusion of blood product(s); administrative services, professional pharmacy services, care coordination and all necessary supplies and equipment (blood products, drugs, and nursing visits coded separately), per diem	
S9560	Home injectable therapy; hormonal therapy (e.g., leuprolide, goserelin), including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	
S9562	Home injectable therapy, palivizumab, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	
T2001	Non-emergency transportation; patient attendant/escort	
T2002	Non-emergency transportation; per diem	
T2003	Non-emergency transportation; encounter/trip	
T2004	Non-emergency transport; commercial carrier, multi-pass	
T2005	Non-emergency transportation; non-ambulatory stretcher van	
T2007	Transportation waiting time, air ambulance and non-emergency vehicle, one-half (1/2) hour increments	
T2042	Hospice routine home care; per diem	
T2043	Hospice continuous home care; per hour	
T2044	Hospice inpatient respite care; per diem	
T2045	Hospice general inpatient care; per diem	
T2046	Hospice long-term care, room and board only; per diem	

T5001 Car seat T5999 Car seat T5999 Car seat T5999 Car seat V2600 Hand held low vision aids V2610 Single lens spectacle mounted V2615 Telescopic and other compound lens V2630 Anterior chamber intraocular lens V2631 Iris supported intraocular lens V2632 Posterior chamber intraocular lens V2703 Posterior chamber intraocular lens V2700 Balance lens, per lens V2701 Siab off prism glass or plastic per lens V2710 Prism per lens V2711 Prism per lens V2713 Press-on lens, fresnell prism, per lens V2714 Tint, plastic, rose V2740 Tint, plastic, rose V2741 Tint, plastic, other than rose V2742 Tint, plastic, other than rose V2743 Tint, plastic, other than rose V2744 Tint, plastic, other than rose V2745 Addition to lens, Tint, any color V2750 Anti-reflective coating per lens V2755 Anti-reflective coating per lens V2756 U Lens/es V2760 Scratch-resistant coating V2761 Mirror coating, any type, solid, gradient or equal, any lens material V2762 Polarization, any lens material, per lens V2780 Occluder lens per lens V2780 Poresize lens per lens V2781 Progressive lens, per lens V2780 Lens, index grit than or equal to 1.66 plastic or grit than or equal to 1.80 glass, excludes polycarbonate, per lens V2784 Lens, index grit than or equal to 1.66 plastic or grit than or equal to 1.80 glass, excludes polycarbonate, per lens V2784 Lens, index grit than or equal to 1.66 plastic or grit than or equal to 1.80 glass, excludes polycarbonate, per lens V2784 Lens, index grit than or equal to 1.66 plastic or grit than or equal to 1.80 glass, excludes polycarbonate, per lens V2784 Lens, index grit than or equal, any index, per lens V2786 Specialty occupational multifocal lens, per lens	T4545	Incontinence product, disposable, penile wrap, each	_
Car seat   W2800			
V2800 Hand held low vision aids V2810 Sigle lens spectate mounted V2811 Telescopic and other compound lens V2830 Anton Charles and State of the Compound lens V2830 Alter of chamber intraocular lens V2831 Its supported intraocular lens V2832 Patient of chamber intraocular lens V2832 Patient of chamber intraocular lens V2702 Salainos lens, per lens V2703 Salainos lens, per lens V2704 Salainos lens, per lens V2705 Prism per lens V2715 Prism per lens V2716 Special base curve glass or plastic per lens V2716 Special base curve glass or plastic per lens V2717 Tent, plastic, other than rose V2717 Tent, plastic, other than rose V2718 Tent, plastic, other than rose V2719 Tent, plastic, other than rose V2719 Tent, plastic, other than rose V2710 Trit, plastic, other than rose V2710 Anti-reflective coating per lens V2710 Anti-reflective coating per lens V2710 Mirror coating, any type, solid, gradient or equal, any lens material V2710 Coccupier lens per lens V2710 Occupier lens per lens V2710 Oversize lens			
Vi2616 To Security of the Security of the Security of the Security of Security			
V2615 Telescopic and other compound lens V2630 Anterior chamber intraocular lens V2631 Itis supported intraocular lens V2631 Itis supported intraocular lens V2702 Edition of the provided intraocular lens V2703 Edition of the provided intraocular lens V2704 Edition of prism glass or plastic per lens V2705 Edition lens, per lens V2706 Edition of prism glass or plastic per lens V2707 Edition of prism glass or plastic per lens V2708 Prism per lens V2709 Special base curve glass or plastic per lens V2709 Telescope on lens, freahen prism, per lens V2714 Telescope on lens, freahen prism, per lens V2715 Altri-reflective coating per lens V2716 Telescope on lens, freahen prism, per lens V2716 Ur Lensles V2716 Ur Lensles V2717 Ur Lensles V2718 Ur Lensles V2719 Ur Lensles V2719 Coccluder lens per lens V2719 Ur Lensles V2710 Ur Lensles V2719 Coccluder lens per lens V2719 Ur Lensles V2720 Ur Lensles V2720 Ur Lensles V2721 Ur Lensles V2722 Ur Lensles V2723 Ur Lensles V2724 Ur Lensles V2724 Ur Lensles V2725 Ur Lensles V2726 Ur Lensles V2727 Ur Lensles V2727 Ur Lensles V2728 Ur Lensles V2729 U			+
V2630   Anterior chamber intraocular lens   V2631   Posterior chamber intraocular lens   V2632   Posterior chamber intraocular lens   V2702   Posterior chamber intraocular lens   V2703   Posterior chamber intraocular lens   V2715   Posterior chamber intraocular lens   V2716   Posterior chamber intraocular lens   V2716   Posterior chamber intraocular lens   V2717   Posterior chamber intraocular lens   V2718   Press-on lens, flesshell prism, per lens   V2719   Press-on lens, flesshell prism, per lens   V2720   Posterior base curve glass or plastic per lens   V2740   Tint, plastic, cose   V2741   Tint, plastic, cose   V2741   Tint, plastic, cose   V2743   Tint, plastic, cose   V2744   Tint, plastic, cose   V2744   Tint, plastic, cose   V2745   Addition to lens, Tint, any color   V2750   Anti-reflective coating per lens   V2750   Anti-reflective coating per lens   V2750   V27		· ·	+
V2632 Posterior chamber intraocular lens V27032 Deluxe lens festure V2703 Balence lens, per lens V2704 Deluxe lens festure V2710 Slab off prising plass or plastic per lens V2711 Slab off prising plass or plastic per lens V2712 Prisspon lens, fresnell prism, per lens V2713 Special base curve glass or plastic per lens V2714 Prisspon lens, fresnell prism, per lens V2740 Tint, plastic, cose V2741 Tint, plastic, cose V2741 Tint, plastic, cose or plastic per lens V2742 Tint, plastic, cose or variety of the variety of		· · · · · · · · · · · · · · · · · · ·	
V2702 Blabance lans, por lans V2703 Deluxe lens feature V2710 Slab off prism glass or plastic per lens V2711 Prism per lens V2712 Prism per lens V2713 Press-on lens, fresnell prism, per lens V2714 Press-on lens, fresnell prism, per lens V2714 Thi, plastic, rose V2740 Thi, plastic, rose V2741 Thi, plastic, rose V2741 Thi, plastic, rose V2743 Thi, plastic, rose V2744 Thi, plastic, rose V2745 Addition to lens, Tint, any color V2746 Addition to lens, Tint, any color V2756 Arti-reflective coating per lens V2756 Arti-reflective coating per lens V2756 Arti-reflective coating per lens V2760 Arti-reflective coating per lens V2760 Arti-reflective coating per lens V2761 Mirror coating, any type, solid, gradient or equal, any lens material V2762 Polarization, any lens material, per lens V2763 Oversize lens per lens V2760 Cordination of the per lens V2760 Cordination of the per lens V2761 Lens, index 1,54 to 1,65 plastic or 1,60 to 1,79 glass, excludes polycarbonate, per lens V2778 Despessive lens, per lens V2781 Progressive lens, per lens V2782 Lens, index 1,54 to 1,65 plastic or 1,60 to 1,79 glass, excludes polycarbonate, per lens V2781 Lens, index grit than or equal to 1,66 plastic or grit than or equal to 1,60 glastic or grit drit or equal, any index, per lens V2781 Perspective ensemble or equal, any index, per lens V2782 Assignment for the progress deconstruction, per procedure V2789 Assignment for the progress deconstruction, per procedure V2790 Mirror for for for for for for for for for			
V2702 Deluce lens feature V2710 Slab off prism glass or plastic per lens V2711 Prism per lens V2712 Prism per lens V2713 Prism per lens V2713 Prism per lens V2724 The prism per lens V2740 The plastic, rose curve glass or plastic per lens V2740 The plastic, rose V2741 Thit, plastic, rose V2741 Thit, plastic, cole that nose V2742 Thit, plastic, cole that nose V2743 Thit, plastic, cole that nose V2743 Thit, plastic, cole that nose V2744 Thit, plastic, cole that nose V2745 All this plastic, rose V2746 Thit, plastic, cole that nose V2747 Thit, plastic, cole that nose V2747 Thit, plastic, cole that nose V2745 Addition to lens. Thit, any color V2750 Anti-reflective coating per lens V2760 Thit plastic, rose V2760 Scratch-resistant coating per lens V2760 Scratch-resistant coating V2761 Infror coating, any lyes, solid, gradlent or equal, any lens material V2762 Polarization, any lens material, per lens V2764 Progressive lens per lens V2769 Occluder lens per lens V2760 Thit progressive lens, per lens V2760 Thit progressive lens per lens V2760 Thit progressive lens, per lens V2760 Thit progressive lens V2760 Thit progressive lens per lens V2760 Thit progressive lens per lens V2760 Thit progressive lens per lens V2760 Thit progressive lens V2760 Thit progressi		1.1	
V27702 Deluxe lens feature V2715 Prism per lens V2715 Prism per lens V2716 Prism per lens V2716 Prism per lens V27170 Special base curve glass or plastic per lens V27170 Special base curve glass or plastic per lens V2718 Press-on lens, flessnell prism, per lens V2720 Special base curve glass or plastic per lens V2741 Tint, plastic, cose V2741 Tint, plastic, cose V2742 Tint, plastic, cose V2743 Tint, plastic, cose V2743 Tint, plastic, cose V2743 Tint, plastic, cose V2745 Addition to lens, Tint, any color V2756 Addition to lens, Tint, any color V2756 Anti-reflective coating per lens V2756 Intensée V2760 Scratch-resistant coating V2761 Mirror coating, any type, solid, gradient or equal, any lens material V2760 Scratch-resistant coating V2761 Mirror coating, any type, solid, gradient or equal, any lens material V2762 Polarization, any lens material, per lens V2763 Oversize lens per lens V2764 Under lens per lens V2769 Oversize lens per lens V2769 Lans, index 1,54 to 1,65 plastic or 1,60 to 1,79 glass, excludes polycarbonate, per lens V2761 Lans, index prit than or equal to 1,65 plastic or 1,60 to 1,79 glass, excludes polycarbonate, per lens V2764 Lens, index prit than or equal to 1,65 plastic or 1,60 to 1,79 glass, excludes polycarbonate, per lens V2764 Lens, polycarbonate or equal, any index, per lens V2765 Lens, index prit than or equal to 1,65 plastic or 1,60 to 1,79 glass, excludes polycarbonate, per lens V2766 Partin per lens V2767 Oversize lens per lens V2768 Partin per lens V2769 Partin per			
V2715 Prism pare lens V2718 Press-on lens, fresnell prism, per lens V2718 Press-on lens, fresnell prism, per lens V2720 Special base curve glass or plastic per lens V2740 Tri., plastic, other than rose V2741 Tri., plastic, other than rose V2742 Tri., plastic, other than rose V2743 Tri., plastic, other than rose V2744 Tri., plastic, other than rose V2745 Anti-reflective coating per lens V2746 Anti-reflective coating per lens V2756 Anti-reflective coating per lens V2767 Anti-reflective coating per lens V2768 V2769 Anti-reflective coating per lens V2760 V2760 Various and various per lens V2761 Mirror coating, any type, solid, gradient or equal, any lens material V2762 Polarization, any lens material, per lens V2763 V2760 Occluder lens per lens V2764 Progressive lens, per lens V2769 V2760 Various per lens V27780 Various Progressive lens, per lens V2781 Progressive lens, per lens V2782 Lens, index 1,54 to 1,65 plastic or 1,60 to 1,79 glass, excludes polycarbonate, per lens V2783 Lens, index signt rhan or equal to 1,66 plastic or grir than or equal to 1,80 glass, excludes polycarbonate, per lens V2784 Lens, polycarbonate or equal, any index, per lens V2785 Lens, polycarbonate or equal multi-coal lens, per lens V2786 Various per lens V2787 Astigmatism-correcting function of intracoular lens V2789 Vision service miscellaneous V2789 Aminoitic membrane for surgical reconstruction, per procedure V2789 Vision service miscellaneous V3790 Aminoitic membrane for surgical reconstruction, per procedure V3791 Vision service miscellaneous V3792 Vision service miscellaneous V3793 Hearing aid, monaural, in the ear V3794 Hearing aid, monaural, in the ear V3795 Hearing aid, monaural, body worn, sin conduction V3796 Blasural, berind the ear V3797 Blasural, berind the ear V3798 Blasural, berind the ear V3799 Blasural, berind the ear V3790 Blasural, berind the ear V3791 Blasural, berind the ear V3793 Blasural, berind the ear V3794 Blasural, berind the ear V3795 Blasural, berind the ear		· ·	
V2715         Priss mer lens           V2780         Special base curve glass or plastic per lens           V2740         Special base curve glass or plastic per lens           V2741         Tint, plastic, rose           V2742         Tint, plastic, rose           V2743         Tint, plastic, rose           V2743         Addition to lens, Tint, any color           V2750         Ant-reflective coating per lens           V2755         Ant-reflective coating per lens           V2760         Sratch-resistant coating           V2761         Mirror coating, any type, solid, gradient or equal, any lens material           V2760         Sratch-resistant coating           V2761         Mirror coating, any type, solid, gradient or equal, any lens material           V2760         Polarization, any lens material, per lens           V27760         Oversize lens per lens           V27770         Outcluter. lens per lens           V27780         Oversize lens per lens           V2781         Progressive lens, per lens           V2782         Lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens           V2783         Lens, index 1.54 to 1.65 plastic or junt than or equal to 1.80 glass, excludes polycarbonate, per lens           V2784         Lens, polycarbonate or equal, an			
V2718         Press-on lens, fresnell prism, per lens           V2740         Tint, plastic, cose           V2741         Tint, plastic, other than rose           V2742         Tint, plastic, other than rose           V2743         Tint, plastic, other than rose           V27442         Tint, plastic, other than rose           V2745         Adrit plastic, other than rose           V2756         Anti-reflective coating per lens           V2756         Anti-reflective coating per lens           V2766         V Lens/es           V27670         Scratch-resistant coating           V2761         Mirror coating, any type, solid, gradient or equal, any lens material           V2762         Polarization, any lens material, per lens           V27700         Occluder lens per lens           V27701         Occluder lens per lens           V27702         Density per lens           V2781         Progressive lens, per lens           V27821         Lens, index 1,54 to 1,65 plastic or 1,60 to 1,79 glass, excludes polycarbonate, per lens           V2783         Lens, index grir than or equal to 1,66 plastic or grir than or equal to 1,80 glass, excludes polycarbonate or equal, any index, per lens           V2784         Lens, polycarbonate or equal, any index, per lens           V2785         Specially occupatio			
V2740   Special base curve glass or plastic per lens   V2740   Tint, plastic, rose   V2741   Tint, plastic, other than rose   V2742   Tint, plastic, other than rose   V2743   Tint, plastic, other than rose   V2744   Tint, plastic, other than rose   V2745   Addition to lens, Tint, any color   V2754   Addition to lens, Tint, any color   V2755   Anti-reflective coating per lens   V2756   V2755   Anti-reflective coating per lens   V2760   V2761   V2761   V2762   V2765   V2765   V2765   V2765   V2765   V2766   V2767		·	
V2741 Tint, plastic, rose V2742 Tint, plastic, other than rose V2743 Tint, plastic, other than rose V2743 Tint, plastic, other than rose V2743 Tint, plastic, other than rose V2744 Tint, plastic, other than rose V2745 Addition to lens, Tint, any color V2750 Anti-reflective coating per lens V2755 Anti-reflective coating per lens V2756 Uv Lens/es V2760 Uv Lens/es V2761 Wirro coating, any type, solid, gradient or equal, any lens material V2762 Polarization, any lens material, per lens V2763 Occluder lens per lens V2770 Occluder lens per lens V2770 Occluder lens per lens V2770 Uversize lens per lens V2771 Progressive lens, per lens V2781 Progressive lens, per lens V2782 Lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens V2784 Lens, index 1.54 to 1.65 plastic or grir than or equal to 1.80 glass, excludes polycarbonate, per lens V2786 Specially occupational multifocal lens, per lens V2787 Asignatism-correcting function of intraocular lens V2788 Presbyopia correcting function of intraocular lens V2789 Amilotic membrane for surgical reconstruction, per procedure V2790 Vision supply, accessory and/or service component of another HCPCS vision code V2790 Vision service miscellaneous V5010 Assessment for hearing aid V5011 Fitting/orientalion/becking of hearing aid V5020 Conformity evaluation V5030 Hearing aid, monaural, body worn, air conduction V5030 Hearing aid, monaural, in the ear V5030 Semi-implantable middle ear hearing prosthesis V5030 Semi-implantable middle ear hearing prosthesis V5030 Binaural, inthe ear V5040 Binaural, behind the ear V5040 Binaural, behind the ear V5040 Binaural, behind the ear			
V2741         Tint, plastic, orber than rose           V2742         Tint, plastic, orber than rose           V2743         Tint, plastic, other than rose           V2745         Addition to lens, Tint, any color           V2750         Anti-reflective coating per lens           V2755         Anti-reflective coating per lens           V2760         Uv Lens/es           V2761         Uv Lens/es           V2762         Mirror coating, any type, solid, gradient or equal, any lens material           V2761         Mirror coating, any type, solid, gradient or equal, any lens material           V2762         Polarization, any lens material, per lens           V2770         Occluder lens per lens           V2770         Occluder lens per lens           V2780         Oversize lens per lens           V2781         Progressive lens, per lens           V2782         Lens, index 154 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens           V2783         Lens, index per lens           V2784         Lens, polycarbonate or equal, any index, per lens           V2785         Pescilary occupational multifical lens, per lens           V2786         Pescilary occupational multifical lens, per lens           V2787         Astigmatism-correcting function of intracocular lens		·	
V2742     Tint, plastic, ober than rose       V2743     Tint, plastic, other than rose       V2745     Anti-reflective coating per lens       V2755     Anti-reflective coating per lens       V2756     UV Lens/es       V2760     Scratch-resistant coating       V2761     Mirror coating, any type, solid, gradient or equal, any lens material       V2762     Polarization, any lens material, per lens       V2770     Occluder lens per lens       V2770     Occluder lens per lens       V2770     Porgressive lens, per lens       V2770     Porgressive lens, per lens       V2770     Porgressive lens, per lens       V2771     Progressive lens, per lens       V27720     Lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens       V2781     Progressive lens, per lens       V2782     Lens, index 1.54 to 1.65 plastic or grtr than or equal to 1.86 plastic or grtr than or equal to 1.80 glass, excludes polycarbonate per lens       V2784     Lens, polycarbonate or equal, any index, per lens       V2785     Specialty occupational multifocal lens, per lens       V2786     Presbyopia correcting function of intracoular lens       V2787     Astigmatism-correcting function of intracoular lens       V2789     Presbyopia correcting function of intracoular lens       V2790     Aminotic membrane for surgical recon			
V2745 Addition to lens, Tint, any color V2750 Anti-reflective coating per lens V2755 Anti-reflective coating per lens V2756 V2			
V2745 Addition to lens, Tint, any color V2750 Anti-reflective coating per lens V2755 Anti-reflective coating per lens V2760 Sctach-resistant coating V2761 Mirror coating, any type, solid, gradient or equal, any lens material V2762 Polarization, any lens material, per lens V2762 Polarization, any lens material, per lens V2760 Occluder lens per lens V27760 Occluder lens per lens V27761 Progressive lens, per lens V27780 Oversize lens per lens V27781 Progressive lens, per lens V27781 Progressive lens, per lens V2781 Lens, index 1,54 to 1,65 plastic or 1,60 to 1,79 glass, excludes polycarbonate, per lens V2781 Lens, index grit than or equal to 1,66 plastic or grit than or equal to 1,80 glass, excludes polycarbonate, per lens V2784 Lens, polycarbonate or equal, any index, per lens V2786 Specialty occupational multiflocal lens, per lens V2787 Asignatism-correcting function of intraocular lens V2788 Presbyopia correcting function of intraocular lens V2789 Amniotic membrane for surgical reconstruction, per procedure V2797 Vision supply, accessory and/or service component of another HCPCS vision code V2799 Vision service miscellaneous V3010 Assessment for hearing aid V3020 Conformity evaluation V3020 Conformity evaluation V3030 Hearing aid, monaural, body worn, bone conduction V3040 Hearing aid, monaural, body worn, bone conduction V3050 Hearing aid, monaural, body worn, bone conduction V3050 Glasses, bone conduction V3050 Semi-implantable middle ear hearing aid V3050 Dispensing fee, unspecified hearing aid V3050 Dispensing fee, binaural, body V3130 Binaural, betwind the ear V3150 Dispensing fee, binaural V3150 Dispensing fee, binaural			
V2756 Anti-reflective coating per lens V2756 UV Lens/es V2756 UV Lens/es V2760 Scratch-resistant coating V2761 Mirror coating, any type, solid, gradient or equal, any lens material V2762 Polarization, any lens material, per lens V2763 Occluder lens per lens V2764 V2767 Occluder lens per lens V2769 Oversize lens per lens V2769 Oversize lens per lens V2761 Progressive lens, per lens V2761 Progressive lens, per lens V2762 Lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens V2783 Lens, index grit than or equal to 1.66 plastic or grit than or equal to 1.80 glass, excludes polycarbonate, per lens V2784 Lens, polycarbonate or equal, any index, per lens V2785 Specialty occupational multifocal lens, per lens V2786 Specialty occupational multifocal lens, per lens V2787 Astigmatism-correcting function of intraocular lens V2788 Pesbyopia correcting function of intraocular lens V2797 Vision supply, accessory and/or service component of another HCPCS vision code V2799 Vision service miscellaneous V5010 Assessment for hearing aid V5011 Fitting/orientation/checking of hearing aid V5020 Conformity evaluation V5030 Hearing aid, monaural, body worn, air conduction Hearing aid, monaural, body worn, air conduction Hearing aid, monaural, body worn, bene conduction V5030 Glasses, air conduction V5030 Glasses, air conduction V5030 Hearing aid, monaural, behind the ear V5040 Hearing aid, monaural, behind the ear V5050 Glasses, air conduction V5050 Dispensing fee, bilateral V5150 Binaural, behind the ear			
V2755 Anti-reflective coating per lens V2760 Sratch-resistant coating V2761 Mirror coating, any type, solid, gradient or equal, any lens material V2762 Polarization, any lens material, per lens V2763 Oversize lens per lens V2764 Polarization, any lens material, per lens V2765 Oversize lens per lens V2766 Oversize lens per lens V2767 Oversize lens, per lens V2768 Oversize lens, per lens V2769 Oversize lens, per lens V2769 Oversize lens, per lens V2760 Lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens V2761 Lens, index grir than or equal to 1.66 plastic or grir than or equal to 1.80 glass, excludes polycarbonate, per lens V2764 Lens, polycarbonate or equal, any index, per lens V2765 Asginatism-correcting function of intraocular lens V2766 Specialty occupational multifocal lens, per lens V2767 Asginatism-correcting function of intraocular lens V2768 Presbyopia correcting function of intraocular lens V2769 Aminotic membrane for surgical reconstruction, per procedure V2790 Vision supply, accessory and/or service component of another HCPCS vision code V2799 Vision service miscellaneous V5010 Assessment for hearing aid V5011 Fittingo/irientation/checking of hearing aid V5014 Repairing aid, monaural, body worn, bone conduction V5040 Hearing aid, monaural, body worn, bone conduction V5050 Hearing aid, monaural, body worn, bone conduction V5060 Hearing aid, monaural, body worn, bone conduction V5070 Glasses, bone conduction V5080 Dispensing fee, unspecified hearing aid V5010 Dispensing fee, unspecified hearing aid V5010 Dispensing fee, unspecified hearing aid V5010 Dispensing fee, binaural, body V5110 Dispensing fee, binaural, body V5110 Dispensing fee, binaural V5110 Binaural, bethind the ear V5110 Binaural, bethind the ear	V2745	•	
V2756 Uv Lens/es  V2761 Mirror coating, any type, solid, gradient or equal, any lens material  V2762 Polarization, any lens material, per lens  V2770 Occluder lens per lens  V2780 Oversize lens per lens  V2781 Progressive lens, per lens  V2782 Lens, index rt rhan or equal to 1.60 to 1.79 glass, excludes polycarbonate, per lens  V2783 Lens, index grt rhan or equal to 1.66 plastic or grt rhan or equal to 1.80 glass, excludes polycarbonate, per lens  V2784 Lens, polycarbonate or equal, any index, per lens  V2785 Lens, polycarbonate or equal, any index, per lens  V2786 Specialty occupational multifocal lens, per lens  V2786 Specialty occupational multifocal lens, per lens  V2787 Astigmatism-correcting function of intraocular lens  V2780 Anniotic membrane for surgical reconstruction, per procedure  V2790 Anniotic membrane for surgical reconstruction, per procedure  V2797 Vision supply, accessory and/or service component of another  HCPCS vision code  V2799 Vision service miscellaneous  V5011 Fitting/orientation/checking of hearing aid  V5014 Repair/modification of a hearing aid  V5014 Repair/modification of a hearing aid  V5014 Repair/modification of a hearing aid  V5050 Hearing aid, monaural, body worn, bone conduction  V5060 Hearing aid, monaural, body worn, bone conduction  V5090 Glasses, air conduction  V5090 Dispensing fee, unspecified hearing aid  V5110 Dispensing fee, bilateral  V5110 Dispensing fee, bilateral	V2750		
V2760 Scratch-resistant coating V2761 Mirror coating, any type, solid, gradient or equal, any lens material V2762 Polarization, any lens material, per lens V2760 Occluder lens per lens V2780 Oversize lens per lens V2781 Progressive lens, per lens V2782 Lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens V2783 Lens, index grit than or equal to 1.66 plastic or grit rhan or equal to 1.80 glass, excludes polycarbonate, per lens V2784 Lens, polycarbonate or equal, any index, per lens V2785 Specialty occupational multifocal lens, per lens V2786 Specialty occupational multifocal lens, per lens V2787 Astigmatism-correcting function of intraocular lens V2788 Presbyopia correcting function of intraocular lens V2797 Vision supply, accessory and/or service component of another HCPCS vision code V2799 Vision service miscellaneous V37010 Assessment for hearing aid V5011 Fitting/orientation/checking of hearing aid V5011 Fitting/orientation/checking of hearing aid V5010 Repair/modification of a hearing aid V5011 Repair/modification of a hearing aid V5010 Hearing aid, monaural, body worn, bone conduction V5030 Hearing aid, monaural, body worn, bone conduction V5040 Hearing aid, monaural, body worn, bone conduction V5050 Hearing aid, monaural, body worn, bone conduction V5060 Glasses, air conduction V5080 Glasses, air conduction V5090 Dispensing fee, unspecified hearing aid V5010 Dispensing fee, bilateral V5100 Binaural, behind the ear V5120 Binaural, behind the ear V5130 Binaural, behind the ear	V2755	<u> </u>	
V2761 Mirror coating, any type, solid, gradient or equal, any lens material V2762 Polarization, any lens material, per lens V2770 Occluder lens per lens V2780 Oversize lens per lens V2781 Progressive lens, per lens V2782 Lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens V2783 Lens, index grtr than or equal to 1.66 plastic or grtr than or equal to 1.80 glass, excludes polycarbonate, per lens V2784 Lens, polycarbonate or equal, any index, per lens V2786 Specialty occupational multifocal lens, per lens V2787 Astigmatism-correcting function of intraocular lens V2788 Astigmatism-correcting function of intraocular lens V2789 Astigmatism-correcting function of intraocular lens V2780 Amniotic membrane for surgical reconstruction, per procedure V2790 Amniotic membrane for surgical reconstruction, per procedure V2790 Vision supply, accessory and/or service component of another HCPCS vision code V2799 Vision service miscellaneous V5010 Assessment for hearing aid V5011 Fitting/orientation/checking of hearing aid V5012 Conformity evaluation V5020 Conformity evaluation V5030 Hearing aid, monaural, body worn, air conduction V5040 Hearing aid, monaural, body worn, air conduction V5050 Hearing aid, monaural, behind the ear V5070 Glasses, air conduction V5080 Glasses, air conduction V5090 Dispensing fee, unspecified hearing aid V5010 Hearing aid, bilateral, body worn V5110 Dispensing fee, bilateral V5110 Binaural, in the ear V5110 Binaural, behind the ear V5110 Binaural, behind the ear	V2756		
V2762 Polarization, any lens material, per lens V2770 Occluder lens per lens V2781 Oversize lens per lens V2782 Lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens V2783 Lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens V2784 Lens, index grtr than or equal to 1.66 plastic or grtr than or equal to 1.80 glass, excludes polycarbonate, per lens V2786 Lens, polycarbonate or equal, any index, per lens V2787 Lens, polycarbonate or equal, any index, per lens V2788 Specialty occupational multifocal lens, per lens V2789 Astigmatism-correcting function of intraocular lens V2789 Presbyopia correcting function of intraocular lens V2790 Amniotic membrane for surgical reconstruction, per procedure V2797 Vision supply, accessory and/or service component of another HCPCS vision code V2799 Vision service miscellaneous Assessment for hearing aid V5010 Assessment for hearing aid V5011 Fitting/orientation/checking of hearing aid V5020 Conformity evaluation V5030 Hearing aid, monaural, body worn, air conduction V5040 Hearing aid, monaural, in the ear V5060 Hearing aid, monaural, behind the ear V5070 Glasses, air conduction V5080 Glasses, in conduction V5090 Dispensing fee, unspecified hearing aid V5120 Binaural, behind the ear V5140 Binaural, behind the ear V5150 Binaural, behind the ear V5150 Binaural, behind the ear V5150 Binaural, behind the ear	V2760		
V2770 Occluder lens per lens V2781 Progressive lens, per lens V2782 Lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens V2783 Lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens V2783 Lens, index grit than or equal to 1.66 plastic or grtr than or equal to 1.80 glass, excludes polycarbonate, per lens V2784 Lens, polycarbonate or equal, any index, per lens V2785 Specialty occupational multifocal lens, per lens V2786 Specialty occupational multifocal lens, per lens V2787 Astigmatism-correcting function of intraocular lens V2787 Astigmatism-correcting function of intraocular lens V2789 Presbyopia correcting function of intraocular lens V2790 Vision supply, accessory and/or service component of another HCPCS vision code V2791 Vision service miscellaneous V3799 Vision service miscellaneous V3790 Assessment for hearing aid V3011 Fitting/orientation/checking of hearing aid V3011 Fitting/orientation/checking of hearing aid V3014 Repair/modification of a hearing aid V3014 Repair/modification of hearing aid V3015 Conformity evaluation V3030 Hearing aid, monaural, body worn, air conduction V3040 Hearing aid, monaural, body worn, air conduction V3050 Hearing aid, monaural, body worn, bene conduction V3050 Hearing aid, monaural, body worn, sir conduction V3050 Hearing aid, monaural, body worn, sir conduction V3050 Hearing aid, monaural, body worn, sir conduction V3050 Hearing aid, monaural, behind the ear V3050 Hearing aid, behind the ear V3050 Hearing aid, bilateral, bedy worn V3050 Hearing aid, bilateral, bedy worn V3050 Binaural, behind the ear V30510 Binaural, behind the ear V3140 Binaural, behind the ear V3150 Binaural, behind the ear	V2761	Mirror coating, any type, solid, gradient or equal, any lens material	
V2770 Occluder lens per lens V2781 Progressive lens, per lens V2782 Lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens V2783 Lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens V2783 Lens, index grit than or equal to 1.66 plastic or grtr than or equal to 1.80 glass, excludes polycarbonate, per lens V2784 Lens, polycarbonate or equal, any index, per lens V2785 Specialty occupational multifocal lens, per lens V2786 Specialty occupational multifocal lens, per lens V2787 Astigmatism-correcting function of intraocular lens V2787 Astigmatism-correcting function of intraocular lens V2789 Presbyopia correcting function of intraocular lens V2790 Vision supply, accessory and/or service component of another HCPCS vision code V2791 Vision service miscellaneous V3799 Vision service miscellaneous V3790 Assessment for hearing aid V3011 Fitting/orientation/checking of hearing aid V3011 Fitting/orientation/checking of hearing aid V3014 Repair/modification of a hearing aid V3014 Repair/modification of hearing aid V3015 Conformity evaluation V3030 Hearing aid, monaural, body worn, air conduction V3040 Hearing aid, monaural, body worn, air conduction V3050 Hearing aid, monaural, body worn, bene conduction V3050 Hearing aid, monaural, body worn, sir conduction V3050 Hearing aid, monaural, body worn, sir conduction V3050 Hearing aid, monaural, body worn, sir conduction V3050 Hearing aid, monaural, behind the ear V3050 Hearing aid, behind the ear V3050 Hearing aid, bilateral, bedy worn V3050 Hearing aid, bilateral, bedy worn V3050 Binaural, behind the ear V30510 Binaural, behind the ear V3140 Binaural, behind the ear V3150 Binaural, behind the ear			
V2780 Oversize lens per lens V2781 Progressive lens, per lens V2782 Lens, index 1,54 to 1,65 plastic or 1,60 to 1,79 glass, excludes polycarbonate, per lens V2783 Lens, index 1,54 to 1,65 plastic or grtr than or equal to 1,80 glass, excludes polycarbonate, per lens V2784 Lens, polycarbonate or equal, any index, per lens V2785 Specialty occupational multifocal lens, per lens V2786 Specialty occupational multifocal lens, per lens V2787 Astigmatism-correcting function of intraocular lens V2788 Presbyopia correcting function of intraocular lens V2790 Amniotic membrane for surgical reconstruction, per procedure V2791 Vision supply, accessory and/or service component of another HCPCs vision code V2799 Vision service miscellaneous V3791 Assessment for hearing aid V5011 Fitting/orientation/checking of hearing aid V5014 Repair/modification of a hearing aid V5014 Repair/modification of a hearing aid V5014 Repair/modification of a hearing aid V5030 Hearing aid, monaural, body worn, air conduction V5030 Hearing aid, monaural, body worn, bone conduction V5030 Hearing aid, monaural, in the ear V5070 Glasses, air conduction V5080 Glasses, bone conduction V5090 Dispensing fee, bilateral V5010 Hearing aid, bilateral, body worn V5110 Dispensing fee, bilateral V5120 Binaural, behind the ear V5130 Binaural, behind the ear V5140 Binaural, behind the ear V5150 Binaural, behind the ear V5160 Dispensing fee, binaural	V2762	Polarization, any lens material, per lens	
V2781 Progressive lens, per lens V2782 Lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens V2783 Lens, index 9 grt rhan or equal to 1.66 plastic or grt rhan or equal to 1.80 glass, excludes polycarbonate, per lens V2784 Lens, polycarbonate or equal, any index, per lens V2786 Specialty occupational multifocal lens, per lens V2787 Astigmatism-correcting function of intraocular lens V2788 Presbyopia correcting function of intraocular lens V2790 Amniotic membrane for surgical reconstruction, per procedure V2797 Vision supply, accessory and/or service component of another HCPCS vision code V2799 Vision service miscellaneous V2790 Vision service miscellaneous V2791 Fitting/orientation/checking of hearing aid V5011 Fitting/orientation/checking of hearing aid V5012 Conformity evaluation V5030 Hearing aid, monaural, body worn, air conduction V5030 Hearing aid, monaural, body worn, bone conduction V5040 Hearing aid, monaural, behind the ear V5050 Glasses, air conduction V5050 Glasses, bone conduction V5090 Dispensing fee, unspecified hearing aid V5010 Hearing aid, body V5010 Binaural, body V5110 Dispensing fee, binaural	V2770	Occluder lens per lens	
V2782 Lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens  V2783 Lens, index grt than or equal to 1.66 plastic or grtr than or equal to 1.80 glass, excludes polycarbonate, per lens  V2784 Lens, polycarbonate or equal, any index, per lens  V2786 Specialty occupational multifocal lens, per lens  V2787 Astigmatism-correcting function of intraocular lens  V2788 Presbyopia correcting function of intraocular lens  V2797 Vision supply, accessory and/or service component of another HCPCS vision code  V2799 Vision service miscellaneous  V2790 Vision service miscellaneous  V2791 Vision service miscellaneous  V2791 Fitting/orientation/checking of hearing aid  V5011 Fitting/orientation/checking of hearing aid  V5012 Conformity evaluation  V5030 Hearing aid, monaural, body worn, air conduction  V5040 Hearing aid, monaural, in the ear  V5050 Glasses, air conduction  V5060 Hearing aid, monaural, behind the ear  V5070 Glasses, bone conduction  V5090 Dispensing fee, unspecified hearing aid  V5095 Semi-implantable middle ear hearing prosthesis  V5100 Dispensing fee, binaural  V5110 Dispensing fee, binaural	V2780	Oversize lens per lens	
v2783 Lens, index grtr than or equal to 1.66 plastic or grtr than or equal to 1.80 glass, excludes polycarbonate, per lens v2784 Lens, polycarbonate or equal, any index, per lens v2786 Specialty occupational multifocal lens, per lens v2787 Astigmatism-correcting function of intraocular lens v2788 Presbyopia correcting function of intraocular lens v2799 Aminotic membrane for surgical reconstruction, per procedure v2797 Vision supply, accessory and/or service component of another HCPCS vision code v2799 Vision service miscellaneous v5010 Assessment for hearing aid v5011 Fitting/orientation/checking of hearing aid v5014 Repair/modification of a hearing aid v5020 Conformity evaluation v5030 Hearing aid, monaural, body worn, air conduction v5030 Hearing aid, monaural, body worn, bone conduction v5040 Hearing aid, monaural, in the ear v5060 Hearing aid, monaural, in the ear v5070 Glasses, air conduction v5080 Glasses, bone conduction v5080 Glasses, bone conduction v5080 Semi-implantable middle ear hearing aid v5095 Semi-implantable middle ear hearing prosthesis v5100 Hearing aid, bilateral, body v5110 Dispensing fee, bilateral v5120 Binaural, behind the ear v5130 Binaural, glasses v5160 Dispensing fee, binaural	V2781	Progressive lens, per lens	
V2783 Lens, index grtr than or equal to 1.66 plastic or grtr than or equal to 1.80 glass, excludes polycarbonate, per lens  V2784 Lens, polycarbonate or equal, any index, per lens  V2786 Specialty occupational multifocal lens, per lens  V2787 Astigmatism-correcting function of intraocular lens  V2788 Presbyopia correcting function of intraocular lens  V2790 Amniotic membrane for surgical reconstruction, per procedure  V2797 Vision supply, accessory and/or service component of another  HCPCS vision code  V2799 Vision service miscellaneous  V2790 Vision service miscellaneous  V5010 Assessment for hearing aid  V5011 Fitting/orientation/checking of hearing aid  V5014 Repair/modification of a hearing aid  V5010 Hearing aid, monaural, body worn, air conduction  V5030 Hearing aid, monaural, body worn, bone conduction  V5040 Hearing aid, monaural, body worn, bone conduction  V5050 Hearing aid, monaural, behind the ear  V5060 Glasses, air conduction  V5070 Glasses, sone conduction  V5090 Dispensing fee, unspecified hearing aid  V5090 Semi-implantable middle ear hearing prosthesis  V5100 Binaural, body  V5110 Binaural, body  V5130 Binaural, behind the ear  V5160 Dispensing fee, binaural	V2782	Lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes	
1.80 glass, excludes polycarbonate, per lens  V2784 Lens, polycarbonate or equal, any index, per lens  V2786 Specialty occupational multifocal lens, per lens  V2787 Astigmatism-correcting function of intraocular lens  V2788 Presbyopia correcting function of intraocular lens  V2790 Amniotic membrane for surgical reconstruction, per procedure  V2797 Vision supply, accessory and/or service component of another  HCPCS vision code  V2799 Vision service miscellaneous  V5010 Assessment for hearing aid  V5011 Fitting/orientation/checking of hearing aid  V5014 Repair/modification of a hearing aid  V5020 Conformity evaluation  V5030 Hearing aid, monaural, body worn, air conduction  V5040 Hearing aid, monaural, body worn, bone conduction  V5050 Hearing aid, monaural, in the ear  V5060 Hearing aid, monaural, behind the ear  V5070 Glasses, air conduction  V5080 Glasses, bone conduction  V5090 Dispensing fee, unspecified hearing aid  V5010 Hearing aid, bilateral, body worn  V5010 Hearing aid, bilateral, body worn  V5010 Binaural, in the ear  V5110 Dispensing fee, bilateral  V5120 Binaural, plasses  V5160 Dispensing fee, binaural		polycarbonate, per lens	
1.80 glass, excludes polycarbonate, per lens  V2784 Lens, polycarbonate or equal, any index, per lens  V2786 Specialty occupational multifocal lens, per lens  V2787 Astigmatism-correcting function of intraocular lens  V2788 Presbyopia correcting function of intraocular lens  V2790 Amniotic membrane for surgical reconstruction, per procedure  V2797 Vision supply, accessory and/or service component of another  HCPCS vision code  V2799 Vision service miscellaneous  V3010 Assessment for hearing aid  V5011 Fitting/orientation/checking of hearing aid  V5014 Repair/modification of a hearing aid  V5020 Conformity evaluation  V5030 Hearing aid, monaural, body worn, air conduction  V5040 Hearing aid, monaural, body worn, bone conduction  V5050 Hearing aid, monaural, in the ear  V5060 Hearing aid, monaural, behind the ear  V5070 Glasses, air conduction  V5080 Glasses, bone conduction  V5090 Dispensing fee, unspecified hearing aid  V5090 Dispensing fee, unspecified hearing prosthesis  V5100 Hearing aid, bilateral, body wom  V5110 Dispensing fee, bilateral  V5120 Binaural, in the ear  V5140 Binaural, in the ear  V5150 Binaural, glasses  V5160 Dispensing fee, binaural	V2783	Lens, index grtr than or equal to 1.66 plastic or grtr than or equal to	
V2784 Lens, polycarbonate or equal, any index, per lens V2786 Specialty occupational multifocal lens, per lens V2787 Astigmatism-correcting function of intraocular lens V2788 Presbyopia correcting function of intraocular lens V2790 Amniotic membrane for surgical reconstruction, per procedure V2797 Vision supply, accessory and/or service component of another HCPCS vision code V2799 Vision service miscellaneous V2799 Vision service miscellaneous V2790 Assessment for hearing aid V2701 Fitting/orientation/checking of hearing aid V3501 Repair/modification of a hearing aid V3501 Repair/modification of a hearing aid V3502 Conformity evaluation V35030 Hearing aid, monaural, body worn, air conduction V35040 Hearing aid, monaural, body worn, bone conduction V35050 Hearing aid, monaural, in the ear V35070 Glasses, air conduction V35080 Glasses, bone conduction V35090 Dispensing fee, unspecified hearing aid V35091 Dispensing fee, unspecified hearing prosthesis V3510 Binaural, body V3510 Binaural, body V3510 Binaural, body V3510 Binaural, behind the ear V3510 Binaural, behind the ear V3510 Binaural, behind the ear V35150 Binaural, behind the ear V35150 Binaural, besind the ear V35150 Binaural, besind the ear			
V2786 Specialty occupational multifocal lens, per lens V2787 Astigmatism-correcting function of intraocular lens V2788 Presbyopia correcting function of intraocular lens V2790 Amniotic membrane for surgical reconstruction, per procedure V2797 Vision supply, accessory and/or service component of another HCPCS vision code V2799 Vision service miscellaneous V2799 Vision service miscellaneous V5010 Assessment for hearing aid V5011 Fitting/orientation/checking of hearing aid V5014 Repair/modification of a hearing aid V5020 Conformity evaluation V5030 Hearing aid, monaural, body worn, air conduction V5030 Hearing aid, monaural, body worn, bone conduction V5040 Hearing aid, monaural, in the ear V5060 Hearing aid, monaural, behind the ear V5060 Glasses, air conduction V5090 Glasses, bone conduction V5090 Dispensing fee, unspecified hearing aid V5090 Semi-implantable middle ear hearing prosthesis V5100 Hearing aid, body worn V5110 Dispensing fee, bilateral V5120 Binaural, body V5130 Binaural, in the ear V5150 Binaural, glasses V5160 Dispensing fee, binaural	V2784	Lens, polycarbonate or equal, any index, per lens	
V2787 Astigmatism-correcting function of intraocular lens V2788 Presbyopia correcting function of intraocular lens V2790 Amniotic membrane for surgical reconstruction, per procedure V2797 Vision supply, accessory and/or service component of another HCPCS vision code V2799 Vision service miscellaneous V2799 Vision service miscellaneous V5010 Assessment for hearing aid V5011 Fitting/orientation/checking of hearing aid V5014 Repair/modification of a hearing aid V5020 Conformity evaluation V5030 Hearing aid, monaural, body worn, air conduction V5040 Hearing aid, monaural, body worn, bone conduction V5050 Hearing aid, monaural, behind the ear V5070 Glasses, air conduction V5080 Glasses, air conduction V5090 Dispensing fee, unspecified hearing aid V5090 Semi-implantable middle ear hearing prosthesis V5100 Hearing aid, bilateral, body worn V5110 Dispensing fee, bilateral V5120 Binaural, in the ear V5150 Binaural, jasses V5160 Dispensing fee, binaural	V2786		
V2788 Presbyopia correcting function of intraocular lens V2790 Amniotic membrane for surgical reconstruction, per procedure V2797 Vision supply, accessory and/or service component of another HCPCS vision code V2799 Vision service miscellaneous V5010 Assessment for hearing aid V5011 Fitting/orientation/checking of hearing aid V5014 Repair/modification of a hearing aid V5015 Hearing aid, monaural, body worn, air conduction V5030 Hearing aid, monaural, body worn, bone conduction V5040 Hearing aid, monaural, in the ear V5050 Hearing aid, monaural, behind the ear V5060 Hearing aid, monaural, behind the ear V5070 Glasses, air conduction V5090 Dispensing fee, unspecified hearing aid V5090 Semi-implantable middle ear hearing prosthesis V5100 Hearing aid, bilateral, body worn V5110 Dispensing fee, bilateral V5120 Binaural, in the ear V5130 Binaural, in the ear V5140 Binaural, behind the ear V5150 Binaural, glasses V5160 Dispensing fee, binaural	V2787		
V2790 Amniotic membrane for surgical reconstruction, per procedure V2797 Vision supply, accessory and/or service component of another HCPCS vision code V2799 Vision service miscellaneous V5010 Assessment for hearing aid V5011 Fitting/orientation/checking of hearing aid V5014 Repair/modification of a hearing aid V5020 Conformity evaluation V5030 Hearing aid, monaural, body worn, air conduction V5040 Hearing aid, monaural, body worn, bone conduction V5040 Hearing aid, monaural, in the ear V5040 Hearing aid, monaural, behind the ear V5060 Hearing aid, monaural, behind the ear V5070 Glasses, air conduction V5080 Glasses, bone conduction V5090 Dispensing fee, unspecified hearing aid V5090 Semi-implantable middle ear hearing prosthesis V5100 Hearing aid, bilateral, body worn V5110 Dispensing fee, bilateral V5120 Binaural, in the ear V5130 Binaural, in the ear V5140 Binaural, glasses V5160 Dispensing fee, binaural	V2788		
V2797 Vision supply, accessory and/or service component of another HCPCS vision code  V2799 Vision service miscellaneous  V5010 Assessment for hearing aid  V5011 Fitting/orientation/checking of hearing aid  V5014 Repair/modification of a hearing aid  V5020 Conformity evaluation  V5030 Hearing aid, monaural, body worn, air conduction  V5040 Hearing aid, monaural, body worn, bone conduction  V5050 Hearing aid, monaural, in the ear  V5060 Hearing aid, monaural, behind the ear  V5070 Glasses, air conduction  V5090 Dispensing fee, unspecified hearing aid  V5095 Semi-implantable middle ear hearing prosthesis  V5100 Hearing aid, bilateral, body worn  V5110 Dispensing fee, bilateral  V5120 Binaural, in the ear  V5130 Binaural, behind the ear  V5150 Binaural, glasses  V5160 Dispensing fee, binaural			
HCPCS vision code  V2799 Vision service miscellaneous  V5010 Assessment for hearing aid  V5011 Fitting/orientation/checking of hearing aid  V5014 Repair/modification of a hearing aid  V5020 Conformity evaluation  V5030 Hearing aid, monaural, body worn, air conduction  V5040 Hearing aid, monaural, body worn, bone conduction  V5050 Hearing aid, monaural, behind the ear  V5060 Hearing aid, monaural, behind the ear  V5070 Glasses, air conduction  V5090 Dispensing fee, unspecified hearing aid  V5095 Semi-implantable middle ear hearing prosthesis  V5100 Hearing aid, bilateral, body worn  V5110 Dispensing fee, bilateral  V5120 Binaural, in the ear  V5130 Binaural, behind the ear  V5150 Binaural, glasses  V5160 Dispensing fee, binaural			†
V5010 Assessment for hearing aid V5011 Fitting/orientation/checking of hearing aid V5014 Repair/modification of a hearing aid V5020 Conformity evaluation V5030 Hearing aid, monaural, body worn, air conduction V5040 Hearing aid, monaural, body worn, bone conduction V5050 Hearing aid, monaural, in the ear V5060 Hearing aid, monaural, behind the ear V5070 Glasses, air conduction V5080 Glasses, bone conduction V5090 Dispensing fee, unspecified hearing aid V5090 Semi-implantable middle ear hearing prosthesis V5100 Hearing aid, bilateral, body worn V5110 Dispensing fee, bilateral V5120 Binaural, body V5130 Binaural, in the ear V5150 Binaural, glasses V5160 Dispensing fee, binaural			
V5010 Assessment for hearing aid V5011 Fitting/orientation/checking of hearing aid V5014 Repair/modification of a hearing aid V5020 Conformity evaluation V5030 Hearing aid, monaural, body worn, air conduction V5040 Hearing aid, monaural, body worn, bone conduction V5050 Hearing aid, monaural, in the ear V5060 Hearing aid, monaural, behind the ear V5070 Glasses, air conduction V5080 Glasses, bone conduction V5090 Dispensing fee, unspecified hearing aid V5090 Semi-implantable middle ear hearing prosthesis V5100 Hearing aid, bilateral, body worn V5110 Dispensing fee, bilateral V5120 Binaural, body V5130 Binaural, in the ear V5150 Binaural, glasses V5160 Dispensing fee, binaural	V2799	Vision service miscellaneous	+
V5011 Fitting/orientation/checking of hearing aid V5014 Repair/modification of a hearing aid V5020 Conformity evaluation V5030 Hearing aid, monaural, body worn, air conduction V5040 Hearing aid, monaural, body worn, bone conduction V5050 Hearing aid, monaural, in the ear V5060 Hearing aid, monaural, behind the ear V5070 Glasses, air conduction V5080 Glasses, bone conduction V5090 Dispensing fee, unspecified hearing aid V5090 Semi-implantable middle ear hearing prosthesis V5100 Hearing aid, bilateral, body worn V5110 Dispensing fee, bilateral V5120 Binaural, body V5130 Binaural, in the ear V5140 Binaural, behind the ear V5150 Binaural, glasses V5160 Dispensing fee, binaural			+
V5014 Repair/modification of a hearing aid V5020 Conformity evaluation V5030 Hearing aid, monaural, body worn, air conduction V5040 Hearing aid, monaural, body worn, bone conduction V5050 Hearing aid, monaural, in the ear V5060 Hearing aid, monaural, behind the ear V5070 Glasses, air conduction V5080 Glasses, bone conduction V5090 Dispensing fee, unspecified hearing aid V5095 Semi-implantable middle ear hearing prosthesis V5100 Hearing aid, bilateral, body worn V5110 Dispensing fee, bilateral V5120 Binaural, in the ear V5140 Binaural, behind the ear V5150 Binaural, glasses V5160 Dispensing fee, binaural		· · · · · · · · · · · · · · · · · · ·	+
V5020 Conformity evaluation V5030 Hearing aid, monaural, body worn, air conduction V5040 Hearing aid, monaural, body worn, bone conduction V5050 Hearing aid, monaural, in the ear V5060 Hearing aid, monaural, behind the ear V5070 Glasses, air conduction V5080 Glasses, bone conduction V5090 Dispensing fee, unspecified hearing aid V5095 Semi-implantable middle ear hearing prosthesis V5100 Hearing aid, bilateral, body worn V5110 Dispensing fee, bilateral V5120 Binaural, body V5130 Binaural, in the ear V5140 Binaural, glasses V5160 Dispensing fee, binaural			+
V5030 Hearing aid, monaural, body worn, air conduction V5040 Hearing aid, monaural, body worn, bone conduction V5050 Hearing aid, monaural, in the ear V5060 Hearing aid, monaural, behind the ear V5070 Glasses, air conduction V5080 Glasses, bone conduction V5090 Dispensing fee, unspecified hearing aid V5095 Semi-implantable middle ear hearing prosthesis V5100 Hearing aid, bilateral, body worn V5110 Dispensing fee, bilateral V5120 Binaural, body V5130 Binaural, in the ear V5140 Binaural, behind the ear V5150 Binaural, glasses V5160 Dispensing fee, binaural		·	+
V5040 Hearing aid, monaural, body worn, bone conduction V5050 Hearing aid, monaural, in the ear V5060 Hearing aid, monaural, behind the ear V5070 Glasses, air conduction V5080 Glasses, bone conduction V5090 Dispensing fee, unspecified hearing aid V5095 Semi-implantable middle ear hearing prosthesis V5100 Hearing aid, bilateral, body worn V5110 Dispensing fee, bilateral V5120 Binaural, body V5130 Binaural, in the ear V5140 Binaural, behind the ear V5150 Binaural, glasses V5160 Dispensing fee, binaural			+
V5050 Hearing aid, monaural, in the ear V5060 Hearing aid, monaural, behind the ear V5070 Glasses, air conduction V5080 Glasses, bone conduction V5090 Dispensing fee, unspecified hearing aid V5095 Semi-implantable middle ear hearing prosthesis V5100 Hearing aid, bilateral, body worn V5110 Dispensing fee, bilateral V5120 Binaural, body V5130 Binaural, in the ear V5140 Binaural, behind the ear V5150 Binaural, glasses V5160 Dispensing fee, binaural		·	+
V5060 Hearing aid, monaural, behind the ear  V5070 Glasses, air conduction  V5080 Glasses, bone conduction  V5090 Dispensing fee, unspecified hearing aid  V5095 Semi-implantable middle ear hearing prosthesis  V5100 Hearing aid, bilateral, body worn  V5110 Dispensing fee, bilateral  V5120 Binaural, body  V5130 Binaural, in the ear  V5140 Binaural, behind the ear  V5150 Binaural, glasses  V5160 Dispensing fee, binaural			+
V5070 Glasses, air conduction V5080 Glasses, bone conduction V5090 Dispensing fee, unspecified hearing aid V5095 Semi-implantable middle ear hearing prosthesis V5100 Hearing aid, bilateral, body worn V5110 Dispensing fee, bilateral V5120 Binaural, body V5130 Binaural, in the ear V5140 Binaural, behind the ear V5150 Binaural, glasses V5160 Dispensing fee, binaural			+
V5080 Glasses, bone conduction V5090 Dispensing fee, unspecified hearing aid V5095 Semi-implantable middle ear hearing prosthesis V5100 Hearing aid, bilateral, body worn V5110 Dispensing fee, bilateral V5120 Binaural, body V5130 Binaural, in the ear V5140 Binaural, behind the ear V5150 Binaural, glasses V5160 Dispensing fee, binaural			+
V5090 Dispensing fee, unspecified hearing aid V5095 Semi-implantable middle ear hearing prosthesis V5100 Hearing aid, bilateral, body worn V5110 Dispensing fee, bilateral V5120 Binaural, body V5130 Binaural, in the ear V5140 Binaural, behind the ear V5150 Binaural, glasses V5160 Dispensing fee, binaural		·	+
V5095 Semi-implantable middle ear hearing prosthesis V5100 Hearing aid, bilateral, body worn V5110 Dispensing fee, bilateral V5120 Binaural, body V5130 Binaural, in the ear V5140 Binaural, behind the ear V5150 Binaural, glasses V5160 Dispensing fee, binaural		·	+
V5100 Hearing aid, bilateral, body worn V5110 Dispensing fee, bilateral V5120 Binaural, body V5130 Binaural, in the ear V5140 Binaural, behind the ear V5150 Binaural, glasses V5160 Dispensing fee, binaural			+
V5110 Dispensing fee, bilateral V5120 Binaural, body V5130 Binaural, in the ear V5140 Binaural, behind the ear V5150 Binaural, glasses V5160 Dispensing fee, binaural			+
V5120 Binaural, body V5130 Binaural, in the ear V5140 Binaural, behind the ear V5150 Binaural, glasses V5160 Dispensing fee, binaural			+
V5130 Binaural, in the ear  V5140 Binaural, behind the ear  V5150 Binaural, glasses  V5160 Dispensing fee, binaural			+
V5140 Binaural, behind the ear V5150 Binaural, glasses V5160 Dispensing fee, binaural			+
V5150 Binaural, glasses V5160 Dispensing fee, binaural		·	+
V5160 Dispensing fee, binaural			<del> </del>
			<del> </del>
V5171 Hearing aid, contralateral routing device, monaural, in the ear (ite)			
	V5171	Hearing aid, contralateral routing device, monaural, in the ear (ite)	

V5172	Hearing aid, contralateral routing device, monaural, in the canal (itc)	
V5181	Hearing aid, contralateral routing device, monaural, behind the ear	
\	(bte)	
V5190	Hearing aid, CROS, glasses	
V5200	Dispensing fee, CROS	
V5211	Hearing aid, contralateral routing system, binaural, ite/ite	
V5212	Hearing aid, contralateral routing system, binaural, ite/itc	
V5213	Hearing aid, contralateral routing system, binaural, ite/bte	
V5214	Hearing aid, contralateral routing system, binaural, itc/itc	
V5215	Hearing aid, contralateral routing system, binaural, itc/bte	
V5221	Hearing aid, contralateral routing system, binaural, bte/bte	
V5230	Hearing aid, BICROS, glasses	
V5240	Dispensing fee, BICROS	
V5241	Dispensing fee, monaural hearing aid, any type	
V5242	Hearing aid, analog, monaural, CIC (completely in the ear canal)	
V5243	Hearing aid, analog, monaural, ITC (in the canal)	
V5244	Hearing aid, digitally programmable analog, monaural, CIC	
V5245	Hearing aid, digitally programmable, analog, monaural, ITC	
V5246	Hearing aid, digitally programmable analog, monaural, ITE (in the ear)	
V5247	Hearing aid, digitally programmable analog, monaural, BTE (behind the ear)	
V5248	Hearing aid, analog, binaural, CIC	
V5249	Hearing aid, analog, binaural, ITC	
V5250	Hearing aid, digitally programmable analog, binaural, CIC	
V5251	Hearing aid, digitally programmable analog, binaural, ITC	
V5252	Hearing aid, digitally programmable, binaural, ITE	
V5253	Hearing aid, digitally programmable, binaural, BTE	
V5254	Hearing aid, digital, monaural, CIC	
V5255	Hearing aid, digital, monaural, ITC	
V5256	Hearing aid, digital, monaural, ITE	
V5257	Hearing aid, digital, monaural, BTE	
V5258	Hearing aid, digital, binaural, CIC	
V5259	Hearing aid, digital, binaural, ITC	
V5260	Hearing aid, digital, binaural, ITE	
V5261	Hearing aid, digital, binaural, BTE	
V5262	Hearing aid, disposable, any type, monaural	
V5263	Hearing aid, disposable, any type, findhadral  Hearing aid, disposable, any type, binaural	
V5264	Ear mold/insert, not disposable, any type	
V5265	Ear mold/insert, disposable, any type	
V5266	Battery for use in hearing device	
V5267	Hearing aid or assistive listening device/supplies/accessories, not otherwise specified	
V5268	Assistive listening device, telephone amplifier, any type	
V5269	Assistive listening device, alerting, any type	
V5270	Assistive listening device, television amplifier, any type	
V5270	Assistive listening device, television caption decoder	
V5271	Assistive listening device, television capiton decoder  Assistive listening device, TDD	
	Ţ ,	
V5273	Assistive listening device, for use with cochlear implant	
V5274	Assistive listening device, not otherwise specified	
V5281	Assistive listening device, personal fm/dm system, monaural, (1	
	receiver, transmitter, microphone), any type	
V5282	Assistive listening device, personal fm/dm system, binaural, (2 receivers, transmitter, microphone), any type	
V5283	Assistive listening device, personal fm/dm neck, loop induction	
	receiver	
V5284	Assistive listening device, personal fm/dm, ear level receiver	
V5285	Assistive listening device, personal fm/dm, direct audio input receiver	
V5286	Assistive listening device, personal blue tooth fm/dm receiver	

Private Duty Nursing and Home Health 651 Hospice; Routine Home Care 652 Hospice; Continuous Home Care 653 Hospice; Continuous Home Care 654 Hospice; Central Dispatent Respite Care 655 Hospice; General Impatient Care 656 Hospice; General Impatient Care 657 Hospice; Direct Physician Care 658 Hospice; Nursing Facility Room and Board 0112 Room and Board Private (one bed) - OB 0114 Room and Board Private (one bed) - Psychiatric 0116 Room and Board Private (one bed) - Psychiatric 0117 Room and Board Private (one bed) - Detoxification 0120 Long term acute care 0121 Room and Board Semiprivate (two beds) - OB 0124 Room and Board Semiprivate (two beds) - Psychiatric 0125 Room and Board Semiprivate (two beds) - Psychiatric 0126 Room and Board Semiprivate (two beds) - Psychiatric 0127 Room and Board Semiprivate (two beds) - Detoxification 0128 Level 1 Rehab 0129 Level 2 Rehab - acute complex 0129 Level 2 Rehab - acute complex 0129 Room & Board - Three and Four Beds Psychiatric 0140 Room & Board - Three and Four Beds Psychiatric 0141 Room & Board - Three and Four Beds Psychiatric 0142 Room & Board - Deluxe Private Destricis (OB) 0144 Room & Board - Deluxe Private Destricis (OB) 0150 Room & Board - Ward Delux Private Destricis (OB) 0161 Room & Board - Ward Delux Private Destricis (OB) 0162 Room & Board - Ward Delux Private Destricis (OB) 0163 Room & Board - Ward Delux Private Destricis (OB) 0164 Room & Board - Ward Delux Private Destricis (OB) 0170 Nursery General Classification 0171 Nursery Newborn - Level II 0172 Nursery Newborn - Level II 0173 Nursery Newborn - Level II 0174 Nursery Newborn - Level II 0175 Subacute Care - Level II - SNF 0196 Seneral classification - SNF 0197 Subacute Care - Level II - SNF 0198 Subacute Care - Level II - SNF 0199 General classification - SNF 0199 Other Subacute Care - Level II - SNF 0190 General classification - SNF 0191 Behavioral Health Partial Hospitalization - intensive 0190 Other Therapout Services - General 0190 General Care - Level II - SNF 0191 Sehavioral Health Partial Hospitaliza	V5287	Assistive listening device, personal fm/dm receiver, not otherwise	
Islaning device		specified	
Vis289 Assistive listering device, personal fin/dim adapter/boot coupling device for receiver, any type  Assistive listering device, transmitter microphone, any type  Revenue Codes  Its Haspice, Room & Board - Private  Hospice, Room & Board - Semi-private Two Bed  Hospice, Room & Board - Semi-private Two Bed  Hospice, Semi-private - Trives and Four Beds  Hospice, Polluse rooms are accommendations with amenities substantially in excess of thought and a substantially in excess of thought and the substantial substantial private Two Beds  Hospice, Roumine Home Care  Hospice, Semi-private Care  Hospice, Institute Respitance Care  Hospice, Breat Physician Care	V5288	Assistive listening device, personal fm/dm transmitter assistive	
device for receiver, any type  Revenue  Revenue    Best		•	
Assistive listening device, transmitter microphone, any type Codes    Codes	V5289		
Revenue Codes  115	1/=000		
Codes		Assistive listening device, transmitter microphone, any type	
Hospice: Room & Board - Private 1155 Hospice: Somi-Board - Semi-private Two Bed 1156 Hospice: Semi-Private - Three and Four Beds 1157 Hospice: Semi-Private - Three and Four Beds 1158 Hospice: Semi-Private - Three and Four Beds 1158 Hospice: Semi-Private - Three and Four Beds 1159 Hospice: Routine service charge for accommodations with inve or more beds 1150 Hospice: Routine service charge for accommodations with five or more beds 1151 Hospice: Routine Home Care 1152 Hospice: Continuous Home Care 1153 Hospice: Continuous Home Care 1154 Hospice: Continuous Home Care 1155 Hospice: Continuous Home Care 1156 Hospice: Continuous Home Care 1156 Hospice: Continuous Home Care 1157 Hospice: Continuous Home Care 1158 Hospice: Continuous Home Care 1159 Hospice: Continuous Home Care 1150 Home And Board Private (one bed) - Potextification 1150 Home And Board Semiprivate (two beds) - Potextification 1151 Hospice: Continuous Home Care 1151 Hospice: Continuous Hom			
Hospice: Semi-Private - Three and Four Beds Hospice: Semi-Private - Three and Four Beds Hospice: Semi-Private - Three and Four Beds Hospice: Delizve rooms are accommodations with amenities substantially in excess of those provided to other patients Hospice: Routine service charge for accommodations with five or more beds Private Duty Nursing and Home Health Hospice: Routine Home Care Hospice: Routine Hospital Care Hospice: Routine Hospital Care Hospice: Dentinuous Home Care Hospice: Dentinuous Home Care Hospice: Direct Physician Care Hospice: Direct Ph		Hospice: Poom & Roard - Private	
Hospice, Semi-Private - Three and Four Beds Hospice, Delivar rooms are accommodations with amenities substantially in excess of those provided to other patients  Hospice; Routine Service charge for accommodations with five or more beds  Private Duty Nursing and Home Health Hospice; Routine Home Care Hospice; Continuous Home Care Hospice; Continuous Home Care Hospice; Continuous Home Care Hospice; Ingatient Respite Care Hospice; General Inpatient Care Hospice; General Inpatient Care Hospice; General Inpatient Care Hospice; General Inpatient Care Hospice; Hospice; Nursing Facility Room and Board Hospice; Hospice; Nursing Facility Room and Board Semiphivate (noe bed) - Depositatic Long term acute care Lorg term acute care Lorg Room and Board Semiphivate (two beds) - Desynchiatric Lorg term and Board Semiphivate (two beds) - Psychiatric Level 1 Rehab Level 1 Rehab Level 2 Rehab - acute complex Room & Board - Three and Four Beds Obstetrics (OB) Room & Board - Three and Four Beds Obstetrics (OB) Room & Board - Three and Four Beds Destetrics (OB) Room & Board - Deluxe Private Obstetrics (OB) Room & Board - Deluxe Private Obstetrics (OB) Room & Board - Mard Obstetrics (OB) Nursery Newborn - Level II - SNF Hospital Room & Board - Partial Hospitalization - Level II - SNF Hospitalizatio		•	
Hospice: Deluxe rooms are accommodations with amenities substantially in excess of those provided to other patients  Hospice; Routine service charge for accommodations with five or more beds  Private Duty Nursing and Home Health  Hospice; Continuous Home Care  Hospice; Continuous Home Care  Hospice; Openiture Respite Care  Hospice; Deneral Ingestier Care  Hospice; Deneral Ingestier Care  Hospice; Deneral Privation Care  Room and Board Private (one bed) - OB  Hospice; Deneral Private (one bed) - OB  Room and Board Private (one bed) - Psychiatric  Room and Board Private (one bed) - Psychiatric  Room and Board Private (one bed) - Psychiatric  Room and Board Semiprivate (two beds) - OB  Hospice; Marchine Care  Room and Board Semiprivate (two beds) - OB  Room and Board Semiprivate (two beds) - OB  Room and Board Semiprivate (two beds) - Detoxification  Room and Board Semiprivate (two beds) - Detoxification  Room and Board Semiprivate (two beds) - Detoxification  Room and Board Semiprivate (two beds) - Psychiatric  Room & Board - Three and Four Beds Obstetrics (OB)  Room & Board - Three and Four Beds Obstetrics (OB)  Room & Board - Three and Four Beds Psychiatric  Room & Board - Deluxe Private Psychiatric  Room & Board - Deluxe Private Psychiatric  Room & Board - Seminary Robuson - Level II  Room & Board - Seminary Robuson - Level II  Room & Board - Seminary Robuson - Level II  Room & Board - Seminary Robuson - Level II  Room & Board - Seminary Robuson - Level II  Room & Board - Seminary Robuson - Level II  Room & Board - Ward Psychiatric  Roo			
substantially in excess of those provided to other patients 155 Hospice; Routine service charge for accommodations with five or more beds 1561 Private Duty Nursing and Home Health 1561 Hospice; Ontinuous Home Care 1562 Hospice; Ontinuous Home Care 1565 Hospice; Ontinuous Home Care 1566 Hospice; Ontinuous Home Care 1567 Hospice; Ontinuous Home Care 1568 Hospice; General Inpatient Care 1568 Hospice; Ontinuous Home Care 1569 Hospice; Ontinuous Home Care 1570 Hospice; Direct Physician Care 1580 Hospice; Ontinuous Home Care 1581 Hospice; Direct Physician Care 1582 Hospice; Nursing Facility Room and Board 1583 Hospice; Nursing Facility Room and Board 1584 Hospice; Nursing Facility Room and Board 1585 Hospice; Nursing Facility Room and Board 1585 Hospice; Nursing Facility Room and Board 1586 Hospice; Nursing Facility Room and Board Private (one bed) - Detoxification 1586 Hospice; Nursing Facility Room and Board Private (one bed) - Detoxification 1580 Long term acute care 1587 Hospice; American Room and Board Semiprivate (two beds) - Detoxification 1588 Level 1 Rehab 1588 Hospice; American Room Room and Board Semiprivate (two beds) - Detoxification 1589 Level 2 Rehab - acute complex 1589 Room & Board - Three and Four Beds Distertics (OB) 1580 Room & Board - Three and Four Beds Psychiatric 1580 Room & Board - Three and Four Beds Psychiatric 1580 Room & Board - Ward Detoxification 1580 General Classification - Nursery Newborn - Level II 1580 Room & Board - Ward Detoxification 1580 General Classification - NIF			
Hospice; Routine service charge for accommodations with five or more beds 551 Private Duty Nursing and Home Health 651 Hospice; Continuous Home Care 652 Hospice; Continuous Home Care 653 Hospice; Inpatient Respite Care 654 Hospice; General Inpatient Care 655 Hospice; Direct Physician Care 656 Hospice; Direct Physician Care 657 Hospice; Direct Physician Care 658 Hospice; Direct Physician Care 658 Hospice; Direct Physician Care 659 Hospice; Direct Physician Care 650 Hospice; Direct Physician Care 650 Hospice; Direct Physician Care 651 Room and Board Private (one bed) - DB 652 Hospice; Direct Physician Care 653 Hospice; Direct Physician Care 654 Hospice; Direct Physician Care 655 Hospice; Direct Physician Care 656 Hospice; Direct Physician Care 657 Hospice; Direct Physician Care 658 Hospice; Direct Physician Care 658 Hospice; Direct Physician Care 658 Hospice; Direct Physician Care 659 Hospice; Direct Physician Care 659 Hospice; Direct Physician Care 650 Hospice; Direct Physician Care			
Hospice; Routine Home Care	155		beds
Hospice; Continuous Home Care	551	Private Duty Nursing and Home Health	
Hospice; Inpatient Respite Care	651	Hospice; Routine Home Care	
Hospice; General Inpatient Care	652	Hospice; Continuous Home Care	
Hospice; Direct Physician Care 658 Hospice; Nursing Facility Room and Board 0112 Room and Board Private (one bed) - OB 0114 Room and Board Private (one bed) - Psychiatric 0116 Room and Board Private (one bed) - Psychiatric 0120 Long term acute care 0122 Room and Board Semiprivate (two beds) - OB 0124 Room and Board Semiprivate (two beds) - OB 0125 Room and Board Semiprivate (two beds) - OB 0126 Room and Board Semiprivate (two beds) - Psychiatric 0127 0128 Level 1 Rehab 0129 Level 2 Rehab - acute complex 0132 Room & Board - Three and Four Beds Obstetrics (OB) 0138 Room & Board - Three and Four Beds Psychiatric 0140 0140 Room & Board - Three and Four Beds Psychiatric 0141 Room & Board - Deluxe Private Destetrics (OB) 0144 Room & Board - Deluxe Private Destetrics (OB) 0152 Room & Board - Deluxe Private Destetrics (OB) 0164 Room & Board - Deluxe Private Detoxification 0152 Room & Board - Deluxe Private Detoxification 0154 Room & Board - Ward Obstetrics (OB) 0155 Room & Board - Ward Destoxification 0156 Room & Board - Ward Detoxification 0170 Nursery General Classification 0171 Nursery Rewborn - Level II 0171 Nursery Newborn - Level II 0172 Nursery Newborn - Level II 0173 Nursery Newborn - Level II 0174 Nursery Newborn - Level II 0175 Subacute Care - Level II - SNF 0190 0190 General classification - SNF 0190 0190 0190 0190 0190 0190 0190 019	655		
Hospices; Nursing Facility Room and Board  Room and Board Private (one bed) - OB  10114 Room and Board Private (one bed) - OB  10114 Room and Board Private (one bed) - Psychiatric  10120 Long term acute care  10121 Room and Board Semiprivate (two beds) - OB  10124 Room and Board Semiprivate (two beds) - OB  10125 Room and Board Semiprivate (two beds) - Psychiatric  10126 Room and Board Semiprivate (two beds) - Psychiatric  10127 Level 1 Rehab  10129 Level 1 Rehab  10129 Level 2 Rehab - acute complex  10132 Room & Board - Three and Four Beds Obstetrics (OB)  10136 Room & Board - Three and Four Beds Obstetrics (OB)  10137 Room & Board - Deluxe Private Obstetrics (OB)  10140 Room & Board - Deluxe Private Psychiatric  10141 Room & Board - Deluxe Private Psychiatric  10142 Room & Board - Deluxe Private Detoxification  10152 Room & Board - Deluxe Private Detoxification  10153 Room & Board - Ward Obstetrics (OB)  10154 Room & Board - Ward Obstetrics (OB)  10155 Room & Board - Ward Obstetrics (OB)  10166 Room & Board - Ward Detoxification  10170 Nursery General Classification  10171 Nursery Newborn - Level II  10172 Nursery Newborn - Level II  10173 Nursery Newborn - Level II  10174 Nursery Newborn - Level II  10175 Subacute Care - Level II - SNF  10190 General classification - SNF  10190 General classification - SNF  10190 General classification - SNF  10191 Subacute Care - Level II - SNF  10192 Subacute Care - Level II - SNF  10193 Subacute Care - Level II - SNF  10194 Subacute Care - Level II - SNF  10195 Subacute Care - Level II - SNF  10196 Subacute Care - Level II - SNF  10197 Subacute Care - Level II - SNF  10198 Subacute Care - Level II - SNF  10199 Other Subacute Care - Level II - SNF  10190 General classification - SNF  1020 Subacute Care - Level II - SNF  1031 Subacute Care - Level II - SNF  1042 Subacute Care - Level III - SNF  1052 Subacute Care - Level II - SNF  1053 Subacute Care - Level II - SNF  1064 Subacute Care - Level II - SNF  1075 Subacute Care - Level II - SNF  1076 Subacute Care - Level II - SN	656		
10112	657		
0114         Room and Board Private (one bed) - Psychiatric           0116         Room and Board Private (one bed) - Detoxification           0120         Long term acute care           0122         Room and Board Semiprivate (two beds) - OB           0124         Room and Board Semiprivate (two beds) - Psychiatric           0126         Room and Board Semiprivate (two beds) - Detoxification           0127         Level 1 Rehab           0129         Level 2 Rehab - acute complex           0132         Room & Board - Three and Four Beds Obstetrics (OB)           0133         Room & Board - Three and Four Beds Psychiatric           0142         Room & Board - Deluxe Private Obstetrics (OB)           0144         Room & Board - Deluxe Private Detoxification           0146         Room & Board - Ward Destetrics (OB)           0152         Room & Board - Ward Destetrics (OB)           0154         Room & Board - Ward Destetrics (OB)           0155         Room & Board - Ward Destetrics (OB)           0154         Room & Board - Ward Destetrics (OB)           0155         Room & Board - Ward Destetrics (OB)           0170         Nursery Newborn - Level I           0171         Nursery Newborn - Level I           0172         Nursery Newborn - Level I           0173	658		
10116		,	
10120		, , ,	
0122         Room and Board Semiprivate (two beds) - OB           0126         Room and Board Semiprivate (two beds) - Psychiatric           0128         Level 1 Rehab           0129         Level 2 Rehab - acute complex           0130         Room & Board - Three and Four Beds Obstetrics (OB)           0131         Room & Board - Three and Four Beds Psychiatric           0142         Room & Board - Deluxe Private Obstetrics (OB)           0143         Room & Board - Deluxe Private Obstetrics (OB)           0144         Room & Board - Deluxe Private Psychiatric           0146         Room & Board - Deluxe Private Detoxification           0152         Room & Board - Ward Obstetrics (OB)           0154         Room & Board - Ward Psychiatric           0155         Room & Board - Ward Psychiatric           0156         Room & Board - Ward Detoxification           0170         Nursery Remedan - Level I           0171         Nursery Newborn - Level II           0172         Nursery Newborn - Level II           0173         Nursery Newborn - Level II           0174         Nursery Newborn - Level II           0175         Nursery Other           0196         General classification - SNF           0197         Subacute Care - Level I I - SNF		, ,	
0124         Room and Board Semiprivate (two beds) - Psychiatric           0128         Level 1 Rehab           0129         Level 2 Rehab - acute complex           0132         Room & Board - Three and Four Beds Obstetrics (OB)           0136         Room & Board - Three and Four Beds Psychiatric           0142         Room & Board - Deluxe Private Obstetrics (OB)           0144         Room & Board - Deluxe Private Psychiatric           0144         Room & Board - Deluxe Private Detoxification           0152         Room & Board - Ward Delevitics (OB)           0154         Room & Board - Ward Obstetrics (OB)           0155         Room & Board - Ward Psychiatric           0156         Room & Board - Ward Psychiatric           0170         Nursery General Classification           0170         Nursery Newborn - Level II           0171         Nursery Newborn - Level II           0172         Nursery Newborn - Level III           0173         Nursery Newborn - Level IV           0179         Nursery Newborn - Level IV           0190         General classification - SNF           0191         Subacute Care - Level II - SNF           0192         Subacute Care - Level II - SNF           0193         Subacute Care - Level II - SNF		<del>U</del>	
Discrete   Room and Board Semiprivate (two beds) - Detoxification		· ` ` '	
Display		· · · · · · ·	
Description		` ` ` `	
Norm & Board - Three and Four Beds Obstetrics (OB)			
10136		'	
0142         Room & Board - Deluxe Private Obstetrics (OB)           0144         Room & Board - Deluxe Private Psychiatric           0146         Room & Board - Deluxe Private Detoxification           0152         Room & Board - Ward Obstetrics (OB)           0154         Room & Board - Ward Destoxification           0156         Room & Board - Ward Detoxification           0170         Nursery Rewborn - Level I           0171         Nursery Newborn - Level II           0172         Nursery Newborn - Level III           0173         Nursery Newborn - Level IV           0174         Nursery Newborn - Level IV           0179         Nursery Other           0190         General classification - SNF           0191         Subacute Care - Level I - SNF           0192         Subacute Care - Level II - SNF           0193         Subacute Care - Level IV - SNF           0194         Subacute Care - Level IV - SNF           0195         Other Subacute Care - SNF           0196         Transplant           0911         Behavioral Health Rehab           0912         Behavioral Health Partial Hospitalization - less intensive           0911         Behavioral Health Partial Hospitalization - less intensive           0910         Other		` ′	
0144 Room & Board - Deluxe Private Psychiatric 0146 Room & Board - Deluxe Private Detoxification 0152 Room & Board - Ward Obstetrics (OB) 0154 Room & Board - Ward Psychiatric 0156 Room & Board - Ward Psychiatric 0156 Room & Board - Ward Detoxification 0170 Nursery General Classification 0171 Nursery Newborn - Level II 0172 Nursery Newborn - Level III 0173 Nursery Newborn - Level III 0174 Nursery Newborn - Level IV 0179 Nursery Newborn - Level IV 0179 Nursery Other 0190 General classification - SNF 0191 Subacute Care - Level I I - SNF 0191 Subacute Care - Level II - SNF 0192 Subacute Care - Level III - SNF 0193 Subacute Care - Level III - SNF 0194 Subacute Care - Level III - SNF 0199 Other Subacute Care - Level III - SNF 0199 Other Subacute Care - Level III - SNF 0190 Other Subacute Care - Level III - SNF 0191 Behavioral Health Partial Hospitalization - less intensive 0191 Behavioral Health Partial Hospitalization - intensive 0191 Behavioral Health Partial Hospitalization - intensive 0190 Other Therapeutic Services - General 0100 Residential treatment - psychiatric 0100 Residential treatment - chemical dependency 0100 Alternative Therapy Services 0101 Alternative Therapy Services 0102 Alternative Therapy Services		· · · · · · · · · · · · · · · · · · ·	
0146 Room & Board - Deluxe Private Detoxification 0152 Room & Board - Ward Obstetrics (OB) 0154 Room & Board - Ward Psychiatric 0156 Room & Board - Ward Detoxification 0170 Nursery General Classification 0171 Nursery Newborn - Level I 0172 Nursery Newborn - Level II 0173 Nursery Newborn - Level II 0174 Nursery Newborn - Level IV 0179 Nursery Newborn - Level IV 0179 Nursery Other 0190 General classification - SNF 0191 Subacute Care - Level I - SNF 0192 Subacute Care - Level II - SNF 0193 Subacute Care - Level II - SNF 0194 Subacute Care - Level II - SNF 0195 Other Subacute Care - Level II - SNF 0196 Other Subacute Care - Level II - SNF 0197 Other Subacute Care - Level II - SNF 0198 Other Subacute Care - SNF 0199 Other Subacute Care - SNF 0199 Other Subacute Care - SNF 0190 Other Subacute Care - Level II - SNF 0191 Behavioral Health Rehab 0191 Behavioral Health Partial Hospitalization - less intensive 0191 Behavioral Health Partial Hospitalization - intensive 0190 Other Therapeutic Services - General 0100 Residential treatment - chemical dependency 0100 Alternative Therapy Services 0101 Alternative Therapy Services 0102 Alternative Therapy Services	0144	( )	
Room & Board - Ward Psychiatric	0146	·	
0156 Room & Board - Ward Detoxification 0170 Nursery General Classification 0171 Nursery Newborn - Level I 0172 Nursery Newborn - Level II 0173 Nursery Newborn - Level II 0174 Nursery Newborn - Level III 0175 Nursery Newborn - Level III 0176 Nursery Newborn - Level III 0177 Nursery Newborn - Level III 0179 Nursery Other 0190 General classification - SNF 0191 Subacute Care - Level I - SNF 0192 Subacute Care - Level II - SNF 0193 Subacute Care - Level III - SNF 0194 Subacute Care - Level III - SNF 0199 Other Subacute Care - SNF 0199 Other Subacute Care - SNF 0362 Transplant 0911 Behavioral Health Rehab 0912 Behavioral Health Partial Hospitalization - less intensive 0913 Behavioral Health Partial Hospitalization - intensive 0940 Other Therapeutic Services - General 1001 Residential treatment - psychiatric 1002 Residential treatment - chemical dependency 2100 Alternative Therapy Services 2101 Alternative Therapy Services	0152	Room & Board - Ward Obstetrics (OB)	
0170     Nursery General Classification       0171     Nursery Newborn - Level I       0172     Nursery Newborn - Level II       0173     Nursery Newborn - Level III       0174     Nursery Newborn - Level IV       0179     Nursery Newborn - Level IV       0179     Nursery Other       0190     General classification - SNF       0191     Subacute Care - Level I - SNF       0192     Subacute Care - Level I - SNF       0193     Subacute Care - Level IV - SNF       0194     Subacute Care - Level IV - SNF       0199     Other Subacute Care - SNF       0362     Transplant       0911     Behavioral Health Rehab       0912     Behavioral Health Partial Hospitalization - less intensive       0913     Behavioral Health Partial Hospitalization - intensive       0940     Other Therapeutic Services - General       1001     Residential treatment - psychiatric       1002     Residential treatment - chemical dependency       2101     Alternative Therapy Services       2102     Alternative Therapy Services       2103     Alternative Therapy Services	0154	Room & Board - Ward Psychiatric	
0171 Nursery Newborn - Level I 0172 Nursery Newborn - Level II 0173 Nursery Newborn - Level III 0174 Nursery Newborn - Level IV 0179 Nursery Other 0190 General classification - SNF 0191 Subacute Care - Level I - SNF 0192 Subacute Care - Level II - SNF 0193 Subacute Care - Level III - SNF 0194 Subacute Care - Level IV - SNF 0199 Other Subacute Care - SNF 0190 Other Subacute Care - SNF 0190 Other Subacute Care - SNF 0191 Behavioral Health Rehab 0191 Behavioral Health Partial Hospitalization - less intensive 0191 Behavioral Health Partial Hospitalization - intensive 0191 Residential treatment - psychiatric 0100 Residential treatment - chemical dependency 0100 Alternative Therapy Services 0100 Alternative Therapy Services 0100 Alternative Therapy Services 0100 Alternative Therapy Services	0156	Room & Board - Ward Detoxification	
Nursery Newborn - Level II  10173 Nursery Newborn - Level III  10174 Nursery Newborn - Level IV  10179 Nursery Other  10190 General classification - SNF  10191 Subacute Care - Level I - SNF  10192 Subacute Care - Level II - SNF  10193 Subacute Care - Level III - SNF  10194 Subacute Care - Level IV - SNF  10199 Other Subacute Care - SNF  10190 Other Subacute Care - SNF  10362 Transplant  10911 Behavioral Health Rehab  10912 Behavioral Health Partial Hospitalization - less intensive  10913 Behavioral Health Partial Hospitalization - intensive  10914 Residential treatment - psychiatric  1001 Residential treatment - chemical dependency  2100 Alternative Therapy Services  2101 Alternative Therapy Services  2102 Alternative Therapy Services	0170	Nursery General Classification	
Nursery Newborn - Level III  10174 Nursery Newborn - Level IV  10179 Nursery Other  10190 General classification - SNF  10191 Subacute Care - Level I - SNF  10192 Subacute Care - Level II - SNF  10193 Subacute Care - Level III - SNF  10194 Subacute Care - Level III - SNF  10195 Other Subacute Care - Level IV - SNF  10196 Other Subacute Care - SNF  10197 Other Subacute Care - SNF  10198 Other Subacute Care - SNF  10199 Other Subacute Care - SNF  1020 Behavioral Health Rehab  1021 Behavioral Health Partial Hospitalization - less intensive  1022 Behavioral Health Partial Hospitalization - intensive  1033 Behavioral Health Partial Hospitalization - intensive  1040 Other Therapeutic Services - General  1040 Residential treatment - psychiatric  1400 Residential treatment - chemical dependency  1500 Alternative Therapy Services  1601 Alternative Therapy Services  1702 Alternative Therapy Services  1703 Alternative Therapy Services	0171	Nursery Newborn - Level I	
Nursery Newborn - Level IV Nursery Other Subacute Care - Level I - SNF Subacute Care - Level II - SNF Subacute Care - Level II - SNF Subacute Care - Level III - SNF Subacute Care - Level IV - SNF Subacute Care - Level IV - SNF Subacute Care - Level IV - SNF Subacute Care - Level III - SNF Subacute Care - Leve	0172	·	
0179     Nursery Other       0190     General classification - SNF       0191     Subacute Care - Level I - SNF       0192     Subacute Care - Level II - SNF       0193     Subacute Care - Level III - SNF       0194     Subacute Care - Level IV - SNF       0199     Other Subacute Care - SNF       0362     Transplant       0911     Behavioral Health Rehab       0912     Behavioral Health Partial Hospitalization - less intensive       0913     Behavioral Health Partial Hospitalization - intensive       0940     Other Therapeutic Services - General       1001     Residential treatment - psychiatric       1002     Residential treatment - chemical dependency       2100     Alternative Therapy Services       2101     Alternative Therapy Services       2102     Alternative Therapy Services       2103     Alternative Therapy Services		·	
General classification - SNF		·	
0191       Subacute Care - Level I - SNF         0192       Subacute Care - Level II - SNF         0193       Subacute Care - Level III - SNF         0194       Subacute Care - Level IV - SNF         0199       Other Subacute Care - SNF         0362       Transplant         0911       Behavioral Health Rehab         0912       Behavioral Health Partial Hospitalization - less intensive         0913       Behavioral Health Partial Hospitalization - intensive         0940       Other Therapeutic Services - General         1001       Residential treatment - psychiatric         1002       Residential treatment - chemical dependency         2100       Alternative Therapy Services         2101       Alternative Therapy Services         2102       Alternative Therapy Services         2103       Alternative Therapy Services		·	
Subacute Care - Level II - SNF  0193 Subacute Care - Level III - SNF  0194 Subacute Care - Level IV - SNF  0199 Other Subacute Care - SNF  0362 Transplant  0911 Behavioral Health Rehab  0912 Behavioral Health Partial Hospitalization - less intensive  0913 Behavioral Health Partial Hospitalization - intensive  0940 Other Therapeutic Services - General  1001 Residential treatment - psychiatric  1002 Residential treatment - chemical dependency  2100 Alternative Therapy Services  2101 Alternative Therapy Services  2102 Alternative Therapy Services  2103 Alternative Therapy Services			
Subacute Care - Level III - SNF O194 Subacute Care - Level IV - SNF O199 Other Subacute Care - SNF O362 Transplant O911 Behavioral Health Rehab O912 Behavioral Health Partial Hospitalization - less intensive O913 Behavioral Health Partial Hospitalization - intensive O940 Other Therapeutic Services - General O010 Residential treatment - psychiatric O02 Residential treatment - chemical dependency O100 Alternative Therapy Services O101 Alternative Therapy Services O102 Alternative Therapy Services O103 Alternative Therapy Services O104 Alternative Therapy Services O105 Alternative Therapy Services O106 Alternative Therapy Services O107 Alternative Therapy Services			
0194Subacute Care - Level IV - SNF0199Other Subacute Care - SNF0362Transplant0911Behavioral Health Rehab0912Behavioral Health Partial Hospitalization - less intensive0913Behavioral Health Partial Hospitalization - intensive0940Other Therapeutic Services - General1001Residential treatment - psychiatric1002Residential treatment - chemical dependency2100Alternative Therapy Services2101Alternative Therapy Services2102Alternative Therapy Services2103Alternative Therapy Services			
Other Subacute Care - SNF O362 Transplant O911 Behavioral Health Rehab O912 Behavioral Health Partial Hospitalization - less intensive O913 Behavioral Health Partial Hospitalization - intensive O940 Other Therapeutic Services - General O011 Residential treatment - psychiatric O022 Residential treatment - chemical dependency O103 Alternative Therapy Services O104 Alternative Therapy Services O105 Alternative Therapy Services O106 Alternative Therapy Services O107 Alternative Therapy Services O108 Alternative Therapy Services O109 Alternative Therapy Services O109 Alternative Therapy Services O109 Alternative Therapy Services			
Transplant  0911 Behavioral Health Rehab  0912 Behavioral Health Partial Hospitalization - less intensive  0913 Behavioral Health Partial Hospitalization - intensive  0940 Other Therapeutic Services - General  1001 Residential treatment - psychiatric  1002 Residential treatment - chemical dependency  2100 Alternative Therapy Services  2101 Alternative Therapy Services  2102 Alternative Therapy Services  2103 Alternative Therapy Services			
0911 Behavioral Health Rehab 0912 Behavioral Health Partial Hospitalization - less intensive 0913 Behavioral Health Partial Hospitalization - intensive 0940 Other Therapeutic Services - General 1001 Residential treatment - psychiatric 1002 Residential treatment - chemical dependency 2100 Alternative Therapy Services 2101 Alternative Therapy Services 2102 Alternative Therapy Services 2103 Alternative Therapy Services			
0912       Behavioral Health Partial Hospitalization - less intensive         0913       Behavioral Health Partial Hospitalization - intensive         0940       Other Therapeutic Services - General         1001       Residential treatment - psychiatric         1002       Residential treatment - chemical dependency         2100       Alternative Therapy Services         2101       Alternative Therapy Services         2102       Alternative Therapy Services         2103       Alternative Therapy Services			
0913 Behavioral Health Partial Hospitalization - intensive 0940 Other Therapeutic Services - General 1001 Residential treatment - psychiatric 1002 Residential treatment - chemical dependency 2100 Alternative Therapy Services 2101 Alternative Therapy Services 2102 Alternative Therapy Services 2103 Alternative Therapy Services			
0940 Other Therapeutic Services - General 1001 Residential treatment - psychiatric 1002 Residential treatment - chemical dependency 2100 Alternative Therapy Services 2101 Alternative Therapy Services 2102 Alternative Therapy Services 2103 Alternative Therapy Services		·	
1001 Residential treatment - psychiatric 1002 Residential treatment - chemical dependency 2100 Alternative Therapy Services 2101 Alternative Therapy Services 2102 Alternative Therapy Services 2103 Alternative Therapy Services	0940	·	
1002 Residential treatment - chemical dependency 2100 Alternative Therapy Services 2101 Alternative Therapy Services 2102 Alternative Therapy Services 2103 Alternative Therapy Services	1001		
2100 Alternative Therapy Services 2101 Alternative Therapy Services 2102 Alternative Therapy Services 2103 Alternative Therapy Services	1002		
2102 Alternative Therapy Services 2103 Alternative Therapy Services	2100	·	
2102 Alternative Therapy Services 2103 Alternative Therapy Services	2101		
	2102		
2104 Alternative Therapy Services	2103		
	2104	Alternative Therapy Services	

	I	1
2105	Alternative Therapy Services	
2106	Alternative Therapy Services	
2107	Alternative Therapy Services	
2108	Alternative Therapy Services	
2109	Alternative Therapy Services	
3100	Reserved	
3101	Adult Day Care, Medical and Social - Hourly	
3102	Adult Day Care, Social - Hourly	
3103	Adult Day Care, Medical and Social - Daily	
3104	Adult Day Care, Social - Daily	
3105	Adult Foster Care - Daily	
3106	Reserved	
3107	Reserved	
3107	Reserved	
3109	Other Adult Care	
	General Classification	
0660		
0661	Hourly Charge/Nursing	
0662	Hourly Charge/Aide/Homemaker/Companion	
0663	Daily Respite Charge	
0664	Reserved	
0665	Reserved	
0666	Reserved	
0667	Reserved	
0668	Reserved	
0669	Other Respite Care	
0681	Level I - Trauma Response	
0682	Level II - Trauma Response	
0683	Level III - Trauma Response	
0684	Level IV - Trauma Response	
0685	Reserved	
0686	Reserved	
0687	Reserved	
0688	Reserved	
0689	Other Trauma Response	
0810	General Classification - acquisition of body components	
0811	Living Donor - acquisition of body components	
0812	Cadaver Donor - acquisition of body components	
0813	Unknown Donor - acquisition of body components	
0814	Unsuccessful Organ Search - Donor Bank Charges -	
	Stem Cell Acquisition-Allogenic -	
0815	ı	
0816	Reserved - acquisition of body components	
0817	Reserved - acquisition of body components	
0818	Reserved - acquisition of body components	
0819	Other Donor - acquisition of body components	
0951	Athletic training	
0990	General Classification	
0991	Cafeteria/Guest Tray	
0992	Private Linen Service	
0993	Telephone/Telecom	
0994	TV/Radio	
0995	Nonpatient Room Rentals	
	'	
0996 0997	Late Discharge Admission Kits	
0998	Beauty Shop/Barber	
0999	Other Convenience Items	
0930	Medical Rehabilitation Day Program	
0931	Medical Rehabilitation Day Program	
0932	Medical Rehabilitation Day Program	
0933	Medical Rehabilitation Day Program	
0934	Medical Rehabilitation Day Program	
0935	Medical Rehabilitation Day Program	
0936	Medical Rehabilitation Day Program	

0937	Medical Rehabilitation Day Program	
0938	Medical Rehabilitation Day Program	
0939	Medical Rehabilitation Day Program	
ICD-10	mouloui rionazimanon zuy riogiam	
F64	Gender identity disorders	Any treatment for transsexualism, gender dysphoria, sexual re-assignment or sex change, including, but not be limited to, drugs, surgery, medical or psychiatric care
F648	Other gender identity disorders	
F649	Gender identity disorder, unspecified	
F642	Gender identity disorder of childhood	
F640	Transsexualism	
F641	Dual role transvestism	
	CHARITY PLAN LIMITATIONS EFF: 1/1/2020 (updated	04/20/2020)
CPT Code		T
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder (includes aural rehabilitation); individual	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)
97010	Hot or cold pack application	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)
97012	Mechanical traction	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)
97014	Electrical stimulation (unattended)	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)
97016	Vasopneumatic devices	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)
97018	Paraffin bath	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)
97022	Whirlpool	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)
97026	Infrared	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)
97032	Electrical stimulation (manual) (15 minutes)	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)
97033	Iontophoresis (15 minutes)	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)
97035	Ultrasound (15 minutes)	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)
97039	Unlisted modality (specify type and time if constant attendance)	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)
97110	Therapeutic exercises to develop strength and endurance, range of motion, and flexibility (15 minutes)	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)
97112	Neuromuscular re-education of movement, balance, coordination, kinesthetic sense, posture, and/or proprioception for sitting and/or standing activities (15 minutes)	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)
97113	Aquatic therapy with therapeutic exercises (15 minutes)	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)

97116	Gait training (includes stair climbing) (15 minutes)	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)	
97124	Massage, including effleurage, petrissage, and/or tapotement (stroking, compression, percussion) (15 minutes)	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a	
		Covered Benefit (Modifier 95, POS 02)	
97140	Manual therapy techniques (e.g., connective tissue massage, joint mobilization and manipulation, and manual traction) (15 minutes)	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)	
97150	Group therapeutic procedure(s) (two or more individuals)	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)	
97161	Physical therapy evaluation: low complexity	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)	
97162	Physical therapy evaluation: moderate complexity	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)	
97163	Physical therapy re-evaluation	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)	
97164	Physical therapy evaluation: high complexity	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)	
97165	Occupational therapy evaluation: low complexity	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)	
97166	Occupational therapy evaluation: moderate complexity	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)	
97167	Occupational therapy evaluation: high complexity	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)	
97168	Occupational therapy re-evaluation	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)	
97530	Dynamic activities to improve functional performance, direct (one-on-one) with the patient (15 minutes)	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)	
97535	Self-care/home management training (e.g., activities of daily living [ADL] and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment), direct one-on-one contact (15 minutes)	PT, OT, ST combined 8 visit limit/year AND Telemedicine/Virtual Care Therapy visits are Not a Covered Benefit (Modifier 95, POS 02)	
97610	Low frequency non-thermal ultrasound per day  PT, OT, ST combined 8 visit limit/year AN Telemedicine/Virtual Care Therapy visits ar Covered Benefit (Modifier 95, POS 02)		
HCPC Cod	les		
A4520	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554	
A4554	Disposble underpads	150 pads per month	
A6530	Gradient compression stocking, below knee, 18-30 mmHg, each	2 every 6 months	
A6531	Gradient compression stocking, below knee, 30-40 mmHg, each	2 every 6 months	
A6532	Gradient compression stocking, below knee, 40-50 mmHg, each 2 every 6 months		
A6533	Gradient compression stocking, thigh length, 18-30 mmHg, each 2 every 6 months		
A6534	Gradient compression stocking, thigh length, 30-40 mmHg, each	2 every 6 months	
A6535	Gradient compression stocking, thigh length, 40-50 mmHg, each	2 every 6 months	
A6536	Gradient compression stocking, full length/chap style, 18-30 mmHg, ea 2 every 6 months		
A6537	Gradient compression stocking, full length/chap style, 30-40 mmHg, ea	-	
A6538	Gradient compression stocking, full length/chap style, 40-50 mmHg, ea	2 every 6 months	

A6539	Gradient compression stocking, waist length, 18-30 mmHg, each	2 every 6 months	
A6540	Gradient compression stocking, waist length, 30-40 mmHg, each	2 every 6 months	
A6541	Gradient compression stocking, waist length, 40-50 mmHg, each	2 every 6 months	
A6549	Gradient compression stocking, unspecified 2 every 6 months		
A7028	Replacement Cushion for Combination Oral/Nasal Mask	1 per 3 months	
A7029	Replacement Pillows for Combination Oral/Nasal Mask	1 per 3 months	
A7031	Replacement Cushion for Full-Face Mask	1 per 3 months	
A7032	·		
A7033	Replacement Pillow for use on Nasal Mask (cannula/pillow)	1 per 3 months	
A7038	, , ,		
A7039	Non Disposable Filter	1 per 12 months	
E0561	Humidifier, Non-Heated	1 per 5 Years	
E0562	Humidifier, Heated	1 per 5 Years	
T4521	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554	
T4522	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554	
T4523	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554	
T4524	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554	
T4525	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554	
T4526	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554	
T4527	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554	
T4528	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554	
T4529	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554	
T4530	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554	
T4531	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554	
T4532	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554	
T4533	Incontinence brief/diaper  3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with He code A4554		
T4534	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554	
T4535	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554	
T4536	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554	

T4537	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554
T4538	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554
T4539	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554
T4540	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554
T4541	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554
T4542	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554
T4543	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554
T4544	Incontinence brief/diaper	3 cases/month or 288 briefs/diapers/month 2 cases/month or 192/month if billed with HCPC code A4554